Infection, Human Immunodeficiency Virus, HIV Infections
Conditions
Keywords
Long-acting cabotegravir, Virologic failure, long-acting rilpivirine, Antiretroviral
Brief summary
The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult subjects with current viral suppression on a regimen with 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent, remain suppressed upon switching to a two-drug intramuscular (IM) long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). This is a Phase 3, multi-phase, randomized, open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1, antiretroviral therapy (ART)-adult subjects who are stably suppressed on a current antiretroviral (ARV) regimen. This study is designed to demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks (Q4W: monthly) compared with maintenance of current ARV regimen containing 2 NRTIs plus an INI, NNRTI, or a PI. Eligible subjects will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue current ART or switch to initiate oral therapy with CAB 30 mg + RPV 25 mg once daily for 4 Weeks followed by Q4 weekly (monthly) CAB LA + RPV LA injections. Following the Maintenance phase at Week 52, subjects who were randomized to continue their current ART regimen will be given an option to switch to CAB LA + RPV LA injections. Those subjects would transition to LA dosing, beginning with 4 weeks oral CAB + RPV therapy at Week 52, and receive the first IM CAB LA + RPV LA injections at Week 56.
Interventions
It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat
It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose
It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection
It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
DRUG2 NRTIs plus an INI, NNRTI, or PI
Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus: * INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen) * NNRTI (either the initial or second cART regimen) * Boosted PI (or atazanavir \[ATV\] unboosted) (either the initial or second PI-based cART regimen)
Sponsors
Janssen Pharmaceuticals
GlaxoSmithKline
ViiV Healthcare
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged 18 years or older (or ≥19 where required by local regulatory agencies), at the time of signing the informed consent. * Must be on uninterrupted current regimen (either the initial or second ARV regimen) for at least 6 months prior to Screening. Any prior switch, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability/safety, access to medications, or convenience/simplification, and must NOT have been done for treatment failure (HIV-1 RNA ≥400 c/mL). * Acceptable stable (initial or second) ARV regimens prior to Screening include 2 NRTIs plus: INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen);NNRTI (either the initial or second cART regimen);Boosted PI (or atazanavir \[ATV\] unboosted) (must be either the initial cART regimen or one historical within class switch is permitted due to safety/tolerability) The addition, removal, or switch of a drug(s) that has been used to treat HIV based on antiretroviral properties of the drug constitutes a change in ART with the following limited exceptions: Historical changes in formulations of ART drugs or booster drugs will not constitute a change in ART regimen if the data support similar exposures and efficacy, and the change must have been at least 3 months prior to Screening; Historical perinatal use of an NRTI when given in addition to an ongoing HAART will not be considered a change in ART regimen; A change in dosing scheme of the same drug from twice daily to once daily will not be considered a change in ART regimen if data support similar exposures and efficacy. * Documented evidence of at least two plasma HIV-1 RNA measurements \<50 c/mL in the 12 months prior to Screening: one within the 6 to 12 month window, and one within 6 months prior to Screening; * Plasma HIV-1 RNA \<50 c/mL at Screening; * A female subjects is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotrophin (hCG) test at screen and a negative urine hCG test at Randomization), not lactating, and at least one of the following conditions applies: 1. Non-reproductive potential defined as: Pre-menopausal females with one of the following: Documented tubal ligation; Documented hysteroscopic tubal occlusion procedure with follow-up; confirmation of bilateral tubal occlusion; Hysterectomy; Documented Bilateral Oophorectomy; Postmenopausal defined as 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. 2. Reproductive potential and agrees to the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication, and until from 30 days prior to the first dose of study medication throughout the study, and for at least 30 days after discontinuation of all oral study medications and for at least 52 weeks after discontinuation of CAB LA and RPV LA. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form. Eligible subjects or their legal guardians (and next of kin when locally required), must sign a written Informed Consent Form before any protocol-specified assessments are conducted. Enrolment of subjects who are unable to provide direct informed consent is optional and will be based on local legal/regulatory requirements and site feasibility to conduct protocol procedures. * Subjects enrolled in France must be affiliated to, or a beneficiary of, a social security category. * All subjects participating in the study should be counselled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom) and on the risk of HIV transmission to an uninfected partner.
Exclusion criteria
* Within 6 months prior to Screening and after confirmed suppression to \<50 c/mL on current ART regimen, any plasma HIV-1 RNA measurement ≥50 c/mL * Within the 6 to 12 month window prior to Screening and after confirmed suppression to \<50 c/mL, any plasma HIV-1 RNA measurement \>200 c/mL, or 2 or more plasma HIV-1 RNA measurements ≥50 c/mL * Any drug holiday during the window between initiating first HIV ART and 6 months prior to Screening, except for brief periods (less than 1 month) where all ART was stopped due to tolerability and/or safety concerns * Any switch to a second line regimen, defined as change of a single drug or multiple drugs simultaneously, due to virologic failure to therapy (defined as a confirmed plasma HIV-1 RNA measurement ≥400 c/mL after initial suppression to \<50 c/mL while on first line HIV therapy regimen) * Abacavir/dolutegravir/lamivudine, (ABC/DTG/3TC) as current ART regimen * A history of use of any regimen consisting of only single NNRTI therapy (even if only for peri-partum treatment), or only single or dual NRTI therapy prior to starting cART * Subjects who are currently participating in or anticipate to be selected for any other interventional study * Women who are pregnant, breastfeeding or plan to become pregnant or breastfeed during the study * Any evidence of an active Center for Disease Control and Prevention (CDC) Stage 3 disease \[CDC, 2014\], except cutaneous Kaposi's sarcoma not requiring systemic therapy and historical or current CD4 cell counts less than 200 cells/mm\^3 * Subjects with moderate to severe hepatic impairment * Any pre-existing physical or mental condition (including substance use disorder) which, in the opinion of the Investigator, may interfere with the subjects ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the subject. * Subjects determined by the Investigator to have a high risk of seizures, including subjects with an unstable or poorly controlled seizure disorder. A subject with a prior history of seizure may be considered for enrolment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrolment * All subjects will be screened for syphilis (rapid plasma reagin \[RPR\]). Subjects with untreated syphilis infection, defined as a positive RPR without clear documentation of treatment, are excluded. Subjects with a serofast RPR result (persistence of a reactive nontreponemal syphilis test) despite history of adequate therapy and no evidence of re-exposure may enrol after consultation with the Medical Monitor. Subjects with a positive RPR test who have not been treated may be rescreened at least 30 days after completion of antibiotic treatment for syphilis * Subjects who, in the investigator's judgment, pose a significant suicide risk. Subject's recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk * The subject has a tattoo or other dermatological condition overlying the gluteus region which may interfere with interpretation of injection site reactions * Evidence of Hepatitis B virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), Hepatitis B surface antibody (anti-HBs) and HBV DNA as follows:•Subjects positive for HBsAg are excluded; * Subjects negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded * Asymptomatic individuals with chronic hepatitis C virus (HCV) infection will not be excluded, however Investigators must carefully assess if therapy specific for HCV infection is required; subjects who are anticipated to require HCV treatment within 12 months must be excluded. (HCV treatment on study may be permitted post Week 48, following consultation with the medical monitor) Subjects with HCV co-infection will be allowed entry into phase 3 studies if: Liver enzymes meet entry criteria; HCV Disease has undergone appropriate work-up, and is not advanced, and will not require treatment prior to the Week 48 visit. Additional information (where available) on subjects with HCV co-infection at screening should include results from any liver biopsy, Fibroscan, ultrasound, or other fibrosis evaluation, history of cirrhosis or other decompensated liver disease, prior treatment, and timing/plan for HCV treatment. In the event that recent biopsy or imaging data is not available or inconclusive, the Fib-4 score will be used to verify eligibility: Fib-4 score \> 3.25 is exclusionary; Fib-4 scores 1.45 - 3.25 requires Medical Monitor consultation Fibrosis 4 Score Formula:( Age x AST ) / ( Platelets x ( sqr \[ ALT \]) * Unstable liver disease (as defined by any of the following: presence of ascites,encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices,or persistent jaundice or cirrhosis), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment) * History of liver cirrhosis with or without hepatitis viral co-infection. * Ongoing or clinically relevant pancreatitis * Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease * Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the subject prior to randomization * Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the subject unable to receive study medication * History or presence of allergy or intolerance to the study drugs or their components or drugs of their class. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia must not be enrolled * Current or anticipated need for chronic anti-coagulation with the exception of the use of low dose acetylsalicylic acid (≤325mg). * Any evidence of primary resistance based on the presence of any major known INI or NNRTI resistance-associated mutation, except for K103N, (International AIDS Society \[IAS\]-USA, 2015) by any historical resistance test result. * Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during the Screening phase to verify a result * Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the subject's participation in the study of an investigational compound * Subject has estimated creatine clearance \<50mL/min per 1.73m\^2 via CKDEPI Method * Alanine aminotransferase (ALT) ≥3 × ULN Exposure to an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to Day 1 of this study; * Treatment with any of the following agents within 28 days of Screening: radiation therapy; cytotoxic chemotherapeutic agents; tuberculosis therapy with the exception of isoniazid (isonicotinylhydrazid,INH); anti-coagulation agents; Immunomodulators that alter immune responses such as chronic systemic corticosteroids, interleukins, or interferons. Note: Subjects using short term (e.g. ≤21 days) systemic corticosteroid treatment; topical, inhaled and intranasal corticosteroids are eligible for enrolment. * Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening * Treatment with any agent, except recognized ART as allowed above, with documented activity against HIV-1 within 28 days of study Day 1 * Use of medications which are associated with Torsade de Pointes. * Current or prior history of etravirine (ETR) * Current use of tipranavir/ritonavir or fosamprenavir/ritonavir * Subjects receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48 | Week 48 | Number of participants with virologic failure endpoint (HIV-1 RNA\>=50 c/mL) as per Food and Drug Administration (FDA) snapshot algorithm at Week 48 was assessed to demonstrate the non-inferior antiviral activity of switching to intramuscular (IM) CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-1 RNA \>=50 copies/mL per snapshot algorithm was determined by the last available on-treatment HIV-1 RNA measurement within the analysis visit window of interest. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48 | Week 48 | Plasma samples were collected for quantitative analysis of HIV-1 RNA. Number of participants with plasma HIV-1 RNA \<50 copies/mL at Week 48 using FDA snapshot algorithm was assessed to demonstrate antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART. The HIV-1 RNA \<50 copies/mL per snapshot algorithm was determined by the last available on-treatment HIV-1 RNA measurement within the analysis visit window of interest. |
| Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48 | Week 48 | Number of participants with plasma HIV-1 RNA \<200 copies/mL at Week 48 using the snapshot algorithm was assessed based on the antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART. |
| Number of Participants With Confirmed Virologic Failure (CVF) | Weeks 8, 12, 20, 24, 32 and 40 | The CVF is defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL. The outcome displays only visits during which at least one new CVF occurs. Plasma samples were collected for quantitative analysis of HIV-1 RNA. |
| Absolute Values for Plasma HIV-1 RNA at Week 48 | Week 48 | Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented. |
| Change From Baseline Values for Plasma HIV-1 RNA | Baseline and Week 48 | Plasma for quantitative HIV-1 RNA were collected at indicated time points. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as: HIV-1 RNA(log 10) at Week 48 - HIV-1 RNA(log 10) at Baseline. |
| Absolute Values for CD4+ Lymphocyte Count at Week 48 | Week 48 | Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to current ART. |
| Change From Baseline Values for CD4+ Lymphocyte Count at Week 48 | Baseline (Day 1) and Week 48 | Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to current ART.Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value at Week 48 minus Baseline value. |
| Number of Participants With Disease Progression | Up to Week 48 | Disease progression was defined as HIV-associated conditions, acquired immunodeficiency syndrome (AIDS), and death through 48 Weeks. Data of participants who experienced disease progression to Centers for Disease Control and Prevention (CDC) Stage III or death has been presented. |
| Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) | Up to Week 48 | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement. Safety Population comprised of all randomized participants who received at least one dose of IP during the maintenance phase of the study (on or after Day 1 visit). Participants will be assessed according to actual treatment received. |
| Ctrough for RPV LA Evaluable | Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples will be collected at indicated time points for PK analysis of RPV LA. |
| Number of Participants With Severity of Adverse Events | Up to Week 48 | Severity of adverse events (AEs) were defined as per The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.0, November 2014. Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE. |
| Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated time points. |
| Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated time points. |
| Absolute Values for Hematology Parameters: Erythrocytes | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated time points. |
| Absolute Values for Hematology Parameters: Hemoglobin | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated time points. |
| Absolute Values for Hematology Parameters: Hematocrit | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated time points. |
| Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value. |
| Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value. |
| Change From Baseline for Hematology Parameters: Erythrocytes | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value. |
| Change From Baseline for Hematology Parameters: Hematocrit | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value. |
| Change From Baseline for Hematology Parameters: Hemoglobin | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value. |
| Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points. |
| Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter-albumin at indicated time points. |
| Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin at indicated time points. |
| Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea at indicated time points. |
| Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter-lipase at indicated time points. |
| Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance at indicated timepoints. Glomerular filtration rate (GFR) will be estimated by the central laboratory using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). |
| Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Baseline (Day 1) and at Weeks 4, 24 and 48. | The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. The urine parameters were graded according to Division of AIDS (DAIDS) scale where Grade 1 indicates mild (trace to 1+), Grade 2 indicates moderate (2+) and Grade 3 indicates severe (3+ or higher). Only participants with abnormal findings for urinalysis at any visit has been presented. |
| Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline (Day 1) and at Weeks 4, 24 and 48 | Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). |
| Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK. Baseline values is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter-albumin. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter-lipase. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance. GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values for Fasting Lipid Panel Over Time Including Week 48 | Baseline (Day 1) and at Week 48 | Blood samples were collected for the analysis of fasting lipid parameters- total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48 | Baseline (Day 1) and at Weeks 4, 24 and 48 | Urine biomarker samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio.Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values in Urine Creatinine Over Time Including Week 48 | Baseline (Day 1) and at Weeks 4, 24 and 48 | Urine biomarker samples were collected for the analysis of urine creatinine. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values in Urine Phosphate Over Time Including Week 48 | Baseline (Day 1) and at Weeks 4, 24 and 48 | Urine biomarker samples were collected for the analysis of urine phosphate. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48 | Baseline (Day 1) and at Week 48 | Urine biomarker samples were collected for the analysis of urine retinol binding protein. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48 | Baseline (Day 1) and at Weeks 4, 24 and 48 | Urine biomarker samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The dipstick test gives results in a semi-quantitative manner. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. The urine specific gravity was measured as the ratio of urine density compared with water density. |
| Change From Baseline Values in Urine pH Over Time Including Week 48 | Baseline (Day 1) and at Weeks 4, 24 and 48 | Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). The dipstick test gives results in a semi-quantitative manner. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48 | Up to Week 48 | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. |
| Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48 | Baseline (Day 1) and at Week 48 | Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Percentage change from Baseline is calculated as: value at Week 48 minus Baseline value divided by Baseline value multiplied by 100. |
| Number of Participants With Phenotypic Resistance Through Week 48 | At the time of CVF | Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria.The CVF population comprised of all participants in ITT-E population who met CVF criteria.Phenotypic Resistance data for following drugs:CAB,dolutegravir(DTG),elvitegravir(EVG), raltegravir(RAL),delavirdine(DLV),efavirenz(EFV),etravirine(ETR),nevirapine(NVP),RPV,lamivudine(3TC),abacavir(ABC),emtricitabine(FTC),tenofovir(TDF),zidovudine(ZDV),stavudine(d4T),didanosine(ddI), atazanavir(ATV),darunavir(DRV),fosamprenavir(FPV),indinavir(IDV),lopinavir(LPV),nelfinavir(NFV),rito-navir(RTV),saquinavir(SQV) and tipranavir(TPV) in participants meeting CVF criteria is presented.Phenotypic resistance, partially sensitive, and Sensitive were defined based on fold change(FC) value from Monogram as:resistance(FC\>clinical higher cutoff/biologic cutoff),partially sensitive(FC \<=clinical higher cutoff and \> clinical lower cutoff),sensitive(FC \<= clinical lower cutoff/biologic cutoff). |
| Number of Participants With Genotypic Resistance Through Week 48 | At the time of CVF | Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented. |
| Number of Participants With AEs by Using Baseline Third Agent Treatment Class Overtime Including Week 48 | Up to Week 48 | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. |
| Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameters to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). |
| Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter: albumin to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). |
| Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter: bilirubin, direct bilirubin and creatinine to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). |
| Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter: creatinine clearance to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). GFR will be estimated by the central laboratory using the CKD-EPI. |
| Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter: lipase to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). |
| Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameters: CO2, chloride, glucose, phosphate, potassium, sodium and urea to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). |
| Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | Baseline (Day 1) and at Week 48 | Blood samples were collected for the analysis of fasting lipid panel: triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). |
| Number of Participants Discontinued or Withdrawn Due to AEs When Baseline Third Agent Treatment Class Was Used Over Time Including Week 48 | Up to Week 48 | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. |
| Plasma Trough Concentration (Ctrough) for CAB LA Evaluable | Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples will be collected at indicated time points for pharmacokinetic (PK) analysis of CAB LA. PK population includes all participants who received CAB and / or RPV and underwent PK sampling during the study, and provided CAB and /or RPV plasma concentration data. |
| Area Under the Curve (AUC) for CAB LA | Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5 and 41 | AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201585 and 201584 # NCT02938520. Blood samples from the current study 201585 were collected at indicated time points to analyze concentration in plasma for CAB LA. |
| AUC for RPV LA | Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5 and 41 | AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201585 and 201584 # NCT02938520. Blood samples from the current study 201585 were collected at indicated time points to analyze concentration in plasma for RPV LA. |
| Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41 | Week 41- 1 Week post dose | Blood samples will be collected at indicated time points for PK analysis of CAB LA. |
| Cmax in Plasma for RPV LA Evaluable at Week 41 | Week 41- 1 Week post dose | Blood samples will be collected at indicated time points for PK analysis of RPV LA. |
| Percentage of Participants With a Virologic Failure Using Snapshot Algorithm by Baseline Third Agent | Week 48 | Percentage of participants with virologic failure endpoint as per FDA snapshot algorithm at Week 48 was assessed based on the non-inferior antiviral activity of switching IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-RNA \>=50 copies/mL per snapshot algorithm was determined using a Cochran-Mantel Haenszel test stratified by baseline third agent class: INI, NNRTI, or PI. |
| Percentage of Participants With Plasma HIV-1 RNA <50copies/mL Using Snapshot Algorithm by Baseline Third Agent | Week 48 | Percentage of participants with HIV-1 RNA \< 50copies/mL endpoint as per FDA snapshot algorithm at Week 48 was assessed based on the non-inferior antiviral activity of switching IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-RNA \<50 copies/mL per snapshot algorithm was determined using a Cochran-Mantel Haenszel test stratified by baseline third agent class: INI, NNRTI, or PI. |
| Number of Participants With Severity of Adverse Events by Baseline Third Agents | Up to Week 48 | Severity of AEs were defined as per The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE. |
| Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameters: ALT, ALP, AST and CK to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter: albumin to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter: bilirubin, direct bilirubin and creatinine to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter: creatinine clearance to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameter: lipase to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48 | Blood samples were collected for the analysis of clinical chemistry parameters: CO2, chloride, glucose, phosphate, potassium, sodium and urea to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | Baseline (Day 1) and at Week 48 | Blood samples were collected for the analysis of fasting lipid panel: triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | At the time of CVF | Plasma samples were collected from participants who met confirmed virologic withdrawal criteria to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented. |
| Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | At the time of CVF | Plasma samples were collected from participants who met confirmed virologic withdrawal criteria to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Phenotypic Resistance data for the following drugs: CAB, DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented. Phenotypic resistance, partially sensitive, and Sensitive were defined based on FC value from Monogram as: resistance (FC\>clinical higher cutoff/biologic cutoff), partially sensitive (FC \<=clinical higher cutoff and \> clinical lower cutoff), sensitive (FC \<= clinical lower cutoff/biologic cutoff). |
| Change From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm | Week 5 and at Weeks 41 and 48 | The PIN questionnaire explores the bother of pain at the injection site and injection site reactions (ISR), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections.This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial.Scores range from 1 to 5, and questions are phrased in such a way as to ensure that 1 always equated with the most favourable perception of vaccination, and 5 the most unfavourable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.The score of a domain is calculated as the mean of all items with the domain.Higher scores represent worse perception of injection. LOCFwas used as primary method of analysis |
| Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire | Baseline (Day 1) and at Weeks 24 and 48 | The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for LISAT is calculated on a 0-100 scale using the formula: LISAT 100=\[100 divided by (20 minus 4)\]\*(LISAT minus 4). A response of 5 in LISAT score shows satisfaction all of the time and 1 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% confidence interval (CI).Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline in HIV Medication, MEDWO Using HATQoL | Baseline and at Weeks 24 and 48 | The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for MEDWO is calculated on a 0-100 scale using the formula: MEDWO 100=\[100 divided by (20 minus 5)\]\*(MEDWO minus 5). A response of 1 in MEDWO score shows less medication worries all of the time and 5 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline in DISWO Using HATQoL | Baseline and at Weeks 24 and 48 | The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for DISWO is calculated on a 0-100 scale using the formula: DISWO 100=\[100 divided by (20 minus 5)\]\*(DISWO minus 5). A response of 1 in DISWO score shows less medication worries all of the time and 5 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12) | Baseline and at Weeks 24 and 48 | The SF-12 questionnaire consists of 7 questions which measures the degree of general health status and mental health distress. Each question is scored 0-5, except for question 2 scored 0-3. The HRQoL using SF-12 for the total score, physical component summary (PCS) and the mental component summary (MCS) were assessed for the two treatment groups. Missing Total or the component scores was imputed using LOCF. The PCS/MCS are calculated using computer software purchased from QualityMetric (http://www.qualitymetric.com). The higher the score, the better will be the health status. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44 | Baseline and at Weeks 4b, 24 and 44 | The HIVTSQ for total treatment satisfaction score is computed with 1-11 items. These 1-11 items are summed to produce a score with a possible range of -33 to 33. The item 12 in the scale will be calculated as an individual score.The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores will be imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score should not be computed and will remain missing.LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. Data has been presented with respect to actual treatment received to the participants |
| Change in Treatment Satisfaction Over Time Using HIVTSQ Change (HIVTSQc) at Week 48 in Q4W Arm | Week 48 | The HIVTSQ for total treatment satisfaction score is computed with 1-11 items. These 1-11 items are summed to produce a score with a possible range of -33 to 33. The item 12 in the scale will be calculated as an individual score.The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores will be imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score should not be computed and will remain missing.LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. Data has been presented with respect to actual treatment received to the participants |
| Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using General Acceptance Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire | Baseline and at Weeks 8, 24 and 48 | The ACCEPT questionnaire is a generic medication acceptance measure assessing how participants weigh advantages and disadvantages of long-term medication.The questionnaire consists of 25 items that capture six dimensions.3 questions that focus on general acceptance of study medication will be analyzed.Items on the scale are rated as 1-5 scores:1:totally disagree,2:somewhat disagree,3:somewhat agree, 4:totally agree and 5:I don't know.Total score of the dimension is calculated as the mean of the recoded items of the dimension and then linearly transformed to be on a scale from 0 to 100:score:Total Score=(mean of the recoded items in the dimension minus1)divided by2\*100.LOCF was used as primary method of analysis.Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI.Baseline value is defined as the latest pre-treatment assessment with a non-missing value.Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value |
| Change From 4b in Tolerability of Injection at Week 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm | Weeks 4b, 5, 40 and 41 | The NRS questionnaire is used to assess the tolerability of injections in CAB LA+RPV LA arm only. The questionnaire consists of one single question and will assess maximum level of pain experienced with the most recent injections ranking from no pain (0) to extreme pain (10). Missing scores was imputed using LOCF. |
| Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Baseline and Weeks 4b, 24 and 44 | HIVTSQc is a 12 item questionnaire. The individual treatment change item scores on HIVTSQc scale are rated as +3 ('much more satisfied', 'much more convenient', 'much more flexible',etc.) to -3 ('much less satisfied', 'much less convenient', 'much less flexible', etc.). The higher the score, the greater the improvement in satisfaction with each aspect of treatment and the lower the score, the greater the deterioration in satisfaction with each aspect of treatment. LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. |
| Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Weeks 5, 41 and 48 | The PIN questionnaire explores the bother of pain at the injection site and injection site reactions(ISR), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections.This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial.Scores range from 1 to 5, and questions are phrased in such a way as to ensure that 1 always equated with the most favourable perception of vaccination, and 5 the most unfavourable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.The score of a domain is calculated as the mean of all items with the domain.Higher scores represent worse perception of injection. LOCF was used as primary method of analysis |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Different Demographic Parameters for Inter-subject Variability | Upto Week 48 | Blood samples were planned to be collected at indicated time points for PK analysis of CAB LA and RPV LA. Demographic parameters including, but not limited to, age, sex, race, body weight, body mass index, and relevant laboratory parameters were planned to be evaluated as potential predictors of inter subject variability for pharmacokinetic parameters. |
Countries
Argentina, Australia, Canada, France, Germany, Italy, Mexico, Russia, South Africa, South Korea, Spain, Sweden, United States
Participant flow
Recruitment details
This was a phase III, randomized, open-label, active-controlled, multi-center, parallel-group, non-inferiority study to evaluate the antiviral activity and safety of two long-acting (LA) injectable drugs, cabotegravir (CAB) plus rilpivirine (RPV) when compared to current standard of care conducted in virologically suppressed human immunodeficiency.
Pre-assignment details
A total of 618 participants were enrolled in the study. Two randomized participants did not receive study treatment. A total of 616 participants contributed to the Intent-to-treat exposed Population and Safety Population. The results presented are based on Week 48 primary analysis.
Participants by arm
| Arm | Count |
|---|---|
| CAB LA+RPV LA (Q4W) During Maintenance phase (Day 1-Week 52), participants received oral CAB 30 milligram (mg)+RPV 25 mg once daily from Day 1 for 4 weeks. At Week 4B, the participants were given the last dose of oral CAB+RPV and the first dose of CAB LA 600 mg+RPV LA 900 mg injections within 2 hours of the final oral dose. Participants received intramuscular (IM) injections of CAB LA 400 mg and RPV LA 600 mg every four weeks (Q4W) through Week 52. After completion of Maintenance phase, participants who chose to enter Extension phase continued to receive both CAB LA and RPV LA. Participants withdrawn from study treatment who received at least one CAB LA+RPV LA injection were required to enter a 52-week long term follow-up period | 308 |
| Current ART During Maintenance phase (Day 1 - Week 52), participants continued to receive current antiretroviral therapy (ART) (protease inhibitor \[PI\] or integrase inhibitor \[INI\] or non-nucleoside reverse transcriptase inhibitor \[NNRTI\]) plus 2 NRTIs for 52 weeks. After completion of the Maintenance phase, participants who chose to enter the Extension phase switched to CAB LA+RPV LA | 308 |
| Total | 616 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 13 | 5 |
| Overall Study | Lack of Efficacy | 3 | 4 |
| Overall Study | Lost to Follow-up | 1 | 1 |
| Overall Study | Ongoing | 1 | 0 |
| Overall Study | Physician Decision | 2 | 0 |
| Overall Study | Protocol-specified withdrawal criterion | 1 | 0 |
| Overall Study | Protocol Violation | 5 | 3 |
| Overall Study | Withdrawal by Subject | 1 | 5 |
Baseline characteristics
| Characteristic | CAB LA+RPV LA (Q4W) | Current ART | Total |
|---|---|---|---|
| Age, Continuous | 41.6 Years STANDARD_DEVIATION 9.99 | 43.2 Years STANDARD_DEVIATION 11.43 | 42.4 Years STANDARD_DEVIATION 10.76 |
| Race/Ethnicity, Customized AI or AN & Black/African American | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized AI or AN & Black/African American & White | 1 Participants | 1 Participants | 2 Participants |
| Race/Ethnicity, Customized American Indian (AI) or Alaska Native (AN) | 8 Participants | 8 Participants | 16 Participants |
| Race/Ethnicity, Customized Asian-Central South Asian Heritage | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian-Japanese/East/South-East Asian Heritage | 21 Participants | 13 Participants | 34 Participants |
| Race/Ethnicity, Customized Black/African American or White | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Black or African American | 62 Participants | 77 Participants | 139 Participants |
| Race/Ethnicity, Customized Native Hawaiian or other Pacific Islander | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized White | 214 Participants | 207 Participants | 421 Participants |
| Sex: Female, Male Female | 99 Participants | 104 Participants | 203 Participants |
| Sex: Female, Male Male | 209 Participants | 204 Participants | 413 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 308 | 1 / 308 |
| other Total, other adverse events | 263 / 308 | 117 / 308 |
| serious Total, serious adverse events | 13 / 308 | 14 / 308 |
Outcome results
Primary
Number of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48
Number of participants with virologic failure endpoint (HIV-1 RNA\>=50 c/mL) as per Food and Drug Administration (FDA) snapshot algorithm at Week 48 was assessed to demonstrate the non-inferior antiviral activity of switching to intramuscular (IM) CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-1 RNA \>=50 copies/mL per snapshot algorithm was determined by the last available on-treatment HIV-1 RNA measurement within the analysis visit window of interest.
Time frame: Week 48
Population: Intent-to treat exposed (ITT-E) participants included all randomized participants who received at least one dose of Investigational Product (IP) during the maintenance phase. Participants were analyzed according to the randomized treatment regardless of what treatment actually received.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48 | 5 Participants |
| Current ART | Number of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48 | 3 Participants |
95% CI: [-1.2, 2.5]
Secondary
Absolute Values for CD4+ Lymphocyte Count at Week 48
Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to current ART.
Time frame: Week 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for CD4+ Lymphocyte Count at Week 48 | 685.3 Cells per cubic millimeter | Standard Deviation 262.97 |
| Current ART | Absolute Values for CD4+ Lymphocyte Count at Week 48 | 716.7 Cells per cubic millimeter | Standard Deviation 292.85 |
Secondary
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin
Blood samples were collected for the analysis of clinical chemistry parameter-albumin at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 20, n=277, 302 | 43.4 Grams per liter | Standard Deviation 2.72 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 8, n=229, 303 | 43.8 Grams per liter | Standard Deviation 3.06 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 24, n=284, 299 | 43.4 Grams per liter | Standard Deviation 2.74 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 44, n=275, 293 | 43.7 Grams per liter | Standard Deviation 2.78 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 28, n=267, 296 | 43.6 Grams per liter | Standard Deviation 2.85 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 12, n=295, 299 | 43.6 Grams per liter | Standard Deviation 2.99 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 32, n=275, 294 | 43.5 Grams per liter | Standard Deviation 2.83 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 4, n=301, 303 | 43.7 Grams per liter | Standard Deviation 2.88 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 36, n=273, 292 | 43.3 Grams per liter | Standard Deviation 2.82 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 16, n=284, 298 | 43.5 Grams per liter | Standard Deviation 2.77 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 40, n=270, 293 | 43.7 Grams per liter | Standard Deviation 2.72 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 48, n=265, 292 | 43.8 Grams per liter | Standard Deviation 2.74 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Baseline (Day 1), n=308, 308 | 44.2 Grams per liter | Standard Deviation 3.12 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 48, n=265, 292 | 44.0 Grams per liter | Standard Deviation 2.92 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 44, n=275, 293 | 43.5 Grams per liter | Standard Deviation 3.02 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Baseline (Day 1), n=308, 308 | 44.3 Grams per liter | Standard Deviation 3.19 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 4, n=301, 303 | 43.8 Grams per liter | Standard Deviation 2.87 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 8, n=229, 303 | 43.7 Grams per liter | Standard Deviation 3.17 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 12, n=295, 299 | 43.9 Grams per liter | Standard Deviation 3.12 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 16, n=284, 298 | 43.5 Grams per liter | Standard Deviation 3.12 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 20, n=277, 302 | 43.5 Grams per liter | Standard Deviation 3.07 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 24, n=284, 299 | 43.5 Grams per liter | Standard Deviation 3.02 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 28, n=267, 296 | 43.3 Grams per liter | Standard Deviation 3.07 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 32, n=275, 294 | 43.4 Grams per liter | Standard Deviation 3.25 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 36, n=273, 292 | 43.4 Grams per liter | Standard Deviation 3.07 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 40, n=270, 293 | 43.4 Grams per liter | Standard Deviation 3.04 |
Secondary
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance
Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance at indicated timepoints. Glomerular filtration rate (GFR) will be estimated by the central laboratory using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 8, n=227, 303 | 100.1 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.19 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 28, n=267, 296 | 98.5 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.66 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 16, n=284, 297 | 100.5 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.26 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 32, n=274, 294 | 99.1 Milliliter per minute per 1.73meter^2 | Standard Deviation 16.89 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 4, n=301, 301 | 98.7 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.26 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 36, n=273, 292 | 99.0 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.19 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 20, n=277, 302 | 99.4 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.37 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 40, n=268, 293 | 98.5 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.32 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 12, n=295, 297 | 100.9 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.72 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 44, n=274, 293 | 98.2 Milliliter per minute per 1.73meter^2 | Standard Deviation 16.96 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 24, n=283, 298 | 98.9 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.04 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 48, n=264, 291 | 97.6 Milliliter per minute per 1.73meter^2 | Standard Deviation 16.97 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Baseline, n=308, 308 | 100.5 Milliliter per minute per 1.73meter^2 | Standard Deviation 18.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 48, n=264, 291 | 99.3 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.09 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Baseline, n=308, 308 | 101.1 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.72 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 4, n=301, 301 | 98.9 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.93 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 8, n=227, 303 | 99.5 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.59 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 12, n=295, 297 | 99.2 Milliliter per minute per 1.73meter^2 | Standard Deviation 18.34 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 16, n=284, 297 | 99.0 Milliliter per minute per 1.73meter^2 | Standard Deviation 18.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 20, n=277, 302 | 98.7 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.73 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 24, n=283, 298 | 98.9 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.44 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 28, n=267, 296 | 99.0 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.33 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 32, n=274, 294 | 98.4 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.54 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 36, n=273, 292 | 98.6 Milliliter per minute per 1.73meter^2 | Standard Deviation 16.85 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 40, n=268, 293 | 98.5 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.37 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance | Week 44, n=274, 293 | 99.0 Milliliter per minute per 1.73meter^2 | Standard Deviation 17.39 |
Secondary
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase
Blood samples were collected for the analysis of clinical chemistry parameter-lipase at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 8, n=227, 303 | 30.6 Units per liter | Standard Deviation 22.7 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 28, n=267, 297 | 32.9 Units per liter | Standard Deviation 27.42 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 16, n=285, 299 | 33.8 Units per liter | Standard Deviation 30.49 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 32, n=274, 294 | 35.7 Units per liter | Standard Deviation 60.63 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 4, n=301, 303 | 35.3 Units per liter | Standard Deviation 52.73 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 36, n=273, 292 | 36.2 Units per liter | Standard Deviation 51.58 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 20, n=278, 302 | 31.0 Units per liter | Standard Deviation 21.73 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 40, n=269, 293 | 35.7 Units per liter | Standard Deviation 36.06 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 12, n=294, 297 | 33.2 Units per liter | Standard Deviation 27.92 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 44, n=274, 293 | 33.3 Units per liter | Standard Deviation 26.29 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 24, n=283, 299 | 33.1 Units per liter | Standard Deviation 24.09 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 48, n=264, 290 | 34.3 Units per liter | Standard Deviation 30.97 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Baseline, n=308, 308 | 30.5 Units per liter | Standard Deviation 22.88 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 48, n=264, 290 | 32.4 Units per liter | Standard Deviation 20.4 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Baseline, n=308, 308 | 30.8 Units per liter | Standard Deviation 19.12 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 4, n=301, 303 | 32.3 Units per liter | Standard Deviation 23.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 8, n=227, 303 | 31.9 Units per liter | Standard Deviation 20.71 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 12, n=294, 297 | 30.0 Units per liter | Standard Deviation 18.06 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 16, n=285, 299 | 33.9 Units per liter | Standard Deviation 34.69 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 20, n=278, 302 | 31.6 Units per liter | Standard Deviation 28.88 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 24, n=283, 299 | 33.8 Units per liter | Standard Deviation 29.69 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 28, n=267, 297 | 33.1 Units per liter | Standard Deviation 19.69 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 32, n=274, 294 | 33.8 Units per liter | Standard Deviation 21.64 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 36, n=273, 292 | 31.6 Units per liter | Standard Deviation 18.46 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 40, n=269, 293 | 31.4 Units per liter | Standard Deviation 15.8 |
| Current ART | Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 44, n=274, 293 | 33.3 Units per liter | Standard Deviation 20.44 |
Secondary
Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK)
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 40, n=270, 293 | 66.2 International units per liter | Standard Deviation 17.58 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 16, n=284, 298 | 23.7 International units per liter | Standard Deviation 22.32 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 44, n=275, 293 | 66.1 International units per liter | Standard Deviation 18.34 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 44, n=275, 293 | 21.6 International units per liter | Standard Deviation 13.1 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 48, n=265, 292 | 66.5 International units per liter | Standard Deviation 18.84 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 4, n=301, 303 | 24.4 International units per liter | Standard Deviation 15.6 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Baseline (Day 1), n=308, 308 | 23.9 International units per liter | Standard Deviation 11.31 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 48, n=265, 292 | 21.8 International units per liter | Standard Deviation 13.54 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 4, n=301, 303 | 23.2 International units per liter | Standard Deviation 11.77 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 20, n=277, 302 | 23.1 International units per liter | Standard Deviation 22.49 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 8, n=229, 303 | 24.3 International units per liter | Standard Deviation 19.49 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Baseline (Day 1), n=308, 308 | 76.6 International units per liter | Standard Deviation 28.2 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 12, n=295, 299 | 26.1 International units per liter | Standard Deviation 64.69 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 44, n=275, 293 | 245.5 International units per liter | Standard Deviation 1189.35 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 16, n=284, 298 | 24.1 International units per liter | Standard Deviation 18.2 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 4, n=301, 303 | 70.4 International units per liter | Standard Deviation 22.75 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 20, n=277, 302 | 23.5 International units per liter | Standard Deviation 15.23 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 24, n=284, 299 | 26.3 International units per liter | Standard Deviation 62.05 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 24, n=284, 298 | 24.2 International units per liter | Standard Deviation 22.89 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 8, n=229, 303 | 68.9 International units per liter | Standard Deviation 21.98 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 28, n=267, 296 | 22.2 International units per liter | Standard Deviation 8.72 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 8, n=229, 303 | 24.0 International units per liter | Standard Deviation 16.85 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 32, n=275, 294 | 22.8 International units per liter | Standard Deviation 13.71 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 12, n=295, 299 | 68.9 International units per liter | Standard Deviation 24.79 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 36, n=273, 292 | 23.0 International units per liter | Standard Deviation 11.27 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 28, n=267, 296 | 21.1 International units per liter | Standard Deviation 12.13 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 40, n=270, 293 | 23.8 International units per liter | Standard Deviation 14.96 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 16, n=284, 298 | 67.9 International units per liter | Standard Deviation 19.76 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 44, n=275, 293 | 22.9 International units per liter | Standard Deviation 14.82 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Baseline (Day 1), n=308, 308 | 23.8 International units per liter | Standard Deviation 13.47 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST Week 48, n=265, 292 | 22.9 International units per liter | Standard Deviation 10.35 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 20, n=277, 302 | 67.6 International units per liter | Standard Deviation 18.72 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Baseline (Day 1), n=308, 308 | 196.6 International units per liter | Standard Deviation 367.3 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 32, n=275, 294 | 21.8 International units per liter | Standard Deviation 12.56 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 4, n=301, 303 | 192.9 International units per liter | Standard Deviation 437.09 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 24, n=284, 299 | 68.1 International units per liter | Standard Deviation 19.15 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 8, n=229, 303 | 275.9 International units per liter | Standard Deviation 1064.72 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 12, n=295, 299 | 29.0 International units per liter | Standard Deviation 114.25 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 12, n=295, 299 | 200.7 International units per liter | Standard Deviation 484.08 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 28, n=267, 296 | 67.6 International units per liter | Standard Deviation 18.89 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 16, n=284, 298 | 253.5 International units per liter | Standard Deviation 849.45 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 36, n=273, 292 | 23.2 International units per liter | Standard Deviation 24.94 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 20, n=277, 302 | 228.4 International units per liter | Standard Deviation 570.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 32, n=275, 294 | 66.6 International units per liter | Standard Deviation 19.14 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 24, n=284, 299 | 193.1 International units per liter | Standard Deviation 444.27 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 48, n=265, 292 | 198.8 International units per liter | Standard Deviation 398.14 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 28, n=267, 296 | 168.8 International units per liter | Standard Deviation 163.54 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 36, n=273, 292 | 66.8 International units per liter | Standard Deviation 20.68 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 32, n=275, 294 | 216.5 International units per liter | Standard Deviation 593.1 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 40, n=270, 293 | 24.5 International units per liter | Standard Deviation 37.39 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 36, n=273, 292 | 186.4 International units per liter | Standard Deviation 325.64 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 40, n=270, 293 | 235.1 International units per liter | Standard Deviation 624.03 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 36, n=273, 292 | 150.7 International units per liter | Standard Deviation 134.4 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 40, n=270, 293 | 160.7 International units per liter | Standard Deviation 179.64 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 44, n=275, 293 | 149.9 International units per liter | Standard Deviation 148.23 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 48, n=265, 292 | 179.0 International units per liter | Standard Deviation 331.51 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Baseline (Day 1), n=308, 308 | 22.4 International units per liter | Standard Deviation 12.9 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 4, n=301, 303 | 22.3 International units per liter | Standard Deviation 11.1 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 8, n=229, 303 | 24.0 International units per liter | Standard Deviation 29.86 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 12, n=295, 299 | 22.7 International units per liter | Standard Deviation 13.48 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 16, n=284, 298 | 21.8 International units per liter | Standard Deviation 11.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 20, n=277, 302 | 21.2 International units per liter | Standard Deviation 10.5 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 24, n=284, 299 | 21.6 International units per liter | Standard Deviation 12.64 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 28, n=267, 296 | 22.1 International units per liter | Standard Deviation 14.62 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 32, n=275, 294 | 21.8 International units per liter | Standard Deviation 12.09 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 36, n=273, 292 | 22.3 International units per liter | Standard Deviation 12.17 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 40, n=270, 293 | 22.1 International units per liter | Standard Deviation 12.78 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 44, n=275, 293 | 22.1 International units per liter | Standard Deviation 13.67 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALT, Week 48, n=265, 292 | 21.7 International units per liter | Standard Deviation 11.08 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Baseline (Day 1), n=308, 308 | 77.5 International units per liter | Standard Deviation 26.77 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 4, n=301, 303 | 75.7 International units per liter | Standard Deviation 25.58 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 8, n=229, 303 | 78.8 International units per liter | Standard Deviation 32.4 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 12, n=295, 299 | 78.6 International units per liter | Standard Deviation 28.87 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 16, n=284, 298 | 77.3 International units per liter | Standard Deviation 27.21 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 20, n=277, 302 | 76.7 International units per liter | Standard Deviation 25.48 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 24, n=284, 299 | 77.5 International units per liter | Standard Deviation 26.36 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 28, n=267, 296 | 77.2 International units per liter | Standard Deviation 26.72 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 32, n=275, 294 | 75.8 International units per liter | Standard Deviation 25.56 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 36, n=273, 292 | 76.4 International units per liter | Standard Deviation 25.93 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 40, n=270, 293 | 76.2 International units per liter | Standard Deviation 26.08 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 44, n=275, 293 | 76.8 International units per liter | Standard Deviation 25.82 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | ALP, Week 48, n=265, 292 | 77.1 International units per liter | Standard Deviation 26.39 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Baseline (Day 1), n=308, 308 | 22.5 International units per liter | Standard Deviation 10.21 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 4, n=301, 303 | 22.7 International units per liter | Standard Deviation 10.93 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 8, n=229, 303 | 22.5 International units per liter | Standard Deviation 12.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 12, n=295, 299 | 23.2 International units per liter | Standard Deviation 10.61 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 16, n=284, 298 | 22.5 International units per liter | Standard Deviation 8.59 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 20, n=277, 302 | 22.0 International units per liter | Standard Deviation 6.83 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 24, n=284, 298 | 22.5 International units per liter | Standard Deviation 9.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 28, n=267, 296 | 22.9 International units per liter | Standard Deviation 9.61 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 32, n=275, 294 | 23.2 International units per liter | Standard Deviation 12.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 36, n=273, 292 | 22.6 International units per liter | Standard Deviation 7.18 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 40, n=270, 293 | 22.5 International units per liter | Standard Deviation 7.79 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST, Week 44, n=275, 293 | 22.6 International units per liter | Standard Deviation 10.26 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | AST Week 48, n=265, 292 | 23.2 International units per liter | Standard Deviation 9.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Baseline (Day 1), n=308, 308 | 160.8 International units per liter | Standard Deviation 367.57 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 4, n=301, 303 | 190.6 International units per liter | Standard Deviation 472.57 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 8, n=229, 303 | 145.4 International units per liter | Standard Deviation 141.19 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 12, n=295, 299 | 177.0 International units per liter | Standard Deviation 321.29 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 16, n=284, 298 | 167.5 International units per liter | Standard Deviation 286.9 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 20, n=277, 302 | 144.5 International units per liter | Standard Deviation 133.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 24, n=284, 299 | 161.2 International units per liter | Standard Deviation 241.73 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 28, n=267, 296 | 182.7 International units per liter | Standard Deviation 420.44 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK) | CK, Week 32, n=275, 294 | 195.9 International units per liter | Standard Deviation 489.99 |
Secondary
Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 32, n=275, 294 | 9.8 Micromoles per liter | Standard Deviation 4.36 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 24, n=284, 298 | 2.2 Micromoles per liter | Standard Deviation 0.99 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 4, n=301, 303 | 9.1 Micromoles per liter | Standard Deviation 3.98 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 28, n=267, 296 | 2.1 Micromoles per liter | Standard Deviation 0.94 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 36, n=273, 292 | 9.3 Micromoles per liter | Standard Deviation 3.79 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 32, n=275, 294 | 2.1 Micromoles per liter | Standard Deviation 1 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 16, n=284, 298 | 10.0 Micromoles per liter | Standard Deviation 10.71 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 36, n=273, 292 | 2.1 Micromoles per liter | Standard Deviation 1.11 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 40, n=270, 293 | 9.6 Micromoles per liter | Standard Deviation 4.07 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 40, n=270, 293 | 2.1 Micromoles per liter | Standard Deviation 1.08 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Baseline (Day 1), n=308, 308 | 9.9 Micromoles per liter | Standard Deviation 9.71 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 48, n=265, 292 | 2.2 Micromoles per liter | Standard Deviation 0.92 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 44, n=275, 293 | 9.6 Micromoles per liter | Standard Deviation 4.19 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Baseline (Day 1), n=308, 308 | 79.05 Micromoles per liter | Standard Deviation 16.38 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 20, n=277, 302 | 9.7 Micromoles per liter | Standard Deviation 4.28 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 4, n=301, 301 | 80.17 Micromoles per liter | Standard Deviation 15.464 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 48, n=265, 292 | 9.7 Micromoles per liter | Standard Deviation 4.24 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 8, n=229, 303 | 78.79 Micromoles per liter | Standard Deviation 16.122 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Baseline (Day 1), n=308, 308 | 2.4 Micromoles per liter | Standard Deviation 1.35 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 12, n=295, 299 | 78.65 Micromoles per liter | Standard Deviation 16.534 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 8, n=229, 303 | 9.3 Micromoles per liter | Standard Deviation 4.05 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 16, n=284, 298 | 78.72 Micromoles per liter | Standard Deviation 15.606 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 4, n=301, 303 | 2.3 Micromoles per liter | Standard Deviation 1.04 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 20, n=277, 302 | 79.75 Micromoles per liter | Standard Deviation 15.695 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 24, n=284, 298 | 9.3 Micromoles per liter | Standard Deviation 3.9 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 24, n=284, 298 | 80.15 Micromoles per liter | Standard Deviation 18.478 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 8, n=229, 303 | 2.3 Micromoles per liter | Standard Deviation 1.08 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 28, n=267, 296 | 80.42 Micromoles per liter | Standard Deviation 16.335 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 44, n=275, 293 | 2.2 Micromoles per liter | Standard Deviation 0.95 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 32, n=275, 294 | 79.65 Micromoles per liter | Standard Deviation 15.044 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 12, n=295, 299 | 2.2 Micromoles per liter | Standard Deviation 1.03 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 36, n=273, 292 | 79.73 Micromoles per liter | Standard Deviation 15.994 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 28, n=267, 296 | 9.8 Micromoles per liter | Standard Deviation 3.99 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 40, n=270, 293 | 80.28 Micromoles per liter | Standard Deviation 15.856 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 16, n=284, 298 | 2.5 Micromoles per liter | Standard Deviation 4.98 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 44, n=275, 293 | 79.98 Micromoles per liter | Standard Deviation 15.775 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 12, n=295, 299 | 9.3 Micromoles per liter | Standard Deviation 4.45 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 48, n=265, 292 | 80.77 Micromoles per liter | Standard Deviation 16.456 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 20, n=277, 302 | 2.2 Micromoles per liter | Standard Deviation 0.95 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 48, n=265, 292 | 78.65 Micromoles per liter | Standard Deviation 16.204 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 44, n=275, 293 | 2.2 Micromoles per liter | Standard Deviation 1.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Baseline (Day 1), n=308, 308 | 9.2 Micromoles per liter | Standard Deviation 6.39 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 4, n=301, 303 | 8.9 Micromoles per liter | Standard Deviation 6.14 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 8, n=229, 303 | 9.4 Micromoles per liter | Standard Deviation 9.06 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 12, n=295, 299 | 9.3 Micromoles per liter | Standard Deviation 6.62 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 16, n=284, 298 | 9.1 Micromoles per liter | Standard Deviation 6.28 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 20, n=277, 302 | 9.3 Micromoles per liter | Standard Deviation 7.56 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 24, n=284, 298 | 9.4 Micromoles per liter | Standard Deviation 8.38 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 28, n=267, 296 | 9.1 Micromoles per liter | Standard Deviation 7.05 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 32, n=275, 294 | 9.3 Micromoles per liter | Standard Deviation 7.05 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 36, n=273, 292 | 9.2 Micromoles per liter | Standard Deviation 7.34 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 40, n=270, 293 | 9.5 Micromoles per liter | Standard Deviation 9.04 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 44, n=275, 293 | 9.7 Micromoles per liter | Standard Deviation 8.49 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Baseline (Day 1), n=308, 308 | 2.2 Micromoles per liter | Standard Deviation 1.25 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 4, n=301, 303 | 2.3 Micromoles per liter | Standard Deviation 1.27 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 8, n=229, 303 | 2.4 Micromoles per liter | Standard Deviation 3.96 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 12, n=295, 299 | 2.3 Micromoles per liter | Standard Deviation 1.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 16, n=284, 298 | 2.1 Micromoles per liter | Standard Deviation 1.08 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 20, n=277, 302 | 2.0 Micromoles per liter | Standard Deviation 1.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 24, n=284, 298 | 2.1 Micromoles per liter | Standard Deviation 1.26 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 28, n=267, 296 | 2.0 Micromoles per liter | Standard Deviation 1.28 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 32, n=275, 294 | 2.0 Micromoles per liter | Standard Deviation 1.22 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 36, n=273, 292 | 2.1 Micromoles per liter | Standard Deviation 1.27 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 40, n=270, 293 | 2.1 Micromoles per liter | Standard Deviation 1.37 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 48, n=265, 292 | 2.2 Micromoles per liter | Standard Deviation 1.23 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Baseline (Day 1), n=308, 308 | 77.83 Micromoles per liter | Standard Deviation 16.497 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 4, n=301, 301 | 79.47 Micromoles per liter | Standard Deviation 16.284 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 8, n=229, 303 | 79.22 Micromoles per liter | Standard Deviation 16.824 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 12, n=295, 299 | 79.50 Micromoles per liter | Standard Deviation 17.191 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 16, n=284, 298 | 79.51 Micromoles per liter | Standard Deviation 17.171 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 20, n=277, 302 | 79.62 Micromoles per liter | Standard Deviation 16.909 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 24, n=284, 298 | 79.05 Micromoles per liter | Standard Deviation 16.673 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 28, n=267, 296 | 79.35 Micromoles per liter | Standard Deviation 16.574 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 32, n=275, 294 | 79.69 Micromoles per liter | Standard Deviation 16.634 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 36, n=273, 292 | 79.34 Micromoles per liter | Standard Deviation 16.527 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 40, n=270, 293 | 79.42 Micromoles per liter | Standard Deviation 16.856 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 44, n=275, 293 | 79.16 Micromoles per liter | Standard Deviation 16.583 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 48, n=265, 292 | 9.5 Micromoles per liter | Standard Deviation 6.36 |
Secondary
Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48
Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 40, n=270, 293 | 23.1 Millimoles per liter | Standard Deviation 2.27 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 24, n=284, 299 | 1.082 Millimoles per liter | Standard Deviation 0.1788 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 36, n=273, 292 | 104.8 Millimoles per liter | Standard Deviation 2.18 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 28, n=267, 296 | 1.072 Millimoles per liter | Standard Deviation 0.1714 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Baseline (Day 1), n=308, 308 | 22.7 Millimoles per liter | Standard Deviation 2.33 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 32, n=275, 294 | 1.061 Millimoles per liter | Standard Deviation 0.173 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 40, n=270, 293 | 104.7 Millimoles per liter | Standard Deviation 2.22 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 36, n=273, 292 | 1.052 Millimoles per liter | Standard Deviation 0.17 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 44, n=275, 293 | 23.0 Millimoles per liter | Standard Deviation 2.19 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 40, n=270, 293 | 1.065 Millimoles per liter | Standard Deviation 0.1789 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 44, n=275, 293 | 104.6 Millimoles per liter | Standard Deviation 2.1 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 44, n=275, 293 | 1.066 Millimoles per liter | Standard Deviation 0.1798 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 20, n=277, 302 | 22.9 Millimoles per liter | Standard Deviation 2.16 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 48, n=265, 292 | 1.077 Millimoles per liter | Standard Deviation 0.1816 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 48, n=265, 292 | 104.4 Millimoles per liter | Standard Deviation 2.38 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Baseline (Day 1), n=308, 308 | 4.16 Millimoles per liter | Standard Deviation 0.281 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 48, n=265, 292 | 22.7 Millimoles per liter | Standard Deviation 2.29 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 4, n=301, 303 | 4.21 Millimoles per liter | Standard Deviation 0.307 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Baseline (Day 1), n=301, 299 | 5.00 Millimoles per liter | Standard Deviation 0.714 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 8, n=229, 303 | 4.16 Millimoles per liter | Standard Deviation 0.296 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 8, n=229, 303 | 23.1 Millimoles per liter | Standard Deviation 2.17 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 12, n=295, 299 | 4.19 Millimoles per liter | Standard Deviation 0.33 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 4, n=216, 226 | 5.17 Millimoles per liter | Standard Deviation 0.747 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 16, n=284, 298 | 4.18 Millimoles per liter | Standard Deviation 0.316 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Baseline (Day 1), n=308, 308 | 103.8 Millimoles per liter | Standard Deviation 2.03 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 20, n=277, 302 | 4.19 Millimoles per liter | Standard Deviation 0.311 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 8, n=153, 218 | 5.16 Millimoles per liter | Standard Deviation 0.99 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 24, n=284, 298 | 4.18 Millimoles per liter | Standard Deviation 0.287 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 24, n=284, 298 | 22.9 Millimoles per liter | Standard Deviation 2.31 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 28, n=267, 296 | 4.19 Millimoles per liter | Standard Deviation 0.346 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 12, n=206, 221 | 5.19 Millimoles per liter | Standard Deviation 0.965 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 32, n=275, 294 | 4.18 Millimoles per liter | Standard Deviation 0.368 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 4, n=301, 303 | 104.3 Millimoles per liter | Standard Deviation 2.13 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 36, n=273, 292 | 4.19 Millimoles per liter | Standard Deviation 0.326 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 16, n=209, 216 | 5.22 Millimoles per liter | Standard Deviation 1.163 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 40, n=270, 293 | 4.20 Millimoles per liter | Standard Deviation 0.301 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 44, n=275, 293 | 139.4 Millimoles per liter | Standard Deviation 1.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 44, n=275, 293 | 4.21 Millimoles per liter | Standard Deviation 0.323 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 20, n=194, 221 | 5.20 Millimoles per liter | Standard Deviation 0.736 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 48, n=265, 292 | 4.15 Millimoles per liter | Standard Deviation 0.271 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 8, n=229, 303 | 104.3 Millimoles per liter | Standard Deviation 2.26 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Baseline (Day 1), n=308, 308 | 139.0 Millimoles per liter | Standard Deviation 1.91 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 24, n=215, 229 | 5.24 Millimoles per liter | Standard Deviation 0.81 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 4, n=301, 303 | 139.3 Millimoles per liter | Standard Deviation 1.7 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 28, n=267, 296 | 22.7 Millimoles per liter | Standard Deviation 2.42 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 8, n=229, 303 | 139.1 Millimoles per liter | Standard Deviation 1.98 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 28, n=190, 226 | 5.16 Millimoles per liter | Standard Deviation 0.697 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 12, n=295, 299 | 139.2 Millimoles per liter | Standard Deviation 1.84 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 12, n=295, 299 | 104.2 Millimoles per liter | Standard Deviation 2.27 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 16, n=284, 298 | 139.1 Millimoles per liter | Standard Deviation 1.98 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 32, n=194, 219 | 5.33 Millimoles per liter | Standard Deviation 1.042 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 20, n=277, 302 | 139.2 Millimoles per liter | Standard Deviation 1.87 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 12, n=295, 299 | 23.2 Millimoles per liter | Standard Deviation 2.14 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 24, n=284, 299 | 139.3 Millimoles per liter | Standard Deviation 1.88 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 36, n=191, 220 | 5.19 Millimoles per liter | Standard Deviation 0.777 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 28, n=267, 296 | 139.5 Millimoles per liter | Standard Deviation 1.77 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 16, n=284, 298 | 104.5 Millimoles per liter | Standard Deviation 2.21 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 32, n=275, 294 | 139.3 Millimoles per liter | Standard Deviation 1.75 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 40, n=195, 218 | 5.30 Millimoles per liter | Standard Deviation 0.797 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 36, n=273, 292 | 139.4 Millimoles per liter | Standard Deviation 1.79 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 32, n=275, 294 | 22.6 Millimoles per liter | Standard Deviation 2.15 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 40, n=270, 293 | 139.4 Millimoles per liter | Standard Deviation 1.93 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 44, n=193, 213 | 5.22 Millimoles per liter | Standard Deviation 0.887 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 48, n=265, 292 | 139.4 Millimoles per liter | Standard Deviation 1.94 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 20, n=277, 302 | 104.7 Millimoles per liter | Standard Deviation 2.41 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Baseline (Day 1), n=308, 308 | 5.23 Millimoles per liter | Standard Deviation 1.546 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 48, n=242, 277 | 5.08 Millimoles per liter | Standard Deviation 0.614 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 4, n=301, 303 | 5.24 Millimoles per liter | Standard Deviation 1.495 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 4, n=301, 303 | 23.7 Millimoles per liter | Standard Deviation 2.49 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 8, n=229, 303 | 5.32 Millimoles per liter | Standard Deviation 1.64 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Baseline (Day 1), n=308, 308 | 1.042 Millimoles per liter | Standard Deviation 0.1771 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 12, n=295, 299 | 5.38 Millimoles per liter | Standard Deviation 1.612 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 24, n=284, 299 | 104.5 Millimoles per liter | Standard Deviation 2.36 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 16, n=284, 298 | 5.30 Millimoles per liter | Standard Deviation 1.662 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 4, n=301, 303 | 1.110 Millimoles per liter | Standard Deviation 0.1793 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 20, n=277, 302 | 5.37 Millimoles per liter | Standard Deviation 1.631 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 36, n=273, 292 | 22.8 Millimoles per liter | Standard Deviation 2.19 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 24, n=284, 299 | 5.49 Millimoles per liter | Standard Deviation 1.749 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 8, n=229, 303 | 1.097 Millimoles per liter | Standard Deviation 0.1944 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 28, n=267, 296 | 5.39 Millimoles per liter | Standard Deviation 1.756 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 28, n=267, 296 | 104.8 Millimoles per liter | Standard Deviation 2.19 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 32, n=275, 294 | 5.44 Millimoles per liter | Standard Deviation 1.624 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 12, n=295, 299 | 1.080 Millimoles per liter | Standard Deviation 0.1872 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 36, n=273, 292 | 5.26 Millimoles per liter | Standard Deviation 1.664 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 16, n=284, 298 | 22.9 Millimoles per liter | Standard Deviation 2.16 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 40, n=270, 293 | 5.47 Millimoles per liter | Standard Deviation 1.593 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 16, n=284, 298 | 1.081 Millimoles per liter | Standard Deviation 0.1796 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 44, n=275, 293 | 5.37 Millimoles per liter | Standard Deviation 1.531 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 32, n=275, 294 | 104.7 Millimoles per liter | Standard Deviation 2.5 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 48, n=265, 292 | 5.48 Millimoles per liter | Standard Deviation 1.648 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 20, n=277, 302 | 1.073 Millimoles per liter | Standard Deviation 0.1746 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 48, n=265, 292 | 5.21 Millimoles per liter | Standard Deviation 1.437 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Baseline (Day 1), n=308, 308 | 22.6 Millimoles per liter | Standard Deviation 2.24 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 4, n=301, 303 | 23.3 Millimoles per liter | Standard Deviation 2.27 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 8, n=229, 303 | 23.2 Millimoles per liter | Standard Deviation 2.47 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 12, n=295, 299 | 23.0 Millimoles per liter | Standard Deviation 2.36 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 16, n=284, 298 | 23.0 Millimoles per liter | Standard Deviation 2.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 20, n=277, 302 | 22.9 Millimoles per liter | Standard Deviation 2.29 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 24, n=284, 298 | 22.8 Millimoles per liter | Standard Deviation 2.41 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 28, n=267, 296 | 22.7 Millimoles per liter | Standard Deviation 2.27 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 32, n=275, 294 | 22.8 Millimoles per liter | Standard Deviation 2.34 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 36, n=273, 292 | 23.0 Millimoles per liter | Standard Deviation 2.26 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 40, n=270, 293 | 23.0 Millimoles per liter | Standard Deviation 2.45 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 44, n=275, 293 | 23.2 Millimoles per liter | Standard Deviation 2.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | CO2, Week 48, n=265, 292 | 22.9 Millimoles per liter | Standard Deviation 2.29 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Baseline (Day 1), n=308, 308 | 103.8 Millimoles per liter | Standard Deviation 2.39 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 4, n=301, 303 | 104.3 Millimoles per liter | Standard Deviation 2.22 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 8, n=229, 303 | 104.2 Millimoles per liter | Standard Deviation 2.4 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 12, n=295, 299 | 104.3 Millimoles per liter | Standard Deviation 2.24 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 16, n=284, 298 | 104.5 Millimoles per liter | Standard Deviation 2.28 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 20, n=277, 302 | 104.5 Millimoles per liter | Standard Deviation 2.38 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 24, n=284, 299 | 104.7 Millimoles per liter | Standard Deviation 2.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 28, n=267, 296 | 104.8 Millimoles per liter | Standard Deviation 2.36 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 32, n=275, 294 | 104.7 Millimoles per liter | Standard Deviation 2.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 36, n=273, 292 | 104.6 Millimoles per liter | Standard Deviation 2.36 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 40, n=270, 293 | 104.6 Millimoles per liter | Standard Deviation 2.61 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 44, n=275, 293 | 104.6 Millimoles per liter | Standard Deviation 2.27 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Chloride, Week 48, n=265, 292 | 104.1 Millimoles per liter | Standard Deviation 2.37 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Baseline (Day 1), n=301, 299 | 5.17 Millimoles per liter | Standard Deviation 0.988 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 4, n=216, 226 | 5.42 Millimoles per liter | Standard Deviation 1.25 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 8, n=153, 218 | 5.35 Millimoles per liter | Standard Deviation 1.037 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 12, n=206, 221 | 5.35 Millimoles per liter | Standard Deviation 1.091 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 16, n=209, 216 | 5.36 Millimoles per liter | Standard Deviation 1.317 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 20, n=194, 221 | 5.37 Millimoles per liter | Standard Deviation 1.209 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 24, n=215, 229 | 5.35 Millimoles per liter | Standard Deviation 0.84 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 28, n=190, 226 | 5.36 Millimoles per liter | Standard Deviation 0.876 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 32, n=194, 219 | 5.45 Millimoles per liter | Standard Deviation 1.102 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 36, n=191, 220 | 5.40 Millimoles per liter | Standard Deviation 1.507 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 40, n=195, 218 | 5.44 Millimoles per liter | Standard Deviation 1.227 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 44, n=193, 213 | 5.44 Millimoles per liter | Standard Deviation 1.317 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Glucose, Week 48, n=242, 277 | 5.22 Millimoles per liter | Standard Deviation 0.963 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Baseline (Day 1), n=308, 308 | 1.051 Millimoles per liter | Standard Deviation 0.1722 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 4, n=301, 303 | 1.066 Millimoles per liter | Standard Deviation 0.1773 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 8, n=229, 303 | 1.042 Millimoles per liter | Standard Deviation 0.1843 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 12, n=295, 299 | 1.062 Millimoles per liter | Standard Deviation 0.1922 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 16, n=284, 298 | 1.052 Millimoles per liter | Standard Deviation 0.1724 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 20, n=277, 302 | 1.061 Millimoles per liter | Standard Deviation 0.1873 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 24, n=284, 299 | 1.057 Millimoles per liter | Standard Deviation 0.1849 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 28, n=267, 296 | 1.053 Millimoles per liter | Standard Deviation 0.1741 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 32, n=275, 294 | 1.054 Millimoles per liter | Standard Deviation 0.1761 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 36, n=273, 292 | 1.049 Millimoles per liter | Standard Deviation 0.1798 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 40, n=270, 293 | 1.046 Millimoles per liter | Standard Deviation 0.1763 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 44, n=275, 293 | 1.052 Millimoles per liter | Standard Deviation 0.1902 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Phosphate, Week 48, n=265, 292 | 1.052 Millimoles per liter | Standard Deviation 0.1834 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Baseline (Day 1), n=308, 308 | 4.17 Millimoles per liter | Standard Deviation 0.314 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 4, n=301, 303 | 4.28 Millimoles per liter | Standard Deviation 0.352 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 8, n=229, 303 | 4.22 Millimoles per liter | Standard Deviation 0.393 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 12, n=295, 299 | 4.24 Millimoles per liter | Standard Deviation 0.332 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 16, n=284, 298 | 4.23 Millimoles per liter | Standard Deviation 0.321 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 20, n=277, 302 | 4.21 Millimoles per liter | Standard Deviation 0.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 24, n=284, 298 | 4.23 Millimoles per liter | Standard Deviation 0.337 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 28, n=267, 296 | 4.24 Millimoles per liter | Standard Deviation 0.391 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 32, n=275, 294 | 4.21 Millimoles per liter | Standard Deviation 0.341 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 36, n=273, 292 | 4.23 Millimoles per liter | Standard Deviation 0.345 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 40, n=270, 293 | 4.23 Millimoles per liter | Standard Deviation 0.322 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 44, n=275, 293 | 4.23 Millimoles per liter | Standard Deviation 0.359 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Potassium, Week 48, n=265, 292 | 4.16 Millimoles per liter | Standard Deviation 0.331 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Baseline (Day 1), n=308, 308 | 139.0 Millimoles per liter | Standard Deviation 1.76 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 4, n=301, 303 | 139.1 Millimoles per liter | Standard Deviation 1.87 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 8, n=229, 303 | 139.0 Millimoles per liter | Standard Deviation 1.8 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 12, n=295, 299 | 139.2 Millimoles per liter | Standard Deviation 1.85 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 16, n=284, 298 | 139.1 Millimoles per liter | Standard Deviation 1.96 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 20, n=277, 302 | 139.3 Millimoles per liter | Standard Deviation 1.81 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 24, n=284, 299 | 139.3 Millimoles per liter | Standard Deviation 1.96 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 28, n=267, 296 | 139.2 Millimoles per liter | Standard Deviation 2.01 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 32, n=275, 294 | 139.5 Millimoles per liter | Standard Deviation 1.84 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 36, n=273, 292 | 139.5 Millimoles per liter | Standard Deviation 2.15 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 44, n=275, 293 | 139.5 Millimoles per liter | Standard Deviation 1.93 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 48, n=265, 292 | 139.4 Millimoles per liter | Standard Deviation 1.83 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Baseline (Day 1), n=308, 308 | 5.22 Millimoles per liter | Standard Deviation 1.632 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 4, n=301, 303 | 5.28 Millimoles per liter | Standard Deviation 1.549 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 8, n=229, 303 | 5.22 Millimoles per liter | Standard Deviation 1.529 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 12, n=295, 299 | 5.30 Millimoles per liter | Standard Deviation 1.649 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 16, n=284, 298 | 5.41 Millimoles per liter | Standard Deviation 1.659 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 20, n=277, 302 | 5.33 Millimoles per liter | Standard Deviation 1.662 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 24, n=284, 299 | 5.36 Millimoles per liter | Standard Deviation 1.639 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 28, n=267, 296 | 5.24 Millimoles per liter | Standard Deviation 1.527 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 32, n=275, 294 | 5.29 Millimoles per liter | Standard Deviation 1.599 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 36, n=273, 292 | 5.20 Millimoles per liter | Standard Deviation 1.485 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 40, n=270, 293 | 5.30 Millimoles per liter | Standard Deviation 1.537 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Urea, Week 44, n=275, 293 | 5.26 Millimoles per liter | Standard Deviation 1.524 |
| Current ART | Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48 | Sodium, Week 40, n=270, 293 | 139.5 Millimoles per liter | Standard Deviation 1.97 |
Secondary
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48
Blood samples were collected for the analysis of clinical chemistry parameters: CO2, chloride, glucose, phosphate, potassium, sodium and urea to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 36, n=44, 50 | 4.25 Millimoles per liter | Standard Deviation 0.345 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 8, n=92, 119 | 5.17 Millimoles per liter | Standard Deviation 1.204 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 16, n=116, 119 | 5.12 Millimoles per liter | Standard Deviation 0.914 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 32, n=137, 148 | 22.5 Millimoles per liter | Standard Deviation 2.11 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 20, n=107, 121 | 5.16 Millimoles per liter | Standard Deviation 0.802 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Baseline, n=51, 54 | 22.3 Millimoles per liter | Standard Deviation 2.53 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 24, n=116, 124 | 5.16 Millimoles per liter | Standard Deviation 0.944 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 36, n=135, 147 | 22.8 Millimoles per liter | Standard Deviation 2.38 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 28, n=105, 120 | 5.08 Millimoles per liter | Standard Deviation 0.635 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 44, n=137, 148 | 104.6 Millimoles per liter | Standard Deviation 2.17 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 32, n=104, 121 | 5.18 Millimoles per liter | Standard Deviation 1 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 40, n=138, 147 | 23.1 Millimoles per liter | Standard Deviation 2.4 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 36, n=103, 120 | 5.07 Millimoles per liter | Standard Deviation 0.856 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 4, n=51, 53 | 23.6 Millimoles per liter | Standard Deviation 2.37 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 40, n=102, 114 | 5.16 Millimoles per liter | Standard Deviation 0.776 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 44, n=99, 116 | 5.15 Millimoles per liter | Standard Deviation 0.877 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 44, n=137, 148 | 23.0 Millimoles per liter | Standard Deviation 2.35 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 48, n=119, 138 | 5.01 Millimoles per liter | Standard Deviation 0.64 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 44, n=47, 51 | 4.24 Millimoles per liter | Standard Deviation 0.348 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Baseline, n=51, 54 | 1.048 Millimoles per liter | Standard Deviation 0.1523 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 48, n=131, 147 | 22.5 Millimoles per liter | Standard Deviation 2.55 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 4, n=51, 53 | 1.116 Millimoles per liter | Standard Deviation 0.1648 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 8, n=34, 53 | 23.0 Millimoles per liter | Standard Deviation 1.95 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 8, n=34, 53 | 1.119 Millimoles per liter | Standard Deviation 0.1891 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Baseline, n=51, 54 | 104.0 Millimoles per liter | Standard Deviation 1.46 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 12, n=50, 52 | 1.073 Millimoles per liter | Standard Deviation 0.1788 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 32, n=93, 95 | 1.045 Millimoles per liter | Standard Deviation 0.1649 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 16, n=48, 53 | 1.111 Millimoles per liter | Standard Deviation 0.2006 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 4, n=51, 53 | 104.5 Millimoles per liter | Standard Deviation 1.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 20, n=46, 53 | 1.119 Millimoles per liter | Standard Deviation 0.1689 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 12, n=50, 52 | 22.9 Millimoles per liter | Standard Deviation 2.14 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 24, n=47, 53 | 1.086 Millimoles per liter | Standard Deviation 0.1647 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 8, n=34, 53 | 104.4 Millimoles per liter | Standard Deviation 2.35 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 28, n=42, 53 | 1.085 Millimoles per liter | Standard Deviation 0.1803 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 48, n=43, 50 | 4.15 Millimoles per liter | Standard Deviation 0.292 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 32, n=45, 51 | 1.109 Millimoles per liter | Standard Deviation 0.1869 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 12, n=50, 52 | 104.4 Millimoles per liter | Standard Deviation 2.02 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 36, n=44, 50 | 1.084 Millimoles per liter | Standard Deviation 0.1659 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 16, n=48, 53 | 23.0 Millimoles per liter | Standard Deviation 2.07 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 40, n=42, 51 | 1.067 Millimoles per liter | Standard Deviation 0.202 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 16, n=48, 53 | 104.4 Millimoles per liter | Standard Deviation 2.08 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 48, n=43, 50 | 1.095 Millimoles per liter | Standard Deviation 0.1636 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 20, n=93, 97 | 4.20 Millimoles per liter | Standard Deviation 0.299 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Baseline, n=102, 99 | 1.045 Millimoles per liter | Standard Deviation 0.1687 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 20, n=46, 53 | 104.8 Millimoles per liter | Standard Deviation 1.98 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 4, n=99, 97 | 1.080 Millimoles per liter | Standard Deviation 0.1725 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 20, n=46, 53 | 23.1 Millimoles per liter | Standard Deviation 2.04 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 24, n=47, 53 | 105.1 Millimoles per liter | Standard Deviation 1.85 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 12, n=99, 95 | 1.068 Millimoles per liter | Standard Deviation 0.197 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 12, n=113, 122 | 5.04 Millimoles per liter | Standard Deviation 0.856 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 20, n=93, 97 | 1.046 Millimoles per liter | Standard Deviation 0.1717 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 28, n=42, 53 | 105.3 Millimoles per liter | Standard Deviation 1.88 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 24, n=94, 95 | 1.066 Millimoles per liter | Standard Deviation 0.1661 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 24, n=47, 53 | 22.7 Millimoles per liter | Standard Deviation 1.95 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 28, n=89, 93 | 1.060 Millimoles per liter | Standard Deviation 0.1602 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 32, n=45, 51 | 105.0 Millimoles per liter | Standard Deviation 2.32 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 44, n=91, 94 | 1.043 Millimoles per liter | Standard Deviation 0.1805 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 36, n=94, 95 | 1.032 Millimoles per liter | Standard Deviation 0.1572 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 36, n=44, 50 | 105.0 Millimoles per liter | Standard Deviation 2.17 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Baseline, n=155, 155 | 1.038 Millimoles per liter | Standard Deviation 0.1905 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 28, n=42, 53 | 22.7 Millimoles per liter | Standard Deviation 2.31 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 8, n=122, 152 | 1.097 Millimoles per liter | Standard Deviation 0.1994 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 40, n=42, 51 | 105.2 Millimoles per liter | Standard Deviation 2.27 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 12, n=146, 152 | 1.091 Millimoles per liter | Standard Deviation 0.1838 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 12, n=99, 95 | 104.1 Millimoles per liter | Standard Deviation 2.31 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 16, n=143, 149 | 1.082 Millimoles per liter | Standard Deviation 0.1827 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 44, n=47, 51 | 105.1 Millimoles per liter | Standard Deviation 1.84 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 20, n=138, 152 | 1.076 Millimoles per liter | Standard Deviation 0.1763 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 32, n=45, 51 | 22.6 Millimoles per liter | Standard Deviation 2.22 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 28, n=136, 150 | 1.076 Millimoles per liter | Standard Deviation 0.1764 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 48, n=43, 50 | 104.4 Millimoles per liter | Standard Deviation 1.72 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 32, n=137, 148 | 1.057 Millimoles per liter | Standard Deviation 0.1722 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Baseline, n=51, 54 | 138.9 Millimoles per liter | Standard Deviation 2.15 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 36, n=135, 147 | 1.055 Millimoles per liter | Standard Deviation 0.179 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Baseline, n=102, 99 | 103.6 Millimoles per liter | Standard Deviation 2.03 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 40, n=138, 147 | 1.071 Millimoles per liter | Standard Deviation 0.1689 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 36, n=44, 50 | 22.6 Millimoles per liter | Standard Deviation 2.21 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 44, n=137, 148 | 1.076 Millimoles per liter | Standard Deviation 0.1795 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 4, n=99, 97 | 104.0 Millimoles per liter | Standard Deviation 2.17 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 48, n=131, 147 | 1.075 Millimoles per liter | Standard Deviation 0.1941 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 40, n=90, 95 | 1.054 Millimoles per liter | Standard Deviation 0.1838 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Baseline, n=51, 54 | 4.13 Millimoles per liter | Standard Deviation 0.288 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 16, n=48, 53 | 4.16 Millimoles per liter | Standard Deviation 0.322 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 8, n=73, 98 | 104.1 Millimoles per liter | Standard Deviation 2.16 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 20, n=46, 53 | 4.18 Millimoles per liter | Standard Deviation 0.291 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 40, n=42, 51 | 22.8 Millimoles per liter | Standard Deviation 2.24 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 24, n=47, 53 | 4.15 Millimoles per liter | Standard Deviation 0.335 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 16, n=93, 96 | 104.7 Millimoles per liter | Standard Deviation 2.05 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 28, n=42, 53 | 4.21 Millimoles per liter | Standard Deviation 0.342 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 4, n=51, 53 | 139.3 Millimoles per liter | Standard Deviation 1.64 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 32, n=45, 51 | 4.15 Millimoles per liter | Standard Deviation 0.326 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 20, n=93, 97 | 104.8 Millimoles per liter | Standard Deviation 2.39 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 44, n=47, 51 | 22.9 Millimoles per liter | Standard Deviation 1.94 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 40, n=42, 51 | 4.23 Millimoles per liter | Standard Deviation 0.293 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 24, n=94, 95 | 104.3 Millimoles per liter | Standard Deviation 2.3 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Baseline, n=102, 99 | 4.17 Millimoles per liter | Standard Deviation 0.245 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 48, n=91, 95 | 1.072 Millimoles per liter | Standard Deviation 0.1721 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 4, n=99, 97 | 4.20 Millimoles per liter | Standard Deviation 0.311 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 28, n=89, 93 | 104.7 Millimoles per liter | Standard Deviation 1.92 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 8, n=73, 98 | 4.14 Millimoles per liter | Standard Deviation 0.306 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 48, n=43, 50 | 23.0 Millimoles per liter | Standard Deviation 2.01 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 12, n=99, 95 | 4.19 Millimoles per liter | Standard Deviation 0.34 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 32, n=93, 95 | 104.5 Millimoles per liter | Standard Deviation 2.33 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 16, n=93, 96 | 4.15 Millimoles per liter | Standard Deviation 0.317 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 8, n=34, 53 | 139.6 Millimoles per liter | Standard Deviation 2.1 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 24, n=94, 95 | 4.19 Millimoles per liter | Standard Deviation 0.304 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 36, n=94, 95 | 104.6 Millimoles per liter | Standard Deviation 2.04 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium,Week 28, n=89, 93 | 4.19 Millimoles per liter | Standard Deviation 0.412 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Baseline, n=102, 99 | 22.8 Millimoles per liter | Standard Deviation 2.09 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 32, n=93, 95 | 4.20 Millimoles per liter | Standard Deviation 0.358 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 40, n=90, 95 | 104.4 Millimoles per liter | Standard Deviation 1.94 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 36, n=94, 95 | 4.19 Millimoles per liter | Standard Deviation 0.365 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 8, n=122, 152 | 104.4 Millimoles per liter | Standard Deviation 2.31 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 40, n=90, 95 | 4.18 Millimoles per liter | Standard Deviation 0.332 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 44, n=91, 94 | 104.5 Millimoles per liter | Standard Deviation 2.12 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 44, n=91, 94 | 4.18 Millimoles per liter | Standard Deviation 0.309 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 4, n=99, 97 | 23.7 Millimoles per liter | Standard Deviation 2.36 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 48, n=91, 95 | 4.15 Millimoles per liter | Standard Deviation 0.266 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 48, n=91, 95 | 104.2 Millimoles per liter | Standard Deviation 2.43 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Baseline, n=155, 155 | 4.16 Millimoles per liter | Standard Deviation 0.302 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 12, n=50, 52 | 139.3 Millimoles per liter | Standard Deviation 1.76 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 4, n=151, 153 | 4.21 Millimoles per liter | Standard Deviation 0.287 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Baseline, n=155, 155 | 103.9 Millimoles per liter | Standard Deviation 2.18 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 8, n=122, 152 | 4.17 Millimoles per liter | Standard Deviation 0.295 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 8, n=73, 98 | 23.0 Millimoles per liter | Standard Deviation 2.1 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 12, n=146, 152 | 4.18 Millimoles per liter | Standard Deviation 0.322 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 4, n=151, 153 | 104.3 Millimoles per liter | Standard Deviation 2.21 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 16, n=143, 149 | 4.20 Millimoles per liter | Standard Deviation 0.313 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 4, n=151, 153 | 1.128 Millimoles per liter | Standard Deviation 0.1867 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium,Week 20, n=138, 152 | 4.20 Millimoles per liter | Standard Deviation 0.326 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 12, n=99, 95 | 23.2 Millimoles per liter | Standard Deviation 2.07 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 24, n=143, 150 | 4.19 Millimoles per liter | Standard Deviation 0.259 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 12, n=146, 152 | 104.3 Millimoles per liter | Standard Deviation 2.33 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 28, n=136, 150 | 4.18 Millimoles per liter | Standard Deviation 0.301 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 16, n=48, 53 | 139.4 Millimoles per liter | Standard Deviation 2.18 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 32, n=137, 148 | 4.17 Millimoles per liter | Standard Deviation 0.388 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 36, n=135, 147 | 4.17 Millimoles per liter | Standard Deviation 0.289 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 16, n=143, 149 | 104.4 Millimoles per liter | Standard Deviation 2.37 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 40, n=138, 147 | 4.20 Millimoles per liter | Standard Deviation 0.283 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 16, n=93, 96 | 22.8 Millimoles per liter | Standard Deviation 2.1 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 44, n=137, 148 | 4.23 Millimoles per liter | Standard Deviation 0.324 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 20, n=138, 152 | 104.6 Millimoles per liter | Standard Deviation 2.55 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 48, n=131, 147 | 4.14 Millimoles per liter | Standard Deviation 0.271 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 20, n=46, 53 | 139.6 Millimoles per liter | Standard Deviation 1.71 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 24, n=143, 151 | 104.4 Millimoles per liter | Standard Deviation 2.52 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 24, n=47, 53 | 139.4 Millimoles per liter | Standard Deviation 2.08 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 20, n=93, 97 | 22.8 Millimoles per liter | Standard Deviation 2.11 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 28, n=42, 53 | 140.3 Millimoles per liter | Standard Deviation 1.59 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 28, n=136, 150 | 104.7 Millimoles per liter | Standard Deviation 2.41 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 32, n=45, 51 | 139.4 Millimoles per liter | Standard Deviation 2.14 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 24, n=143, 151 | 1.091 Millimoles per liter | Standard Deviation 0.1914 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 36, n=44, 50 | 139.7 Millimoles per liter | Standard Deviation 1.63 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 32, n=137, 148 | 104.7 Millimoles per liter | Standard Deviation 2.68 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 40, n=42, 51 | 139.8 Millimoles per liter | Standard Deviation 1.94 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 24, n=94, 95 | 22.8 Millimoles per liter | Standard Deviation 2.22 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 44, n=47, 51 | 139.7 Millimoles per liter | Standard Deviation 1.78 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 36, n=135, 147 | 105.0 Millimoles per liter | Standard Deviation 2.28 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 48, n=43, 50 | 139.8 Millimoles per liter | Standard Deviation 1.86 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 44, n=47, 51 | 1.084 Millimoles per liter | Standard Deviation 0.1785 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Baseline, n=102, 99 | 138.8 Millimoles per liter | Standard Deviation 1.62 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 40, n=138, 147 | 104.7 Millimoles per liter | Standard Deviation 2.36 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 4, n=99, 97 | 139.2 Millimoles per liter | Standard Deviation 1.58 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 28, n=89, 93 | 22.5 Millimoles per liter | Standard Deviation 2.21 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 8, n=73, 98 | 138.8 Millimoles per liter | Standard Deviation 2 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 48, n=131, 147 | 104.6 Millimoles per liter | Standard Deviation 2.54 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 12, n=99, 95 | 139.1 Millimoles per liter | Standard Deviation 1.97 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Baseline, n=51, 53 | 5.11 Millimoles per liter | Standard Deviation 0.878 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 16, n=93, 96 | 139.1 Millimoles per liter | Standard Deviation 1.87 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 48, n=131, 147 | 139.4 Millimoles per liter | Standard Deviation 1.93 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 20, n=93, 97 | 139.4 Millimoles per liter | Standard Deviation 1.92 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 4, n=43, 43 | 5.06 Millimoles per liter | Standard Deviation 0.481 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 24, n=94, 95 | 139.3 Millimoles per liter | Standard Deviation 1.86 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 32, n=93, 95 | 22.8 Millimoles per liter | Standard Deviation 2.17 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 28, n=89, 93 | 139.4 Millimoles per liter | Standard Deviation 1.65 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 8, n=25, 41 | 5.11 Millimoles per liter | Standard Deviation 0.456 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 32, n=93, 95 | 139.4 Millimoles per liter | Standard Deviation 1.63 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 4, n=51, 53 | 4.25 Millimoles per liter | Standard Deviation 0.355 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 36, n=94, 95 | 139.2 Millimoles per liter | Standard Deviation 1.84 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 12, n=40, 43 | 5.21 Millimoles per liter | Standard Deviation 0.533 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 40, n=90, 95 | 139.3 Millimoles per liter | Standard Deviation 2.01 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 36, n=94, 95 | 22.8 Millimoles per liter | Standard Deviation 1.9 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 44, n=91, 94 | 139.3 Millimoles per liter | Standard Deviation 1.67 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 16, n=39, 44 | 5.24 Millimoles per liter | Standard Deviation 0.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 48, n=91, 95 | 139.3 Millimoles per liter | Standard Deviation 1.98 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Baseline, n=155, 155 | 139.1 Millimoles per liter | Standard Deviation 2 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 44, n=47, 51 | 5.38 Millimoles per liter | Standard Deviation 1.483 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 4, n=151, 153 | 139.4 Millimoles per liter | Standard Deviation 1.79 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 20, n=35, 42 | 5.11 Millimoles per liter | Standard Deviation 0.58 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 8, n=122, 152 | 139.1 Millimoles per liter | Standard Deviation 1.91 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 40, n=90, 95 | 23.1 Millimoles per liter | Standard Deviation 2.07 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 12, n=146, 152 | 139.2 Millimoles per liter | Standard Deviation 1.78 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 24, n=38, 43 | 5.31 Millimoles per liter | Standard Deviation 0.526 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 16, n=143, 149 | 139.0 Millimoles per liter | Standard Deviation 1.99 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 8, n=73, 98 | 1.086 Millimoles per liter | Standard Deviation 0.1901 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 20, n=138, 152 | 139.0 Millimoles per liter | Standard Deviation 1.87 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 28, n=32, 43 | 5.16 Millimoles per liter | Standard Deviation 0.651 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 24, n=143, 151 | 139.2 Millimoles per liter | Standard Deviation 1.83 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 44, n=91, 94 | 23.1 Millimoles per liter | Standard Deviation 2.08 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 28, n=136, 150 | 139.3 Millimoles per liter | Standard Deviation 1.84 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 32, n=36, 42 | 5.37 Millimoles per liter | Standard Deviation 0.7 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 32, n=137, 148 | 139.2 Millimoles per liter | Standard Deviation 1.68 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 48, n=43, 50 | 5.22 Millimoles per liter | Standard Deviation 1.469 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 36, n=135, 147 | 139.4 Millimoles per liter | Standard Deviation 1.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 36, n=35, 42 | 5.13 Millimoles per liter | Standard Deviation 0.525 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 40, n=138, 147 | 139.4 Millimoles per liter | Standard Deviation 1.87 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 48, n=91, 95 | 22.9 Millimoles per liter | Standard Deviation 1.97 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 44, n=137, 148 | 139.5 Millimoles per liter | Standard Deviation 1.88 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Baseline, n=51, 54 | 4.97 Millimoles per liter | Standard Deviation 1.409 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 40, n=34, 41 | 5.31 Millimoles per liter | Standard Deviation 0.464 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 4, n=51, 53 | 4.99 Millimoles per liter | Standard Deviation 1.21 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 48, n=131, 147 | 5.32 Millimoles per liter | Standard Deviation 1.671 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 8, n=34, 53 | 5.10 Millimoles per liter | Standard Deviation 1.353 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 44, n=40, 40 | 5.13 Millimoles per liter | Standard Deviation 0.681 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 12, n=50, 52 | 5.03 Millimoles per liter | Standard Deviation 1.368 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Baseline, n=155, 155 | 22.7 Millimoles per liter | Standard Deviation 2.41 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 16, n=48, 53 | 5.20 Millimoles per liter | Standard Deviation 1.295 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 48, n=39, 48 | 5.16 Millimoles per liter | Standard Deviation 0.647 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 20, n=46, 53 | 5.18 Millimoles per liter | Standard Deviation 1.216 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 8, n=34, 53 | 4.18 Millimoles per liter | Standard Deviation 0.283 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 24, n=47, 53 | 5.44 Millimoles per liter | Standard Deviation 1.587 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Baseline, n=98, 96 | 5.06 Millimoles per liter | Standard Deviation 0.638 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 28, n=42, 53 | 5.21 Millimoles per liter | Standard Deviation 1.358 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 4, n=151, 153 | 23.7 Millimoles per liter | Standard Deviation 2.63 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 32, n=45, 51 | 5.13 Millimoles per liter | Standard Deviation 1.135 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 4, n=55, 54 | 5.39 Millimoles per liter | Standard Deviation 0.771 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 36, n=44, 50 | 4.99 Millimoles per liter | Standard Deviation 1.31 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 16, n=93, 96 | 1.063 Millimoles per liter | Standard Deviation 0.1623 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 40, n=42, 51 | 5.35 Millimoles per liter | Standard Deviation 1.227 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 8, n=36, 58 | 5.16 Millimoles per liter | Standard Deviation 0.584 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 8, n=122, 152 | 23.2 Millimoles per liter | Standard Deviation 2.28 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Baseline, n=102, 99 | 5.76 Millimoles per liter | Standard Deviation 1.528 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 12, n=53, 56 | 5.50 Millimoles per liter | Standard Deviation 1.317 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 4, n=99, 97 | 5.63 Millimoles per liter | Standard Deviation 1.471 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 36, n=135, 147 | 5.07 Millimoles per liter | Standard Deviation 1.719 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 8, n=73, 98 | 5.80 Millimoles per liter | Standard Deviation 1.617 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 16, n=54, 53 | 5.41 Millimoles per liter | Standard Deviation 1.727 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 12, n=99, 95 | 5.81 Millimoles per liter | Standard Deviation 1.536 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 12, n=146, 152 | 23.2 Millimoles per liter | Standard Deviation 2.18 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 16, n=93, 96 | 5.76 Millimoles per liter | Standard Deviation 1.577 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 24, n=61, 62 | 5.34 Millimoles per liter | Standard Deviation 0.66 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 20, n=93, 97 | 5.75 Millimoles per liter | Standard Deviation 1.64 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 12, n=50, 52 | 4.25 Millimoles per liter | Standard Deviation 0.335 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 24, n=94, 95 | 5.84 Millimoles per liter | Standard Deviation 1.578 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 28, n=53, 63 | 5.32 Millimoles per liter | Standard Deviation 0.817 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 28, n=89, 93 | 5.76 Millimoles per liter | Standard Deviation 1.593 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 16, n=143, 149 | 23.0 Millimoles per liter | Standard Deviation 2.24 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 32, n=93, 95 | 5.67 Millimoles per liter | Standard Deviation 1.537 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 32, n=54, 56 | 5.57 Millimoles per liter | Standard Deviation 1.26 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 36, n=94, 95 | 5.67 Millimoles per liter | Standard Deviation 1.67 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 40, n=138, 147 | 5.30 Millimoles per liter | Standard Deviation 1.616 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 40, n=90, 95 | 5.81 Millimoles per liter | Standard Deviation 1.669 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 36, n=53, 58 | 5.46 Millimoles per liter | Standard Deviation 0.697 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 44, n=91, 94 | 5.59 Millimoles per liter | Standard Deviation 1.607 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 20, n=138, 152 | 22.9 Millimoles per liter | Standard Deviation 2.24 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 48, n=91, 95 | 5.83 Millimoles per liter | Standard Deviation 1.654 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 40, n=59, 63 | 5.53 Millimoles per liter | Standard Deviation 0.931 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Baseline, n=155, 155 | 4.96 Millimoles per liter | Standard Deviation 1.519 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 20, n=52, 58 | 5.36 Millimoles per liter | Standard Deviation 0.674 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 4, n=151, 153 | 5.08 Millimoles per liter | Standard Deviation 1.556 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 44, n=54, 57 | 5.40 Millimoles per liter | Standard Deviation 1.02 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 8, n=122, 152 | 5.09 Millimoles per liter | Standard Deviation 1.675 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 24, n=143, 150 | 23.0 Millimoles per liter | Standard Deviation 2.49 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 12, n=146, 152 | 5.20 Millimoles per liter | Standard Deviation 1.684 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 48, n=84, 91 | 5.16 Millimoles per liter | Standard Deviation 0.549 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 16, n=143, 149 | 5.03 Millimoles per liter | Standard Deviation 1.768 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 44, n=137, 148 | 5.23 Millimoles per liter | Standard Deviation 1.489 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 20, n=138, 152 | 5.18 Millimoles per liter | Standard Deviation 1.709 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Baseline, n=152, 150 | 4.93 Millimoles per liter | Standard Deviation 0.697 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 24, n=143, 151 | 5.29 Millimoles per liter | Standard Deviation 1.878 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 28, n=136, 150 | 22.8 Millimoles per liter | Standard Deviation 2.58 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 28, n=136, 150 | 5.20 Millimoles per liter | Standard Deviation 1.931 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 4, n=118, 129 | 5.11 Millimoles per liter | Standard Deviation 0.798 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 32, n=137, 148 | 5.38 Millimoles per liter | Standard Deviation 1.796 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 24, n=143, 151 | 1.052 Millimoles per liter | Standard Deviation 0.1882 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 44, n=137, 148 | 105.0 Millimoles per liter | Standard Deviation 2.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 48, n=131, 147 | 104.5 Millimoles per liter | Standard Deviation 2.46 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 16, n=54, 53 | 5.25 Millimoles per liter | Standard Deviation 0.624 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 8, n=92, 119 | 5.35 Millimoles per liter | Standard Deviation 1.03 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 12, n=113, 122 | 5.30 Millimoles per liter | Standard Deviation 1.067 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 40, n=102, 114 | 5.53 Millimoles per liter | Standard Deviation 1.558 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 40, n=42, 51 | 1.053 Millimoles per liter | Standard Deviation 0.1932 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 16, n=93, 96 | 1.061 Millimoles per liter | Standard Deviation 0.1702 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 28, n=89, 93 | 1.065 Millimoles per liter | Standard Deviation 0.1835 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 32, n=93, 95 | 1.045 Millimoles per liter | Standard Deviation 0.1569 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 36, n=94, 95 | 1.059 Millimoles per liter | Standard Deviation 0.18 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Baseline, n=155, 155 | 1.040 Millimoles per liter | Standard Deviation 0.1741 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 20, n=138, 152 | 1.037 Millimoles per liter | Standard Deviation 0.1806 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Baseline, n=51, 54 | 4.10 Millimoles per liter | Standard Deviation 0.308 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 4, n=51, 53 | 4.31 Millimoles per liter | Standard Deviation 0.395 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 8, n=34, 53 | 4.19 Millimoles per liter | Standard Deviation 0.331 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 12, n=50, 52 | 4.31 Millimoles per liter | Standard Deviation 0.364 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 40, n=42, 51 | 4.26 Millimoles per liter | Standard Deviation 0.363 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 44, n=47, 51 | 4.32 Millimoles per liter | Standard Deviation 0.375 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 20, n=93, 97 | 4.18 Millimoles per liter | Standard Deviation 0.289 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 32, n=137, 148 | 4.20 Millimoles per liter | Standard Deviation 0.349 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 48, n=131, 147 | 4.17 Millimoles per liter | Standard Deviation 0.352 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Baseline, n=51, 54 | 138.7 Millimoles per liter | Standard Deviation 2.1 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 4, n=51, 53 | 139.0 Millimoles per liter | Standard Deviation 2.08 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 8, n=34, 53 | 139.0 Millimoles per liter | Standard Deviation 1.95 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 12, n=50, 52 | 139.4 Millimoles per liter | Standard Deviation 2.03 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 16, n=48, 53 | 139.0 Millimoles per liter | Standard Deviation 1.75 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 48, n=91, 95 | 139.0 Millimoles per liter | Standard Deviation 1.76 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 44, n=137, 148 | 139.7 Millimoles per liter | Standard Deviation 1.92 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 48, n=131, 147 | 139.5 Millimoles per liter | Standard Deviation 1.82 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 44, n=47, 51 | 5.10 Millimoles per liter | Standard Deviation 1.517 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 48, n=131, 147 | 5.06 Millimoles per liter | Standard Deviation 1.38 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 32, n=137, 148 | 5.14 Millimoles per liter | Standard Deviation 1.687 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 36, n=135, 147 | 5.13 Millimoles per liter | Standard Deviation 1.493 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 40, n=138, 147 | 5.07 Millimoles per liter | Standard Deviation 1.377 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 44, n=137, 148 | 5.18 Millimoles per liter | Standard Deviation 1.613 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Baseline, n=51, 54 | 22.7 Millimoles per liter | Standard Deviation 2.17 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 4, n=51, 53 | 23.4 Millimoles per liter | Standard Deviation 2.28 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 8, n=34, 53 | 23.0 Millimoles per liter | Standard Deviation 2.53 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 12, n=50, 52 | 22.9 Millimoles per liter | Standard Deviation 2.41 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 16, n=48, 53 | 22.9 Millimoles per liter | Standard Deviation 2.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 20, n=46, 53 | 22.7 Millimoles per liter | Standard Deviation 2.59 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 24, n=47, 53 | 22.8 Millimoles per liter | Standard Deviation 2.62 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 28, n=42, 53 | 22.5 Millimoles per liter | Standard Deviation 2.48 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 32, n=45, 51 | 22.6 Millimoles per liter | Standard Deviation 2.84 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 36, n=44, 50 | 22.4 Millimoles per liter | Standard Deviation 2.36 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 40, n=42, 51 | 23.1 Millimoles per liter | Standard Deviation 2.37 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 44, n=47, 51 | 23.1 Millimoles per liter | Standard Deviation 2.37 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 48, n=43, 50 | 22.7 Millimoles per liter | Standard Deviation 2.19 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Baseline, n=102, 99 | 22.9 Millimoles per liter | Standard Deviation 2.08 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 4, n=99, 97 | 23.7 Millimoles per liter | Standard Deviation 2.28 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 8, n=73, 98 | 23.6 Millimoles per liter | Standard Deviation 2.2 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 12, n=99, 95 | 23.3 Millimoles per liter | Standard Deviation 2.26 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 16, n=93, 96 | 23.5 Millimoles per liter | Standard Deviation 2.39 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 20, n=93, 97 | 23.6 Millimoles per liter | Standard Deviation 2.14 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 24, n=94, 95 | 23.1 Millimoles per liter | Standard Deviation 2.21 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 28, n=89, 93 | 23.1 Millimoles per liter | Standard Deviation 2.14 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 32, n=93, 95 | 23.0 Millimoles per liter | Standard Deviation 2.09 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 36, n=94, 95 | 23.5 Millimoles per liter | Standard Deviation 2.12 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 40, n=90, 95 | 23.2 Millimoles per liter | Standard Deviation 2.09 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 44, n=91, 94 | 23.7 Millimoles per liter | Standard Deviation 2.11 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 48, n=91, 95 | 23.3 Millimoles per liter | Standard Deviation 2.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Baseline, n=155, 155 | 22.3 Millimoles per liter | Standard Deviation 2.35 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 4, n=151, 153 | 23.0 Millimoles per liter | Standard Deviation 2.24 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 8, n=122, 152 | 23.1 Millimoles per liter | Standard Deviation 2.61 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 12, n=146, 152 | 22.8 Millimoles per liter | Standard Deviation 2.39 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 16, n=143, 149 | 22.8 Millimoles per liter | Standard Deviation 2.23 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 20, n=138, 152 | 22.5 Millimoles per liter | Standard Deviation 2.2 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 24, n=143, 150 | 22.7 Millimoles per liter | Standard Deviation 2.45 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 28, n=136, 150 | 22.6 Millimoles per liter | Standard Deviation 2.27 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 32, n=137, 148 | 22.7 Millimoles per liter | Standard Deviation 2.29 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 36, n=135, 147 | 22.8 Millimoles per liter | Standard Deviation 2.27 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 40, n=138, 147 | 22.8 Millimoles per liter | Standard Deviation 2.68 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 44, n=137, 148 | 22.8 Millimoles per liter | Standard Deviation 2.38 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 48, n=131, 147 | 22.6 Millimoles per liter | Standard Deviation 2.29 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Baseline, n=51, 54 | 103.5 Millimoles per liter | Standard Deviation 2.61 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 4, n=51, 53 | 104.0 Millimoles per liter | Standard Deviation 2.1 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 8, n=34, 53 | 104.2 Millimoles per liter | Standard Deviation 2.28 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 12, n=50, 52 | 104.3 Millimoles per liter | Standard Deviation 2.13 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 16, n=48, 53 | 104.5 Millimoles per liter | Standard Deviation 2.1 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 20, n=46, 53 | 104.2 Millimoles per liter | Standard Deviation 1.97 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 24, n=47, 53 | 104.7 Millimoles per liter | Standard Deviation 2.02 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 28, n=42, 53 | 104.6 Millimoles per liter | Standard Deviation 2.47 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 32, n=45, 51 | 104.4 Millimoles per liter | Standard Deviation 1.92 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 36, n=44, 50 | 104.4 Millimoles per liter | Standard Deviation 2.27 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 40, n=42, 51 | 104.5 Millimoles per liter | Standard Deviation 2.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 44, n=47, 51 | 104.5 Millimoles per liter | Standard Deviation 1.88 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 48, n=43, 50 | 104.3 Millimoles per liter | Standard Deviation 1.88 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Baseline, n=102, 99 | 103.5 Millimoles per liter | Standard Deviation 2.26 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 4, n=99, 97 | 104.0 Millimoles per liter | Standard Deviation 2.15 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 12, n=99, 95 | 104.0 Millimoles per liter | Standard Deviation 2.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 16, n=93, 96 | 104.2 Millimoles per liter | Standard Deviation 2.26 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 20, n=93, 97 | 103.8 Millimoles per liter | Standard Deviation 2.36 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 24, n=94, 95 | 104.1 Millimoles per liter | Standard Deviation 2.5 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 28, n=89, 93 | 104.0 Millimoles per liter | Standard Deviation 2.16 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 32, n=93, 95 | 104.2 Millimoles per liter | Standard Deviation 2.47 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 36, n=94, 95 | 104.1 Millimoles per liter | Standard Deviation 2.4 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 40, n=90, 95 | 103.9 Millimoles per liter | Standard Deviation 2.48 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 44, n=91, 94 | 104.0 Millimoles per liter | Standard Deviation 2.27 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 48, n=91, 95 | 103.2 Millimoles per liter | Standard Deviation 2.26 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Baseline, n=155, 155 | 104.0 Millimoles per liter | Standard Deviation 2.37 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 4, n=151, 153 | 104.6 Millimoles per liter | Standard Deviation 2.29 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 8, n=122, 152 | 104.7 Millimoles per liter | Standard Deviation 2.22 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 12, n=146, 152 | 104.5 Millimoles per liter | Standard Deviation 2.23 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 16, n=143, 149 | 104.8 Millimoles per liter | Standard Deviation 2.34 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 20, n=138, 152 | 105.1 Millimoles per liter | Standard Deviation 2.38 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 24, n=143, 151 | 105.1 Millimoles per liter | Standard Deviation 2.18 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 28, n=136, 150 | 105.3 Millimoles per liter | Standard Deviation 2.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 32, n=137, 148 | 105.1 Millimoles per liter | Standard Deviation 2.26 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 36, n=135, 147 | 105.1 Millimoles per liter | Standard Deviation 2.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 40, n=138, 147 | 105.0 Millimoles per liter | Standard Deviation 2.7 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Baseline, n=51, 53 | 5.03 Millimoles per liter | Standard Deviation 0.505 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 4, n=43, 43 | 5.29 Millimoles per liter | Standard Deviation 0.452 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 8, n=25, 41 | 5.18 Millimoles per liter | Standard Deviation 0.462 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 12, n=40, 43 | 5.25 Millimoles per liter | Standard Deviation 0.535 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 16, n=39, 44 | 5.26 Millimoles per liter | Standard Deviation 0.614 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 20, n=35, 42 | 5.29 Millimoles per liter | Standard Deviation 0.718 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 24, n=38, 43 | 5.29 Millimoles per liter | Standard Deviation 0.747 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 28, n=32, 43 | 5.12 Millimoles per liter | Standard Deviation 0.512 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 32, n=36, 42 | 5.31 Millimoles per liter | Standard Deviation 0.643 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 36, n=35, 42 | 5.23 Millimoles per liter | Standard Deviation 0.513 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 40, n=34, 41 | 5.17 Millimoles per liter | Standard Deviation 0.555 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 44, n=40, 40 | 5.20 Millimoles per liter | Standard Deviation 0.408 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 48, n=39, 48 | 5.18 Millimoles per liter | Standard Deviation 0.661 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Baseline, n=98, 96 | 5.25 Millimoles per liter | Standard Deviation 0.801 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 4, n=55, 54 | 5.37 Millimoles per liter | Standard Deviation 1.043 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 8, n=36, 58 | 5.49 Millimoles per liter | Standard Deviation 1.307 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 12, n=53, 56 | 5.51 Millimoles per liter | Standard Deviation 1.414 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 20, n=52, 58 | 5.21 Millimoles per liter | Standard Deviation 0.793 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 24, n=61, 62 | 5.36 Millimoles per liter | Standard Deviation 0.753 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 28, n=53, 63 | 5.45 Millimoles per liter | Standard Deviation 0.94 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 32, n=54, 56 | 5.52 Millimoles per liter | Standard Deviation 0.839 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 36, n=53, 58 | 5.34 Millimoles per liter | Standard Deviation 1.142 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 40, n=59, 63 | 5.46 Millimoles per liter | Standard Deviation 0.765 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 44, n=54, 57 | 5.43 Millimoles per liter | Standard Deviation 0.637 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 48, n=84, 91 | 5.24 Millimoles per liter | Standard Deviation 0.752 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Baseline, n=152, 150 | 5.17 Millimoles per liter | Standard Deviation 1.201 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 4, n=118, 129 | 5.48 Millimoles per liter | Standard Deviation 1.49 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 16, n=116, 119 | 5.45 Millimoles per liter | Standard Deviation 1.683 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 20, n=107, 121 | 5.48 Millimoles per liter | Standard Deviation 1.476 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 24, n=116, 124 | 5.36 Millimoles per liter | Standard Deviation 0.914 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 28, n=105, 120 | 5.40 Millimoles per liter | Standard Deviation 0.934 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 32, n=104, 121 | 5.47 Millimoles per liter | Standard Deviation 1.316 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 36, n=103, 120 | 5.49 Millimoles per liter | Standard Deviation 1.857 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 44, n=99, 116 | 5.53 Millimoles per liter | Standard Deviation 1.708 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 48, n=119, 138 | 5.23 Millimoles per liter | Standard Deviation 1.16 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Baseline, n=51, 54 | 1.060 Millimoles per liter | Standard Deviation 0.1719 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 4, n=51, 53 | 1.069 Millimoles per liter | Standard Deviation 0.1647 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 8, n=34, 53 | 1.041 Millimoles per liter | Standard Deviation 0.1664 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 12, n=50, 52 | 1.064 Millimoles per liter | Standard Deviation 0.1872 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 16, n=48, 53 | 1.051 Millimoles per liter | Standard Deviation 0.1849 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 20, n=46, 53 | 1.076 Millimoles per liter | Standard Deviation 0.2187 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 24, n=47, 53 | 1.077 Millimoles per liter | Standard Deviation 0.1631 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 28, n=42, 53 | 1.076 Millimoles per liter | Standard Deviation 0.197 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 32, n=45, 51 | 1.081 Millimoles per liter | Standard Deviation 0.1769 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 36, n=44, 50 | 1.058 Millimoles per liter | Standard Deviation 0.183 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 44, n=47, 51 | 1.063 Millimoles per liter | Standard Deviation 0.2227 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 48, n=43, 50 | 1.070 Millimoles per liter | Standard Deviation 0.1804 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Baseline, n=102, 99 | 1.063 Millimoles per liter | Standard Deviation 0.17 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 4, n=99, 97 | 1.082 Millimoles per liter | Standard Deviation 0.1857 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 8, n=73, 98 | 1.071 Millimoles per liter | Standard Deviation 0.2001 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 12, n=99, 95 | 1.078 Millimoles per liter | Standard Deviation 0.1823 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 20, n=93, 97 | 1.091 Millimoles per liter | Standard Deviation 0.1757 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 24, n=94, 95 | 1.052 Millimoles per liter | Standard Deviation 0.1921 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 40, n=90, 95 | 1.062 Millimoles per liter | Standard Deviation 0.1731 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 44, n=91, 94 | 1.066 Millimoles per liter | Standard Deviation 0.2029 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 48, n=91, 95 | 1.066 Millimoles per liter | Standard Deviation 0.1918 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 4, n=151, 153 | 1.056 Millimoles per liter | Standard Deviation 0.1764 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 8, n=122, 152 | 1.024 Millimoles per liter | Standard Deviation 0.1784 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 12, n=146, 152 | 1.051 Millimoles per liter | Standard Deviation 0.2002 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 16, n=143, 149 | 1.046 Millimoles per liter | Standard Deviation 0.17 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 8, n=73, 98 | 103.5 Millimoles per liter | Standard Deviation 2.58 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 28, n=136, 150 | 1.038 Millimoles per liter | Standard Deviation 0.1585 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 32, n=137, 148 | 1.050 Millimoles per liter | Standard Deviation 0.1874 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 36, n=135, 147 | 1.039 Millimoles per liter | Standard Deviation 0.1793 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 40, n=138, 147 | 1.033 Millimoles per liter | Standard Deviation 0.1724 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 44, n=137, 148 | 1.040 Millimoles per liter | Standard Deviation 0.1693 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 48, n=131, 147 | 1.037 Millimoles per liter | Standard Deviation 0.1789 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 16, n=48, 53 | 4.30 Millimoles per liter | Standard Deviation 0.359 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 20, n=46, 53 | 4.29 Millimoles per liter | Standard Deviation 0.314 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 24, n=47, 53 | 4.30 Millimoles per liter | Standard Deviation 0.379 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 28, n=42, 53 | 4.26 Millimoles per liter | Standard Deviation 0.348 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 32, n=45, 51 | 4.31 Millimoles per liter | Standard Deviation 0.367 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 36, n=44, 50 | 4.26 Millimoles per liter | Standard Deviation 0.378 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 48, n=43, 50 | 4.12 Millimoles per liter | Standard Deviation 0.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Baseline, n=102, 99 | 4.18 Millimoles per liter | Standard Deviation 0.289 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 4, n=99, 97 | 4.26 Millimoles per liter | Standard Deviation 0.359 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 8, n=73, 98 | 4.24 Millimoles per liter | Standard Deviation 0.462 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 12, n=99, 95 | 4.18 Millimoles per liter | Standard Deviation 0.291 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 16, n=93, 96 | 4.19 Millimoles per liter | Standard Deviation 0.297 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 24, n=94, 95 | 4.21 Millimoles per liter | Standard Deviation 0.304 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium,Week 28, n=89, 93 | 4.22 Millimoles per liter | Standard Deviation 0.341 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 32, n=93, 95 | 4.19 Millimoles per liter | Standard Deviation 0.307 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 36, n=94, 95 | 4.23 Millimoles per liter | Standard Deviation 0.332 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 40, n=90, 95 | 4.19 Millimoles per liter | Standard Deviation 0.297 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 44, n=91, 94 | 4.17 Millimoles per liter | Standard Deviation 0.314 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 48, n=91, 95 | 4.16 Millimoles per liter | Standard Deviation 0.305 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Baseline, n=155, 155 | 4.18 Millimoles per liter | Standard Deviation 0.331 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 4, n=151, 153 | 4.28 Millimoles per liter | Standard Deviation 0.333 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 8, n=122, 152 | 4.23 Millimoles per liter | Standard Deviation 0.366 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 12, n=146, 152 | 4.26 Millimoles per liter | Standard Deviation 0.341 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 16, n=143, 149 | 4.23 Millimoles per liter | Standard Deviation 0.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium,Week 20, n=138, 152 | 4.21 Millimoles per liter | Standard Deviation 0.337 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 24, n=143, 150 | 4.22 Millimoles per liter | Standard Deviation 0.341 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 28, n=136, 150 | 4.25 Millimoles per liter | Standard Deviation 0.434 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 36, n=135, 147 | 4.22 Millimoles per liter | Standard Deviation 0.343 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 40, n=138, 147 | 4.26 Millimoles per liter | Standard Deviation 0.321 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 44, n=137, 148 | 4.24 Millimoles per liter | Standard Deviation 0.374 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 20, n=46, 53 | 139.1 Millimoles per liter | Standard Deviation 1.97 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 24, n=47, 53 | 139.1 Millimoles per liter | Standard Deviation 2.07 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 28, n=42, 53 | 139.5 Millimoles per liter | Standard Deviation 2.49 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 32, n=45, 51 | 139.3 Millimoles per liter | Standard Deviation 2.28 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 36, n=44, 50 | 139.4 Millimoles per liter | Standard Deviation 2.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 40, n=42, 51 | 139.4 Millimoles per liter | Standard Deviation 1.93 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 44, n=47, 51 | 139.4 Millimoles per liter | Standard Deviation 2.09 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 48, n=43, 50 | 139.6 Millimoles per liter | Standard Deviation 1.9 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Baseline, n=102, 99 | 139.0 Millimoles per liter | Standard Deviation 1.67 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 4, n=99, 97 | 139.1 Millimoles per liter | Standard Deviation 1.72 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 8, n=73, 98 | 138.8 Millimoles per liter | Standard Deviation 1.79 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 12, n=99, 95 | 139.0 Millimoles per liter | Standard Deviation 1.88 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 16, n=93, 96 | 139.4 Millimoles per liter | Standard Deviation 1.89 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 20, n=93, 97 | 139.2 Millimoles per liter | Standard Deviation 1.67 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 24, n=94, 95 | 139.1 Millimoles per liter | Standard Deviation 1.91 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 28, n=89, 93 | 138.8 Millimoles per liter | Standard Deviation 1.67 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 32, n=93, 95 | 139.2 Millimoles per liter | Standard Deviation 1.68 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 36, n=94, 95 | 139.4 Millimoles per liter | Standard Deviation 1.99 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 40, n=90, 95 | 139.3 Millimoles per liter | Standard Deviation 1.83 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 44, n=91, 94 | 139.4 Millimoles per liter | Standard Deviation 1.88 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Baseline, n=155, 155 | 139.2 Millimoles per liter | Standard Deviation 1.68 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 4, n=151, 153 | 139.2 Millimoles per liter | Standard Deviation 1.9 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 8, n=122, 152 | 139.2 Millimoles per liter | Standard Deviation 1.76 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 12, n=146, 152 | 139.2 Millimoles per liter | Standard Deviation 1.77 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 16, n=143, 149 | 139.0 Millimoles per liter | Standard Deviation 2.06 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 20, n=138, 152 | 139.5 Millimoles per liter | Standard Deviation 1.83 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 24, n=143, 151 | 139.4 Millimoles per liter | Standard Deviation 1.94 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 28, n=136, 150 | 139.4 Millimoles per liter | Standard Deviation 1.99 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 32, n=137, 148 | 139.7 Millimoles per liter | Standard Deviation 1.75 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 36, n=135, 147 | 139.7 Millimoles per liter | Standard Deviation 2.19 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 40, n=138, 147 | 139.7 Millimoles per liter | Standard Deviation 2.06 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Baseline, n=51, 54 | 4.89 Millimoles per liter | Standard Deviation 1.316 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 4, n=51, 53 | 4.91 Millimoles per liter | Standard Deviation 1.455 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 8, n=34, 53 | 4.88 Millimoles per liter | Standard Deviation 1.447 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 12, n=50, 52 | 4.85 Millimoles per liter | Standard Deviation 1.48 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 16, n=48, 53 | 5.09 Millimoles per liter | Standard Deviation 1.754 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 20, n=46, 53 | 5.07 Millimoles per liter | Standard Deviation 1.535 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 24, n=47, 53 | 5.00 Millimoles per liter | Standard Deviation 1.414 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 28, n=42, 53 | 4.90 Millimoles per liter | Standard Deviation 1.53 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 32, n=45, 51 | 5.09 Millimoles per liter | Standard Deviation 1.482 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 36, n=44, 50 | 4.78 Millimoles per liter | Standard Deviation 1.411 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 40, n=42, 51 | 5.30 Millimoles per liter | Standard Deviation 1.758 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 48, n=43, 50 | 5.11 Millimoles per liter | Standard Deviation 1.489 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Baseline, n=102, 99 | 5.61 Millimoles per liter | Standard Deviation 1.894 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 4, n=99, 97 | 5.77 Millimoles per liter | Standard Deviation 1.676 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 8, n=73, 98 | 5.60 Millimoles per liter | Standard Deviation 1.607 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 12, n=99, 95 | 5.83 Millimoles per liter | Standard Deviation 1.724 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 16, n=93, 96 | 5.70 Millimoles per liter | Standard Deviation 1.574 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 20, n=93, 97 | 5.76 Millimoles per liter | Standard Deviation 1.58 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 24, n=94, 95 | 5.72 Millimoles per liter | Standard Deviation 1.774 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 28, n=89, 93 | 5.65 Millimoles per liter | Standard Deviation 1.435 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 32, n=93, 95 | 5.63 Millimoles per liter | Standard Deviation 1.477 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 36, n=94, 95 | 5.53 Millimoles per liter | Standard Deviation 1.456 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 40, n=90, 95 | 5.66 Millimoles per liter | Standard Deviation 1.593 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 44, n=91, 94 | 5.46 Millimoles per liter | Standard Deviation 1.368 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 48, n=91, 95 | 5.50 Millimoles per liter | Standard Deviation 1.468 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Baseline, n=155, 155 | 5.10 Millimoles per liter | Standard Deviation 1.51 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 4, n=151, 153 | 5.09 Millimoles per liter | Standard Deviation 1.426 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 8, n=122, 152 | 5.10 Millimoles per liter | Standard Deviation 1.465 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 12, n=146, 152 | 5.13 Millimoles per liter | Standard Deviation 1.583 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 16, n=143, 149 | 5.34 Millimoles per liter | Standard Deviation 1.66 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 20, n=138, 152 | 5.15 Millimoles per liter | Standard Deviation 1.713 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 24, n=143, 151 | 5.26 Millimoles per liter | Standard Deviation 1.591 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 28, n=136, 150 | 5.10 Millimoles per liter | Standard Deviation 1.537 |
Secondary
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin
Blood samples were collected for the analysis of clinical chemistry parameter: albumin to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 48, n=91, 95 | 44.3 Grams per Liter | Standard Deviation 2.58 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 36, n=44, 50 | 43.5 Grams per Liter | Standard Deviation 2.87 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 44, n=47, 51 | 43.6 Grams per Liter | Standard Deviation 2.58 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 48, n=43, 50 | 43.9 Grams per Liter | Standard Deviation 2.97 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Baseline, n=102, 99 | 44.3 Grams per Liter | Standard Deviation 3.08 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 4, n=151, 153 | 43.4 Grams per Liter | Standard Deviation 2.83 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 16, n=143, 149 | 43.3 Grams per Liter | Standard Deviation 2.61 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 44, n=137, 148 | 43.7 Grams per Liter | Standard Deviation 2.74 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 48, n=131, 147 | 43.4 Grams per Liter | Standard Deviation 2.73 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Baseline, n=51, 54 | 43.9 Grams per Liter | Standard Deviation 3.22 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 4, n=51, 53 | 44.1 Grams per Liter | Standard Deviation 2.9 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 8, n=34, 53 | 44.6 Grams per Liter | Standard Deviation 3.36 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 12, n=50, 52 | 43.7 Grams per Liter | Standard Deviation 3.25 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 16, n=48, 53 | 43.8 Grams per Liter | Standard Deviation 3.19 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 20, n=46, 53 | 43.6 Grams per Liter | Standard Deviation 2.7 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 24, n=47, 53 | 43.5 Grams per Liter | Standard Deviation 2.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 28, n=42, 53 | 43.5 Grams per Liter | Standard Deviation 2.74 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 40, n=42, 51 | 44.2 Grams per Liter | Standard Deviation 2.64 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 4, n=99, 97 | 43.9 Grams per Liter | Standard Deviation 2.91 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 8, n=73, 98 | 43.7 Grams per Liter | Standard Deviation 3.07 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 12, n=99, 95 | 44.1 Grams per Liter | Standard Deviation 3.01 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 16, n=93, 96 | 43.9 Grams per Liter | Standard Deviation 2.77 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 20, n=93, 97 | 43.6 Grams per Liter | Standard Deviation 2.7 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 24, n=94, 95 | 43.4 Grams per Liter | Standard Deviation 3.03 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 28, n=89, 93 | 44.0 Grams per Liter | Standard Deviation 2.97 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 32, n=93, 95 | 44.1 Grams per Liter | Standard Deviation 2.87 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 36, n=94, 95 | 43.6 Grams per Liter | Standard Deviation 2.74 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 40, n=90, 95 | 44.1 Grams per Liter | Standard Deviation 2.79 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 44, n=91, 94 | 43.6 Grams per Liter | Standard Deviation 2.96 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 32, n=45, 51 | 43.2 Grams per Liter | Standard Deviation 2.85 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Baseline, n=155, 155 | 44.1 Grams per Liter | Standard Deviation 3.11 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 8, n=122, 152 | 43.6 Grams per Liter | Standard Deviation 2.96 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 12, n=146, 152 | 43.3 Grams per Liter | Standard Deviation 2.86 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 20, n=138, 152 | 43.1 Grams per Liter | Standard Deviation 2.75 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 24, n=143, 151 | 43.4 Grams per Liter | Standard Deviation 2.54 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 28, n=136, 150 | 43.3 Grams per Liter | Standard Deviation 2.78 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 32, n=137, 148 | 43.2 Grams per Liter | Standard Deviation 2.74 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 36, n=135, 147 | 43.0 Grams per Liter | Standard Deviation 2.86 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 40, n=138, 147 | 43.3 Grams per Liter | Standard Deviation 2.66 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 20, n=138, 152 | 43.2 Grams per Liter | Standard Deviation 2.98 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 32, n=45, 51 | 43.7 Grams per Liter | Standard Deviation 3.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 4, n=99, 97 | 43.8 Grams per Liter | Standard Deviation 2.57 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 36, n=44, 50 | 43.4 Grams per Liter | Standard Deviation 3.02 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 44, n=91, 94 | 43.8 Grams per Liter | Standard Deviation 2.83 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 44, n=47, 51 | 43.9 Grams per Liter | Standard Deviation 3.03 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 8, n=73, 98 | 43.9 Grams per Liter | Standard Deviation 3.1 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 48, n=43, 50 | 44.5 Grams per Liter | Standard Deviation 2.44 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 32, n=137, 148 | 43.1 Grams per Liter | Standard Deviation 3.43 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Baseline, n=102, 99 | 44.9 Grams per Liter | Standard Deviation 3.21 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 16, n=93, 96 | 43.7 Grams per Liter | Standard Deviation 2.76 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 32, n=93, 95 | 43.7 Grams per Liter | Standard Deviation 2.89 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Baseline, n=155, 155 | 44.0 Grams per Liter | Standard Deviation 3.1 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 12, n=99, 95 | 44.3 Grams per Liter | Standard Deviation 2.62 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 4, n=151, 153 | 43.7 Grams per Liter | Standard Deviation 3.04 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 48, n=91, 95 | 44.3 Grams per Liter | Standard Deviation 2.73 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 16, n=143, 149 | 43.3 Grams per Liter | Standard Deviation 3.27 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 40, n=138, 147 | 43.1 Grams per Liter | Standard Deviation 3.2 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 24, n=143, 151 | 43.4 Grams per Liter | Standard Deviation 3.01 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 44, n=137, 148 | 43.2 Grams per Liter | Standard Deviation 3.13 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 20, n=93, 97 | 44.1 Grams per Liter | Standard Deviation 2.87 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 48, n=131, 147 | 43.6 Grams per Liter | Standard Deviation 3.14 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Baseline, n=51, 54 | 44.2 Grams per Liter | Standard Deviation 3.36 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 24, n=94, 95 | 43.9 Grams per Liter | Standard Deviation 3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 4, n=51, 53 | 43.9 Grams per Liter | Standard Deviation 2.92 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 8, n=122, 152 | 43.4 Grams per Liter | Standard Deviation 3.16 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 8, n=34, 53 | 44.1 Grams per Liter | Standard Deviation 3.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 28, n=89, 93 | 43.9 Grams per Liter | Standard Deviation 2.87 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 12, n=50, 52 | 43.8 Grams per Liter | Standard Deviation 3.56 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 28, n=136, 150 | 43.2 Grams per Liter | Standard Deviation 3.03 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 16, n=48, 53 | 43.4 Grams per Liter | Standard Deviation 3.36 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 12, n=146, 152 | 43.7 Grams per Liter | Standard Deviation 3.25 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 20, n=46, 53 | 43.3 Grams per Liter | Standard Deviation 3.57 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 36, n=94, 95 | 43.7 Grams per Liter | Standard Deviation 2.6 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 24, n=47, 53 | 43.3 Grams per Liter | Standard Deviation 3.09 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 36, n=135, 147 | 43.3 Grams per Liter | Standard Deviation 3.37 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 28, n=42, 53 | 42.8 Grams per Liter | Standard Deviation 3.43 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 40, n=90, 95 | 43.6 Grams per Liter | Standard Deviation 2.7 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 40, n=42, 51 | 43.9 Grams per Liter | Standard Deviation 3.11 |
Secondary
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK
Blood samples were collected for the analysis of clinical chemistry parameters to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 4, n=99, 97 | 225.9 International units per liter | Standard Deviation 484.5 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 40, n=90, 95 | 65.1 International units per liter | Standard Deviation 17.07 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 28, n=89, 93 | 21.5 International units per liter | Standard Deviation 13.06 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 44, n=91, 94 | 64.0 International units per liter | Standard Deviation 16.71 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Baseline, n=51, 54 | 19.3 International units per liter | Standard Deviation 11.23 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 48, n=91, 95 | 65.1 International units per liter | Standard Deviation 15.98 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Baseline, n=155, 155 | 84.4 International units per liter | Standard Deviation 32.47 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 32, n=93, 95 | 22.5 International units per liter | Standard Deviation 10.95 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 4, n=151, 153 | 73.4 International units per liter | Standard Deviation 26.16 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 36, n=94, 95 | 26.5 International units per liter | Standard Deviation 38.41 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 8, n=122, 152 | 70.9 International units per liter | Standard Deviation 20 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 24, n=143, 150 | 25.1 International units per liter | Standard Deviation 30.4 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 12, n=146, 152 | 72.0 International units per liter | Standard Deviation 30.68 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 40, n=90, 95 | 30.2 International units per liter | Standard Deviation 61.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 16, n=143, 149 | 69.9 International units per liter | Standard Deviation 22.37 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 4, n=51, 53 | 28.7 International units per liter | Standard Deviation 20.12 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 20, n=138, 152 | 69.3 International units per liter | Standard Deviation 20.51 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 44, n=91, 94 | 23.2 International units per liter | Standard Deviation 15.03 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 24, n=143, 151 | 70.2 International units per liter | Standard Deviation 21.08 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 48, n=91, 95 | 24.4 International units per liter | Standard Deviation 17.58 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 28, n=136, 150 | 69.3 International units per liter | Standard Deviation 20.91 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 8, n=73, 98 | 306.8 International units per liter | Standard Deviation 791.76 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 32, n=137, 148 | 69.1 International units per liter | Standard Deviation 21.6 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Baseline, n=155, 155 | 24.6 International units per liter | Standard Deviation 12.67 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 36, n=135, 147 | 69.3 International units per liter | Standard Deviation 23.22 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 8, n=34, 53 | 25.8 International units per liter | Standard Deviation 19.28 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 40, n=138, 147 | 67.1 International units per liter | Standard Deviation 18.98 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 44, n=137, 148 | 68.4 International units per liter | Standard Deviation 19.94 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 4, n=151, 153 | 21.6 International units per liter | Standard Deviation 10.72 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 48, n=131, 147 | 68.5 International units per liter | Standard Deviation 21.69 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 8, n=122, 152 | 20.8 International units per liter | Standard Deviation 10.13 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Baseline, n=51, 54 | 19.7 International units per liter | Standard Deviation 6.97 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 12, n=146, 152 | 33.9 International units per liter | Standard Deviation 161.81 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 4, n=51, 53 | 23.5 International units per liter | Standard Deviation 9.76 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 12, n=50, 52 | 24.7 International units per liter | Standard Deviation 17.09 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 8, n=34, 53 | 23.4 International units per liter | Standard Deviation 11.04 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 16, n=143, 149 | 23.2 International units per liter | Standard Deviation 27.18 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 12, n=50, 52 | 22.5 International units per liter | Standard Deviation 11.6 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 4, n=99, 97 | 26.5 International units per liter | Standard Deviation 18.35 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 16, n=48, 53 | 23.7 International units per liter | Standard Deviation 15.77 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 20, n=138, 152 | 22.6 International units per liter | Standard Deviation 27.36 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 20, n=46, 53 | 24.1 International units per liter | Standard Deviation 20.53 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 16, n=48, 53 | 26.3 International units per liter | Standard Deviation 19.89 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 24, n=47, 53 | 21.5 International units per liter | Standard Deviation 7.02 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 24, n=143, 151 | 27.4 International units per liter | Standard Deviation 85.7 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 28, n=42, 53 | 22.9 International units per liter | Standard Deviation 9.2 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 36, n=94, 95 | 190.7 International units per liter | Standard Deviation 268.67 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 32, n=45, 51 | 23.0 International units per liter | Standard Deviation 13.51 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 28, n=136, 150 | 20.6 International units per liter | Standard Deviation 11.45 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 36, n=44, 50 | 21.5 International units per liter | Standard Deviation 7.88 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 20, n=46, 53 | 24.9 International units per liter | Standard Deviation 18.46 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 44, n=47, 51 | 21.6 International units per liter | Standard Deviation 8.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 32, n=137, 148 | 21.1 International units per liter | Standard Deviation 12.69 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 48, n=43, 50 | 21.6 International units per liter | Standard Deviation 7.59 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 4, n=151, 153 | 192.5 International units per liter | Standard Deviation 472.95 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Baseline, n=102, 99 | 24.5 International units per liter | Standard Deviation 13.03 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 36, n=135, 147 | 21.2 International units per liter | Standard Deviation 12.38 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 4, n=99, 97 | 24.5 International units per liter | Standard Deviation 13.22 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 24, n=47, 53 | 24.1 International units per liter | Standard Deviation 13.75 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 8, n=73, 98 | 26.8 International units per liter | Standard Deviation 25.34 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 40, n=138, 147 | 20.8 International units per liter | Standard Deviation 10.63 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 12, n=99, 95 | 23.2 International units per liter | Standard Deviation 10.47 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Baseline, n=51, 54 | 121.3 International units per liter | Standard Deviation 173.52 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 16, n=93, 96 | 22.5 International units per liter | Standard Deviation 8.78 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 44, n=137, 148 | 20.0 International units per liter | Standard Deviation 9.61 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 20, n=93, 97 | 22.8 International units per liter | Standard Deviation 10.11 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 28, n=42, 53 | 22.0 International units per liter | Standard Deviation 12.42 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 24, n=94, 95 | 24.4 International units per liter | Standard Deviation 12.42 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 48, n=131, 147 | 19.8 International units per liter | Standard Deviation 9.62 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 28, n=89, 93 | 21.3 International units per liter | Standard Deviation 7.14 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 8, n=122, 152 | 290.4 International units per liter | Standard Deviation 1322.89 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 32, n=93, 95 | 22.2 International units per liter | Standard Deviation 7.77 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Baseline, n=51, 54 | 73.8 International units per liter | Standard Deviation 24.9 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 36, n=94, 95 | 23.9 International units per liter | Standard Deviation 15.06 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 32, n=45, 51 | 22.7 International units per liter | Standard Deviation 15.18 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 40, n=90, 95 | 25.4 International units per liter | Standard Deviation 18.01 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 4, n=51, 53 | 70.4 International units per liter | Standard Deviation 20.03 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 44, n=91, 94 | 25.6 International units per liter | Standard Deviation 23.29 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 40, n=42, 51 | 25.1 International units per liter | Standard Deviation 23.51 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 48, n=91, 95 | 24.9 International units per liter | Standard Deviation 13.88 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 8, n=34, 53 | 72.4 International units per liter | Standard Deviation 34.86 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Baseline, n=155, 155 | 24.8 International units per liter | Standard Deviation 10.99 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 36, n=44, 50 | 22.3 International units per liter | Standard Deviation 15.09 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 4, n=151, 153 | 22.2 International units per liter | Standard Deviation 11.35 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 12, n=50, 52 | 68.2 International units per liter | Standard Deviation 17.49 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 12, n=146, 152 | 29.4 International units per liter | Standard Deviation 91.34 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 12, n=146, 152 | 198.5 International units per liter | Standard Deviation 430.65 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 16, n=143, 149 | 25.3 International units per liter | Standard Deviation 22.91 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 16, n=48, 53 | 66.9 International units per liter | Standard Deviation 15.7 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 20, n=138, 152 | 23.8 International units per liter | Standard Deviation 16.12 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 40, n=42, 51 | 24.9 International units per liter | Standard Deviation 19.63 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 28, n=136, 150 | 22.6 International units per liter | Standard Deviation 9.49 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 20, n=46, 53 | 67.7 International units per liter | Standard Deviation 16.36 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 32, n=137, 148 | 23.2 International units per liter | Standard Deviation 16.69 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 8, n=122, 152 | 23.0 International units per liter | Standard Deviation 17.16 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 36, n=135, 147 | 22.8 International units per liter | Standard Deviation 8.9 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 28, n=42, 53 | 67.3 International units per liter | Standard Deviation 17.71 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 40, n=138, 147 | 22.3 International units per liter | Standard Deviation 7.66 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 44, n=47, 51 | 23.2 International units per liter | Standard Deviation 17.05 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 44, n=137, 148 | 21.7 International units per liter | Standard Deviation 7.11 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 32, n=45, 51 | 63.8 International units per liter | Standard Deviation 16.09 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 48, n=131, 147 | 22.0 International units per liter | Standard Deviation 7.86 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 4, n=51, 53 | 130.0 International units per liter | Standard Deviation 94.61 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 24, n=143, 151 | 210.9 International units per liter | Standard Deviation 582.66 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 8, n=34, 53 | 157.7 International units per liter | Standard Deviation 174.37 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 36, n=44, 50 | 64.3 International units per liter | Standard Deviation 16.5 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 12, n=50, 52 | 124.2 International units per liter | Standard Deviation 71.36 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 48, n=43, 50 | 22.5 International units per liter | Standard Deviation 13.28 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 16, n=48, 53 | 142.3 International units per liter | Standard Deviation 197.96 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 40, n=42, 51 | 65.5 International units per liter | Standard Deviation 13.63 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 20, n=46, 53 | 227.9 International units per liter | Standard Deviation 689.65 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 24, n=47, 53 | 67.6 International units per liter | Standard Deviation 16.14 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 24, n=47, 53 | 120.8 International units per liter | Standard Deviation 72.63 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 28, n=42, 53 | 185.9 International units per liter | Standard Deviation 237.49 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 44, n=47, 51 | 63.0 International units per liter | Standard Deviation 15.76 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 32, n=45, 51 | 282.5 International units per liter | Standard Deviation 959.49 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 48, n=43, 50 | 63.6 International units per liter | Standard Deviation 14.22 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 36, n=44, 50 | 115.5 International units per liter | Standard Deviation 81.36 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 36, n=135, 147 | 206.4 International units per liter | Standard Deviation 401.19 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 40, n=42, 51 | 319.4 International units per liter | Standard Deviation 1169.15 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Baseline, n=102, 99 | 66.3 International units per liter | Standard Deviation 17.31 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 48, n=43, 50 | 123.5 International units per liter | Standard Deviation 90.77 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 8, n=73, 98 | 28.4 International units per liter | Standard Deviation 22.77 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Baseline, n=102, 99 | 257.9 International units per liter | Standard Deviation 565.99 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 4, n=99, 97 | 65.9 International units per liter | Standard Deviation 17.25 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 12, n=99, 95 | 242.5 International units per liter | Standard Deviation 649.06 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 12, n=99, 95 | 23.8 International units per liter | Standard Deviation 14.21 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 16, n=93, 96 | 198.6 International units per liter | Standard Deviation 335.16 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 8, n=73, 98 | 64.0 International units per liter | Standard Deviation 16.21 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 20, n=93, 97 | 200.9 International units per liter | Standard Deviation 301.61 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 44, n=47, 51 | 117.2 International units per liter | Standard Deviation 74.25 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 24, n=94, 95 | 202.1 International units per liter | Standard Deviation 276.49 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 12, n=99, 95 | 64.7 International units per liter | Standard Deviation 16.33 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 28, n=89, 93 | 151.1 International units per liter | Standard Deviation 128.42 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 16, n=93, 96 | 23.2 International units per liter | Standard Deviation 13.62 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 32, n=93, 95 | 182.2 International units per liter | Standard Deviation 202.28 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 16, n=93, 96 | 65.3 International units per liter | Standard Deviation 17.01 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 40, n=90, 95 | 286.9 International units per liter | Standard Deviation 705.76 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 40, n=138, 147 | 175.6 International units per liter | Standard Deviation 156.39 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 44, n=91, 94 | 457.7 International units per liter | Standard Deviation 2054.68 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 20, n=93, 97 | 64.9 International units per liter | Standard Deviation 16.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 48, n=91, 95 | 278.9 International units per liter | Standard Deviation 651.96 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 20, n=93, 97 | 23.0 International units per liter | Standard Deviation 15.29 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Baseline, n=155, 155 | 180.9 International units per liter | Standard Deviation 210.84 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 24, n=94, 95 | 65.0 International units per liter | Standard Deviation 17.08 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 28, n=89, 93 | 65.0 International units per liter | Standard Deviation 15.81 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 16, n=143, 149 | 326.5 International units per liter | Standard Deviation 1157.93 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 48, n=131, 147 | 167.8 International units per liter | Standard Deviation 132.83 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 20, n=138, 152 | 247.2 International units per liter | Standard Deviation 661.97 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 32, n=93, 95 | 64.4 International units per liter | Standard Deviation 16.12 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 28, n=136, 150 | 175.0 International units per liter | Standard Deviation 156.46 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 24, n=94, 95 | 25.7 International units per liter | Standard Deviation 20.09 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 32, n=137, 148 | 218.0 International units per liter | Standard Deviation 617.2 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 36, n=94, 95 | 64.3 International units per liter | Standard Deviation 18.15 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 44, n=137, 148 | 148.6 International units per liter | Standard Deviation 94.67 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Baseline, n=102, 99 | 24.8 International units per liter | Standard Deviation 15.23 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 44, n=137, 148 | 159.7 International units per liter | Standard Deviation 171.66 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Baseline, n=102, 99 | 21.2 International units per liter | Standard Deviation 10.93 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 8, n=73, 98 | 26.8 International units per liter | Standard Deviation 49.37 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 32, n=93, 95 | 21.1 International units per liter | Standard Deviation 12.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 44, n=91, 94 | 20.7 International units per liter | Standard Deviation 10.01 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 4, n=151, 153 | 23.7 International units per liter | Standard Deviation 11.16 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 20, n=46, 53 | 70.8 International units per liter | Standard Deviation 20.96 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 44, n=47, 51 | 69.1 International units per liter | Standard Deviation 20.67 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 24, n=94, 95 | 64.4 International units per liter | Standard Deviation 19.46 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 48, n=91, 95 | 63.0 International units per liter | Standard Deviation 18.76 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 40, n=138, 147 | 87.8 International units per liter | Standard Deviation 27.07 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 36, n=44, 50 | 21.8 International units per liter | Standard Deviation 7.04 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 8, n=122, 152 | 22.8 International units per liter | Standard Deviation 7.19 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 24, n=143, 150 | 23.1 International units per liter | Standard Deviation 8.25 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 48, n=131, 147 | 24.2 International units per liter | Standard Deviation 9.16 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Baseline, n=51, 54 | 111.8 International units per liter | Standard Deviation 66.03 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 24, n=47, 53 | 128.9 International units per liter | Standard Deviation 85.38 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 40, n=42, 51 | 109.9 International units per liter | Standard Deviation 53.99 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 4, n=99, 97 | 193.6 International units per liter | Standard Deviation 415.15 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 8, n=73, 98 | 158.0 International units per liter | Standard Deviation 164.72 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 32, n=93, 95 | 175.1 International units per liter | Standard Deviation 256.84 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 4, n=151, 153 | 170.1 International units per liter | Standard Deviation 226.58 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 8, n=122, 152 | 141.1 International units per liter | Standard Deviation 106.01 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 20, n=138, 152 | 144.9 International units per liter | Standard Deviation 131.72 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 32, n=137, 148 | 238.8 International units per liter | Standard Deviation 656.12 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 36, n=135, 147 | 155.5 International units per liter | Standard Deviation 134.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 48, n=131, 147 | 171.3 International units per liter | Standard Deviation 256.04 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Baseline, n=51, 54 | 18.7 International units per liter | Standard Deviation 9.13 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 4, n=51, 53 | 19.8 International units per liter | Standard Deviation 12.29 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 8, n=34, 53 | 19.6 International units per liter | Standard Deviation 10.43 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 12, n=50, 52 | 20.1 International units per liter | Standard Deviation 14.19 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 16, n=48, 53 | 20.0 International units per liter | Standard Deviation 12.04 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 20, n=46, 53 | 19.0 International units per liter | Standard Deviation 9.52 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 24, n=47, 53 | 19.1 International units per liter | Standard Deviation 10.02 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 28, n=42, 53 | 19.4 International units per liter | Standard Deviation 10.45 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 32, n=45, 51 | 18.8 International units per liter | Standard Deviation 8.18 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 36, n=44, 50 | 20.7 International units per liter | Standard Deviation 13.18 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 40, n=42, 51 | 19.5 International units per liter | Standard Deviation 13.46 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 44, n=47, 51 | 19.3 International units per liter | Standard Deviation 14.23 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 48, n=43, 50 | 19.0 International units per liter | Standard Deviation 8.52 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 4, n=99, 97 | 21.7 International units per liter | Standard Deviation 10.09 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 12, n=99, 95 | 22.9 International units per liter | Standard Deviation 16.05 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 16, n=93, 96 | 21.2 International units per liter | Standard Deviation 11.24 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 20, n=93, 97 | 20.7 International units per liter | Standard Deviation 9.83 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 24, n=94, 95 | 21.0 International units per liter | Standard Deviation 13.4 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 28, n=89, 93 | 20.9 International units per liter | Standard Deviation 14.1 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 36, n=94, 95 | 20.5 International units per liter | Standard Deviation 9.38 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 40, n=90, 95 | 20.6 International units per liter | Standard Deviation 9.2 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 48, n=91, 95 | 20.3 International units per liter | Standard Deviation 9.79 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Baseline, n=155, 155 | 24.4 International units per liter | Standard Deviation 14.74 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 8, n=122, 152 | 23.7 International units per liter | Standard Deviation 12.94 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 12, n=146, 152 | 23.6 International units per liter | Standard Deviation 11.27 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 16, n=143, 149 | 22.8 International units per liter | Standard Deviation 11.06 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 20, n=138, 152 | 22.3 International units per liter | Standard Deviation 11.15 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 24, n=143, 151 | 22.9 International units per liter | Standard Deviation 12.88 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 28, n=136, 150 | 23.8 International units per liter | Standard Deviation 16 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 32, n=137, 148 | 23.4 International units per liter | Standard Deviation 12.86 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 36, n=135, 147 | 24.1 International units per liter | Standard Deviation 13.19 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 40, n=138, 147 | 23.9 International units per liter | Standard Deviation 14.24 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 44, n=137, 148 | 23.9 International units per liter | Standard Deviation 15.22 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 48, n=131, 147 | 23.5 International units per liter | Standard Deviation 12.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Baseline, n=51, 54 | 70.2 International units per liter | Standard Deviation 19.56 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 4, n=51, 53 | 67.7 International units per liter | Standard Deviation 19.24 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 8, n=34, 53 | 70.9 International units per liter | Standard Deviation 23.18 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 12, n=50, 52 | 71.6 International units per liter | Standard Deviation 23.6 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 16, n=48, 53 | 71.2 International units per liter | Standard Deviation 21.5 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 24, n=47, 53 | 70.3 International units per liter | Standard Deviation 19.23 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 28, n=42, 53 | 73.7 International units per liter | Standard Deviation 21.89 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 32, n=45, 51 | 69.8 International units per liter | Standard Deviation 21.44 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 36, n=44, 50 | 71.7 International units per liter | Standard Deviation 23.57 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 40, n=42, 51 | 68.5 International units per liter | Standard Deviation 19.55 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 48, n=43, 50 | 69.9 International units per liter | Standard Deviation 18.94 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Baseline, n=102, 99 | 64.9 International units per liter | Standard Deviation 19.05 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 4, n=99, 97 | 64.4 International units per liter | Standard Deviation 18.77 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 8, n=73, 98 | 69.7 International units per liter | Standard Deviation 38.92 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 12, n=99, 95 | 67.7 International units per liter | Standard Deviation 27.73 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 16, n=93, 96 | 64.4 International units per liter | Standard Deviation 20.89 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 20, n=93, 97 | 64.2 International units per liter | Standard Deviation 19.58 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 28, n=89, 93 | 63.3 International units per liter | Standard Deviation 18.76 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 32, n=93, 95 | 62.3 International units per liter | Standard Deviation 17.96 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 36, n=94, 95 | 62.2 International units per liter | Standard Deviation 18.12 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 40, n=90, 95 | 62.2 International units per liter | Standard Deviation 18.22 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 44, n=91, 94 | 64.1 International units per liter | Standard Deviation 19.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Baseline, n=155, 155 | 88.1 International units per liter | Standard Deviation 28.83 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 4, n=151, 153 | 85.6 International units per liter | Standard Deviation 27.39 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 8, n=122, 152 | 87.4 International units per liter | Standard Deviation 28.15 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 12, n=146, 152 | 87.8 International units per liter | Standard Deviation 28.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 16, n=143, 149 | 87.7 International units per liter | Standard Deviation 28.55 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 20, n=138, 152 | 86.7 International units per liter | Standard Deviation 26.18 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 24, n=143, 151 | 88.3 International units per liter | Standard Deviation 27.77 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 28, n=136, 150 | 87.0 International units per liter | Standard Deviation 28.4 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 32, n=137, 148 | 86.5 International units per liter | Standard Deviation 26.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 36, n=135, 147 | 87.1 International units per liter | Standard Deviation 26.24 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 44, n=137, 148 | 87.5 International units per liter | Standard Deviation 26.53 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 48, n=131, 147 | 88.6 International units per liter | Standard Deviation 27.61 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Baseline, n=51, 54 | 20.1 International units per liter | Standard Deviation 5.66 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 4, n=51, 53 | 22.5 International units per liter | Standard Deviation 17.53 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 8, n=34, 53 | 20.0 International units per liter | Standard Deviation 5.24 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 12, n=50, 52 | 21.8 International units per liter | Standard Deviation 9.63 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 16, n=48, 53 | 22.0 International units per liter | Standard Deviation 10.39 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 20, n=46, 53 | 20.6 International units per liter | Standard Deviation 6.35 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 24, n=47, 53 | 21.7 International units per liter | Standard Deviation 11.65 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 28, n=42, 53 | 22.0 International units per liter | Standard Deviation 8.47 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 32, n=45, 51 | 20.3 International units per liter | Standard Deviation 5.57 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 40, n=42, 51 | 20.5 International units per liter | Standard Deviation 7.55 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 44, n=47, 51 | 21.4 International units per liter | Standard Deviation 13.16 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 48, n=43, 50 | 22.2 International units per liter | Standard Deviation 8.85 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Baseline, n=102, 99 | 22.2 International units per liter | Standard Deviation 13.13 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 4, n=99, 97 | 22.0 International units per liter | Standard Deviation 10.41 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 8, n=73, 98 | 23.6 International units per liter | Standard Deviation 19.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 12, n=99, 95 | 23.2 International units per liter | Standard Deviation 13.1 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 16, n=93, 96 | 22.5 International units per liter | Standard Deviation 9.96 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 20, n=93, 97 | 21.4 International units per liter | Standard Deviation 6.12 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 24, n=94, 95 | 22.0 International units per liter | Standard Deviation 9.44 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 28, n=89, 93 | 21.6 International units per liter | Standard Deviation 8.49 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 32, n=93, 95 | 21.6 International units per liter | Standard Deviation 7.87 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 36, n=94, 95 | 21.1 International units per liter | Standard Deviation 5.43 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 40, n=90, 95 | 21.8 International units per liter | Standard Deviation 7.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 44, n=91, 94 | 21.4 International units per liter | Standard Deviation 6.51 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 48, n=91, 95 | 22.4 International units per liter | Standard Deviation 9.7 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Baseline, n=155, 155 | 23.6 International units per liter | Standard Deviation 9.16 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 4, n=151, 153 | 23.2 International units per liter | Standard Deviation 7.95 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 12, n=146, 152 | 23.6 International units per liter | Standard Deviation 9.12 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 16, n=143, 149 | 22.6 International units per liter | Standard Deviation 6.8 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 20, n=138, 152 | 22.9 International units per liter | Standard Deviation 7.33 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 28, n=136, 150 | 24.0 International units per liter | Standard Deviation 10.53 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 32, n=137, 148 | 25.1 International units per liter | Standard Deviation 15.63 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 36, n=135, 147 | 23.9 International units per liter | Standard Deviation 7.99 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 40, n=138, 147 | 23.7 International units per liter | Standard Deviation 8.01 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 44, n=137, 148 | 23.8 International units per liter | Standard Deviation 10.98 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 4, n=51, 53 | 244.2 International units per liter | Standard Deviation 908.06 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 8, n=34, 53 | 134.2 International units per liter | Standard Deviation 179.01 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 12, n=50, 52 | 168.8 International units per liter | Standard Deviation 406.86 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 16, n=48, 53 | 127.0 International units per liter | Standard Deviation 82.59 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 20, n=46, 53 | 117.5 International units per liter | Standard Deviation 76.83 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 28, n=42, 53 | 124.2 International units per liter | Standard Deviation 96.15 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 32, n=45, 51 | 110.1 International units per liter | Standard Deviation 58.84 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 36, n=44, 50 | 130.9 International units per liter | Standard Deviation 95.59 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 44, n=47, 51 | 114.4 International units per liter | Standard Deviation 62.44 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 48, n=43, 50 | 183.1 International units per liter | Standard Deviation 485.07 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Baseline, n=102, 99 | 214.3 International units per liter | Standard Deviation 627.94 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 12, n=99, 95 | 195.3 International units per liter | Standard Deviation 383.74 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 16, n=93, 96 | 216.4 International units per liter | Standard Deviation 422.21 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 20, n=93, 97 | 158.8 International units per liter | Standard Deviation 156.94 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 24, n=94, 95 | 178.8 International units per liter | Standard Deviation 356.6 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 28, n=89, 93 | 192.6 International units per liter | Standard Deviation 463.71 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 36, n=94, 95 | 153.8 International units per liter | Standard Deviation 151.29 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 40, n=90, 95 | 178.2 International units per liter | Standard Deviation 200.25 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 44, n=91, 94 | 153.6 International units per liter | Standard Deviation 139.48 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 48, n=91, 95 | 188.7 International units per liter | Standard Deviation 339.93 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Baseline, n=155, 155 | 143.8 International units per liter | Standard Deviation 118.05 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 12, n=146, 152 | 168.5 International units per liter | Standard Deviation 236.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 16, n=143, 149 | 150.4 International units per liter | Standard Deviation 214.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 24, n=143, 151 | 161.5 International units per liter | Standard Deviation 182.51 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 28, n=136, 150 | 197.3 International units per liter | Standard Deviation 460.97 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 40, n=138, 147 | 166.9 International units per liter | Standard Deviation 191.28 |
Secondary
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Blood samples were collected for the analysis of clinical chemistry parameter: bilirubin, direct bilirubin and creatinine to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 48, n=43, 50 | 2.3 Micromoles per liter | Standard Deviation 0.93 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 16, n=93, 96 | 9.8 Micromoles per liter | Standard Deviation 4.29 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Baseline, n=102, 99 | 2.4 Micromoles per liter | Standard Deviation 0.96 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 4, n=51, 53 | 9.3 Micromoles per liter | Standard Deviation 3.81 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 4, n=99, 97 | 2.4 Micromoles per liter | Standard Deviation 0.9 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 20, n=93, 97 | 10.1 Micromoles per liter | Standard Deviation 4.05 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 8, n=73, 98 | 2.4 Micromoles per liter | Standard Deviation 1.02 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 32, n=93, 95 | 2.2 Micromoles per liter | Standard Deviation 0.94 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 12, n=99, 95 | 2.3 Micromoles per liter | Standard Deviation 0.98 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 24, n=94, 94 | 9.4 Micromoles per liter | Standard Deviation 4.11 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 16, n=93, 96 | 2.3 Micromoles per liter | Standard Deviation 1.03 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 12, n=50, 52 | 8.1 Micromoles per liter | Standard Deviation 3.44 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 20, n=93, 97 | 2.2 Micromoles per liter | Standard Deviation 0.85 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 28, n=89, 93 | 10.3 Micromoles per liter | Standard Deviation 3.53 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 24, n=94, 94 | 2.2 Micromoles per liter | Standard Deviation 1.02 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 8, n=34, 53 | 2.3 Micromoles per liter | Standard Deviation 1.12 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 36, n=94, 95 | 2.2 Micromoles per liter | Standard Deviation 1.25 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 32, n=93, 95 | 9.9 Micromoles per liter | Standard Deviation 4.42 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 40, n=90, 95 | 2.2 Micromoles per liter | Standard Deviation 1.06 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 16, n=48, 53 | 8.7 Micromoles per liter | Standard Deviation 3.95 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 48, n=91, 95 | 2.3 Micromoles per liter | Standard Deviation 0.82 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 36, n=94, 95 | 9.8 Micromoles per liter | Standard Deviation 4.09 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Baseline, n=155, 155 | 2.1 Micromoles per liter | Standard Deviation 1 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, direct bilirubin, Week 16, n=48, 53 | 2.0 Micromoles per liter | Standard Deviation 0.87 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 4, n=151, 153 | 2.2 Micromoles per liter | Standard Deviation 1.06 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 40, n=90, 95 | 9.9 Micromoles per liter | Standard Deviation 4.12 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 8, n=122, 152 | 2.2 Micromoles per liter | Standard Deviation 1.1 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 12, n=146, 152 | 2.2 Micromoles per liter | Standard Deviation 1.12 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 20, n=46, 53 | 9.3 Micromoles per liter | Standard Deviation 3.6 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 44, n=91, 94 | 10.1 Micromoles per liter | Standard Deviation 4.75 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 20, n=138, 152 | 2.2 Micromoles per liter | Standard Deviation 1.07 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin. Week 44, n=91, 94 | 2.3 Micromoles per liter | Standard Deviation 0.99 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 4, n=151, 153 | 8.7 Micromoles per liter | Standard Deviation 4.1 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 28, n=136, 150 | 2.1 Micromoles per liter | Standard Deviation 1.01 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 24, n=47, 53 | 9.5 Micromoles per liter | Standard Deviation 3.42 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 32, n=137, 148 | 2.1 Micromoles per liter | Standard Deviation 1.08 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 8, n=122, 152 | 8.9 Micromoles per liter | Standard Deviation 4.01 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 36, n=135, 147 | 2.1 Micromoles per liter | Standard Deviation 1.1 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 48, n=91, 95 | 10.3 Micromoles per liter | Standard Deviation 4.37 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 40, n=138, 147 | 2.1 Micromoles per liter | Standard Deviation 1.18 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 12, n=146, 152 | 9.3 Micromoles per liter | Standard Deviation 4.66 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 44, n=137, 148 | 2.1 Micromoles per liter | Standard Deviation 0.96 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 28, n=42, 53 | 9.4 Micromoles per liter | Standard Deviation 4.29 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 48, n=131, 147 | 2.2 Micromoles per liter | Standard Deviation 0.98 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 16, n=143, 149 | 10.5 Micromoles per liter | Standard Deviation 14.51 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Baseline, n=51, 54 | 71.41 Micromoles per liter | Standard Deviation 12.315 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 16, n=143, 149 | 2.7 Micromoles per liter | Standard Deviation 6.95 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 4, n=51, 53 | 72.87 Micromoles per liter | Standard Deviation 11.632 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 20, n=138, 152 | 9.6 Micromoles per liter | Standard Deviation 4.63 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 12, n=50, 52 | 70.05 Micromoles per liter | Standard Deviation 11.609 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 32, n=45, 51 | 9.7 Micromoles per liter | Standard Deviation 3.66 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 16, n=48, 53 | 71.05 Micromoles per liter | Standard Deviation 11.778 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 24, n=143, 151 | 9.1 Micromoles per liter | Standard Deviation 3.93 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 20, n=46, 53 | 73.40 Micromoles per liter | Standard Deviation 12.191 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Week 24, Direct bilirubin, n=143, 151 | 2.1 Micromoles per liter | Standard Deviation 1.04 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 24, n=47, 53 | 72.75 Micromoles per liter | Standard Deviation 11.654 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 28, n=136, 150 | 9.7 Micromoles per liter | Standard Deviation 4.17 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 28, n=42, 53 | 75.18 Micromoles per liter | Standard Deviation 13.118 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 36, n=44, 50 | 8.3 Micromoles per liter | Standard Deviation 3.17 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 32, n=45, 51 | 74.59 Micromoles per liter | Standard Deviation 13.73 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 32, n=137, 148 | 9.7 Micromoles per liter | Standard Deviation 4.55 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 36, n=44, 50 | 74.41 Micromoles per liter | Standard Deviation 12.217 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 20, n=46, 53 | 2.2 Micromoles per liter | Standard Deviation 0.79 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 40, n=42, 51 | 74.31 Micromoles per liter | Standard Deviation 11.749 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 36, n=135, 147 | 9.3 Micromoles per liter | Standard Deviation 3.72 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 44, n=47, 51 | 75.38 Micromoles per liter | Standard Deviation 13.405 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 40, n=42, 51 | 9.2 Micromoles per liter | Standard Deviation 3.51 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 48, n=43, 50 | 76.95 Micromoles per liter | Standard Deviation 13.021 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 40, n=138, 147 | 9.6 Micromoles per liter | Standard Deviation 4.21 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Baseline, n=102, 99 | 88.16 Micromoles per liter | Standard Deviation 16.835 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 8, n=34, 53 | 71.66 Micromoles per liter | Standard Deviation 13.012 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 4, n=99, 95 | 86.39 Micromoles per liter | Standard Deviation 14.472 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 44, n=137, 148 | 9.4 Micromoles per liter | Standard Deviation 4.03 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 8, n=73, 98 | 85.52 Micromoles per liter | Standard Deviation 15.851 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 44, n=47, 51 | 9.5 Micromoles per liter | Standard Deviation 3.41 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 12, n=99, 95 | 85.53 Micromoles per liter | Standard Deviation 17.539 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 48, n=131, 147 | 9.4 Micromoles per liter | Standard Deviation 4.28 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 16, n=93, 96 | 84.99 Micromoles per liter | Standard Deviation 15.429 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 8, n=34, 53 | 8.9 Micromoles per liter | Standard Deviation 3.45 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 20, n=93, 97 | 85.01 Micromoles per liter | Standard Deviation 14.695 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Baseline, n=51, 54 | 3.6 Micromoles per liter | Standard Deviation 2.13 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 24, n=94, 94 | 84.21 Micromoles per liter | Standard Deviation 15.039 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 48, n=43, 50 | 9.3 Micromoles per liter | Standard Deviation 3.77 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 28, n=89, 93 | 84.84 Micromoles per liter | Standard Deviation 15.67 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 4, n=51, 53 | 2.4 Micromoles per liter | Standard Deviation 1.2 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 32, n=93, 95 | 85.42 Micromoles per liter | Standard Deviation 15.349 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 40, n=90, 95 | 85.92 Micromoles per liter | Standard Deviation 14.651 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 36, n=94, 95 | 84.49 Micromoles per liter | Standard Deviation 15.189 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Baseline, n=102, 99 | 9.4 Micromoles per liter | Standard Deviation 3.94 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 44, n=91, 94 | 84.66 Micromoles per liter | Standard Deviation 15.701 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 12, n=50, 52 | 1.9 Micromoles per liter | Standard Deviation 0.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 48, n=91, 95 | 85.27 Micromoles per liter | Standard Deviation 15.683 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Baseline, n=155, 155 | 7.4 Micromoles per liter | Standard Deviation 3.3 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Baseline, n=155, 155 | 75.57 Micromoles per liter | Standard Deviation 14.604 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 24, n=47, 53 | 2.2 Micromoles per liter | Standard Deviation 0.75 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 4, n=151, 153 | 78.57 Micromoles per liter | Standard Deviation 15.814 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 4, n=99, 97 | 9.5 Micromoles per liter | Standard Deviation 3.88 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 8, n=122, 152 | 76.75 Micromoles per liter | Standard Deviation 15.759 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 28, n=42, 53 | 2.1 Micromoles per liter | Standard Deviation 1.08 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 12, n=146, 152 | 76.93 Micromoles per liter | Standard Deviation 15.495 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 20, n=138, 152 | 78.32 Micromoles per liter | Standard Deviation 16.372 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 16, n=143, 149 | 77.22 Micromoles per liter | Standard Deviation 15.406 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 32, n=45, 51 | 2.2 Micromoles per liter | Standard Deviation 0.88 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 24, n=143, 151 | 79.92 Micromoles per liter | Standard Deviation 21.43 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 8, n=73, 98 | 10.1 Micromoles per liter | Standard Deviation 4.29 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 28, n=136, 150 | 79.13 Micromoles per liter | Standard Deviation 17.039 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 36, n=44, 50 | 1.9 Micromoles per liter | Standard Deviation 0.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 32, n=137, 148 | 77.40 Micromoles per liter | Standard Deviation 14.117 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Baseline, n=51, 54 | 18.3 Micromoles per liter | Standard Deviation 20.54 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 36, n=135, 147 | 78.15 Micromoles per liter | Standard Deviation 16.839 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 40, n=42, 51 | 2.0 Micromoles per liter | Standard Deviation 0.77 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 40, n=138, 147 | 78.42 Micromoles per liter | Standard Deviation 16.662 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 12, n=99, 95 | 9.9 Micromoles per liter | Standard Deviation 4.5 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 44, n=137, 148 | 78.45 Micromoles per liter | Standard Deviation 15.909 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 44, n=47, 51 | 2.1 Micromoles per liter | Standard Deviation 0.83 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 48, n=131, 147 | 78.91 Micromoles per liter | Standard Deviation 17.389 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 28, n=89, 93 | 2.2 Micromoles per liter | Standard Deviation 0.74 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 48, n=131, 147 | 75.67 Micromoles per liter | Standard Deviation 14.794 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 44, n=91, 94 | 9.0 Micromoles per liter | Standard Deviation 3.4 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 48, n=91, 95 | 8.9 Micromoles per liter | Standard Deviation 3.76 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, direct bilirubin, Week 16, n=48, 53 | 2.9 Micromoles per liter | Standard Deviation 1.45 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 20, n=46, 53 | 2.9 Micromoles per liter | Standard Deviation 2.17 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 24, n=94, 94 | 2.0 Micromoles per liter | Standard Deviation 0.78 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 32, n=93, 95 | 1.9 Micromoles per liter | Standard Deviation 0.77 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 40, n=90, 95 | 2.0 Micromoles per liter | Standard Deviation 1.11 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 8, n=122, 152 | 1.9 Micromoles per liter | Standard Deviation 0.97 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 4, n=51, 53 | 72.53 Micromoles per liter | Standard Deviation 14.574 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 36, n=94, 95 | 87.20 Micromoles per liter | Standard Deviation 15.835 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 16, n=143, 149 | 77.00 Micromoles per liter | Standard Deviation 16.025 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Baseline, n=51, 54 | 13.9 Micromoles per liter | Standard Deviation 11.07 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 8, n=34, 53 | 14.2 Micromoles per liter | Standard Deviation 10.79 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 12, n=50, 52 | 15.6 Micromoles per liter | Standard Deviation 11.7 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 16, n=48, 53 | 14.7 Micromoles per liter | Standard Deviation 10.78 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 20, n=46, 53 | 15.6 Micromoles per liter | Standard Deviation 14.96 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 24, n=47, 53 | 16.8 Micromoles per liter | Standard Deviation 16.15 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 28, n=42, 53 | 15.0 Micromoles per liter | Standard Deviation 12.75 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 32, n=45, 51 | 17.1 Micromoles per liter | Standard Deviation 12.45 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 36, n=44, 50 | 16.0 Micromoles per liter | Standard Deviation 14.09 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 40, n=42, 51 | 17.9 Micromoles per liter | Standard Deviation 18.08 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 44, n=47, 51 | 18.1 Micromoles per liter | Standard Deviation 16.62 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 48, n=43, 50 | 16.7 Micromoles per liter | Standard Deviation 10.73 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Baseline, n=102, 99 | 9.7 Micromoles per liter | Standard Deviation 5.07 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 4, n=99, 97 | 9.0 Micromoles per liter | Standard Deviation 4.77 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 8, n=73, 98 | 10.7 Micromoles per liter | Standard Deviation 12.28 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 12, n=99, 95 | 9.2 Micromoles per liter | Standard Deviation 3.91 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 16, n=93, 96 | 9.6 Micromoles per liter | Standard Deviation 3.8 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 20, n=93, 97 | 9.3 Micromoles per liter | Standard Deviation 3.6 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 24, n=94, 94 | 9.1 Micromoles per liter | Standard Deviation 3.81 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 28, n=89, 93 | 9.5 Micromoles per liter | Standard Deviation 4.67 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 32, n=93, 95 | 8.8 Micromoles per liter | Standard Deviation 3.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 36, n=94, 95 | 9.1 Micromoles per liter | Standard Deviation 3.76 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 40, n=90, 95 | 8.9 Micromoles per liter | Standard Deviation 3.63 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Baseline, n=155, 155 | 7.2 Micromoles per liter | Standard Deviation 3.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 4, n=151, 153 | 6.9 Micromoles per liter | Standard Deviation 2.98 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 8, n=122, 152 | 6.8 Micromoles per liter | Standard Deviation 3.4 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 12, n=146, 152 | 7.1 Micromoles per liter | Standard Deviation 3.5 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 16, n=143, 149 | 6.8 Micromoles per liter | Standard Deviation 3.52 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 20, n=138, 152 | 7.1 Micromoles per liter | Standard Deviation 3.15 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 24, n=143, 151 | 6.9 Micromoles per liter | Standard Deviation 3.75 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 28, n=136, 150 | 6.9 Micromoles per liter | Standard Deviation 3.29 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 32, n=137, 148 | 6.9 Micromoles per liter | Standard Deviation 3.52 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 36, n=135, 147 | 7.0 Micromoles per liter | Standard Deviation 3.33 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 40, n=138, 147 | 7.0 Micromoles per liter | Standard Deviation 3.43 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 44, n=137, 148 | 7.1 Micromoles per liter | Standard Deviation 3.25 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 48, n=131, 147 | 7.3 Micromoles per liter | Standard Deviation 3.19 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Baseline, n=51, 54 | 2.9 Micromoles per liter | Standard Deviation 1.68 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 4, n=51, 53 | 3.3 Micromoles per liter | Standard Deviation 1.67 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 8, n=34, 53 | 2.8 Micromoles per liter | Standard Deviation 1.68 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 12, n=50, 52 | 3.2 Micromoles per liter | Standard Deviation 1.95 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 24, n=47, 53 | 3.1 Micromoles per liter | Standard Deviation 2.02 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 28, n=42, 53 | 2.7 Micromoles per liter | Standard Deviation 1.84 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 32, n=45, 51 | 3.1 Micromoles per liter | Standard Deviation 1.84 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 36, n=44, 50 | 3.1 Micromoles per liter | Standard Deviation 1.95 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 40, n=42, 51 | 3.2 Micromoles per liter | Standard Deviation 2.05 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 44, n=47, 51 | 3.3 Micromoles per liter | Standard Deviation 1.99 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 48, n=43, 50 | 3.2 Micromoles per liter | Standard Deviation 1.71 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Baseline, n=102, 99 | 2.3 Micromoles per liter | Standard Deviation 1.16 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 4, n=99, 97 | 2.3 Micromoles per liter | Standard Deviation 1.18 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 8, n=73, 98 | 3.0 Micromoles per liter | Standard Deviation 6.7 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 12, n=99, 95 | 2.3 Micromoles per liter | Standard Deviation 1.06 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 16, n=93, 96 | 2.1 Micromoles per liter | Standard Deviation 0.87 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 20, n=93, 97 | 2.1 Micromoles per liter | Standard Deviation 0.89 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 28, n=89, 93 | 2.1 Micromoles per liter | Standard Deviation 1.12 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 36, n=94, 95 | 2.0 Micromoles per liter | Standard Deviation 0.97 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin. Week 44, n=91, 94 | 2.1 Micromoles per liter | Standard Deviation 0.95 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 48, n=91, 95 | 2.2 Micromoles per liter | Standard Deviation 1 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Baseline, n=155, 155 | 1.9 Micromoles per liter | Standard Deviation 1 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 4, n=151, 153 | 2.0 Micromoles per liter | Standard Deviation 0.96 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 12, n=146, 152 | 1.9 Micromoles per liter | Standard Deviation 0.98 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 16, n=143, 149 | 1.9 Micromoles per liter | Standard Deviation 0.9 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 20, n=138, 152 | 1.7 Micromoles per liter | Standard Deviation 0.97 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Week 24, Direct bilirubin, n=143, 151 | 1.8 Micromoles per liter | Standard Deviation 0.95 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 28, n=136, 150 | 1.7 Micromoles per liter | Standard Deviation 1.01 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 32, n=137, 148 | 1.7 Micromoles per liter | Standard Deviation 0.94 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 36, n=135, 147 | 1.7 Micromoles per liter | Standard Deviation 0.94 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 40, n=138, 147 | 1.7 Micromoles per liter | Standard Deviation 1 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 44, n=137, 148 | 1.8 Micromoles per liter | Standard Deviation 0.91 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 48, n=131, 147 | 1.9 Micromoles per liter | Standard Deviation 0.96 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Baseline, n=51, 54 | 70.20 Micromoles per liter | Standard Deviation 13.391 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 8, n=34, 53 | 71.54 Micromoles per liter | Standard Deviation 14.362 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 12, n=50, 52 | 73.22 Micromoles per liter | Standard Deviation 14.968 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 16, n=48, 53 | 73.25 Micromoles per liter | Standard Deviation 15.74 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 20, n=46, 53 | 75.37 Micromoles per liter | Standard Deviation 15.799 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 24, n=47, 53 | 72.84 Micromoles per liter | Standard Deviation 14.549 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 28, n=42, 53 | 73.42 Micromoles per liter | Standard Deviation 14.738 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 32, n=45, 51 | 73.93 Micromoles per liter | Standard Deviation 15.399 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 36, n=44, 50 | 72.37 Micromoles per liter | Standard Deviation 14.57 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 40, n=42, 51 | 73.73 Micromoles per liter | Standard Deviation 15.726 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 44, n=47, 51 | 73.00 Micromoles per liter | Standard Deviation 14.885 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 48, n=43, 50 | 72.21 Micromoles per liter | Standard Deviation 15.031 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Baseline, n=102, 99 | 86.34 Micromoles per liter | Standard Deviation 17.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 4, n=99, 95 | 87.66 Micromoles per liter | Standard Deviation 16.208 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 8, n=73, 98 | 88.11 Micromoles per liter | Standard Deviation 17.308 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 12, n=99, 95 | 89.36 Micromoles per liter | Standard Deviation 17.923 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 16, n=93, 96 | 86.85 Micromoles per liter | Standard Deviation 17.32 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 20, n=93, 97 | 87.06 Micromoles per liter | Standard Deviation 16.987 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 24, n=94, 94 | 87.02 Micromoles per liter | Standard Deviation 16.777 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 28, n=89, 93 | 87.41 Micromoles per liter | Standard Deviation 17.065 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 32, n=93, 95 | 86.91 Micromoles per liter | Standard Deviation 15.628 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 40, n=90, 95 | 87.70 Micromoles per liter | Standard Deviation 17.119 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 44, n=91, 94 | 87.08 Micromoles per liter | Standard Deviation 16.694 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 48, n=91, 95 | 86.64 Micromoles per liter | Standard Deviation 15.958 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Baseline, n=155, 155 | 75.06 Micromoles per liter | Standard Deviation 14.671 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 4, n=151, 153 | 76.79 Micromoles per liter | Standard Deviation 14.908 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 8, n=122, 152 | 76.17 Micromoles per liter | Standard Deviation 14.876 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 12, n=146, 152 | 75.50 Micromoles per liter | Standard Deviation 14.723 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 20, n=138, 152 | 76.36 Micromoles per liter | Standard Deviation 15.744 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 24, n=143, 151 | 76.26 Micromoles per liter | Standard Deviation 15.534 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 28, n=136, 150 | 76.45 Micromoles per liter | Standard Deviation 15.06 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 32, n=137, 148 | 77.05 Micromoles per liter | Standard Deviation 16.2 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 36, n=135, 147 | 76.64 Micromoles per liter | Standard Deviation 15.734 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 40, n=138, 147 | 76.04 Micromoles per liter | Standard Deviation 15.083 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 44, n=137, 148 | 76.25 Micromoles per liter | Standard Deviation 15.257 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 4, n=51, 53 | 14.4 Micromoles per liter | Standard Deviation 10.37 |
Secondary
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance
Blood samples were collected for the analysis of clinical chemistry parameter: creatinine clearance to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). GFR will be estimated by the central laboratory using the CKD-EPI.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 28, n=42, 53 | 100.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.62 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 20, n=93, 97 | 95.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.97 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 4, n=51, 53 | 103.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.59 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 24, n=94, 94 | 95.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.88 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 32, n=45, 51 | 101.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.38 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 28, n=89, 93 | 95.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 17 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 40, n=89, 95 | 94.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.32 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 32, n=92, 95 | 94.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.16 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 36, n=44, 50 | 100.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.68 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 8, n=34, 53 | 104.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 14.52 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 40, n=42, 51 | 100.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 14.54 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 44, n=91, 94 | 94.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.64 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 36, n=135, 147 | 100.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 18.02 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 48, n=90, 94 | 95.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.2 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 44, n=47, 51 | 99.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 18 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Baseline, n=155, 155 | 104.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.78 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 12, n=50, 52 | 107.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 14.95 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 4, n=151, 153 | 100.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 18.35 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 48, n=43, 50 | 98.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.31 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 8, n=121, 152 | 102.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.23 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 20, n=46, 53 | 102.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.17 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 12, n=146, 152 | 103.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 18.02 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Baseline, n=102, 99 | 92.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.62 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 16, n=143, 148 | 102.5 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.66 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 16, n=48, 53 | 105.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.88 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 20, n=138, 152 | 101.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.94 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 4, n=99, 95 | 93.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.07 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 24, n=142, 151 | 99.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 18.18 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Baseline, n=51, 54 | 105.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.67 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 28, n=136, 150 | 99.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 18.23 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 8, n=72, 98 | 94.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.05 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 32, n=137, 148 | 101.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.1 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 24, n=47, 53 | 103.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 14.64 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 40, n=137, 147 | 100.5 Milliliters per minute per 1.73meter^2 | Standard Deviation 18.4 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 12, n=99, 93 | 94.5 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.82 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 44, n=136, 148 | 99.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.23 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 36, n=94, 95 | 95.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.81 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 48, n=131, 147 | 98.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.35 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 16, n=93, 96 | 94.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.02 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 48, n=131, 147 | 102.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.83 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 36, n=135, 147 | 101.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.46 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Baseline, n=51, 54 | 104.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.22 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 4, n=51, 53 | 102.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.68 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 8, n=34, 53 | 103.5 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.61 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 12, n=50, 52 | 101.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.94 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 20, n=46, 53 | 99.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.53 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 24, n=47, 53 | 101.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.54 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 28, n=42, 53 | 100.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 14.58 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 32, n=45, 51 | 100.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.04 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 36, n=44, 50 | 101.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 14.42 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 40, n=42, 51 | 100.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.51 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 44, n=47, 51 | 101.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 48, n=43, 50 | 102.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.45 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Baseline, n=102, 99 | 94.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 18.82 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 4, n=99, 95 | 93.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 18.22 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 8, n=72, 98 | 93.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 18.12 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 12, n=99, 93 | 91.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 18.81 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 16, n=93, 96 | 94.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 18.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 20, n=93, 97 | 93.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.48 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 24, n=94, 94 | 93.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.21 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 28, n=89, 93 | 93.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.89 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 32, n=92, 95 | 93.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.94 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 36, n=94, 95 | 92.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.65 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 40, n=89, 95 | 92.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 18.15 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 44, n=91, 94 | 93.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.94 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 48, n=90, 94 | 93.5 Milliliters per minute per 1.73meter^2 | Standard Deviation 17 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Baseline, n=155, 155 | 103.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.85 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 4, n=151, 153 | 101.5 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.72 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 8, n=121, 152 | 102.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.85 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 12, n=146, 152 | 103.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.47 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 16, n=143, 148 | 101.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 18.66 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 20, n=138, 152 | 101.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.61 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 24, n=142, 151 | 101.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.43 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 28, n=136, 150 | 101.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.2 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 32, n=137, 148 | 101.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 17.79 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 40, n=137, 147 | 101.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.68 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 44, n=136, 148 | 101.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 16.96 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 16, n=48, 53 | 101.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 15.99 |
Secondary
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase
Blood samples were collected for the analysis of clinical chemistry parameter: lipase to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 24, n=47, 53 | 25.8 Units per liter | Standard Deviation 11.74 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Baseline, n=51, 54 | 27.6 Units per liter | Standard Deviation 21.69 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 4, n=51, 53 | 25.5 Units per liter | Standard Deviation 14.41 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 8, n=34, 53 | 23.4 Units per liter | Standard Deviation 10.96 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 12, n=49, 52 | 26.4 Units per liter | Standard Deviation 12 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 16, n=47, 53 | 28.1 Units per liter | Standard Deviation 13.01 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 20, n=46, 53 | 25.8 Units per liter | Standard Deviation 11.37 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 28, n=42, 53 | 26.4 Units per liter | Standard Deviation 10.86 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 32, n=45, 51 | 26.9 Units per liter | Standard Deviation 12.18 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 36, n=44, 50 | 27.1 Units per liter | Standard Deviation 13.69 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 40, n=42, 51 | 30.5 Units per liter | Standard Deviation 19.78 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 44, n=47, 51 | 27.1 Units per liter | Standard Deviation 10.7 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 48, n=43, 50 | 26.3 Units per liter | Standard Deviation 12.02 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Baseline, n=102, 99 | 29.3 Units per liter | Standard Deviation 20.9 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 4, n=99, 97 | 36.8 Units per liter | Standard Deviation 43.46 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 8, n=72, 98 | 28.8 Units per liter | Standard Deviation 16.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 12, n=99, 93 | 33.1 Units per liter | Standard Deviation 20.98 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 16, n=93, 97 | 34.4 Units per liter | Standard Deviation 33.09 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 20, n=94, 97 | 32.0 Units per liter | Standard Deviation 28.19 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 24, n=94, 95 | 32.0 Units per liter | Standard Deviation 19.15 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 28, n=89, 94 | 35.1 Units per liter | Standard Deviation 38.32 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 32, n=92, 95 | 32.6 Units per liter | Standard Deviation 23 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 36, n=94, 95 | 35.0 Units per liter | Standard Deviation 32.32 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 40, n=89, 95 | 33.8 Units per liter | Standard Deviation 20.14 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 44, n=91, 94 | 34.6 Units per liter | Standard Deviation 34.66 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 48, n=90, 94 | 35.1 Units per liter | Standard Deviation 36.88 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Baseline, n=155, 155 | 32.1 Units per liter | Standard Deviation 24.46 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 4, n=151, 153 | 37.6 Units per liter | Standard Deviation 64.95 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 8, n=121, 152 | 33.8 Units per liter | Standard Deviation 27.26 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 12, n=146, 152 | 35.6 Units per liter | Standard Deviation 34.76 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 16, n=145, 149 | 35.3 Units per liter | Standard Deviation 32.66 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 20, n=138, 152 | 32.0 Units per liter | Standard Deviation 19.03 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 24, n=142, 151 | 36.2 Units per liter | Standard Deviation 29.08 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 28, n=136, 150 | 33.4 Units per liter | Standard Deviation 21.71 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 32, n=137, 148 | 40.6 Units per liter | Standard Deviation 83.2 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 36, n=135, 147 | 39.9 Units per liter | Standard Deviation 67.63 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 40, n=138, 147 | 38.6 Units per liter | Standard Deviation 46.34 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 44, n=136, 148 | 34.5 Units per liter | Standard Deviation 23.27 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 48, n=131, 146 | 36.3 Units per liter | Standard Deviation 30.6 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 8, n=121, 152 | 33.4 Units per liter | Standard Deviation 21.17 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 24, n=47, 53 | 30.5 Units per liter | Standard Deviation 15.48 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 48, n=131, 146 | 32.8 Units per liter | Standard Deviation 20.04 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 24, n=94, 95 | 30.1 Units per liter | Standard Deviation 21.56 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Baseline, n=51, 54 | 33.0 Units per liter | Standard Deviation 22.44 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 28, n=136, 150 | 33.1 Units per liter | Standard Deviation 17.2 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 4, n=51, 53 | 34.4 Units per liter | Standard Deviation 20.77 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 28, n=89, 94 | 32.8 Units per liter | Standard Deviation 24.85 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 8, n=34, 53 | 35.7 Units per liter | Standard Deviation 28.85 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 12, n=146, 152 | 29.7 Units per liter | Standard Deviation 14.64 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 12, n=49, 52 | 31.2 Units per liter | Standard Deviation 15.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 32, n=92, 95 | 32.7 Units per liter | Standard Deviation 21.75 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 16, n=47, 53 | 34.6 Units per liter | Standard Deviation 18.14 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 44, n=136, 148 | 32.9 Units per liter | Standard Deviation 19.81 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 20, n=46, 53 | 32.7 Units per liter | Standard Deviation 16.37 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 36, n=94, 95 | 27.6 Units per liter | Standard Deviation 12.2 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 28, n=42, 53 | 33.4 Units per liter | Standard Deviation 15.92 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 16, n=145, 149 | 36.8 Units per liter | Standard Deviation 46.27 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 32, n=45, 51 | 36.2 Units per liter | Standard Deviation 24.23 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 40, n=89, 95 | 29.6 Units per liter | Standard Deviation 14.21 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 36, n=44, 50 | 32.7 Units per liter | Standard Deviation 17.14 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 32, n=137, 148 | 33.6 Units per liter | Standard Deviation 20.7 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 40, n=42, 51 | 32.0 Units per liter | Standard Deviation 15.16 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 44, n=91, 94 | 32.8 Units per liter | Standard Deviation 22.45 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 44, n=47, 51 | 35.2 Units per liter | Standard Deviation 18.59 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 20, n=138, 152 | 32.9 Units per liter | Standard Deviation 37.34 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 48, n=43, 50 | 32.7 Units per liter | Standard Deviation 15.62 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 48, n=90, 94 | 31.6 Units per liter | Standard Deviation 23.18 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Baseline, n=102, 99 | 28.2 Units per liter | Standard Deviation 16.64 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 40, n=138, 147 | 32.3 Units per liter | Standard Deviation 16.96 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 4, n=99, 97 | 32.1 Units per liter | Standard Deviation 31.31 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Baseline, n=155, 155 | 31.8 Units per liter | Standard Deviation 19.3 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 8, n=72, 98 | 27.7 Units per liter | Standard Deviation 12.72 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 24, n=142, 151 | 37.2 Units per liter | Standard Deviation 36.77 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 12, n=99, 93 | 29.8 Units per liter | Standard Deviation 23.81 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 4, n=151, 153 | 31.7 Units per liter | Standard Deviation 17.6 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 16, n=93, 97 | 28.9 Units per liter | Standard Deviation 14.77 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 36, n=135, 147 | 33.9 Units per liter | Standard Deviation 21.66 |
| Current ART | Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 20, n=94, 97 | 29.1 Units per liter | Standard Deviation 16.34 |
Secondary
Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48
Blood samples were collected for the analysis of fasting lipid panel: triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).
Time frame: Baseline (Day 1) and at Week 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, HDL cholesterol, Week 48, n=119, 120 | 1.442 Millimoles per liter | Standard Deviation 0.4413 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Cholesterol, Baseline, n=136, 140 | 4.87 Millimoles per liter | Standard Deviation 0.958 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Triglycerides, Week 48, n=72, 77 | 1.405 Millimoles per liter | Standard Deviation 0.9068 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Cholesterol, Week 48, n=119, 120 | 4.93 Millimoles per liter | Standard Deviation 0.904 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Triglycerides, Baseline, n=46, 50 | 1.951 Millimoles per liter | Standard Deviation 1.8801 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, HDL cholesterol, Week 48, n=40, 45 | 1.505 Millimoles per liter | Standard Deviation 0.5459 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Triglycerides, Baseline, n=136, 140 | 1.322 Millimoles per liter | Standard Deviation 0.7986 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, HDL cholesterol, Week 48, n=72, 77 | 1.288 Millimoles per liter | Standard Deviation 0.3664 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, HDL cholesterol, Baseline, n=82, 84 | 1.257 Millimoles per liter | Standard Deviation 0.345 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, HDL cholesterol, Baseline, n=136, 140 | 1.449 Millimoles per liter | Standard Deviation 0.4756 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Cholesterol, Baseline, n=46, 50 | 4.98 Millimoles per liter | Standard Deviation 0.96 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Triglycerides, Week 48, n=40, 45 | 1.309 Millimoles per liter | Standard Deviation 0.7647 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, LDL cholesterol, Baseline, n=43, 48 | 2.734 Millimoles per liter | Standard Deviation 0.7891 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Cholesterol, Week 48, n=40, 45 | 5.07 Millimoles per liter | Standard Deviation 0.775 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, LDL cholesterol, Week 48, n=37, 43 | 2.944 Millimoles per liter | Standard Deviation 0.7175 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, HDL cholesterol, Baseline, n=46, 50 | 1.389 Millimoles per liter | Standard Deviation 0.4943 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, LDL cholesterol, Basline, n=81, 83 | 2.881 Millimoles per liter | Standard Deviation 0.9196 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Cholesterol, Baseline, n=82, 84 | 4.81 Millimoles per liter | Standard Deviation 1.077 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, LDL cholesterol, Week 48, n=71, 76 | 2.975 Millimoles per liter | Standard Deviation 0.8787 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Triglycerides, Baseline, n=82, 84 | 1.470 Millimoles per liter | Standard Deviation 1.0152 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, LDL cholesterol, Baseline, n=134, 137 | 2.834 Millimoles per liter | Standard Deviation 0.8442 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Cholesterol, Week 48, n=72, 77 | 4.90 Millimoles per liter | Standard Deviation 0.881 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, LDL cholesterol, Week 48, n=116, 119 | 2.900 Millimoles per liter | Standard Deviation 0.8415 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Triglycerides, Week 48, n=119, 120 | 1.305 Millimoles per liter | Standard Deviation 0.8771 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, LDL cholesterol, Week 48, n=116, 119 | 2.834 Millimoles per liter | Standard Deviation 0.8763 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Triglycerides, Week 48, n=119, 120 | 1.316 Millimoles per liter | Standard Deviation 0.7914 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, HDL cholesterol, Baseline, n=46, 50 | 1.537 Millimoles per liter | Standard Deviation 0.6096 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, HDL cholesterol, Baseline, n=82, 84 | 1.383 Millimoles per liter | Standard Deviation 0.389 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Triglycerides, Baseline, n=46, 50 | 1.894 Millimoles per liter | Standard Deviation 1.4058 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Triglycerides, Week 48, n=40, 45 | 1.772 Millimoles per liter | Standard Deviation 1.1828 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Triglycerides, Baseline, n=82, 84 | 1.426 Millimoles per liter | Standard Deviation 0.872 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Triglycerides, Week 48, n=72, 77 | 1.307 Millimoles per liter | Standard Deviation 0.7427 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Triglycerides, Baseline, n=136, 140 | 1.506 Millimoles per liter | Standard Deviation 1.4388 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Cholesterol, Baseline, n=46, 50 | 5.14 Millimoles per liter | Standard Deviation 1.152 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Cholesterol, Week 48, n=40, 45 | 5.16 Millimoles per liter | Standard Deviation 1.13 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Cholesterol, Baseline, n=82, 84 | 5.01 Millimoles per liter | Standard Deviation 1.08 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Cholesterol, Week 48, n=72, 77 | 4.87 Millimoles per liter | Standard Deviation 0.997 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Cholesterol, Baseline, n=136, 140 | 4.98 Millimoles per liter | Standard Deviation 1.007 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Cholesterol, Week 48, n=119, 120 | 4.91 Millimoles per liter | Standard Deviation 1.007 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, HDL cholesterol, Week 48, n=40, 45 | 1.550 Millimoles per liter | Standard Deviation 0.595 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, HDL cholesterol, Week 48, n=72, 77 | 1.323 Millimoles per liter | Standard Deviation 0.3588 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, HDL cholesterol, Baseline, n=136, 140 | 1.405 Millimoles per liter | Standard Deviation 0.4401 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, HDL cholesterol, Week 48, n=119, 120 | 1.471 Millimoles per liter | Standard Deviation 0.4226 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, LDL cholesterol, Baseline, n=43, 48 | 2.743 Millimoles per liter | Standard Deviation 0.7948 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, LDL cholesterol, Week 48, n=37, 43 | 2.784 Millimoles per liter | Standard Deviation 0.8477 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, LDL cholesterol, Basline, n=81, 83 | 2.946 Millimoles per liter | Standard Deviation 0.8614 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, LDL cholesterol, Week 48, n=71, 76 | 2.939 Millimoles per liter | Standard Deviation 0.8591 |
| Current ART | Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, LDL cholesterol, Baseline, n=134, 137 | 2.901 Millimoles per liter | Standard Deviation 0.8714 |
Secondary
Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume
Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 8, n=218, 301 | 92.7 Femtoliters | Standard Deviation 5.76 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 28, n=268, 297 | 90.2 Femtoliters | Standard Deviation 5.68 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 16, n=280, 296 | 90.6 Femtoliters | Standard Deviation 5.48 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 32, n=268, 291 | 90.1 Femtoliters | Standard Deviation 5.55 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 4, n=300, 300 | 94.6 Femtoliters | Standard Deviation 6.88 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 36, n=267, 288 | 89.8 Femtoliters | Standard Deviation 5.64 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 20, n=276, 298 | 90.3 Femtoliters | Standard Deviation 5.37 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 40, n=264, 289 | 89.9 Femtoliters | Standard Deviation 5.57 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 12, n=294, 293 | 91.7 Femtoliters | Standard Deviation 5.69 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 44, n=273, 286 | 89.9 Femtoliters | Standard Deviation 5.52 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 24, n=279, 294 | 90.2 Femtoliters | Standard Deviation 5.44 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 48, n=255, 284 | 89.9 Femtoliters | Standard Deviation 5.58 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Baseline, n=308, 308 | 95.7 Femtoliters | Standard Deviation 7.97 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 48, n=255, 284 | 96.2 Femtoliters | Standard Deviation 9.38 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Baseline, n=308, 308 | 96.6 Femtoliters | Standard Deviation 9.35 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 4, n=300, 300 | 96.9 Femtoliters | Standard Deviation 9.31 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 8, n=218, 301 | 96.8 Femtoliters | Standard Deviation 9.25 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 12, n=294, 293 | 96.9 Femtoliters | Standard Deviation 9.34 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 16, n=280, 296 | 96.8 Femtoliters | Standard Deviation 9.64 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 20, n=276, 298 | 97.0 Femtoliters | Standard Deviation 9.63 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 24, n=279, 294 | 96.9 Femtoliters | Standard Deviation 9.75 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 28, n=268, 297 | 97.2 Femtoliters | Standard Deviation 9.77 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 32, n=268, 291 | 96.7 Femtoliters | Standard Deviation 9.36 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 36, n=267, 288 | 96.5 Femtoliters | Standard Deviation 9.08 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 40, n=264, 289 | 96.5 Femtoliters | Standard Deviation 9.05 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 44, n=273, 286 | 96.2 Femtoliters | Standard Deviation 9.08 |
Secondary
Absolute Values for Hematology Parameters: Erythrocytes
Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocytes | Week 8, n=218, 301 | 4.68 10^12 cells per liter | Standard Deviation 0.479 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocytes | Week 28, n=268, 297 | 4.85 10^12 cells per liter | Standard Deviation 0.456 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocytes | Week 16, n=280, 296 | 4.84 10^12 cells per liter | Standard Deviation 0.475 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocytes | Week 32, n=268, 291 | 4.84 10^12 cells per liter | Standard Deviation 0.452 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocytes | Week 4, n=300, 300 | 4.59 10^12 cells per liter | Standard Deviation 0.503 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocytes | Week 36, n=267, 288 | 4.81 10^12 cells per liter | Standard Deviation 0.462 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocytes | Week 20, n=276, 298 | 4.86 10^12 cells per liter | Standard Deviation 0.459 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocytes | Week 40, n=264, 289 | 4.84 10^12 cells per liter | Standard Deviation 0.456 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocytes | Week 12, n=294, 293 | 4.79 10^12 cells per liter | Standard Deviation 0.464 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocytes | Week 44, n=273, 286 | 4.86 10^12 cells per liter | Standard Deviation 0.448 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocytes | Week 24, n=279, 294 | 4.86 10^12 cells per liter | Standard Deviation 0.471 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocytes | Week 48, n=255, 284 | 4.81 10^12 cells per liter | Standard Deviation 0.448 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Erythrocytes | Baseline, n=308, 308 | 4.55 10^12 cells per liter | Standard Deviation 0.563 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocytes | Week 48, n=255, 284 | 4.50 10^12 cells per liter | Standard Deviation 0.6 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocytes | Baseline, n=308, 308 | 4.49 10^12 cells per liter | Standard Deviation 0.57 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocytes | Week 4, n=300, 300 | 4.45 10^12 cells per liter | Standard Deviation 0.567 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocytes | Week 8, n=218, 301 | 4.49 10^12 cells per liter | Standard Deviation 0.566 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocytes | Week 12, n=294, 293 | 4.51 10^12 cells per liter | Standard Deviation 0.58 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocytes | Week 16, n=280, 296 | 4.48 10^12 cells per liter | Standard Deviation 0.549 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocytes | Week 20, n=276, 298 | 4.48 10^12 cells per liter | Standard Deviation 0.586 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocytes | Week 24, n=279, 294 | 4.48 10^12 cells per liter | Standard Deviation 0.572 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocytes | Week 28, n=268, 297 | 4.47 10^12 cells per liter | Standard Deviation 0.565 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocytes | Week 32, n=268, 291 | 4.48 10^12 cells per liter | Standard Deviation 0.55 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocytes | Week 36, n=267, 288 | 4.49 10^12 cells per liter | Standard Deviation 0.561 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocytes | Week 40, n=264, 289 | 4.49 10^12 cells per liter | Standard Deviation 0.572 |
| Current ART | Absolute Values for Hematology Parameters: Erythrocytes | Week 44, n=273, 286 | 4.49 10^12 cells per liter | Standard Deviation 0.572 |
Secondary
Absolute Values for Hematology Parameters: Hematocrit
Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hematocrit | Week 8, n=218, 301 | 0.4327 Proportion of red blood cells in blood | Standard Deviation 0.0457 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hematocrit | Week 28, n=268, 297 | 0.4364 Proportion of red blood cells in blood | Standard Deviation 0.04607 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hematocrit | Week 16, n=280, 296 | 0.4369 Proportion of red blood cells in blood | Standard Deviation 0.04626 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hematocrit | Week 32, n=268, 291 | 0.4350 Proportion of red blood cells in blood | Standard Deviation 0.04311 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hematocrit | Week 12, n=294, 293 | 0.4379 Proportion of red blood cells in blood | Standard Deviation 0.04483 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hematocrit | Week 36, n=267, 288 | 0.4311 Proportion of red blood cells in blood | Standard Deviation 0.04462 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hematocrit | Week 4, n=300, 300 | 0.4325 Proportion of red blood cells in blood | Standard Deviation 0.0457 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hematocrit | Week 40, n=264, 289 | 0.4342 Proportion of red blood cells in blood | Standard Deviation 0.04381 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hematocrit | Week 20, n=276, 298 | 0.4378 Proportion of red blood cells in blood | Standard Deviation 0.04476 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hematocrit | Week 44, n=273, 286 | 0.4357 Proportion of red blood cells in blood | Standard Deviation 0.04288 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hematocrit | Baseline, n=308, 308 | 0.4333 Proportion of red blood cells in blood | Standard Deviation 0.04804 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hematocrit | Week 48, n=255, 284 | 0.4318 Proportion of red blood cells in blood | Standard Deviation 0.04438 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hematocrit | Week 24, n=279, 294 | 0.4376 Proportion of red blood cells in blood | Standard Deviation 0.04589 |
| Current ART | Absolute Values for Hematology Parameters: Hematocrit | Week 48, n=255, 284 | 0.4286 Proportion of red blood cells in blood | Standard Deviation 0.04465 |
| Current ART | Absolute Values for Hematology Parameters: Hematocrit | Baseline, n=308, 308 | 0.4305 Proportion of red blood cells in blood | Standard Deviation 0.04454 |
| Current ART | Absolute Values for Hematology Parameters: Hematocrit | Week 4, n=300, 300 | 0.4283 Proportion of red blood cells in blood | Standard Deviation 0.04548 |
| Current ART | Absolute Values for Hematology Parameters: Hematocrit | Week 8, n=218, 301 | 0.4310 Proportion of red blood cells in blood | Standard Deviation 0.0458 |
| Current ART | Absolute Values for Hematology Parameters: Hematocrit | Week 16, n=280, 296 | 0.4304 Proportion of red blood cells in blood | Standard Deviation 0.04418 |
| Current ART | Absolute Values for Hematology Parameters: Hematocrit | Week 20, n=276, 298 | 0.4312 Proportion of red blood cells in blood | Standard Deviation 0.04755 |
| Current ART | Absolute Values for Hematology Parameters: Hematocrit | Week 24, n=279, 294 | 0.4312 Proportion of red blood cells in blood | Standard Deviation 0.04595 |
| Current ART | Absolute Values for Hematology Parameters: Hematocrit | Week 28, n=268, 297 | 0.4308 Proportion of red blood cells in blood | Standard Deviation 0.04555 |
| Current ART | Absolute Values for Hematology Parameters: Hematocrit | Week 32, n=268, 291 | 0.4299 Proportion of red blood cells in blood | Standard Deviation 0.04431 |
| Current ART | Absolute Values for Hematology Parameters: Hematocrit | Week 36, n=267, 288 | 0.4295 Proportion of red blood cells in blood | Standard Deviation 0.04348 |
| Current ART | Absolute Values for Hematology Parameters: Hematocrit | Week 40, n=264, 289 | 0.4300 Proportion of red blood cells in blood | Standard Deviation 0.04449 |
| Current ART | Absolute Values for Hematology Parameters: Hematocrit | Week 44, n=273, 286 | 0.4282 Proportion of red blood cells in blood | Standard Deviation 0.04472 |
| Current ART | Absolute Values for Hematology Parameters: Hematocrit | Week 12, n=294, 293 | 0.4338 Proportion of red blood cells in blood | Standard Deviation 0.0464 |
Secondary
Absolute Values for Hematology Parameters: Hemoglobin
Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hemoglobin | Week 8, n=218, 301 | 141.5 Grams per liter | Standard Deviation 16.08 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hemoglobin | Week 28, n=268, 297 | 142.8 Grams per liter | Standard Deviation 16.05 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hemoglobin | Week 16, n=280, 296 | 142.5 Grams per liter | Standard Deviation 16.19 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hemoglobin | Week 32, n=268, 291 | 143.0 Grams per liter | Standard Deviation 15.42 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hemoglobin | Week 4, n=300, 300 | 141.7 Grams per liter | Standard Deviation 16.3 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hemoglobin | Week 36, n=267, 288 | 142.7 Grams per liter | Standard Deviation 16.31 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hemoglobin | Week 20, n=276, 298 | 142.6 Grams per liter | Standard Deviation 15.52 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hemoglobin | Week 40, n=264, 289 | 143.5 Grams per liter | Standard Deviation 15.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hemoglobin | Week 12, n=294, 293 | 142.4 Grams per liter | Standard Deviation 15.9 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hemoglobin | Week 44, n=273, 286 | 143.6 Grams per liter | Standard Deviation 15.66 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hemoglobin | Week 24, n=279, 294 | 143.3 Grams per liter | Standard Deviation 15.66 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hemoglobin | Week 48, n=255, 284 | 142.7 Grams per liter | Standard Deviation 15.93 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters: Hemoglobin | Baseline, n=308, 308 | 142.2 Grams per liter | Standard Deviation 17.24 |
| Current ART | Absolute Values for Hematology Parameters: Hemoglobin | Week 48, n=255, 284 | 142.8 Grams per liter | Standard Deviation 16.34 |
| Current ART | Absolute Values for Hematology Parameters: Hemoglobin | Baseline, n=308, 308 | 141.4 Grams per liter | Standard Deviation 16.29 |
| Current ART | Absolute Values for Hematology Parameters: Hemoglobin | Week 4, n=300, 300 | 140.5 Grams per liter | Standard Deviation 16.44 |
| Current ART | Absolute Values for Hematology Parameters: Hemoglobin | Week 8, n=218, 301 | 141.2 Grams per liter | Standard Deviation 16.51 |
| Current ART | Absolute Values for Hematology Parameters: Hemoglobin | Week 12, n=294, 293 | 141.6 Grams per liter | Standard Deviation 16.62 |
| Current ART | Absolute Values for Hematology Parameters: Hemoglobin | Week 16, n=280, 296 | 140.5 Grams per liter | Standard Deviation 15.81 |
| Current ART | Absolute Values for Hematology Parameters: Hemoglobin | Week 20, n=276, 298 | 141.2 Grams per liter | Standard Deviation 16.62 |
| Current ART | Absolute Values for Hematology Parameters: Hemoglobin | Week 24, n=279, 294 | 141.6 Grams per liter | Standard Deviation 16.18 |
| Current ART | Absolute Values for Hematology Parameters: Hemoglobin | Week 28, n=268, 297 | 140.9 Grams per liter | Standard Deviation 15.89 |
| Current ART | Absolute Values for Hematology Parameters: Hemoglobin | Week 32, n=268, 291 | 141.8 Grams per liter | Standard Deviation 15.81 |
| Current ART | Absolute Values for Hematology Parameters: Hemoglobin | Week 36, n=267, 288 | 142.3 Grams per liter | Standard Deviation 15.72 |
| Current ART | Absolute Values for Hematology Parameters: Hemoglobin | Week 40, n=264, 289 | 142.4 Grams per liter | Standard Deviation 15.9 |
| Current ART | Absolute Values for Hematology Parameters: Hemoglobin | Week 44, n=273, 286 | 142.1 Grams per liter | Standard Deviation 16.38 |
Secondary
Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated time points.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 44, n=258, 268 | 0.409 10^9 cells per liter | Standard Deviation 0.1643 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 36, n=260, 282 | 0.150 10^9 cells per liter | Standard Deviation 0.1403 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 44, n=269, 279 | 6.15 10^9 cells per liter | Standard Deviation 1.884 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 4, n=299, 291 | 2.127 10^9 cells per liter | Standard Deviation 0.6942 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 28, n=266, 295 | 3.528 10^9 cells per liter | Standard Deviation 1.5464 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Baseline, n=308, 307 | 0.353 10^9 cells per liter | Standard Deviation 0.1745 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 48, n=246, 274 | 0.407 10^9 cells per liter | Standard Deviation 0.16 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Baseline, n=308, 308 | 231.1 10^9 cells per liter | Standard Deviation 56.75 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 4, n=300, 298 | 233.5 10^9 cells per liter | Standard Deviation 55.09 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 8, n=216, 298 | 227.4 10^9 cells per liter | Standard Deviation 47.04 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 12, n=294, 290 | 230.2 10^9 cells per liter | Standard Deviation 57.32 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 16, n=279, 294 | 226.1 10^9 cells per liter | Standard Deviation 56.82 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 20, n=274, 297 | 226.5 10^9 cells per liter | Standard Deviation 58.11 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 24, n=279, 292 | 224.9 10^9 cells per liter | Standard Deviation 53.19 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 28, n=268, 295 | 224.7 10^9 cells per liter | Standard Deviation 54.15 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 32, n=267, 289 | 226.5 10^9 cells per liter | Standard Deviation 50.84 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 36, n=267, 284 | 229.0 10^9 cells per liter | Standard Deviation 53.9 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 40, n=263, 288 | 230.1 10^9 cells per liter | Standard Deviation 53.48 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 44, n=270, 286 | 235.5 10^9 cells per liter | Standard Deviation 55.8 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 48, n=253, 281 | 230.5 10^9 cells per liter | Standard Deviation 54.33 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Baseline, n=308, 307 | 0.021 10^9 cells per liter | Standard Deviation 0.0147 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 4, n=299, 291 | 0.024 10^9 cells per liter | Standard Deviation 0.0153 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 8, n=216, 294 | 0.023 10^9 cells per liter | Standard Deviation 0.0188 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 12, n=293, 290 | 0.022 10^9 cells per liter | Standard Deviation 0.0154 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 16, n=274, 292 | 0.022 10^9 cells per liter | Standard Deviation 0.0147 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 20, n=273, 292 | 0.023 10^9 cells per liter | Standard Deviation 0.0182 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 24, n=277, 292 | 0.023 10^9 cells per liter | Standard Deviation 0.0139 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 28, n=266, 295 | 0.024 10^9 cells per liter | Standard Deviation 0.015 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 32, n=262, 283 | 0.025 10^9 cells per liter | Standard Deviation 0.0171 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 36, n=260, 282 | 0.029 10^9 cells per liter | Standard Deviation 0.0211 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 40, n=258, 280 | 0.035 10^9 cells per liter | Standard Deviation 0.0266 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 44, n=258, 268 | 0.037 10^9 cells per liter | Standard Deviation 0.0275 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 48, n=246, 274 | 0.040 10^9 cells per liter | Standard Deviation 0.0253 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Baseline, n=308, 307 | 0.142 10^9 cells per liter | Standard Deviation 0.1409 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 4, n=299, 291 | 0.168 10^9 cells per liter | Standard Deviation 0.1587 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 8, n=216, 294 | 0.154 10^9 cells per liter | Standard Deviation 0.1379 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 12, n=293, 290 | 0.142 10^9 cells per liter | Standard Deviation 0.1172 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 16, n=274, 292 | 0.153 10^9 cells per liter | Standard Deviation 0.1395 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 20, n=273, 292 | 0.152 10^9 cells per liter | Standard Deviation 0.148 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 24, n=277, 292 | 0.143 10^9 cells per liter | Standard Deviation 0.1323 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 28, n=266, 295 | 0.144 10^9 cells per liter | Standard Deviation 0.1266 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 32, n=262, 283 | 0.170 10^9 cells per liter | Standard Deviation 0.1643 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 40, n=258, 280 | 0.161 10^9 cells per liter | Standard Deviation 0.1206 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 44, n=258, 268 | 0.175 10^9 cells per liter | Standard Deviation 0.1471 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 48, n=246, 274 | 0.174 10^9 cells per liter | Standard Deviation 0.1412 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Baseline, n=308, 307 | 5.87 10^9 cells per liter | Standard Deviation 1.928 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 4, n=300, 298 | 6.43 10^9 cells per liter | Standard Deviation 2.154 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 8, n=217, 301 | 6.14 10^9 cells per liter | Standard Deviation 1.875 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 12, n=294, 293 | 6.24 10^9 cells per liter | Standard Deviation 1.876 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 16, n=279, 295 | 6.27 10^9 cells per liter | Standard Deviation 1.92 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 20, n=276, 298 | 6.27 10^9 cells per liter | Standard Deviation 1.947 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 24, n=279, 294 | 6.18 10^9 cells per liter | Standard Deviation 1.931 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 28, n=268, 297 | 6.08 10^9 cells per liter | Standard Deviation 1.949 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 32, n=267, 288 | 6.30 10^9 cells per liter | Standard Deviation 1.914 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 36, n=264, 285 | 6.14 10^9 cells per liter | Standard Deviation 1.831 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 40, n=264, 286 | 6.24 10^9 cells per liter | Standard Deviation 2.046 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 48, n=252, 282 | 6.01 10^9 cells per liter | Standard Deviation 1.943 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Baseline, n=308, 307 | 1.943 10^9 cells per liter | Standard Deviation 0.6073 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 8, n=216, 294 | 1.995 10^9 cells per liter | Standard Deviation 0.6347 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 12, n=293, 290 | 1.984 10^9 cells per liter | Standard Deviation 0.6428 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 16, n=274, 292 | 2.057 10^9 cells per liter | Standard Deviation 0.684 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 20, n=273, 292 | 2.035 10^9 cells per liter | Standard Deviation 0.614 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 24, n=277, 292 | 2.016 10^9 cells per liter | Standard Deviation 0.6523 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 28, n=266, 295 | 2.049 10^9 cells per liter | Standard Deviation 0.696 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 32, n=262, 283 | 2.020 10^9 cells per liter | Standard Deviation 0.6157 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 36, n=260, 282 | 1.960 10^9 cells per liter | Standard Deviation 0.6009 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 40, n=258, 280 | 1.994 10^9 cells per liter | Standard Deviation 0.6149 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 44, n=258, 268 | 2.016 10^9 cells per liter | Standard Deviation 0.6457 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 48, n=246, 274 | 1.900 10^9 cells per liter | Standard Deviation 0.5725 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Baseline, n=308, 307 | 3.437 10^9 cells per liter | Standard Deviation 1.6106 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 4, n=299, 291 | 3.708 10^9 cells per liter | Standard Deviation 1.8763 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 8, n=216, 294 | 3.597 10^9 cells per liter | Standard Deviation 1.6128 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 12, n=293, 290 | 3.724 10^9 cells per liter | Standard Deviation 1.5751 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 16, n=274, 292 | 3.670 10^9 cells per liter | Standard Deviation 1.6777 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 20, n=273, 292 | 3.707 10^9 cells per liter | Standard Deviation 1.6532 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 24, n=277, 292 | 3.613 10^9 cells per liter | Standard Deviation 1.5978 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 32, n=262, 283 | 3.704 10^9 cells per liter | Standard Deviation 1.6196 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 36, n=260, 282 | 3.629 10^9 cells per liter | Standard Deviation 1.5688 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 40, n=258, 280 | 3.688 10^9 cells per liter | Standard Deviation 1.7685 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 44, n=258, 268 | 3.571 10^9 cells per liter | Standard Deviation 1.5425 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 48, n=246, 274 | 3.450 10^9 cells per liter | Standard Deviation 1.5649 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 4, n=299, 291 | 0.404 10^9 cells per liter | Standard Deviation 0.1951 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 8, n=216, 294 | 0.369 10^9 cells per liter | Standard Deviation 0.1628 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 12, n=293, 290 | 0.375 10^9 cells per liter | Standard Deviation 0.1563 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 16, n=274, 292 | 0.364 10^9 cells per liter | Standard Deviation 0.1537 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 20, n=273, 292 | 0.356 10^9 cells per liter | Standard Deviation 0.1526 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 24, n=277, 292 | 0.370 10^9 cells per liter | Standard Deviation 0.1632 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 28, n=266, 295 | 0.354 10^9 cells per liter | Standard Deviation 0.1631 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 32, n=262, 283 | 0.378 10^9 cells per liter | Standard Deviation 0.1629 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 36, n=260, 282 | 0.376 10^9 cells per liter | Standard Deviation 0.1593 |
| CAB LA+RPV LA (Q4W) | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 40, n=258, 280 | 0.402 10^9 cells per liter | Standard Deviation 0.1612 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Baseline, n=308, 307 | 0.339 10^9 cells per liter | Standard Deviation 0.1596 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 4, n=300, 298 | 5.81 10^9 cells per liter | Standard Deviation 1.733 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Baseline, n=308, 307 | 3.209 10^9 cells per liter | Standard Deviation 1.5748 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 44, n=269, 279 | 5.66 10^9 cells per liter | Standard Deviation 1.745 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Baseline, n=308, 307 | 1.940 10^9 cells per liter | Standard Deviation 0.688 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 8, n=217, 301 | 5.64 10^9 cells per liter | Standard Deviation 1.663 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 24, n=277, 292 | 0.341 10^9 cells per liter | Standard Deviation 0.1632 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 28, n=266, 295 | 3.221 10^9 cells per liter | Standard Deviation 1.2962 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 48, n=246, 274 | 3.172 10^9 cells per liter | Standard Deviation 1.3627 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 12, n=294, 293 | 5.77 10^9 cells per liter | Standard Deviation 1.751 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 44, n=258, 268 | 0.388 10^9 cells per liter | Standard Deviation 0.1795 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 4, n=299, 291 | 3.244 10^9 cells per liter | Standard Deviation 1.3931 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 48, n=246, 274 | 0.384 10^9 cells per liter | Standard Deviation 0.1742 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 16, n=279, 295 | 5.82 10^9 cells per liter | Standard Deviation 1.756 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Baseline, n=308, 308 | 232.9 10^9 cells per liter | Standard Deviation 59.28 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 4, n=299, 291 | 0.367 10^9 cells per liter | Standard Deviation 0.1694 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 4, n=300, 298 | 238.1 10^9 cells per liter | Standard Deviation 61.98 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 20, n=276, 298 | 5.70 10^9 cells per liter | Standard Deviation 1.721 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 8, n=216, 298 | 234.0 10^9 cells per liter | Standard Deviation 61.84 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 8, n=216, 294 | 3.190 10^9 cells per liter | Standard Deviation 1.337 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 12, n=294, 290 | 237.8 10^9 cells per liter | Standard Deviation 64.42 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 24, n=279, 294 | 5.78 10^9 cells per liter | Standard Deviation 1.756 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 16, n=279, 294 | 236.4 10^9 cells per liter | Standard Deviation 61.63 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 36, n=260, 282 | 0.366 10^9 cells per liter | Standard Deviation 0.1824 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 20, n=274, 297 | 237.7 10^9 cells per liter | Standard Deviation 61.51 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 28, n=268, 297 | 5.73 10^9 cells per liter | Standard Deviation 1.637 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 24, n=279, 292 | 239.8 10^9 cells per liter | Standard Deviation 64.11 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 12, n=293, 290 | 3.268 10^9 cells per liter | Standard Deviation 1.4153 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 28, n=268, 295 | 239.0 10^9 cells per liter | Standard Deviation 62.32 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 32, n=267, 288 | 5.73 10^9 cells per liter | Standard Deviation 1.666 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 32, n=267, 289 | 239.3 10^9 cells per liter | Standard Deviation 59.53 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 8, n=216, 294 | 0.358 10^9 cells per liter | Standard Deviation 0.1875 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 36, n=267, 284 | 242.9 10^9 cells per liter | Standard Deviation 66.12 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 36, n=264, 285 | 5.80 10^9 cells per liter | Standard Deviation 1.968 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 40, n=263, 288 | 240.8 10^9 cells per liter | Standard Deviation 61.92 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 16, n=274, 292 | 3.308 10^9 cells per liter | Standard Deviation 1.387 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 44, n=270, 286 | 241.4 10^9 cells per liter | Standard Deviation 61.73 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 40, n=264, 286 | 5.74 10^9 cells per liter | Standard Deviation 1.713 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 48, n=253, 281 | 240.2 10^9 cells per liter | Standard Deviation 62.95 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 28, n=266, 295 | 0.333 10^9 cells per liter | Standard Deviation 0.1592 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Baseline, n=308, 307 | 0.021 10^9 cells per liter | Standard Deviation 0.0148 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 48, n=252, 282 | 5.62 10^9 cells per liter | Standard Deviation 1.679 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 4, n=299, 291 | 0.023 10^9 cells per liter | Standard Deviation 0.0161 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 20, n=273, 292 | 3.188 10^9 cells per liter | Standard Deviation 1.3345 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 8, n=216, 294 | 0.022 10^9 cells per liter | Standard Deviation 0.0155 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 4, n=299, 291 | 2.059 10^9 cells per liter | Standard Deviation 0.6929 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 12, n=293, 290 | 0.022 10^9 cells per liter | Standard Deviation 0.0157 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 12, n=293, 290 | 0.342 10^9 cells per liter | Standard Deviation 0.1693 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 16, n=274, 292 | 0.022 10^9 cells per liter | Standard Deviation 0.014 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 8, n=216, 294 | 1.975 10^9 cells per liter | Standard Deviation 0.6549 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 20, n=273, 292 | 0.024 10^9 cells per liter | Standard Deviation 0.0195 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 24, n=277, 292 | 3.289 10^9 cells per liter | Standard Deviation 1.4381 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 24, n=277, 292 | 0.024 10^9 cells per liter | Standard Deviation 0.0133 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 12, n=293, 290 | 2.026 10^9 cells per liter | Standard Deviation 0.6996 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 28, n=266, 295 | 0.023 10^9 cells per liter | Standard Deviation 0.0138 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 32, n=262, 283 | 0.131 10^9 cells per liter | Standard Deviation 0.1319 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 32, n=262, 283 | 0.024 10^9 cells per liter | Standard Deviation 0.0159 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 16, n=274, 292 | 2.029 10^9 cells per liter | Standard Deviation 0.6584 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 36, n=260, 282 | 0.028 10^9 cells per liter | Standard Deviation 0.019 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 32, n=262, 283 | 3.228 10^9 cells per liter | Standard Deviation 1.2909 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 40, n=258, 280 | 0.031 10^9 cells per liter | Standard Deviation 0.0206 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 20, n=273, 292 | 2.030 10^9 cells per liter | Standard Deviation 0.6906 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 44, n=258, 268 | 0.033 10^9 cells per liter | Standard Deviation 0.0222 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 16, n=274, 292 | 0.345 10^9 cells per liter | Standard Deviation 0.1645 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 48, n=246, 274 | 0.039 10^9 cells per liter | Standard Deviation 0.0249 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 24, n=277, 292 | 1.980 10^9 cells per liter | Standard Deviation 0.6047 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Baseline, n=308, 307 | 0.140 10^9 cells per liter | Standard Deviation 0.1538 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 36, n=260, 282 | 3.314 10^9 cells per liter | Standard Deviation 1.6341 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 4, n=299, 291 | 0.145 10^9 cells per liter | Standard Deviation 0.1422 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 28, n=266, 295 | 2.016 10^9 cells per liter | Standard Deviation 0.6476 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 8, n=216, 294 | 0.131 10^9 cells per liter | Standard Deviation 0.1333 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 32, n=262, 283 | 0.351 10^9 cells per liter | Standard Deviation 0.1801 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 12, n=293, 290 | 0.132 10^9 cells per liter | Standard Deviation 0.1471 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 32, n=262, 283 | 2.007 10^9 cells per liter | Standard Deviation 0.6511 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 16, n=274, 292 | 0.131 10^9 cells per liter | Standard Deviation 0.1584 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 40, n=258, 280 | 3.280 10^9 cells per liter | Standard Deviation 1.419 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 20, n=273, 292 | 0.116 10^9 cells per liter | Standard Deviation 0.1094 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 36, n=260, 282 | 1.984 10^9 cells per liter | Standard Deviation 0.6444 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 24, n=277, 292 | 0.121 10^9 cells per liter | Standard Deviation 0.1337 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 20, n=273, 292 | 0.342 10^9 cells per liter | Standard Deviation 0.1632 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 28, n=266, 295 | 0.129 10^9 cells per liter | Standard Deviation 0.132 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 40, n=258, 280 | 1.957 10^9 cells per liter | Standard Deviation 0.6305 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 36, n=260, 282 | 0.132 10^9 cells per liter | Standard Deviation 0.1162 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 44, n=258, 268 | 3.169 10^9 cells per liter | Standard Deviation 1.414 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 40, n=258, 280 | 0.132 10^9 cells per liter | Standard Deviation 0.1124 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 44, n=258, 268 | 1.970 10^9 cells per liter | Standard Deviation 0.6219 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 44, n=258, 268 | 0.136 10^9 cells per liter | Standard Deviation 0.1126 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 40, n=258, 280 | 0.359 10^9 cells per liter | Standard Deviation 0.1823 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 48, n=246, 274 | 0.140 10^9 cells per liter | Standard Deviation 0.1265 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 48, n=246, 274 | 1.915 10^9 cells per liter | Standard Deviation 0.6204 |
| Current ART | Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Baseline, n=308, 307 | 5.65 10^9 cells per liter | Standard Deviation 1.897 |
Secondary
Absolute Values for Plasma HIV-1 RNA at Week 48
Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented.
Time frame: Week 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Absolute Values for Plasma HIV-1 RNA at Week 48 | 1.505 log10 copies/mL | Standard Deviation 0.047 |
| Current ART | Absolute Values for Plasma HIV-1 RNA at Week 48 | 1.518 log10 copies/mL | Standard Deviation 0.1123 |
Secondary
Area Under the Curve (AUC) for CAB LA
AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201585 and 201584 # NCT02938520. Blood samples from the current study 201585 were collected at indicated time points to analyze concentration in plasma for CAB LA.
Time frame: Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5 and 41
Population: PK population. Only those participants with data available at the specified data points were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| CAB LA+RPV LA (Q4W) | Area Under the Curve (AUC) for CAB LA | 2324.29 Hours*microgram per milliliter |
Secondary
AUC for RPV LA
AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201585 and 201584 # NCT02938520. Blood samples from the current study 201585 were collected at indicated time points to analyze concentration in plasma for RPV LA.
Time frame: Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5 and 41
Population: PK population. Only those participants with data available at the specified data points were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| CAB LA+RPV LA (Q4W) | AUC for RPV LA | 67119.84 Hours*nanogram per milliliter |
Secondary
Change From 4b in Tolerability of Injection at Week 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm
The NRS questionnaire is used to assess the tolerability of injections in CAB LA+RPV LA arm only. The questionnaire consists of one single question and will assess maximum level of pain experienced with the most recent injections ranking from no pain (0) to extreme pain (10). Missing scores was imputed using LOCF.
Time frame: Weeks 4b, 5, 40 and 41
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From 4b in Tolerability of Injection at Week 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm | Week 5 | 2.0 Scores on a scale | Standard Deviation 2.94 |
| CAB LA+RPV LA (Q4W) | Change From 4b in Tolerability of Injection at Week 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm | Week 40 | 0.5 Scores on a scale | Standard Deviation 2.79 |
| CAB LA+RPV LA (Q4W) | Change From 4b in Tolerability of Injection at Week 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm | Week 41 | 0.4 Scores on a scale | Standard Deviation 2.83 |
Secondary
Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 32, n=262, 282 | 0.022 10^9 cells per liters | Standard Deviation 0.1629 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 36, n=260, 281 | 0.008 10^9 cells per liters | Standard Deviation 0.5333 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 4, n=299, 290 | 0.003 10^9 cells per liters | Standard Deviation 0.0202 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 8, n=216, 293 | 0.003 10^9 cells per liters | Standard Deviation 0.0204 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 12, n=293, 289 | 0.002 10^9 cells per liters | Standard Deviation 0.0205 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 16, n=274, 291 | 0.001 10^9 cells per liters | Standard Deviation 0.0186 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 20, n=273, 291 | 0.002 10^9 cells per liters | Standard Deviation 0.0225 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 24, n=277, 291 | 0.002 10^9 cells per liters | Standard Deviation 0.0169 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 28, n=266, 294 | 0.003 10^9 cells per liters | Standard Deviation 0.02 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 36, n=260, 281 | 0.009 10^9 cells per liters | Standard Deviation 0.0231 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 40, n=258, 279 | 0.014 10^9 cells per liters | Standard Deviation 0.0292 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 44, n=258, 267 | 0.017 10^9 cells per liters | Standard Deviation 0.0283 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 48, n=246, 273 | 0.019 10^9 cells per liters | Standard Deviation 0.0273 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 4, n=299, 290 | 0.026 10^9 cells per liters | Standard Deviation 0.1394 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 8, n=216, 293 | 0.015 10^9 cells per liters | Standard Deviation 0.1278 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 12, n=293, 289 | -0.003 10^9 cells per liters | Standard Deviation 0.1155 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 16, n=274, 291 | 0.009 10^9 cells per liters | Standard Deviation 0.1246 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 20, n=273, 291 | 0.009 10^9 cells per liters | Standard Deviation 0.141 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 24, n=277, 291 | 0.002 10^9 cells per liters | Standard Deviation 0.1228 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 28, n=266, 294 | -0.002 10^9 cells per liters | Standard Deviation 0.1298 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 32, n=262, 282 | 0.005 10^9 cells per liters | Standard Deviation 0.0199 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 36, n=260, 281 | 0.002 10^9 cells per liters | Standard Deviation 0.1413 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 40, n=258, 279 | 0.019 10^9 cells per liters | Standard Deviation 0.1319 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 44, n=258, 267 | 0.032 10^9 cells per liters | Standard Deviation 0.1388 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 48, n=246, 273 | 0.032 10^9 cells per liters | Standard Deviation 0.1321 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 4, n=300, 297 | 0.54 10^9 cells per liters | Standard Deviation 1.599 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 8, n=217, 300 | 0.19 10^9 cells per liters | Standard Deviation 1.579 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 12, n=294, 292 | 0.35 10^9 cells per liters | Standard Deviation 1.743 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 16, n=279, 294 | 0.34 10^9 cells per liters | Standard Deviation 1.653 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 20, n=276, 297 | 0.46 10^9 cells per liters | Standard Deviation 1.565 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 24, n=279, 293 | 0.32 10^9 cells per liters | Standard Deviation 1.72 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 28, n=268, 296 | 0.25 10^9 cells per liters | Standard Deviation 1.651 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 32, n=267, 287 | 0.43 10^9 cells per liters | Standard Deviation 1.602 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 36, n=264, 284 | 0.33 10^9 cells per liters | Standard Deviation 1.699 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 40, n=264, 285 | 0.35 10^9 cells per liters | Standard Deviation 1.808 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 44, n=269, 278 | 0.22 10^9 cells per liters | Standard Deviation 1.581 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 48, n=252, 281 | 0.09 10^9 cells per liters | Standard Deviation 1.646 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 4, n=299, 290 | 0.174 10^9 cells per liters | Standard Deviation 0.5185 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 8, n=216, 293 | 0.068 10^9 cells per liters | Standard Deviation 0.5319 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 12, n=293, 289 | 0.033 10^9 cells per liters | Standard Deviation 0.5073 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 16, n=274, 291 | 0.114 10^9 cells per liters | Standard Deviation 0.5596 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 20, n=273, 291 | 0.071 10^9 cells per liters | Standard Deviation 0.5274 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 24, n=277, 291 | 0.079 10^9 cells per liters | Standard Deviation 0.5408 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 28, n=266, 294 | 0.101 10^9 cells per liters | Standard Deviation 0.6133 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 32, n=262, 282 | 0.063 10^9 cells per liters | Standard Deviation 0.5392 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 40, n=258, 279 | 0.020 10^9 cells per liters | Standard Deviation 0.5171 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 44, n=258, 267 | 0.045 10^9 cells per liters | Standard Deviation 0.543 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 48, n=246, 273 | -0.063 10^9 cells per liters | Standard Deviation 0.5528 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 4, n=299, 290 | 0.258 10^9 cells per liters | Standard Deviation 1.5445 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 8, n=216, 293 | 0.080 10^9 cells per liters | Standard Deviation 1.4401 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 12, n=293, 289 | 0.283 10^9 cells per liters | Standard Deviation 1.6227 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 16, n=274, 291 | 0.181 10^9 cells per liters | Standard Deviation 1.5415 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 20, n=273, 291 | 0.341 10^9 cells per liters | Standard Deviation 1.4475 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 24, n=277, 291 | 0.175 10^9 cells per liters | Standard Deviation 1.5883 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 28, n=266, 294 | 0.129 10^9 cells per liters | Standard Deviation 1.4052 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 32, n=262, 282 | 0.291 10^9 cells per liters | Standard Deviation 1.6015 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 36, n=260, 281 | 0.289 10^9 cells per liters | Standard Deviation 1.5702 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 40, n=258, 279 | 0.245 10^9 cells per liters | Standard Deviation 1.6621 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 44, n=258, 267 | 0.063 10^9 cells per liters | Standard Deviation 1.4874 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 48, n=246, 273 | 0.009 10^9 cells per liters | Standard Deviation 1.5413 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 4, n=299, 290 | 0.049 10^9 cells per liters | Standard Deviation 0.1663 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes Week 8, n=216, 293 | 0.014 10^9 cells per liters | Standard Deviation 0.1433 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 12, n=293, 289 | 0.018 10^9 cells per liters | Standard Deviation 0.1553 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 16, n=274, 291 | 0.005 10^9 cells per liters | Standard Deviation 0.1588 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 20, n=273, 291 | 0.003 10^9 cells per liters | Standard Deviation 0.1527 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 24, n=277, 291 | 0.012 10^9 cells per liters | Standard Deviation 0.1484 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 28, n=266, 294 | 0.001 10^9 cells per liters | Standard Deviation 0.1548 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 32, n=262, 282 | 0.019 10^9 cells per liters | Standard Deviation 0.1535 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 36, n=260, 281 | 0.016 10^9 cells per liters | Standard Deviation 0.1501 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 40, n=258, 279 | 0.039 10^9 cells per liters | Standard Deviation 0.1507 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 44, n=258, 267 | 0.045 10^9 cells per liters | Standard Deviation 0.1673 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 48, n=246, 273 | 0.047 10^9 cells per liters | Standard Deviation 0.1502 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 4, n=300, 298 | 1.8 10^9 cells per liters | Standard Deviation 38.02 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 8, n=216, 298 | -5.5 10^9 cells per liters | Standard Deviation 31.98 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 12, n=294, 290 | -0.8 10^9 cells per liters | Standard Deviation 40.83 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 16, n=279, 294 | -5.2 10^9 cells per liters | Standard Deviation 40.67 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 20, n=274, 297 | -3.7 10^9 cells per liters | Standard Deviation 36.87 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 24, n=279, 292 | -4.7 10^9 cells per liters | Standard Deviation 35.22 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 28, n=268, 295 | -5.3 10^9 cells per liters | Standard Deviation 35.22 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 32, n=267, 289 | -2.6 10^9 cells per liters | Standard Deviation 36.51 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 36, n=267, 284 | -1.2 10^9 cells per liters | Standard Deviation 37.26 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 40, n=263, 288 | 0.0 10^9 cells per liters | Standard Deviation 40.74 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 44, n=270, 286 | 4.5 10^9 cells per liters | Standard Deviation 38.31 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 48, n=253, 281 | 0.0 10^9 cells per liters | Standard Deviation 38.63 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 20, n=273, 291 | 0.086 10^9 cells per liters | Standard Deviation 0.5411 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 40, n=258, 279 | 0.011 10^9 cells per liters | Standard Deviation 0.0233 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 36, n=260, 281 | -0.012 10^9 cells per liters | Standard Deviation 0.1382 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 8, n=216, 298 | 0.7 10^9 cells per liters | Standard Deviation 35.15 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 36, n=260, 281 | 0.036 10^9 cells per liters | Standard Deviation 0.5525 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 20, n=273, 291 | -0.019 10^9 cells per liters | Standard Deviation 1.4228 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 24, n=277, 291 | 0.049 10^9 cells per liters | Standard Deviation 0.4863 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 4, n=299, 290 | 0.003 10^9 cells per liters | Standard Deviation 0.0185 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 16, n=274, 291 | 0.003 10^9 cells per liters | Standard Deviation 0.1403 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 8, n=216, 293 | 0.000 10^9 cells per liters | Standard Deviation 0.0181 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 28, n=266, 294 | 0.069 10^9 cells per liters | Standard Deviation 0.6005 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 12, n=293, 289 | 0.001 10^9 cells per liters | Standard Deviation 0.0197 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 40, n=263, 288 | 9.7 10^9 cells per liters | Standard Deviation 39.91 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 16, n=274, 291 | 0.001 10^9 cells per liters | Standard Deviation 0.0181 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 32, n=262, 282 | 0.064 10^9 cells per liters | Standard Deviation 0.5757 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 20, n=273, 291 | 0.002 10^9 cells per liters | Standard Deviation 0.0212 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 20, n=273, 291 | 0.004 10^9 cells per liters | Standard Deviation 0.1328 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 24, n=277, 291 | 0.003 10^9 cells per liters | Standard Deviation 0.0167 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 40, n=258, 279 | 0.035 10^9 cells per liters | Standard Deviation 0.528 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 28, n=266, 294 | 0.002 10^9 cells per liters | Standard Deviation 0.0181 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 32, n=262, 282 | 0.003 10^9 cells per liters | Standard Deviation 0.0189 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 12, n=294, 290 | 5.5 10^9 cells per liters | Standard Deviation 36.76 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 36, n=260, 281 | 0.007 10^9 cells per liters | Standard Deviation 0.0217 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 44, n=258, 267 | 0.045 10^9 cells per liters | Standard Deviation 0.5472 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 24, n=277, 291 | 0.002 10^9 cells per liters | Standard Deviation 0.1331 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 44, n=258, 267 | 0.012 10^9 cells per liters | Standard Deviation 0.0239 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 48, n=246, 273 | -0.035 10^9 cells per liters | Standard Deviation 0.5115 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Basophils, Week 48, n=246, 273 | 0.018 10^9 cells per liters | Standard Deviation 0.0263 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 32, n=267, 289 | 6.5 10^9 cells per liters | Standard Deviation 35.99 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 4, n=299, 290 | 0.009 10^9 cells per liters | Standard Deviation 0.1409 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 4, n=299, 290 | 0.004 10^9 cells per liters | Standard Deviation 1.3601 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 8, n=216, 293 | -0.008 10^9 cells per liters | Standard Deviation 0.1319 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 28, n=266, 294 | -0.004 10^9 cells per liters | Standard Deviation 0.1343 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 12, n=293, 289 | -0.010 10^9 cells per liters | Standard Deviation 0.1533 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 8, n=216, 293 | -0.031 10^9 cells per liters | Standard Deviation 1.3599 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 16, n=274, 291 | -0.011 10^9 cells per liters | Standard Deviation 0.1759 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 16, n=279, 294 | 4.3 10^9 cells per liters | Standard Deviation 34.61 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 20, n=273, 291 | -0.027 10^9 cells per liters | Standard Deviation 0.1352 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 12, n=293, 289 | 0.028 10^9 cells per liters | Standard Deviation 1.3884 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 24, n=277, 291 | -0.021 10^9 cells per liters | Standard Deviation 0.149 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 32, n=262, 282 | 0.011 10^9 cells per liters | Standard Deviation 0.1585 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 28, n=266, 294 | -0.011 10^9 cells per liters | Standard Deviation 0.1387 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 16, n=274, 291 | 0.080 10^9 cells per liters | Standard Deviation 1.4451 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 32, n=262, 282 | -0.012 10^9 cells per liters | Standard Deviation 0.1511 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 48, n=253, 281 | 10.4 10^9 cells per liters | Standard Deviation 41.75 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 36, n=260, 281 | 0.024 10^9 cells per liters | Standard Deviation 0.1551 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 40, n=258, 279 | -0.006 10^9 cells per liters | Standard Deviation 0.1283 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 24, n=277, 291 | 0.056 10^9 cells per liters | Standard Deviation 1.5091 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 44, n=258, 267 | -0.004 10^9 cells per liters | Standard Deviation 0.1061 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 20, n=274, 297 | 5.5 10^9 cells per liters | Standard Deviation 38.86 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Eosinophils, Week 48, n=246, 273 | 0.002 10^9 cells per liters | Standard Deviation 0.1253 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 28, n=266, 294 | -0.001 10^9 cells per liters | Standard Deviation 1.3377 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 4, n=300, 297 | 0.13 10^9 cells per liters | Standard Deviation 1.544 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 40, n=258, 279 | 0.020 10^9 cells per liters | Standard Deviation 0.155 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 8, n=217, 300 | -0.02 10^9 cells per liters | Standard Deviation 1.548 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 32, n=262, 282 | 0.008 10^9 cells per liters | Standard Deviation 1.443 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 12, n=294, 292 | 0.10 10^9 cells per liters | Standard Deviation 1.571 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 36, n=267, 284 | 9.8 10^9 cells per liters | Standard Deviation 44.52 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 16, n=279, 294 | 0.17 10^9 cells per liters | Standard Deviation 1.558 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 36, n=260, 281 | 0.077 10^9 cells per liters | Standard Deviation 1.6758 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 20, n=276, 297 | 0.04 10^9 cells per liters | Standard Deviation 1.529 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 44, n=258, 267 | 0.045 10^9 cells per liters | Standard Deviation 0.1539 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 24, n=279, 293 | 0.10 10^9 cells per liters | Standard Deviation 1.661 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 40, n=258, 279 | 0.075 10^9 cells per liters | Standard Deviation 1.5336 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 28, n=268, 296 | 0.07 10^9 cells per liters | Standard Deviation 1.471 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 24, n=279, 292 | 6.7 10^9 cells per liters | Standard Deviation 41.78 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 32, n=267, 287 | 0.07 10^9 cells per liters | Standard Deviation 1.631 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 44, n=258, 267 | -0.105 10^9 cells per liters | Standard Deviation 1.4587 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 36, n=264, 284 | 0.13 10^9 cells per liters | Standard Deviation 1.821 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 48, n=246, 273 | 0.039 10^9 cells per liters | Standard Deviation 0.1499 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 40, n=264, 285 | 0.12 10^9 cells per liters | Standard Deviation 1.675 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Neutrophils, Week 48, n=246, 273 | -0.066 10^9 cells per liters | Standard Deviation 1.3969 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 44, n=269, 278 | -0.03 10^9 cells per liters | Standard Deviation 1.561 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 44, n=270, 286 | 9.2 10^9 cells per liters | Standard Deviation 42.82 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Leukocytes, Week 48, n=252, 281 | -0.06 10^9 cells per liters | Standard Deviation 1.538 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 4, n=299, 290 | 0.030 10^9 cells per liters | Standard Deviation 0.127 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 4, n=299, 290 | 0.128 10^9 cells per liters | Standard Deviation 0.5618 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 4, n=300, 298 | 4.3 10^9 cells per liters | Standard Deviation 36.15 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 8, n=216, 293 | 0.023 10^9 cells per liters | Standard Deviation 0.525 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes Week 8, n=216, 293 | 0.018 10^9 cells per liters | Standard Deviation 0.1591 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 12, n=293, 289 | 0.079 10^9 cells per liters | Standard Deviation 0.5844 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Platelets, Week 28, n=268, 295 | 5.4 10^9 cells per liters | Standard Deviation 38.41 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Lymphocytes, Week 16, n=274, 291 | 0.095 10^9 cells per liters | Standard Deviation 0.5389 |
| Current ART | Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets | Monocytes, Week 12, n=293, 289 | 0.001 10^9 cells per liters | Standard Deviation 0.1367 |
Secondary
Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume
Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 4, n=300, 300 | -1.1 Femtoliters | Standard Deviation 2.71 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 8, n=218, 301 | -3.0 Femtoliters | Standard Deviation 4.3 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 12, n=294, 293 | -3.9 Femtoliters | Standard Deviation 5.23 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 16, n=280, 296 | -4.9 Femtoliters | Standard Deviation 5.86 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 20, n=276, 298 | -5.3 Femtoliters | Standard Deviation 5.98 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 24, n=279, 294 | -5.4 Femtoliters | Standard Deviation 5.97 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 28, n=268, 297 | -5.5 Femtoliters | Standard Deviation 6.11 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 32, n=268, 291 | -5.5 Femtoliters | Standard Deviation 6.1 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 36, n=267, 288 | -5.8 Femtoliters | Standard Deviation 6.24 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 40, n=264, 289 | -5.6 Femtoliters | Standard Deviation 6.21 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 44, n=273, 286 | -5.8 Femtoliters | Standard Deviation 6.33 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 48, n=255, 284 | -5.7 Femtoliters | Standard Deviation 6.76 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 44, n=273, 286 | -0.3 Femtoliters | Standard Deviation 3.68 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 4, n=300, 300 | 0.2 Femtoliters | Standard Deviation 1.82 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 28, n=268, 297 | 0.4 Femtoliters | Standard Deviation 3.46 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 8, n=218, 301 | 0.1 Femtoliters | Standard Deviation 1.76 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 40, n=264, 289 | -0.1 Femtoliters | Standard Deviation 3.62 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 12, n=294, 293 | 0.2 Femtoliters | Standard Deviation 2.08 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 32, n=268, 291 | 0.1 Femtoliters | Standard Deviation 3.47 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 16, n=280, 296 | 0.2 Femtoliters | Standard Deviation 2.42 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 48, n=255, 284 | -0.4 Femtoliters | Standard Deviation 3.57 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 20, n=276, 298 | 0.3 Femtoliters | Standard Deviation 2.88 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 36, n=267, 288 | -0.0 Femtoliters | Standard Deviation 3.69 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume | Week 24, n=279, 294 | 0.3 Femtoliters | Standard Deviation 3.24 |
Secondary
Change From Baseline for Hematology Parameters: Erythrocytes
Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocytes | Week 28, n=268, 297 | 0.28 10^12 cells per liter | Standard Deviation 0.386 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocytes | Week 8, n=218, 301 | 0.14 10^12 cells per liter | Standard Deviation 0.331 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocytes | Week 32, n=268, 291 | 0.29 10^12 cells per liter | Standard Deviation 0.393 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocytes | Week 16, n=280, 296 | 0.28 10^12 cells per liter | Standard Deviation 0.38 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocytes | Week 36, n=267, 288 | 0.26 10^12 cells per liter | Standard Deviation 0.401 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocytes | Week 4, n=300, 300 | 0.04 10^12 cells per liter | Standard Deviation 0.255 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocytes | Week 40, n=264, 289 | 0.27 10^12 cells per liter | Standard Deviation 0.396 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocytes | Week 20, n=276, 298 | 0.30 10^12 cells per liter | Standard Deviation 0.408 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocytes | Week 44, n=273, 286 | 0.31 10^12 cells per liter | Standard Deviation 0.391 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocytes | Week 24, n=279, 294 | 0.32 10^12 cells per liter | Standard Deviation 0.397 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocytes | Week 48, n=255, 284 | 0.25 10^12 cells per liter | Standard Deviation 0.394 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Erythrocytes | Week 12, n=294, 293 | 0.23 10^12 cells per liter | Standard Deviation 0.374 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocytes | Week 48, n=255, 284 | -0.01 10^12 cells per liter | Standard Deviation 0.262 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocytes | Week 4, n=300, 300 | -0.03 10^12 cells per liter | Standard Deviation 0.226 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocytes | Week 8, n=218, 301 | -0.01 10^12 cells per liter | Standard Deviation 0.249 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocytes | Week 12, n=294, 293 | 0.01 10^12 cells per liter | Standard Deviation 0.252 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocytes | Week 16, n=280, 296 | -0.01 10^12 cells per liter | Standard Deviation 0.256 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocytes | Week 24, n=279, 294 | -0.01 10^12 cells per liter | Standard Deviation 0.246 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocytes | Week 28, n=268, 297 | -0.01 10^12 cells per liter | Standard Deviation 0.246 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocytes | Week 32, n=268, 291 | -0.01 10^12 cells per liter | Standard Deviation 0.261 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocytes | Week 36, n=267, 288 | -0.01 10^12 cells per liter | Standard Deviation 0.259 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocytes | Week 40, n=264, 289 | -0.01 10^12 cells per liter | Standard Deviation 0.26 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocytes | Week 44, n=273, 286 | -0.01 10^12 cells per liter | Standard Deviation 0.264 |
| Current ART | Change From Baseline for Hematology Parameters: Erythrocytes | Week 20, n=276, 298 | -0.01 10^12 cells per liter | Standard Deviation 0.273 |
Secondary
Change From Baseline for Hematology Parameters: Hematocrit
Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hematocrit | Week 4, n=300, 300 | -0.0003 Proportion of red blood cells in blood | Standard Deviation 0.02236 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hematocrit | Week 8, n=218, 301 | 0.0007 Proportion of red blood cells in blood | Standard Deviation 0.02613 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hematocrit | Week 12, n=294, 293 | 0.0042 Proportion of red blood cells in blood | Standard Deviation 0.02607 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hematocrit | Week 16, n=280, 296 | 0.0038 Proportion of red blood cells in blood | Standard Deviation 0.02509 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hematocrit | Week 20, n=276, 298 | 0.0043 Proportion of red blood cells in blood | Standard Deviation 0.02742 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hematocrit | Week 24, n=279, 294 | 0.0052 Proportion of red blood cells in blood | Standard Deviation 0.0279 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hematocrit | Week 28, n=268, 297 | 0.0023 Proportion of red blood cells in blood | Standard Deviation 0.02699 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hematocrit | Week 32, n=268, 291 | 0.0022 Proportion of red blood cells in blood | Standard Deviation 0.02872 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hematocrit | Week 36, n=267, 288 | -0.0012 Proportion of red blood cells in blood | Standard Deviation 0.02793 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hematocrit | Week 40, n=264, 289 | -0.0001 Proportion of red blood cells in blood | Standard Deviation 0.02741 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hematocrit | Week 44, n=273, 286 | 0.0031 Proportion of red blood cells in blood | Standard Deviation 0.02896 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hematocrit | Week 48, n=255, 284 | -0.0021 Proportion of red blood cells in blood | Standard Deviation 0.02717 |
| Current ART | Change From Baseline for Hematology Parameters: Hematocrit | Week 44, n=273, 286 | -0.0025 Proportion of red blood cells in blood | Standard Deviation 0.02814 |
| Current ART | Change From Baseline for Hematology Parameters: Hematocrit | Week 4, n=300, 300 | -0.0023 Proportion of red blood cells in blood | Standard Deviation 0.02194 |
| Current ART | Change From Baseline for Hematology Parameters: Hematocrit | Week 28, n=268, 297 | 0.0002 Proportion of red blood cells in blood | Standard Deviation 0.02603 |
| Current ART | Change From Baseline for Hematology Parameters: Hematocrit | Week 8, n=218, 301 | -0.0005 Proportion of red blood cells in blood | Standard Deviation 0.0233 |
| Current ART | Change From Baseline for Hematology Parameters: Hematocrit | Week 40, n=264, 289 | -0.0011 Proportion of red blood cells in blood | Standard Deviation 0.02781 |
| Current ART | Change From Baseline for Hematology Parameters: Hematocrit | Week 12, n=294, 293 | 0.0020 Proportion of red blood cells in blood | Standard Deviation 0.02408 |
| Current ART | Change From Baseline for Hematology Parameters: Hematocrit | Week 32, n=268, 291 | -0.0011 Proportion of red blood cells in blood | Standard Deviation 0.02916 |
| Current ART | Change From Baseline for Hematology Parameters: Hematocrit | Week 16, n=280, 296 | -0.0007 Proportion of red blood cells in blood | Standard Deviation 0.02513 |
| Current ART | Change From Baseline for Hematology Parameters: Hematocrit | Week 48, n=255, 284 | -0.0031 Proportion of red blood cells in blood | Standard Deviation 0.027 |
| Current ART | Change From Baseline for Hematology Parameters: Hematocrit | Week 20, n=276, 298 | 0.0002 Proportion of red blood cells in blood | Standard Deviation 0.02613 |
| Current ART | Change From Baseline for Hematology Parameters: Hematocrit | Week 36, n=267, 288 | -0.0011 Proportion of red blood cells in blood | Standard Deviation 0.02797 |
| Current ART | Change From Baseline for Hematology Parameters: Hematocrit | Week 24, n=279, 294 | 0.0002 Proportion of red blood cells in blood | Standard Deviation 0.02576 |
Secondary
Change From Baseline for Hematology Parameters: Hemoglobin
Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hemoglobin | Week 4, n=300, 300 | -0.4 Grams per liter | Standard Deviation 6.91 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hemoglobin | Week 8, n=218, 301 | -0.4 Grams per liter | Standard Deviation 8.18 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hemoglobin | Week 12, n=294, 293 | 0.0 Grams per liter | Standard Deviation 8.14 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hemoglobin | Week 16, n=280, 296 | 0.4 Grams per liter | Standard Deviation 8.22 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hemoglobin | Week 20, n=276, 298 | 0.3 Grams per liter | Standard Deviation 8.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hemoglobin | Week 24, n=279, 294 | 1.2 Grams per liter | Standard Deviation 8.78 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hemoglobin | Week 28, n=268, 297 | 0.3 Grams per liter | Standard Deviation 8.49 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hemoglobin | Week 32, n=268, 291 | 0.9 Grams per liter | Standard Deviation 8.94 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hemoglobin | Week 36, n=267, 288 | 0.7 Grams per liter | Standard Deviation 9.03 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hemoglobin | Week 40, n=264, 289 | 0.8 Grams per liter | Standard Deviation 8.96 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hemoglobin | Week 44, n=273, 286 | 1.7 Grams per liter | Standard Deviation 9.49 |
| CAB LA+RPV LA (Q4W) | Change From Baseline for Hematology Parameters: Hemoglobin | Week 48, n=255, 284 | 0.2 Grams per liter | Standard Deviation 9.26 |
| Current ART | Change From Baseline for Hematology Parameters: Hemoglobin | Week 44, n=273, 286 | 0.6 Grams per liter | Standard Deviation 9.53 |
| Current ART | Change From Baseline for Hematology Parameters: Hemoglobin | Week 4, n=300, 300 | -1.0 Grams per liter | Standard Deviation 6.73 |
| Current ART | Change From Baseline for Hematology Parameters: Hemoglobin | Week 28, n=268, 297 | -0.6 Grams per liter | Standard Deviation 8.68 |
| Current ART | Change From Baseline for Hematology Parameters: Hemoglobin | Week 8, n=218, 301 | -0.6 Grams per liter | Standard Deviation 7.33 |
| Current ART | Change From Baseline for Hematology Parameters: Hemoglobin | Week 40, n=264, 289 | 0.7 Grams per liter | Standard Deviation 9.29 |
| Current ART | Change From Baseline for Hematology Parameters: Hemoglobin | Week 12, n=294, 293 | -0.3 Grams per liter | Standard Deviation 7.52 |
| Current ART | Change From Baseline for Hematology Parameters: Hemoglobin | Week 32, n=268, 291 | 0.2 Grams per liter | Standard Deviation 9.45 |
| Current ART | Change From Baseline for Hematology Parameters: Hemoglobin | Week 16, n=280, 296 | -1.2 Grams per liter | Standard Deviation 7.75 |
| Current ART | Change From Baseline for Hematology Parameters: Hemoglobin | Week 48, n=255, 284 | 0.9 Grams per liter | Standard Deviation 9.07 |
| Current ART | Change From Baseline for Hematology Parameters: Hemoglobin | Week 20, n=276, 298 | -0.5 Grams per liter | Standard Deviation 8.55 |
| Current ART | Change From Baseline for Hematology Parameters: Hemoglobin | Week 36, n=267, 288 | 0.8 Grams per liter | Standard Deviation 9.32 |
| Current ART | Change From Baseline for Hematology Parameters: Hemoglobin | Week 24, n=279, 294 | -0.0 Grams per liter | Standard Deviation 8.46 |
Secondary
Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK
Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK. Baseline values is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 48, n=265, 292 | -10.9 International units per liter | Standard Deviation 23.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 44, n=275, 293 | -2.2 International units per liter | Standard Deviation 13.97 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 4, n=301, 303 | -0.3 International units per liter | Standard Deviation 12.52 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 20, n=277, 302 | -0.8 International units per liter | Standard Deviation 22.62 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 8, n=229, 303 | 1.2 International units per liter | Standard Deviation 19.73 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 48, n=265, 292 | -1.9 International units per liter | Standard Deviation 13.43 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 16, n=284, 298 | 0.1 International units per liter | Standard Deviation 18.49 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 8, n=229, 303 | 0.7 International units per liter | Standard Deviation 15.35 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 20, n=277, 302 | -0.5 International units per liter | Standard Deviation 17.02 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 4, n=301, 303 | -6.0 International units per liter | Standard Deviation 12.74 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 24, n=284, 298 | 0.1 International units per liter | Standard Deviation 24.12 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 24, n=284, 299 | 2.2 International units per liter | Standard Deviation 61.65 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 28, n=267, 296 | -1.4 International units per liter | Standard Deviation 8.77 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 8, n=229, 303 | -6.7 International units per liter | Standard Deviation 16.59 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 32, n=275, 294 | -1.2 International units per liter | Standard Deviation 16.08 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 12, n=295, 299 | 2.3 International units per liter | Standard Deviation 65.03 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 36, n=273, 292 | -1.2 International units per liter | Standard Deviation 12.95 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 12, n=295, 299 | -8.0 International units per liter | Standard Deviation 20.87 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 40, n=270, 293 | -0.2 International units per liter | Standard Deviation 17.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 28, n=267, 296 | -2.7 International units per liter | Standard Deviation 11.14 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 44, n=275, 293 | -1.1 International units per liter | Standard Deviation 16.51 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 16, n=284, 298 | -9.7 International units per liter | Standard Deviation 19.47 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST Week 48, n=265, 292 | -1.0 International units per liter | Standard Deviation 12.79 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 12, n=295, 299 | 5.2 International units per liter | Standard Deviation 113.34 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 4, n=301, 303 | -0.1 International units per liter | Standard Deviation 548.15 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 20, n=277, 302 | -9.2 International units per liter | Standard Deviation 19.05 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 8, n=229, 303 | 98.2 International units per liter | Standard Deviation 1076.99 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 32, n=275, 294 | -1.9 International units per liter | Standard Deviation 14.44 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 12, n=295, 299 | 6.0 International units per liter | Standard Deviation 585.45 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 24, n=284, 299 | -9.0 International units per liter | Standard Deviation 19.02 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 16, n=284, 298 | 54.2 International units per liter | Standard Deviation 882.23 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 4, n=301, 303 | 0.8 International units per liter | Standard Deviation 13.98 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 20, n=277, 302 | 31.2 International units per liter | Standard Deviation 653.11 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 28, n=267, 296 | -10.1 International units per liter | Standard Deviation 19.08 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 24, n=284, 299 | -9.2 International units per liter | Standard Deviation 538.95 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 36, n=273, 292 | -0.8 International units per liter | Standard Deviation 23.51 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 28, n=267, 296 | -1.9 International units per liter | Standard Deviation 213.98 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 32, n=275, 294 | -9.9 International units per liter | Standard Deviation 19.1 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 32, n=275, 294 | 13.3 International units per liter | Standard Deviation 699.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 16, n=284, 298 | -0.1 International units per liter | Standard Deviation 21.8 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 36, n=273, 292 | -18.2 International units per liter | Standard Deviation 476.64 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 40, n=270, 293 | -10.4 International units per liter | Standard Deviation 20.71 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 40, n=270, 293 | 39.7 International units per liter | Standard Deviation 704.18 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 40, n=270, 293 | 0.6 International units per liter | Standard Deviation 36.29 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 44, n=275, 293 | 47.4 International units per liter | Standard Deviation 1185.55 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 44, n=275, 293 | -11.4 International units per liter | Standard Deviation 20.64 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 48, n=265, 292 | -0.6 International units per liter | Standard Deviation 528.71 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 36, n=273, 292 | -10.5 International units per liter | Standard Deviation 20.41 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 48, n=265, 292 | 18.1 International units per liter | Standard Deviation 463.49 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 36, n=273, 292 | -1.1 International units per liter | Standard Deviation 11.44 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 8, n=229, 303 | -0.1 International units per liter | Standard Deviation 13.68 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 4, n=301, 303 | 0.1 International units per liter | Standard Deviation 9.65 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 8, n=229, 303 | 1.6 International units per liter | Standard Deviation 29.98 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 12, n=295, 299 | 0.4 International units per liter | Standard Deviation 11.6 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 16, n=284, 298 | -0.6 International units per liter | Standard Deviation 10.14 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 20, n=277, 302 | -1.1 International units per liter | Standard Deviation 10.86 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 24, n=284, 299 | -0.6 International units per liter | Standard Deviation 10.57 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 28, n=267, 296 | -0.2 International units per liter | Standard Deviation 12.52 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 32, n=275, 294 | -0.5 International units per liter | Standard Deviation 11.49 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 36, n=273, 292 | 0.1 International units per liter | Standard Deviation 10.95 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 40, n=270, 293 | -0.2 International units per liter | Standard Deviation 11.82 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 44, n=275, 293 | -0.2 International units per liter | Standard Deviation 12.37 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALT, Week 48, n=265, 292 | -0.6 International units per liter | Standard Deviation 10.5 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 4, n=301, 303 | -2.2 International units per liter | Standard Deviation 8.85 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 8, n=229, 303 | 1.1 International units per liter | Standard Deviation 20.99 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 12, n=295, 299 | 0.9 International units per liter | Standard Deviation 14.45 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 16, n=284, 298 | -0.5 International units per liter | Standard Deviation 10.35 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 20, n=277, 302 | -1.0 International units per liter | Standard Deviation 11.65 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 24, n=284, 299 | -0.1 International units per liter | Standard Deviation 10.67 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 28, n=267, 296 | -0.2 International units per liter | Standard Deviation 11.44 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 32, n=275, 294 | -1.7 International units per liter | Standard Deviation 11.29 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 40, n=270, 293 | -1.1 International units per liter | Standard Deviation 11.34 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 44, n=275, 293 | -0.7 International units per liter | Standard Deviation 12.02 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | ALP, Week 48, n=265, 292 | -0.3 International units per liter | Standard Deviation 12.51 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 4, n=301, 303 | 0.2 International units per liter | Standard Deviation 10.02 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 12, n=295, 299 | 0.6 International units per liter | Standard Deviation 8.82 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 16, n=284, 298 | -0.1 International units per liter | Standard Deviation 9.71 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 20, n=277, 302 | -0.6 International units per liter | Standard Deviation 9.8 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 24, n=284, 298 | 0.0 International units per liter | Standard Deviation 9.57 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 28, n=267, 296 | 0.3 International units per liter | Standard Deviation 11.19 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 32, n=275, 294 | 0.6 International units per liter | Standard Deviation 13.4 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 36, n=273, 292 | 0.1 International units per liter | Standard Deviation 9.61 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 40, n=270, 293 | 0.0 International units per liter | Standard Deviation 10.64 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST, Week 44, n=275, 293 | 0.1 International units per liter | Standard Deviation 11.09 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | AST Week 48, n=265, 292 | 0.7 International units per liter | Standard Deviation 10.75 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 4, n=301, 303 | 30.8 International units per liter | Standard Deviation 435.12 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 8, n=229, 303 | -16.5 International units per liter | Standard Deviation 344.96 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 12, n=295, 299 | 14.9 International units per liter | Standard Deviation 288.85 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 16, n=284, 298 | 5.8 International units per liter | Standard Deviation 411.52 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 20, n=277, 302 | -16.7 International units per liter | Standard Deviation 363.3 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 24, n=284, 299 | -0.7 International units per liter | Standard Deviation 353.99 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 28, n=267, 296 | 20.8 International units per liter | Standard Deviation 538.83 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 32, n=275, 294 | 34.0 International units per liter | Standard Deviation 597.29 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 36, n=273, 292 | -10.8 International units per liter | Standard Deviation 358.72 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 40, n=270, 293 | -0.3 International units per liter | Standard Deviation 373.96 |
| Current ART | Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK | CK, Week 44, n=275, 293 | -10.9 International units per liter | Standard Deviation 350.64 |
Secondary
Change From Baseline in DISWO Using HATQoL
The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for DISWO is calculated on a 0-100 scale using the formula: DISWO 100=\[100 divided by (20 minus 5)\]\*(DISWO minus 5). A response of 1 in DISWO score shows less medication worries all of the time and 5 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline and at Weeks 24 and 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline in DISWO Using HATQoL | Week 24, n=291, 290 | 8.3 Scores on a scale |
| CAB LA+RPV LA (Q4W) | Change From Baseline in DISWO Using HATQoL | Week 48, n=291, 296 | 4.6 Scores on a scale |
| Current ART | Change From Baseline in DISWO Using HATQoL | Week 24, n=291, 290 | 3.0 Scores on a scale |
| Current ART | Change From Baseline in DISWO Using HATQoL | Week 48, n=291, 296 | 2.6 Scores on a scale |
p-value: 0.00895% CI: [1.4, 9.1]ANCOVA
p-value: 0.34795% CI: [-2.2, 6.2]ANCOVA
Secondary
Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12)
The SF-12 questionnaire consists of 7 questions which measures the degree of general health status and mental health distress. Each question is scored 0-5, except for question 2 scored 0-3. The HRQoL using SF-12 for the total score, physical component summary (PCS) and the mental component summary (MCS) were assessed for the two treatment groups. Missing Total or the component scores was imputed using LOCF. The PCS/MCS are calculated using computer software purchased from QualityMetric (http://www.qualitymetric.com). The higher the score, the better will be the health status. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline and at Weeks 24 and 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12) | Total score, Week 24, n=291, 289 | 0.0 Scores on a scale |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12) | Total score, Week 48, n=293, 296 | -0.0 Scores on a scale |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12) | MCS, Week 24, n=289, 286 | 0.288 Scores on a scale |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12) | MCS, Week 48, n=291, 293 | 0.260 Scores on a scale |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12) | PCS, Week 24, n=286, 288 | 0.650 Scores on a scale |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12) | PCS, Week 48, n=288, 295 | 0.758 Scores on a scale |
| Current ART | Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12) | PCS, Week 24, n=286, 288 | -0.047 Scores on a scale |
| Current ART | Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12) | Total score, Week 24, n=291, 289 | -0.2 Scores on a scale |
| Current ART | Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12) | MCS, Week 48, n=291, 293 | -0.375 Scores on a scale |
| Current ART | Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12) | Total score, Week 48, n=293, 296 | 0.0 Scores on a scale |
| Current ART | Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12) | PCS, Week 48, n=288, 295 | 0.062 Scores on a scale |
| Current ART | Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12) | MCS, Week 24, n=289, 286 | -0.388 Scores on a scale |
p-value: 0.34495% CI: [-0.2, 0.7]ANCOVA
p-value: 0.78595% CI: [-0.6, 0.4]ANCOVA
p-value: 0.28295% CI: [-0.557, 1.909]ANCOVA
p-value: 0.32795% CI: [-0.637, 1.907]ANCOVA
p-value: 0.08695% CI: [-0.1, 1.494]ANCOVA
p-value: 0.09295% CI: [-0.113, 1.505]ANCOVA
Secondary
Change From Baseline in HIV Medication, MEDWO Using HATQoL
The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for MEDWO is calculated on a 0-100 scale using the formula: MEDWO 100=\[100 divided by (20 minus 5)\]\*(MEDWO minus 5). A response of 1 in MEDWO score shows less medication worries all of the time and 5 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline and at Weeks 24 and 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline in HIV Medication, MEDWO Using HATQoL | Week 24, n=292, 290 | 4.2 Scores on a scale |
| CAB LA+RPV LA (Q4W) | Change From Baseline in HIV Medication, MEDWO Using HATQoL | Week 48, n=292, 296 | 4.0 Scores on a scale |
| Current ART | Change From Baseline in HIV Medication, MEDWO Using HATQoL | Week 24, n=292, 290 | -0.7 Scores on a scale |
| Current ART | Change From Baseline in HIV Medication, MEDWO Using HATQoL | Week 48, n=292, 296 | -2.4 Scores on a scale |
p-value: <0.00195% CI: [2.8, 7.1]ANCOVA
p-value: <0.00195% CI: [4, 8.8]ANCOVA
Secondary
Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44
HIVTSQc is a 12 item questionnaire. The individual treatment change item scores on HIVTSQc scale are rated as +3 ('much more satisfied', 'much more convenient', 'much more flexible',etc.) to -3 ('much less satisfied', 'much less convenient', 'much less flexible', etc.). The higher the score, the greater the improvement in satisfaction with each aspect of treatment and the lower the score, the greater the deterioration in satisfaction with each aspect of treatment. LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline and Weeks 4b, 24 and 44
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 8; Week 24; n=299, 288 | 0.7 Scores on a scale | Standard Deviation 1.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 1; Week 24; n=300, 287 | 0.4 Scores on a scale | Standard Deviation 1.46 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 8; Week 44; n=299, 294 | 0.6 Scores on a scale | Standard Deviation 1.31 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 4; Week 4b; n=295, 0 | 0.3 Scores on a scale | Standard Deviation 1.21 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 9; Week 4b; n=294, 0 | 0.4 Scores on a scale | Standard Deviation 1.22 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 9; Week 24; n=299, 288 | 0.6 Scores on a scale | Standard Deviation 1.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 4; Week 24; n=300, 288 | 0.5 Scores on a scale | Standard Deviation 1.29 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 9; Week 44; n=299, 294 | 0.5 Scores on a scale | Standard Deviation 1.32 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 2; Week 4b; n=295, 0 | 0.0 Scores on a scale | Standard Deviation 0.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 10; Week 4b; n=293, 0 | 0.8 Scores on a scale | Standard Deviation 1.44 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 10; Week 24; n=298, 287 | 1.2 Scores on a scale | Standard Deviation 1.56 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 4; Week 44; n=300, 294 | 0.4 Scores on a scale | Standard Deviation 1.3 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 10; Week 44; n=298, 293 | 1.1 Scores on a scale | Standard Deviation 1.64 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 2; Week 24; n=300, 287 | 0.1 Scores on a scale | Standard Deviation 0.7 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 11; Week 4b; n=292, 0 | 0.4 Scores on a scale | Standard Deviation 1.23 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 11; Week 24; n=297, 287 | 0.7 Scores on a scale | Standard Deviation 1.31 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 5; Week 4b; n=295, 0 | 0.5 Scores on a scale | Standard Deviation 1.24 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 11; Week 44; n=297, 293 | 0.6 Scores on a scale | Standard Deviation 1.45 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 5; Week 24; n=300, 288 | 0.8 Scores on a scale | Standard Deviation 1.32 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 12; Week 4b; n=293, 0 | 0.3 Scores on a scale | Standard Deviation 1.41 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 12; Week 24; n=298, 287 | 0.0 Scores on a scale | Standard Deviation 1.52 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 1; Week 4b; n=294, 0 | 0.3 Scores on a scale | Standard Deviation 1.42 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 12; Week 44; n=298, 293 | 0.0 Scores on a scale | Standard Deviation 1.58 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 5; Week 44; n=300, 294 | 0.8 Scores on a scale | Standard Deviation 1.42 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 2; Week 44; n=300, 293 | 0.1 Scores on a scale | Standard Deviation 0.84 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 6; Week 4b; n=294, 0 | 0.5 Scores on a scale | Standard Deviation 1.63 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 6; Week 24; n=299, 288 | 0.8 Scores on a scale | Standard Deviation 1.77 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 3; Week 4b; n=295, 0 | 0.4 Scores on a scale | Standard Deviation 1.35 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 6; Week 44; n=299, 293 | 0.9 Scores on a scale | Standard Deviation 1.72 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 3; Week 24; n=300, 288 | 0.3 Scores on a scale | Standard Deviation 1.47 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 7; Week 4b; n=295, 0 | 0.2 Scores on a scale | Standard Deviation 0.9 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 7; Week 24; n=300, 288 | 0.2 Scores on a scale | Standard Deviation 0.94 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 1; Week 44; n=300, 293 | 0.5 Scores on a scale | Standard Deviation 1.42 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 7; Week 44; n=300, 294 | 0.2 Scores on a scale | Standard Deviation 0.99 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 3; Week 44; n=300, 294 | 0.3 Scores on a scale | Standard Deviation 1.45 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 8; Week 4b; n=294, 0 | 0.3 Scores on a scale | Standard Deviation 1.21 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 12; Week 44; n=298, 293 | 0.2 Scores on a scale | Standard Deviation 1.17 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 1; Week 24; n=300, 287 | -0.1 Scores on a scale | Standard Deviation 1.04 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 1; Week 44; n=300, 293 | -0.1 Scores on a scale | Standard Deviation 1.21 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 2; Week 24; n=300, 287 | 0.0 Scores on a scale | Standard Deviation 0.68 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 3; Week 24; n=300, 288 | 0.1 Scores on a scale | Standard Deviation 1.12 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 3; Week 44; n=300, 294 | 0.0 Scores on a scale | Standard Deviation 1.26 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 4; Week 24; n=300, 288 | -0.0 Scores on a scale | Standard Deviation 1.16 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 4; Week 44; n=300, 294 | -0.1 Scores on a scale | Standard Deviation 1.22 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 5; Week 24; n=300, 288 | 0.1 Scores on a scale | Standard Deviation 1.31 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 5; Week 44; n=300, 294 | 0.0 Scores on a scale | Standard Deviation 1.37 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 6; Week 24; n=299, 288 | 0.2 Scores on a scale | Standard Deviation 1.79 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 6; Week 44; n=299, 293 | 0.2 Scores on a scale | Standard Deviation 1.78 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 7; Week 24; n=300, 288 | 0.1 Scores on a scale | Standard Deviation 1 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 7; Week 44; n=300, 294 | 0.2 Scores on a scale | Standard Deviation 1.08 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 8; Week 24; n=299, 288 | 0.1 Scores on a scale | Standard Deviation 1.2 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 8; Week 44; n=299, 294 | 0.0 Scores on a scale | Standard Deviation 1.27 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 9; Week 24; n=299, 288 | 0.1 Scores on a scale | Standard Deviation 1.2 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 9; Week 44; n=299, 294 | 0.0 Scores on a scale | Standard Deviation 1.25 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 10; Week 24; n=298, 287 | 0.3 Scores on a scale | Standard Deviation 1.38 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 10; Week 44; n=298, 293 | 0.2 Scores on a scale | Standard Deviation 1.6 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 11; Week 24; n=297, 287 | 0.1 Scores on a scale | Standard Deviation 1.28 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 11; Week 44; n=297, 293 | 0.1 Scores on a scale | Standard Deviation 1.38 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 12; Week 24; n=298, 287 | 0.1 Scores on a scale | Standard Deviation 1.14 |
| Current ART | Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44 | Item 2; Week 44; n=300, 293 | -0.1 Scores on a scale | Standard Deviation 0.82 |
Secondary
Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire
The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for LISAT is calculated on a 0-100 scale using the formula: LISAT 100=\[100 divided by (20 minus 4)\]\*(LISAT minus 4). A response of 5 in LISAT score shows satisfaction all of the time and 1 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% confidence interval (CI).Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 24 and 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire | Week 24, n=292, 291 | 1.0 Scores on a scale |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire | Week 48, n=292, 297 | 1.1 Scores on a scale |
| Current ART | Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire | Week 24, n=292, 291 | 1.1 Scores on a scale |
| Current ART | Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire | Week 48, n=292, 297 | 0.1 Scores on a scale |
p-value: 0.94495% CI: [-2.4, 2.2]ANCOVA
p-value: 0.38595% CI: [-1.3, 3.4]ANCOVA
Secondary
Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44
The HIVTSQ for total treatment satisfaction score is computed with 1-11 items. These 1-11 items are summed to produce a score with a possible range of -33 to 33. The item 12 in the scale will be calculated as an individual score.The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores will be imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score should not be computed and will remain missing.LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. Data has been presented with respect to actual treatment received to the participants
Time frame: Baseline and at Weeks 4b, 24 and 44
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44 | Week 4b, n=295, 0 | 3.99 Scores on a scale | Standard Deviation 8.982 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44 | Week 24, n=300, 288 | 6.39 Scores on a scale | Standard Deviation 10.328 |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44 | Week 44, n=300, 294 | 6.02 Scores on a scale | Standard Deviation 10.808 |
| Current ART | Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44 | Week 24, n=300, 288 | 1.08 Scores on a scale | Standard Deviation 8.51 |
| Current ART | Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44 | Week 44, n=300, 294 | 0.54 Scores on a scale | Standard Deviation 9.877 |
Secondary
Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using General Acceptance Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire
The ACCEPT questionnaire is a generic medication acceptance measure assessing how participants weigh advantages and disadvantages of long-term medication.The questionnaire consists of 25 items that capture six dimensions.3 questions that focus on general acceptance of study medication will be analyzed.Items on the scale are rated as 1-5 scores:1:totally disagree,2:somewhat disagree,3:somewhat agree, 4:totally agree and 5:I don't know.Total score of the dimension is calculated as the mean of the recoded items of the dimension and then linearly transformed to be on a scale from 0 to 100:score:Total Score=(mean of the recoded items in the dimension minus1)divided by2\*100.LOCF was used as primary method of analysis.Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI.Baseline value is defined as the latest pre-treatment assessment with a non-missing value.Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value
Time frame: Baseline and at Weeks 8, 24 and 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using General Acceptance Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire | Week 8, n=302, 287 | 8.9 Scores on a scale |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using General Acceptance Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire | Week 24, 303, 295 | 12.3 Scores on a scale |
| CAB LA+RPV LA (Q4W) | Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using General Acceptance Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire | Week 48, n=302, 298 | 13.7 Scores on a scale |
| Current ART | Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using General Acceptance Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire | Week 8, n=302, 287 | 1.0 Scores on a scale |
| Current ART | Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using General Acceptance Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire | Week 24, 303, 295 | 5.5 Scores on a scale |
| Current ART | Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using General Acceptance Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire | Week 48, n=302, 298 | 3.0 Scores on a scale |
p-value: <0.00195% CI: [4.1, 11.7]ANCOVA
p-value: <0.00195% CI: [3.3, 10.4]ANCOVA
p-value: <0.00195% CI: [7.1, 14.4]ANCOVA
Secondary
Change From Baseline Values for CD4+ Lymphocyte Count at Week 48
Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to current ART.Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value at Week 48 minus Baseline value.
Time frame: Baseline (Day 1) and Week 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for CD4+ Lymphocyte Count at Week 48 | 9.9 Cells per cubic millimeter | Standard Deviation 187.24 |
| Current ART | Change From Baseline Values for CD4+ Lymphocyte Count at Week 48 | 19.4 Cells per cubic millimeter | Standard Deviation 168.8 |
Secondary
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin
Blood samples were collected for the analysis of clinical chemistry parameter-albumin. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 4, n=301, 303 | -0.5 Grams per liter | Standard Deviation 2.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 8, n=229, 303 | -0.3 Grams per liter | Standard Deviation 2.76 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 12, n=295, 299 | -0.6 Grams per liter | Standard Deviation 2.72 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 16, n=284, 298 | -0.6 Grams per liter | Standard Deviation 2.78 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 20, n=277, 302 | -0.8 Grams per liter | Standard Deviation 2.78 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 24, n=284, 299 | -0.7 Grams per liter | Standard Deviation 2.69 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 28, n=267, 296 | -0.7 Grams per liter | Standard Deviation 2.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 32, n=275, 294 | -0.6 Grams per liter | Standard Deviation 2.78 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 36, n=273, 292 | -0.9 Grams per liter | Standard Deviation 2.71 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 40, n=270, 293 | -0.5 Grams per liter | Standard Deviation 2.53 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 44, n=275, 293 | -0.4 Grams per liter | Standard Deviation 2.58 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 48, n=265, 292 | -0.4 Grams per liter | Standard Deviation 2.64 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 44, n=275, 293 | -0.8 Grams per liter | Standard Deviation 2.47 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 4, n=301, 303 | -0.5 Grams per liter | Standard Deviation 2.49 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 28, n=267, 296 | -1.0 Grams per liter | Standard Deviation 2.47 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 8, n=229, 303 | -0.7 Grams per liter | Standard Deviation 2.7 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 40, n=270, 293 | -1.0 Grams per liter | Standard Deviation 2.61 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 12, n=295, 299 | -0.4 Grams per liter | Standard Deviation 2.63 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 32, n=275, 294 | -1.0 Grams per liter | Standard Deviation 2.56 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 16, n=284, 298 | -0.8 Grams per liter | Standard Deviation 2.7 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 48, n=265, 292 | -0.4 Grams per liter | Standard Deviation 2.55 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 20, n=277, 302 | -0.8 Grams per liter | Standard Deviation 2.56 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 36, n=273, 292 | -0.9 Grams per liter | Standard Deviation 2.65 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin | Week 24, n=284, 299 | -0.8 Grams per liter | Standard Deviation 2.59 |
Secondary
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance.
Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance. GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 4, n=301, 301 | -1.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.51 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 8, n=227, 303 | 0.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.88 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 12, n=295, 297 | 0.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.28 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 16, n=284, 297 | 0.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.63 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 20, n=277, 302 | -1.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.37 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 24, n=283, 298 | -1.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.52 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 28, n=267, 296 | -1.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 11.47 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 32, n=274, 294 | -1.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 11.11 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 36, n=273, 292 | -1.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 11.26 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 40, n=268, 293 | -1.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.7 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 44, n=274, 293 | -2.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.45 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 48, n=264, 291 | -2.5 Milliliters per minute per 1.73meter^2 | Standard Deviation 11.8 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 44, n=274, 293 | -2.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.74 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 4, n=301, 301 | -2.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.18 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 28, n=267, 296 | -2.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.93 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 8, n=227, 303 | -1.5 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.06 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 40, n=268, 293 | -2.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.1 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 12, n=295, 297 | -1.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.02 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 32, n=274, 294 | -3.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.94 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 16, n=284, 297 | -1.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.69 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 48, n=264, 291 | -1.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.5 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 20, n=277, 302 | -2.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.55 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 36, n=273, 292 | -2.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.52 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance. | Week 24, n=283, 298 | -2.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.76 |
Secondary
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase
Blood samples were collected for the analysis of clinical chemistry parameter-lipase. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 4, n=301, 303 | 5.2 Units per liter | Standard Deviation 41.42 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 24, n=283, 299 | 2.1 Units per liter | Standard Deviation 20.79 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 12, n=294, 297 | 2.7 Units per liter | Standard Deviation 25.12 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 28, n=267, 297 | 2.2 Units per liter | Standard Deviation 24.93 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 44, n=274, 293 | 2.0 Units per liter | Standard Deviation 22.57 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 32, n=274, 294 | 5.2 Units per liter | Standard Deviation 57.44 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 16, n=285, 299 | 2.6 Units per liter | Standard Deviation 24.79 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 36, n=273, 292 | 5.1 Units per liter | Standard Deviation 49.92 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 8, n=227, 303 | 1.2 Units per liter | Standard Deviation 19.31 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 40, n=269, 293 | 5.1 Units per liter | Standard Deviation 33.58 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 48, n=264, 290 | 3.0 Units per liter | Standard Deviation 28.26 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 20, n=278, 302 | 0.9 Units per liter | Standard Deviation 15.65 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 48, n=264, 290 | 1.5 Units per liter | Standard Deviation 19 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 44, n=274, 293 | 2.3 Units per liter | Standard Deviation 21.13 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 4, n=301, 303 | 1.5 Units per liter | Standard Deviation 23.88 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 8, n=227, 303 | 1.0 Units per liter | Standard Deviation 17.96 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 12, n=294, 297 | -0.8 Units per liter | Standard Deviation 18.59 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 16, n=285, 299 | 3.5 Units per liter | Standard Deviation 31.03 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 20, n=278, 302 | 0.8 Units per liter | Standard Deviation 28.95 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 24, n=283, 299 | 3.0 Units per liter | Standard Deviation 23.85 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 28, n=267, 297 | 2.3 Units per liter | Standard Deviation 18.96 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 32, n=274, 294 | 3.1 Units per liter | Standard Deviation 21.31 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 36, n=273, 292 | 0.7 Units per liter | Standard Deviation 17.39 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase | Week 40, n=269, 293 | 0.5 Units per liter | Standard Deviation 17.6 |
Secondary
Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48
Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 28, n=267, 296 | 0.037 Millimoles per liter | Standard Deviation 0.1822 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 16, n=284, 298 | 0.3 Millimoles per liter | Standard Deviation 2.42 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 32, n=275, 294 | 0.021 Millimoles per liter | Standard Deviation 0.198 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 40, n=270, 293 | 0.8 Millimoles per liter | Standard Deviation 2.24 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 36, n=273, 292 | 0.011 Millimoles per liter | Standard Deviation 0.1846 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 40, n=270, 293 | 0.5 Millimoles per liter | Standard Deviation 2.49 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 40, n=270, 293 | 0.024 Millimoles per liter | Standard Deviation 0.2035 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 44, n=275, 293 | 0.7 Millimoles per liter | Standard Deviation 2.2 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 44, n=275, 293 | 0.027 Millimoles per liter | Standard Deviation 0.1982 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 16, n=284, 298 | 0.6 Millimoles per liter | Standard Deviation 2.41 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 48, n=265, 292 | 0.034 Millimoles per liter | Standard Deviation 0.2007 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 48, n=265, 292 | 0.5 Millimoles per liter | Standard Deviation 2.36 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 4, n=301, 303 | 0.05 Millimoles per liter | Standard Deviation 0.342 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 44, n=275, 293 | 0.5 Millimoles per liter | Standard Deviation 2.34 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 8, n=229, 303 | 0.01 Millimoles per liter | Standard Deviation 0.311 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 4, n=218, 226 | 0.17 Millimoles per liter | Standard Deviation 0.721 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 12, n=295, 299 | 0.04 Millimoles per liter | Standard Deviation 0.341 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 20, n=277, 302 | 0.2 Millimoles per liter | Standard Deviation 2.26 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 16, n=284, 298 | 0.01 Millimoles per liter | Standard Deviation 0.341 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 8, n=151, 213 | 0.22 Millimoles per liter | Standard Deviation 0.841 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 20, n=277, 302 | 0.04 Millimoles per liter | Standard Deviation 0.345 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 48, n=265, 292 | 0.1 Millimoles per liter | Standard Deviation 2.41 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 24, n=284, 298 | 0.03 Millimoles per liter | Standard Deviation 0.325 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 12, n=204, 216 | 0.19 Millimoles per liter | Standard Deviation 0.855 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 28, n=267, 296 | 0.04 Millimoles per liter | Standard Deviation 0.38 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 8, n=229, 303 | 0.4 Millimoles per liter | Standard Deviation 2.31 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 32, n=275, 294 | 0.02 Millimoles per liter | Standard Deviation 0.39 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 16, n=207, 211 | 0.23 Millimoles per liter | Standard Deviation 1.05 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 36, n=273, 292 | 0.03 Millimoles per liter | Standard Deviation 0.356 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 4, n=301, 303 | 0.4 Millimoles per liter | Standard Deviation 2.05 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 40, n=270, 293 | 0.04 Millimoles per liter | Standard Deviation 0.344 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 20, n=192, 216 | 0.19 Millimoles per liter | Standard Deviation 0.712 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 44, n=275, 293 | 0.06 Millimoles per liter | Standard Deviation 0.344 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 24, n=284, 298 | 0.2 Millimoles per liter | Standard Deviation 2.46 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 48, n=265, 292 | -0.02 Millimoles per liter | Standard Deviation 0.299 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 24, n=212, 224 | 0.23 Millimoles per liter | Standard Deviation 0.71 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 4, n=301, 303 | 0.3 Millimoles per liter | Standard Deviation 1.84 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 8, n=229, 303 | 0.3 Millimoles per liter | Standard Deviation 2.12 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 8, n=229, 303 | 0.2 Millimoles per liter | Standard Deviation 1.99 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 28, n=188, 225 | 0.17 Millimoles per liter | Standard Deviation 0.793 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 12, n=295, 299 | 0.2 Millimoles per liter | Standard Deviation 2.07 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 36, n=190, 215 | 0.18 Millimoles per liter | Standard Deviation 0.803 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 16, n=284, 298 | 0.1 Millimoles per liter | Standard Deviation 2.18 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 32, n=192, 213 | 0.35 Millimoles per liter | Standard Deviation 0.956 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 20, n=277, 302 | 0.3 Millimoles per liter | Standard Deviation 2.1 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 12, n=295, 299 | 0.4 Millimoles per liter | Standard Deviation 2.3 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 24, n=284, 299 | 0.3 Millimoles per liter | Standard Deviation 2.07 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 28, n=267, 296 | 0.1 Millimoles per liter | Standard Deviation 2.47 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 28, n=267, 296 | 0.5 Millimoles per liter | Standard Deviation 2.11 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 40, n=193, 213 | 0.27 Millimoles per liter | Standard Deviation 0.833 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 32, n=275, 294 | 0.3 Millimoles per liter | Standard Deviation 2.05 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 20, n=277, 302 | 0.8 Millimoles per liter | Standard Deviation 2.32 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 36, n=273, 292 | 0.5 Millimoles per liter | Standard Deviation 2.01 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 44, n=193, 213 | 0.23 Millimoles per liter | Standard Deviation 0.895 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 40, n=270, 293 | 0.4 Millimoles per liter | Standard Deviation 2.02 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 12, n=295, 299 | 0.5 Millimoles per liter | Standard Deviation 2.42 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 44, n=275, 293 | 0.5 Millimoles per liter | Standard Deviation 2.03 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 48, n=238, 274 | 0.04 Millimoles per liter | Standard Deviation 0.693 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 48, n=265, 292 | 0.4 Millimoles per liter | Standard Deviation 2.2 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 24, n=284, 299 | 0.6 Millimoles per liter | Standard Deviation 2.48 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 4, n=301, 303 | 0.01 Millimoles per liter | Standard Deviation 1.369 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 4, n=301, 303 | 0.066 Millimoles per liter | Standard Deviation 0.1666 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 8, n=229, 303 | 0.07 Millimoles per liter | Standard Deviation 1.453 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 32, n=275, 294 | 0.0 Millimoles per liter | Standard Deviation 2.37 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 12, n=295, 299 | 0.15 Millimoles per liter | Standard Deviation 1.409 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 8, n=229, 303 | 0.062 Millimoles per liter | Standard Deviation 0.1862 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 16, n=284, 298 | 0.08 Millimoles per liter | Standard Deviation 1.387 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 28, n=267, 296 | 0.9 Millimoles per liter | Standard Deviation 2.21 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 20, n=277, 302 | 0.15 Millimoles per liter | Standard Deviation 1.399 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 12, n=295, 299 | 0.041 Millimoles per liter | Standard Deviation 0.1978 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 24, n=284, 299 | 0.25 Millimoles per liter | Standard Deviation 1.42 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 4, n=301, 303 | 1.0 Millimoles per liter | Standard Deviation 2.53 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 28, n=267, 296 | 0.15 Millimoles per liter | Standard Deviation 1.524 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 16, n=284, 298 | 0.041 Millimoles per liter | Standard Deviation 0.2012 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 32, n=275, 294 | 0.20 Millimoles per liter | Standard Deviation 1.511 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 32, n=275, 294 | 0.8 Millimoles per liter | Standard Deviation 2.41 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 36, n=273, 292 | 0.06 Millimoles per liter | Standard Deviation 1.42 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 20, n=277, 302 | 0.035 Millimoles per liter | Standard Deviation 0.1871 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 40, n=270, 293 | 0.19 Millimoles per liter | Standard Deviation 1.4 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 36, n=273, 292 | 0.2 Millimoles per liter | Standard Deviation 2.37 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 44, n=275, 293 | 0.13 Millimoles per liter | Standard Deviation 1.426 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 24, n=284, 299 | 0.042 Millimoles per liter | Standard Deviation 0.1963 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 48, n=265, 292 | 0.24 Millimoles per liter | Standard Deviation 1.465 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 36, n=273, 292 | 0.9 Millimoles per liter | Standard Deviation 2.18 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 48, n=265, 292 | -0.01 Millimoles per liter | Standard Deviation 1.312 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 4, n=301, 303 | 0.7 Millimoles per liter | Standard Deviation 2.21 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 8, n=229, 303 | 0.6 Millimoles per liter | Standard Deviation 2.52 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 12, n=295, 299 | 0.3 Millimoles per liter | Standard Deviation 2.39 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 16, n=284, 298 | 0.5 Millimoles per liter | Standard Deviation 2.41 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 20, n=277, 302 | 0.3 Millimoles per liter | Standard Deviation 2.31 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 24, n=284, 298 | 0.2 Millimoles per liter | Standard Deviation 2.44 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 28, n=267, 296 | 0.1 Millimoles per liter | Standard Deviation 2.39 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 32, n=275, 294 | 0.2 Millimoles per liter | Standard Deviation 2.31 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 36, n=273, 292 | 0.3 Millimoles per liter | Standard Deviation 2.39 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 40, n=270, 293 | 0.4 Millimoles per liter | Standard Deviation 2.29 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 44, n=275, 293 | 0.5 Millimoles per liter | Standard Deviation 2.19 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | CO2, Week 48, n=265, 292 | 0.2 Millimoles per liter | Standard Deviation 2.31 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 4, n=301, 303 | 0.5 Millimoles per liter | Standard Deviation 2.13 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 8, n=229, 303 | 0.5 Millimoles per liter | Standard Deviation 2.19 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 16, n=284, 298 | 0.8 Millimoles per liter | Standard Deviation 2.25 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 20, n=277, 302 | 0.8 Millimoles per liter | Standard Deviation 2.38 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 24, n=284, 299 | 0.9 Millimoles per liter | Standard Deviation 2.26 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 28, n=267, 296 | 1.0 Millimoles per liter | Standard Deviation 2.55 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 32, n=275, 294 | 0.9 Millimoles per liter | Standard Deviation 2.33 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 36, n=273, 292 | 0.9 Millimoles per liter | Standard Deviation 2.48 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 40, n=270, 293 | 0.8 Millimoles per liter | Standard Deviation 2.76 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 44, n=275, 293 | 0.8 Millimoles per liter | Standard Deviation 2.28 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 48, n=265, 292 | 0.3 Millimoles per liter | Standard Deviation 2.38 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 4, n=218, 226 | 0.21 Millimoles per liter | Standard Deviation 0.9 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 8, n=151, 213 | 0.22 Millimoles per liter | Standard Deviation 0.832 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 12, n=204, 216 | 0.19 Millimoles per liter | Standard Deviation 0.974 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 16, n=207, 211 | 0.27 Millimoles per liter | Standard Deviation 1.084 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 20, n=192, 216 | 0.19 Millimoles per liter | Standard Deviation 0.961 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 24, n=212, 224 | 0.16 Millimoles per liter | Standard Deviation 0.881 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 28, n=188, 225 | 0.28 Millimoles per liter | Standard Deviation 0.903 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 32, n=192, 213 | 0.27 Millimoles per liter | Standard Deviation 0.939 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 36, n=190, 215 | 0.26 Millimoles per liter | Standard Deviation 1.07 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 40, n=193, 213 | 0.25 Millimoles per liter | Standard Deviation 0.891 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 44, n=193, 213 | 0.27 Millimoles per liter | Standard Deviation 0.898 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Glucose, Week 48, n=238, 274 | 0.02 Millimoles per liter | Standard Deviation 0.924 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 4, n=301, 303 | 0.015 Millimoles per liter | Standard Deviation 0.1595 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 8, n=229, 303 | -0.006 Millimoles per liter | Standard Deviation 0.1609 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 12, n=295, 299 | 0.013 Millimoles per liter | Standard Deviation 0.1742 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 16, n=284, 298 | 0.003 Millimoles per liter | Standard Deviation 0.164 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 20, n=277, 302 | 0.010 Millimoles per liter | Standard Deviation 0.1839 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 24, n=284, 299 | 0.006 Millimoles per liter | Standard Deviation 0.1845 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 28, n=267, 296 | 0.004 Millimoles per liter | Standard Deviation 0.1823 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 32, n=275, 294 | 0.005 Millimoles per liter | Standard Deviation 0.1886 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 36, n=273, 292 | -0.002 Millimoles per liter | Standard Deviation 0.1855 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 40, n=270, 293 | -0.004 Millimoles per liter | Standard Deviation 0.1736 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 44, n=275, 293 | 0.004 Millimoles per liter | Standard Deviation 0.1811 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Phosphate, Week 48, n=265, 292 | 0.003 Millimoles per liter | Standard Deviation 0.1741 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 4, n=301, 303 | 0.11 Millimoles per liter | Standard Deviation 0.375 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 8, n=229, 303 | 0.06 Millimoles per liter | Standard Deviation 0.393 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 12, n=295, 299 | 0.08 Millimoles per liter | Standard Deviation 0.356 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 16, n=284, 298 | 0.06 Millimoles per liter | Standard Deviation 0.34 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 20, n=277, 302 | 0.05 Millimoles per liter | Standard Deviation 0.359 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 24, n=284, 298 | 0.07 Millimoles per liter | Standard Deviation 0.337 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 28, n=267, 296 | 0.07 Millimoles per liter | Standard Deviation 0.389 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 32, n=275, 294 | 0.05 Millimoles per liter | Standard Deviation 0.347 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 36, n=273, 292 | 0.07 Millimoles per liter | Standard Deviation 0.359 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 40, n=270, 293 | 0.07 Millimoles per liter | Standard Deviation 0.35 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 44, n=275, 293 | 0.07 Millimoles per liter | Standard Deviation 0.372 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Potassium, Week 48, n=265, 292 | 0.00 Millimoles per liter | Standard Deviation 0.332 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 4, n=301, 303 | 0.1 Millimoles per liter | Standard Deviation 1.99 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 8, n=229, 303 | -0.1 Millimoles per liter | Standard Deviation 1.92 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 12, n=295, 299 | 0.2 Millimoles per liter | Standard Deviation 1.91 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 16, n=284, 298 | 0.1 Millimoles per liter | Standard Deviation 2.06 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 20, n=277, 302 | 0.3 Millimoles per liter | Standard Deviation 1.95 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 24, n=284, 299 | 0.2 Millimoles per liter | Standard Deviation 1.95 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 28, n=267, 296 | 0.2 Millimoles per liter | Standard Deviation 2.24 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 32, n=275, 294 | 0.4 Millimoles per liter | Standard Deviation 1.89 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 36, n=273, 292 | 0.5 Millimoles per liter | Standard Deviation 2.19 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 40, n=270, 293 | 0.5 Millimoles per liter | Standard Deviation 2.07 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 44, n=275, 293 | 0.5 Millimoles per liter | Standard Deviation 2.05 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Sodium, Week 48, n=265, 292 | 0.3 Millimoles per liter | Standard Deviation 1.95 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 4, n=301, 303 | 0.08 Millimoles per liter | Standard Deviation 1.334 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 8, n=229, 303 | 0.00 Millimoles per liter | Standard Deviation 1.363 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 12, n=295, 299 | 0.09 Millimoles per liter | Standard Deviation 1.381 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 16, n=284, 298 | 0.19 Millimoles per liter | Standard Deviation 1.496 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 20, n=277, 302 | 0.11 Millimoles per liter | Standard Deviation 1.461 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 24, n=284, 299 | 0.15 Millimoles per liter | Standard Deviation 1.311 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 28, n=267, 296 | 0.00 Millimoles per liter | Standard Deviation 1.439 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 32, n=275, 294 | 0.06 Millimoles per liter | Standard Deviation 1.415 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 36, n=273, 292 | -0.02 Millimoles per liter | Standard Deviation 1.386 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 40, n=270, 293 | 0.09 Millimoles per liter | Standard Deviation 1.452 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Urea, Week 44, n=275, 293 | 0.02 Millimoles per liter | Standard Deviation 1.467 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48 | Chloride, Week 12, n=295, 299 | 0.5 Millimoles per liter | Standard Deviation 2.25 |
Secondary
Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 28, n=267, 296 | -0.3 Micromoles per liter | Standard Deviation 1.55 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 40, n=270, 293 | -0.3 Micromoles per liter | Standard Deviation 10.61 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 32, n=275, 294 | -0.3 Micromoles per liter | Standard Deviation 1.61 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 8, n=229, 303 | -0.1 Micromoles per liter | Standard Deviation 6.92 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 36, n=273, 292 | -0.3 Micromoles per liter | Standard Deviation 1.7 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 44, n=275, 293 | -0.4 Micromoles per liter | Standard Deviation 10.11 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 40, n=270, 293 | -0.3 Micromoles per liter | Standard Deviation 1.68 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 20, n=277, 302 | -0.2 Micromoles per liter | Standard Deviation 10.04 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 44, n=275, 293 | -0.2 Micromoles per liter | Standard Deviation 1.55 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 48, n=265, 292 | -0.3 Micromoles per liter | Standard Deviation 10.57 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 48, n=265, 292 | -0.2 Micromoles per liter | Standard Deviation 1.54 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 4, n=301, 303 | -0.8 Micromoles per liter | Standard Deviation 9.87 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 4, n=301, 301 | 1.15 Micromoles per liter | Standard Deviation 8.205 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 4, n=301, 303 | -0.1 Micromoles per liter | Standard Deviation 1.48 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 8, n=229, 303 | -0.66 Micromoles per liter | Standard Deviation 9.042 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 24, n=284, 298 | -0.6 Micromoles per liter | Standard Deviation 9.9 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 12, n=295, 299 | -0.38 Micromoles per liter | Standard Deviation 9.38 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 8, n=229, 303 | -0.1 Micromoles per liter | Standard Deviation 1.42 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 16, n=284, 298 | -0.60 Micromoles per liter | Standard Deviation 9.225 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 12, n=295, 299 | -0.6 Micromoles per liter | Standard Deviation 10.23 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 20, n=277, 302 | 0.53 Micromoles per liter | Standard Deviation 9.39 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 12, n=295, 299 | -0.2 Micromoles per liter | Standard Deviation 1.61 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 24, n=284, 298 | 0.90 Micromoles per liter | Standard Deviation 12.494 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 28, n=267, 296 | 0.0 Micromoles per liter | Standard Deviation 10.46 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 28, n=267, 296 | 1.14 Micromoles per liter | Standard Deviation 10.998 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 16, n=284, 298 | 0.1 Micromoles per liter | Standard Deviation 5.02 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 32, n=275, 294 | 0.33 Micromoles per liter | Standard Deviation 10.102 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 36, n=273, 292 | -0.6 Micromoles per liter | Standard Deviation 10.39 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 36, n=273, 292 | 0.34 Micromoles per liter | Standard Deviation 10.585 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 20, n=277, 302 | -0.3 Micromoles per liter | Standard Deviation 1.52 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 40, n=270, 293 | 0.88 Micromoles per liter | Standard Deviation 9.986 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 32, n=275, 294 | -0.1 Micromoles per liter | Standard Deviation 10.36 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 44, n=275, 293 | 1.03 Micromoles per liter | Standard Deviation 11.253 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 24, n=284, 298 | -0.2 Micromoles per liter | Standard Deviation 1.55 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 48, n=265, 292 | 1.59 Micromoles per liter | Standard Deviation 11.253 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 16, n=284, 298 | 0.2 Micromoles per liter | Standard Deviation 14 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 48, n=265, 292 | 0.82 Micromoles per liter | Standard Deviation 7.846 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 4, n=301, 303 | -0.3 Micromoles per liter | Standard Deviation 4.17 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 8, n=229, 303 | 0.1 Micromoles per liter | Standard Deviation 7.66 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 12, n=295, 299 | 0.1 Micromoles per liter | Standard Deviation 4.56 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 16, n=284, 298 | -0.2 Micromoles per liter | Standard Deviation 4.12 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 20, n=277, 302 | 0.0 Micromoles per liter | Standard Deviation 6.1 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 24, n=284, 298 | 0.2 Micromoles per liter | Standard Deviation 5.9 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 28, n=267, 296 | -0.1 Micromoles per liter | Standard Deviation 4.76 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 36, n=273, 292 | 0.1 Micromoles per liter | Standard Deviation 4.55 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 40, n=270, 293 | 0.2 Micromoles per liter | Standard Deviation 6.28 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 44, n=275, 293 | 0.4 Micromoles per liter | Standard Deviation 5.24 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 48, n=265, 292 | 0.2 Micromoles per liter | Standard Deviation 3.91 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 4, n=301, 303 | 0.1 Micromoles per liter | Standard Deviation 1.2 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 8, n=229, 303 | 0.2 Micromoles per liter | Standard Deviation 3.96 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 12, n=295, 299 | 0.1 Micromoles per liter | Standard Deviation 1.21 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 16, n=284, 298 | -0.1 Micromoles per liter | Standard Deviation 1.12 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 20, n=277, 302 | -0.2 Micromoles per liter | Standard Deviation 1.29 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 24, n=284, 298 | -0.1 Micromoles per liter | Standard Deviation 1.24 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 28, n=267, 296 | -0.2 Micromoles per liter | Standard Deviation 1.29 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 32, n=275, 294 | -0.2 Micromoles per liter | Standard Deviation 1.24 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 36, n=273, 292 | -0.1 Micromoles per liter | Standard Deviation 1.2 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 40, n=270, 293 | -0.2 Micromoles per liter | Standard Deviation 1.18 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 44, n=275, 293 | -0.1 Micromoles per liter | Standard Deviation 1.19 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Direct bilirubin, Week 48, n=265, 292 | 0.0 Micromoles per liter | Standard Deviation 1.23 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 4, n=301, 301 | 1.80 Micromoles per liter | Standard Deviation 8.022 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 8, n=229, 303 | 1.23 Micromoles per liter | Standard Deviation 7.56 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 12, n=295, 299 | 1.71 Micromoles per liter | Standard Deviation 7.638 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 16, n=284, 298 | 1.62 Micromoles per liter | Standard Deviation 8.169 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 20, n=277, 302 | 1.80 Micromoles per liter | Standard Deviation 8.454 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 24, n=284, 298 | 1.36 Micromoles per liter | Standard Deviation 8.038 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 28, n=267, 296 | 1.59 Micromoles per liter | Standard Deviation 8.303 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 32, n=275, 294 | 1.95 Micromoles per liter | Standard Deviation 8.331 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 36, n=273, 292 | 1.62 Micromoles per liter | Standard Deviation 7.891 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 40, n=270, 293 | 1.64 Micromoles per liter | Standard Deviation 8.318 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Creatinine, Week 44, n=275, 293 | 1.40 Micromoles per liter | Standard Deviation 8.008 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | Bilirubin, Week 32, n=275, 294 | 0.0 Micromoles per liter | Standard Deviation 4.94 |
Secondary
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48
Blood samples were collected for the analysis of clinical chemistry parameters: CO2, chloride, glucose, phosphate, potassium, sodium and urea to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 4, n=51, 53 | 1.3 Millimoles per liter | Standard Deviation 2.63 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 8, n=34, 53 | 0.4 Millimoles per liter | Standard Deviation 2.36 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 16, n=48, 53 | 0.8 Millimoles per liter | Standard Deviation 2.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 20, n=46, 53 | 0.9 Millimoles per liter | Standard Deviation 2.53 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 24, n=47, 53 | 0.4 Millimoles per liter | Standard Deviation 2.23 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 28, n=42, 53 | 0.6 Millimoles per liter | Standard Deviation 2.54 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 32, n=45, 51 | 0.5 Millimoles per liter | Standard Deviation 2.35 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 36, n=94, 95 | 0.0 Millimoles per liter | Standard Deviation 2.36 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 24, n=94, 95 | 0.6 Millimoles per liter | Standard Deviation 2.46 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 4, n=151, 153 | 0.4 Millimoles per liter | Standard Deviation 2.15 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 8, n=122, 152 | 0.4 Millimoles per liter | Standard Deviation 2.05 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 24, n=143, 151 | 0.5 Millimoles per liter | Standard Deviation 2.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 28, n=136, 150 | 0.8 Millimoles per liter | Standard Deviation 2.38 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 48, n=131, 147 | 0.6 Millimoles per liter | Standard Deviation 2.45 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 12, n=40, 42 | 0.03 Millimoles per liter | Standard Deviation 0.925 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 40, n=34, 40 | 0.11 Millimoles per liter | Standard Deviation 1.035 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 44, n=40, 40 | 0.01 Millimoles per liter | Standard Deviation 1.008 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 12, n=52, 55 | 0.36 Millimoles per liter | Standard Deviation 0.996 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 16, n=53, 52 | 0.35 Millimoles per liter | Standard Deviation 1.437 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 28, n=52, 62 | 0.17 Millimoles per liter | Standard Deviation 0.681 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 40, n=59, 62 | 0.36 Millimoles per liter | Standard Deviation 0.922 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 48, n=81, 90 | 0.04 Millimoles per liter | Standard Deviation 0.577 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 4, n=116, 124 | 0.20 Millimoles per liter | Standard Deviation 0.666 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 32, n=103, 117 | 0.32 Millimoles per liter | Standard Deviation 0.811 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 28, n=42, 53 | 0.035 Millimoles per liter | Standard Deviation 0.214 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 36, n=44, 50 | 0.032 Millimoles per liter | Standard Deviation 0.1818 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 36, n=94, 95 | -0.002 Millimoles per liter | Standard Deviation 0.1496 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 48, n=91, 95 | 0.028 Millimoles per liter | Standard Deviation 0.1684 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 4, n=51, 53 | 0.12 Millimoles per liter | Standard Deviation 0.369 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 12, n=50, 52 | 0.12 Millimoles per liter | Standard Deviation 0.353 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 16, n=48, 53 | 0.02 Millimoles per liter | Standard Deviation 0.343 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 24, n=47, 53 | 0.01 Millimoles per liter | Standard Deviation 0.354 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 28, n=42, 53 | 0.09 Millimoles per liter | Standard Deviation 0.338 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 8, n=73, 98 | -0.02 Millimoles per liter | Standard Deviation 0.282 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 8, n=122, 152 | 0.02 Millimoles per liter | Standard Deviation 0.342 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 48, n=131, 147 | -0.02 Millimoles per liter | Standard Deviation 0.311 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 36, n=135, 147 | 0.4 Millimoles per liter | Standard Deviation 2.05 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 4, n=51, 53 | 0.02 Millimoles per liter | Standard Deviation 1.449 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 12, n=50, 52 | 0.04 Millimoles per liter | Standard Deviation 1.446 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 16, n=48, 53 | 0.25 Millimoles per liter | Standard Deviation 1.309 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 24, n=47, 53 | 0.41 Millimoles per liter | Standard Deviation 1.248 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 28, n=42, 53 | 0.18 Millimoles per liter | Standard Deviation 1.352 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 36, n=44, 50 | 0.01 Millimoles per liter | Standard Deviation 1.449 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 40, n=42, 51 | 0.17 Millimoles per liter | Standard Deviation 1.291 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 44, n=47, 51 | 0.36 Millimoles per liter | Standard Deviation 1.258 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 8, n=73, 98 | -0.14 Millimoles per liter | Standard Deviation 1.799 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 12, n=99, 95 | 0.05 Millimoles per liter | Standard Deviation 1.554 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 28, n=89, 93 | 0.01 Millimoles per liter | Standard Deviation 1.57 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 32, n=93, 95 | -0.09 Millimoles per liter | Standard Deviation 1.592 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 4, n=151, 153 | 0.10 Millimoles per liter | Standard Deviation 1.265 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 8, n=122, 152 | 0.16 Millimoles per liter | Standard Deviation 1.286 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 16, n=143, 149 | 0.07 Millimoles per liter | Standard Deviation 1.407 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 20, n=138, 152 | 0.25 Millimoles per liter | Standard Deviation 1.296 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 28, n=136, 150 | 0.22 Millimoles per liter | Standard Deviation 1.549 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 32, n=137, 148 | 0.41 Millimoles per liter | Standard Deviation 1.41 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 36, n=135, 147 | 0.19 Millimoles per liter | Standard Deviation 1.339 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 4, n=99, 97 | 1.0 Millimoles per liter | Standard Deviation 2.37 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 8, n=73, 98 | 0.5 Millimoles per liter | Standard Deviation 2.29 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 12, n=99, 95 | 0.4 Millimoles per liter | Standard Deviation 2.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 16, n=93, 96 | 0.1 Millimoles per liter | Standard Deviation 2.56 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 20, n=93, 97 | 0.1 Millimoles per liter | Standard Deviation 2.07 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 24, n=94, 95 | 0.1 Millimoles per liter | Standard Deviation 2.32 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 28, n=89, 93 | -0.3 Millimoles per liter | Standard Deviation 2.3 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 32, n=93, 95 | 0.2 Millimoles per liter | Standard Deviation 2.33 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 40, n=90, 95 | 0.5 Millimoles per liter | Standard Deviation 2.43 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 44, n=91, 94 | 0.5 Millimoles per liter | Standard Deviation 2.36 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 48, n=91, 95 | 0.1 Millimoles per liter | Standard Deviation 2.12 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 4, n=151, 153 | 0.9 Millimoles per liter | Standard Deviation 2.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 8, n=122, 152 | 0.4 Millimoles per liter | Standard Deviation 2.32 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 12, n=146, 152 | 0.5 Millimoles per liter | Standard Deviation 2.38 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 16, n=143, 149 | 0.3 Millimoles per liter | Standard Deviation 2.25 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 12, n=50, 52 | 0.7 Millimoles per liter | Standard Deviation 2.84 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 20, n=138, 152 | 0.1 Millimoles per liter | Standard Deviation 2.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 24, n=143, 150 | 0.3 Millimoles per liter | Standard Deviation 2.63 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 28, n=136, 150 | 0.1 Millimoles per liter | Standard Deviation 2.54 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 32, n=137, 148 | -0.2 Millimoles per liter | Standard Deviation 2.39 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 36, n=135, 147 | 0.1 Millimoles per liter | Standard Deviation 2.38 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 40, n=138, 147 | 0.4 Millimoles per liter | Standard Deviation 2.64 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 44, n=137, 148 | 0.4 Millimoles per liter | Standard Deviation 2.35 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 36, n=44, 50 | 0.5 Millimoles per liter | Standard Deviation 2.38 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 48, n=131, 147 | -0.1 Millimoles per liter | Standard Deviation 2.47 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 40, n=42, 51 | 0.5 Millimoles per liter | Standard Deviation 2.1 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 44, n=47, 51 | 0.7 Millimoles per liter | Standard Deviation 2.29 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 4, n=51, 53 | 0.5 Millimoles per liter | Standard Deviation 1.8 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 48, n=43, 50 | 0.9 Millimoles per liter | Standard Deviation 2.69 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 8, n=34, 53 | 0.2 Millimoles per liter | Standard Deviation 2.59 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 16, n=48, 53 | 0.5 Millimoles per liter | Standard Deviation 2.46 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 12, n=50, 52 | 0.5 Millimoles per liter | Standard Deviation 2.39 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 20, n=46, 53 | 0.8 Millimoles per liter | Standard Deviation 2.2 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 24, n=47, 53 | 1.1 Millimoles per liter | Standard Deviation 2.07 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 28, n=42, 53 | 1.5 Millimoles per liter | Standard Deviation 2.19 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 32, n=45, 51 | 0.9 Millimoles per liter | Standard Deviation 2.43 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 12, n=146, 152 | 0.4 Millimoles per liter | Standard Deviation 2.12 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 16, n=143, 149 | 0.5 Millimoles per liter | Standard Deviation 2.37 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 20, n=138, 152 | 0.7 Millimoles per liter | Standard Deviation 2.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 32, n=137, 148 | 0.8 Millimoles per liter | Standard Deviation 2.44 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 36, n=135, 147 | 1.0 Millimoles per liter | Standard Deviation 2.15 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 40, n=138, 147 | 0.6 Millimoles per liter | Standard Deviation 2.2 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 44, n=137, 148 | 0.6 Millimoles per liter | Standard Deviation 2.07 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 36, n=44, 50 | 1.0 Millimoles per liter | Standard Deviation 2.28 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 4, n=43, 43 | -0.08 Millimoles per liter | Standard Deviation 0.922 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 8, n=25, 41 | 0.17 Millimoles per liter | Standard Deviation 0.513 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 40, n=42, 51 | 1.3 Millimoles per liter | Standard Deviation 2.35 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 44, n=47, 51 | 1.1 Millimoles per liter | Standard Deviation 2.21 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 16, n=39, 43 | 0.11 Millimoles per liter | Standard Deviation 1.163 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 48, n=43, 50 | 0.5 Millimoles per liter | Standard Deviation 2.1 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 20, n=35, 41 | -0.07 Millimoles per liter | Standard Deviation 1.058 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 4, n=99, 97 | 0.3 Millimoles per liter | Standard Deviation 2.02 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 24, n=38, 42 | 0.11 Millimoles per liter | Standard Deviation 0.705 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 28, n=32, 43 | -0.03 Millimoles per liter | Standard Deviation 1.342 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 32, n=36, 41 | 0.23 Millimoles per liter | Standard Deviation 1.148 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 36, n=35, 41 | -0.01 Millimoles per liter | Standard Deviation 1.014 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 8, n=73, 98 | 0.2 Millimoles per liter | Standard Deviation 2.02 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 12, n=99, 95 | 0.4 Millimoles per liter | Standard Deviation 2.53 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 48, n=39, 48 | -0.01 Millimoles per liter | Standard Deviation 0.977 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 4, n=55, 52 | 0.30 Millimoles per liter | Standard Deviation 0.613 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 8, n=36, 57 | 0.12 Millimoles per liter | Standard Deviation 0.595 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 16, n=93, 96 | 0.9 Millimoles per liter | Standard Deviation 2.45 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 20, n=93, 97 | 1.0 Millimoles per liter | Standard Deviation 2.44 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 28, n=89, 93 | 0.8 Millimoles per liter | Standard Deviation 1.92 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 20, n=51, 57 | 0.25 Millimoles per liter | Standard Deviation 0.515 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 32, n=93, 95 | 0.7 Millimoles per liter | Standard Deviation 2.39 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 36, n=94, 95 | 0.8 Millimoles per liter | Standard Deviation 2.2 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 40, n=90, 95 | 0.7 Millimoles per liter | Standard Deviation 2.24 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 24, n=59, 61 | 0.24 Millimoles per liter | Standard Deviation 0.596 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 44, n=91, 94 | 0.7 Millimoles per liter | Standard Deviation 2.38 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 32, n=53, 55 | 0.48 Millimoles per liter | Standard Deviation 1.071 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 48, n=91, 95 | 0.4 Millimoles per liter | Standard Deviation 2.37 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 36, n=53, 57 | 0.34 Millimoles per liter | Standard Deviation 0.642 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 40, n=90, 95 | 0.01 Millimoles per liter | Standard Deviation 0.288 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 44, n=54, 57 | 0.33 Millimoles per liter | Standard Deviation 0.971 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 44, n=91, 94 | 0.01 Millimoles per liter | Standard Deviation 0.265 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 48, n=91, 95 | -0.03 Millimoles per liter | Standard Deviation 0.249 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 12, n=99, 95 | 0.024 Millimoles per liter | Standard Deviation 0.2108 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 16, n=93, 96 | 0.031 Millimoles per liter | Standard Deviation 0.1895 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 4, n=151, 153 | 0.05 Millimoles per liter | Standard Deviation 0.354 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 20, n=93, 97 | 0.012 Millimoles per liter | Standard Deviation 0.1764 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 8, n=90, 116 | 0.27 Millimoles per liter | Standard Deviation 0.987 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 12, n=146, 152 | 0.02 Millimoles per liter | Standard Deviation 0.351 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 16, n=143, 149 | 0.03 Millimoles per liter | Standard Deviation 0.373 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium,Week 20, n=138, 152 | 0.04 Millimoles per liter | Standard Deviation 0.358 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 12, n=112, 119 | 0.16 Millimoles per liter | Standard Deviation 0.746 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 24, n=143, 150 | 0.04 Millimoles per liter | Standard Deviation 0.329 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 28, n=136, 150 | 0.03 Millimoles per liter | Standard Deviation 0.364 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 16, n=115, 116 | 0.22 Millimoles per liter | Standard Deviation 0.767 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 24, n=94, 95 | 0.031 Millimoles per liter | Standard Deviation 0.1501 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 28, n=89, 93 | 0.032 Millimoles per liter | Standard Deviation 0.1628 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 32, n=137, 148 | 0.01 Millimoles per liter | Standard Deviation 0.442 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 32, n=93, 95 | 0.012 Millimoles per liter | Standard Deviation 0.1751 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 36, n=135, 147 | 0.02 Millimoles per liter | Standard Deviation 0.359 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 40, n=138, 147 | 0.05 Millimoles per liter | Standard Deviation 0.375 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 40, n=90, 95 | 0.018 Millimoles per liter | Standard Deviation 0.1766 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 44, n=91, 94 | 0.005 Millimoles per liter | Standard Deviation 0.1695 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 20, n=106, 118 | 0.25 Millimoles per liter | Standard Deviation 0.636 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 44, n=137, 148 | 0.08 Millimoles per liter | Standard Deviation 0.364 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 24, n=115, 121 | 0.27 Millimoles per liter | Standard Deviation 0.763 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 28, n=104, 120 | 0.23 Millimoles per liter | Standard Deviation 0.596 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 4, n=151, 153 | 0.085 Millimoles per liter | Standard Deviation 0.1785 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 8, n=122, 152 | 0.061 Millimoles per liter | Standard Deviation 0.2002 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 36, n=102, 117 | 0.17 Millimoles per liter | Standard Deviation 0.789 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 12, n=146, 152 | 0.057 Millimoles per liter | Standard Deviation 0.1946 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 16, n=143, 149 | 0.043 Millimoles per liter | Standard Deviation 0.2088 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 4, n=51, 53 | 0.4 Millimoles per liter | Standard Deviation 1.93 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 20, n=138, 152 | 0.039 Millimoles per liter | Standard Deviation 0.1935 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 8, n=34, 53 | 0.9 Millimoles per liter | Standard Deviation 2.21 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 24, n=143, 151 | 0.050 Millimoles per liter | Standard Deviation 0.222 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 12, n=50, 52 | 0.5 Millimoles per liter | Standard Deviation 2.09 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 28, n=136, 150 | 0.040 Millimoles per liter | Standard Deviation 0.185 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 16, n=48, 53 | 0.5 Millimoles per liter | Standard Deviation 2.3 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 32, n=137, 148 | 0.018 Millimoles per liter | Standard Deviation 0.2056 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 20, n=46, 53 | 0.6 Millimoles per liter | Standard Deviation 2.15 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 24, n=47, 53 | 0.5 Millimoles per liter | Standard Deviation 2.33 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 36, n=135, 147 | 0.014 Millimoles per liter | Standard Deviation 0.2069 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 28, n=42, 53 | 1.3 Millimoles per liter | Standard Deviation 2.06 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 32, n=45, 51 | 0.5 Millimoles per liter | Standard Deviation 2.47 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 36, n=44, 50 | 0.8 Millimoles per liter | Standard Deviation 2.21 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 40, n=42, 51 | 0.8 Millimoles per liter | Standard Deviation 2.2 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 40, n=138, 147 | 0.026 Millimoles per liter | Standard Deviation 0.2095 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 44, n=137, 148 | 0.041 Millimoles per liter | Standard Deviation 0.2112 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 40, n=100, 111 | 0.27 Millimoles per liter | Standard Deviation 0.692 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 44, n=99, 116 | 0.26 Millimoles per liter | Standard Deviation 0.793 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 48, n=131, 147 | 0.034 Millimoles per liter | Standard Deviation 0.222 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 44, n=47, 51 | 0.8 Millimoles per liter | Standard Deviation 2.1 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 48, n=43, 50 | 0.9 Millimoles per liter | Standard Deviation 1.98 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 4, n=99, 97 | 0.3 Millimoles per liter | Standard Deviation 1.62 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 8, n=73, 98 | 0.1 Millimoles per liter | Standard Deviation 1.98 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 48, n=118, 136 | 0.06 Millimoles per liter | Standard Deviation 0.659 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 8, n=34, 53 | 0.05 Millimoles per liter | Standard Deviation 0.245 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 12, n=99, 95 | 0.3 Millimoles per liter | Standard Deviation 2.11 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 4, n=51, 53 | 0.068 Millimoles per liter | Standard Deviation 0.1513 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 16, n=93, 96 | 0.3 Millimoles per liter | Standard Deviation 1.95 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 20, n=46, 53 | 0.05 Millimoles per liter | Standard Deviation 0.338 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 8, n=34, 53 | 0.076 Millimoles per liter | Standard Deviation 0.2023 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 20, n=93, 97 | 0.5 Millimoles per liter | Standard Deviation 1.94 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 24, n=94, 95 | 0.5 Millimoles per liter | Standard Deviation 1.79 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 28, n=89, 93 | 0.5 Millimoles per liter | Standard Deviation 1.74 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 32, n=93, 95 | 0.5 Millimoles per liter | Standard Deviation 1.87 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 36, n=94, 95 | 0.4 Millimoles per liter | Standard Deviation 1.86 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 12, n=50, 52 | 0.025 Millimoles per liter | Standard Deviation 0.1794 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 40, n=90, 95 | 0.5 Millimoles per liter | Standard Deviation 1.91 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 44, n=91, 94 | 0.5 Millimoles per liter | Standard Deviation 1.77 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 48, n=91, 95 | 0.4 Millimoles per liter | Standard Deviation 2 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 32, n=45, 51 | 0.02 Millimoles per liter | Standard Deviation 0.356 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 16, n=48, 53 | 0.056 Millimoles per liter | Standard Deviation 0.2028 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 20, n=46, 53 | 0.069 Millimoles per liter | Standard Deviation 0.1864 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 24, n=47, 53 | 0.037 Millimoles per liter | Standard Deviation 0.1971 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 32, n=45, 51 | 0.053 Millimoles per liter | Standard Deviation 0.2191 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 40, n=42, 51 | 0.027 Millimoles per liter | Standard Deviation 0.2392 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 44, n=47, 51 | 0.033 Millimoles per liter | Standard Deviation 0.2107 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 48, n=43, 50 | 0.048 Millimoles per liter | Standard Deviation 0.1994 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 4, n=99, 97 | 0.036 Millimoles per liter | Standard Deviation 0.1518 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 8, n=73, 98 | 0.056 Millimoles per liter | Standard Deviation 0.1532 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 36, n=44, 50 | 0.12 Millimoles per liter | Standard Deviation 0.363 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 40, n=42, 51 | 0.09 Millimoles per liter | Standard Deviation 0.348 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 44, n=47, 51 | 0.10 Millimoles per liter | Standard Deviation 0.409 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 48, n=43, 50 | 0.02 Millimoles per liter | Standard Deviation 0.359 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 4, n=99, 97 | 0.03 Millimoles per liter | Standard Deviation 0.308 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 12, n=99, 95 | 0.02 Millimoles per liter | Standard Deviation 0.316 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 16, n=93, 96 | -0.01 Millimoles per liter | Standard Deviation 0.286 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 20, n=93, 97 | 0.03 Millimoles per liter | Standard Deviation 0.333 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 24, n=94, 95 | 0.02 Millimoles per liter | Standard Deviation 0.304 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium,Week 28, n=89, 93 | 0.02 Millimoles per liter | Standard Deviation 0.422 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 32, n=93, 95 | 0.02 Millimoles per liter | Standard Deviation 0.322 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 36, n=94, 95 | 0.01 Millimoles per liter | Standard Deviation 0.345 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 24, n=143, 151 | 0.33 Millimoles per liter | Standard Deviation 1.499 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 40, n=138, 147 | 0.32 Millimoles per liter | Standard Deviation 1.347 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 44, n=137, 148 | 0.25 Millimoles per liter | Standard Deviation 1.346 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 48, n=131, 147 | 0.37 Millimoles per liter | Standard Deviation 1.389 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 4, n=151, 153 | 0.2 Millimoles per liter | Standard Deviation 1.95 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 8, n=122, 152 | 0.2 Millimoles per liter | Standard Deviation 1.91 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 12, n=146, 152 | 0.1 Millimoles per liter | Standard Deviation 2.04 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 16, n=143, 149 | -0.1 Millimoles per liter | Standard Deviation 2.28 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 20, n=138, 152 | -0.1 Millimoles per liter | Standard Deviation 2.14 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 24, n=143, 151 | 0.1 Millimoles per liter | Standard Deviation 2.14 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 28, n=136, 150 | 0.3 Millimoles per liter | Standard Deviation 2.29 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 32, n=137, 148 | 0.1 Millimoles per liter | Standard Deviation 2.01 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 40, n=138, 147 | 0.3 Millimoles per liter | Standard Deviation 2.04 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 44, n=137, 148 | 0.5 Millimoles per liter | Standard Deviation 2.17 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 48, n=131, 147 | 0.3 Millimoles per liter | Standard Deviation 2.39 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 8, n=34, 53 | 0.21 Millimoles per liter | Standard Deviation 1.142 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 20, n=46, 53 | 0.18 Millimoles per liter | Standard Deviation 1.425 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 32, n=45, 51 | 0.12 Millimoles per liter | Standard Deviation 1.567 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 48, n=43, 50 | 0.10 Millimoles per liter | Standard Deviation 1.303 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 4, n=99, 97 | -0.14 Millimoles per liter | Standard Deviation 1.477 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 16, n=93, 96 | 0.01 Millimoles per liter | Standard Deviation 1.402 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 20, n=93, 97 | 0.01 Millimoles per liter | Standard Deviation 1.531 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 24, n=94, 95 | 0.04 Millimoles per liter | Standard Deviation 1.367 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 36, n=94, 95 | -0.10 Millimoles per liter | Standard Deviation 1.514 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 40, n=90, 95 | 0.01 Millimoles per liter | Standard Deviation 1.519 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 44, n=91, 94 | -0.16 Millimoles per liter | Standard Deviation 1.583 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 48, n=91, 95 | 0.11 Millimoles per liter | Standard Deviation 1.633 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 12, n=146, 152 | 0.26 Millimoles per liter | Standard Deviation 1.29 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 32, n=93, 95 | 0.7 Millimoles per liter | Standard Deviation 2.45 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 36, n=135, 147 | 0.5 Millimoles per liter | Standard Deviation 2.22 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 36, n=94, 95 | 0.5 Millimoles per liter | Standard Deviation 2.32 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 20, n=51, 57 | -0.06 Millimoles per liter | Standard Deviation 0.676 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 20, n=46, 53 | 0.0 Millimoles per liter | Standard Deviation 2.26 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 8, n=73, 98 | -0.3 Millimoles per liter | Standard Deviation 1.87 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 24, n=47, 53 | 0.1 Millimoles per liter | Standard Deviation 1.94 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 48, n=118, 136 | 0.02 Millimoles per liter | Standard Deviation 1.074 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 28, n=42, 53 | -0.2 Millimoles per liter | Standard Deviation 2.37 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 40, n=90, 95 | 0.4 Millimoles per liter | Standard Deviation 2.69 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 32, n=45, 51 | -0.2 Millimoles per liter | Standard Deviation 2.36 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 32, n=93, 95 | 0.1 Millimoles per liter | Standard Deviation 2.34 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 16, n=93, 96 | 0.01 Millimoles per liter | Standard Deviation 0.319 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 36, n=94, 95 | 0.5 Millimoles per liter | Standard Deviation 2.58 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 36, n=135, 147 | 0.5 Millimoles per liter | Standard Deviation 2.37 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 16, n=48, 53 | 1.0 Millimoles per liter | Standard Deviation 2.31 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 44, n=91, 94 | 0.5 Millimoles per liter | Standard Deviation 2.41 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 48, n=91, 95 | -0.3 Millimoles per liter | Standard Deviation 2.36 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 28, n=52, 62 | 0.33 Millimoles per liter | Standard Deviation 0.763 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 4, n=151, 153 | 0.6 Millimoles per liter | Standard Deviation 2.17 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 32, n=93, 95 | 0.01 Millimoles per liter | Standard Deviation 1.522 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 8, n=122, 152 | 0.7 Millimoles per liter | Standard Deviation 1.91 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 8, n=34, 53 | 0.08 Millimoles per liter | Standard Deviation 0.307 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 24, n=143, 151 | 1.1 Millimoles per liter | Standard Deviation 2.24 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 36, n=94, 95 | 0.05 Millimoles per liter | Standard Deviation 0.349 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 20, n=93, 97 | 0.00 Millimoles per liter | Standard Deviation 0.313 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 48, n=131, 147 | 0.5 Millimoles per liter | Standard Deviation 2.36 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 4, n=43, 43 | 0.32 Millimoles per liter | Standard Deviation 0.401 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 36, n=53, 57 | 0.19 Millimoles per liter | Standard Deviation 1.063 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 28, n=32, 43 | 0.16 Millimoles per liter | Standard Deviation 0.441 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 36, n=35, 41 | 0.22 Millimoles per liter | Standard Deviation 0.483 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 4, n=51, 53 | 0.009 Millimoles per liter | Standard Deviation 0.1682 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 40, n=34, 40 | 0.18 Millimoles per liter | Standard Deviation 0.497 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 12, n=99, 95 | 0.0 Millimoles per liter | Standard Deviation 1.69 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 4, n=55, 52 | 0.07 Millimoles per liter | Standard Deviation 0.774 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 40, n=90, 95 | 0.01 Millimoles per liter | Standard Deviation 0.329 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 40, n=138, 147 | 0.5 Millimoles per liter | Standard Deviation 2.12 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 24, n=59, 61 | 0.04 Millimoles per liter | Standard Deviation 0.652 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 8, n=73, 98 | 0.010 Millimoles per liter | Standard Deviation 0.1676 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 32, n=53, 55 | 0.32 Millimoles per liter | Standard Deviation 0.876 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 44, n=91, 94 | 0.00 Millimoles per liter | Standard Deviation 0.327 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 40, n=59, 62 | 0.14 Millimoles per liter | Standard Deviation 0.566 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 44, n=54, 57 | 0.16 Millimoles per liter | Standard Deviation 0.626 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 48, n=81, 90 | -0.03 Millimoles per liter | Standard Deviation 0.796 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 12, n=50, 52 | 0.19 Millimoles per liter | Standard Deviation 0.388 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 4, n=116, 124 | 0.24 Millimoles per liter | Standard Deviation 1.055 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 16, n=115, 116 | 0.33 Millimoles per liter | Standard Deviation 1.347 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 16, n=48, 53 | 0.19 Millimoles per liter | Standard Deviation 0.398 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 32, n=103, 117 | 0.24 Millimoles per liter | Standard Deviation 1.062 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 40, n=100, 111 | 0.33 Millimoles per liter | Standard Deviation 1.118 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 20, n=46, 53 | 0.017 Millimoles per liter | Standard Deviation 0.1924 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 24, n=47, 53 | 0.018 Millimoles per liter | Standard Deviation 0.1735 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 48, n=91, 95 | -0.01 Millimoles per liter | Standard Deviation 0.292 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 12, n=99, 95 | 0.017 Millimoles per liter | Standard Deviation 0.1808 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 24, n=94, 95 | -0.011 Millimoles per liter | Standard Deviation 0.1785 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 24, n=94, 95 | 0.04 Millimoles per liter | Standard Deviation 0.315 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 20, n=46, 53 | 0.18 Millimoles per liter | Standard Deviation 0.42 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 48, n=91, 95 | 0.002 Millimoles per liter | Standard Deviation 0.2072 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 16, n=143, 149 | 0.008 Millimoles per liter | Standard Deviation 0.1613 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 24, n=143, 151 | 0.012 Millimoles per liter | Standard Deviation 0.1923 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 32, n=137, 148 | 0.011 Millimoles per liter | Standard Deviation 0.202 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 4, n=151, 153 | 0.10 Millimoles per liter | Standard Deviation 0.368 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 4, n=51, 53 | 0.20 Millimoles per liter | Standard Deviation 0.447 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 16, n=93, 96 | 0.001 Millimoles per liter | Standard Deviation 0.1708 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 12, n=99, 95 | 0.21 Millimoles per liter | Standard Deviation 1.481 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 8, n=122, 152 | 0.05 Millimoles per liter | Standard Deviation 0.355 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 24, n=47, 53 | 0.19 Millimoles per liter | Standard Deviation 0.384 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 20, n=93, 97 | 0.025 Millimoles per liter | Standard Deviation 0.1823 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 36, n=44, 50 | 0.14 Millimoles per liter | Standard Deviation 0.371 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 44, n=47, 51 | 0.21 Millimoles per liter | Standard Deviation 0.433 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 4, n=99, 97 | 0.08 Millimoles per liter | Standard Deviation 0.335 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 8, n=34, 53 | -0.019 Millimoles per liter | Standard Deviation 0.1752 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 8, n=90, 116 | 0.23 Millimoles per liter | Standard Deviation 0.795 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 16, n=93, 96 | 0.4 Millimoles per liter | Standard Deviation 1.97 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 4, n=51, 53 | 0.3 Millimoles per liter | Standard Deviation 2.11 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 16, n=48, 53 | 0.3 Millimoles per liter | Standard Deviation 2.24 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 20, n=46, 53 | 0.4 Millimoles per liter | Standard Deviation 2.12 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 44, n=47, 51 | 0.7 Millimoles per liter | Standard Deviation 2.49 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 40, n=90, 95 | 0.2 Millimoles per liter | Standard Deviation 2.01 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 28, n=136, 150 | 0.2 Millimoles per liter | Standard Deviation 2.18 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 12, n=146, 152 | 0.08 Millimoles per liter | Standard Deviation 0.353 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium,Week 28, n=89, 93 | 0.03 Millimoles per liter | Standard Deviation 0.372 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 16, n=143, 149 | 0.05 Millimoles per liter | Standard Deviation 0.32 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 12, n=50, 52 | -0.01 Millimoles per liter | Standard Deviation 1.312 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 20, n=93, 97 | 0.1 Millimoles per liter | Standard Deviation 1.86 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 20, n=46, 53 | 0.17 Millimoles per liter | Standard Deviation 1.275 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 44, n=137, 148 | 0.5 Millimoles per liter | Standard Deviation 1.96 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 24, n=47, 53 | 0.10 Millimoles per liter | Standard Deviation 1.182 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium,Week 20, n=138, 152 | 0.03 Millimoles per liter | Standard Deviation 0.355 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 24, n=94, 95 | 0.0 Millimoles per liter | Standard Deviation 1.73 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 24, n=143, 150 | 0.04 Millimoles per liter | Standard Deviation 0.324 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 40, n=42, 51 | 0.33 Millimoles per liter | Standard Deviation 1.714 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 32, n=93, 95 | 0.01 Millimoles per liter | Standard Deviation 0.289 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 44, n=47, 51 | 0.13 Millimoles per liter | Standard Deviation 1.276 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 4, n=99, 97 | 0.19 Millimoles per liter | Standard Deviation 1.635 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 12, n=112, 119 | 0.11 Millimoles per liter | Standard Deviation 0.887 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 8, n=73, 98 | 0.01 Millimoles per liter | Standard Deviation 1.601 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 28, n=89, 93 | -0.3 Millimoles per liter | Standard Deviation 1.93 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 24, n=94, 95 | 0.12 Millimoles per liter | Standard Deviation 1.441 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 40, n=90, 95 | 0.12 Millimoles per liter | Standard Deviation 1.469 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 28, n=89, 93 | -0.02 Millimoles per liter | Standard Deviation 1.579 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 32, n=93, 95 | 0.2 Millimoles per liter | Standard Deviation 1.75 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 44, n=91, 94 | -0.19 Millimoles per liter | Standard Deviation 1.721 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 28, n=89, 93 | 0.006 Millimoles per liter | Standard Deviation 0.1806 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 4, n=151, 153 | 0.04 Millimoles per liter | Standard Deviation 1.185 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 28, n=136, 150 | 0.08 Millimoles per liter | Standard Deviation 0.412 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 8, n=122, 152 | 0.01 Millimoles per liter | Standard Deviation 1.252 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 12, n=146, 152 | 0.06 Millimoles per liter | Standard Deviation 1.344 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 48, n=131, 147 | 0.4 Millimoles per liter | Standard Deviation 1.97 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 16, n=143, 149 | 0.28 Millimoles per liter | Standard Deviation 1.609 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 32, n=137, 148 | 0.02 Millimoles per liter | Standard Deviation 0.348 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 20, n=138, 152 | 0.07 Millimoles per liter | Standard Deviation 1.507 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 24, n=143, 151 | 0.18 Millimoles per liter | Standard Deviation 1.276 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 36, n=94, 95 | 0.3 Millimoles per liter | Standard Deviation 1.88 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 28, n=136, 150 | 0.02 Millimoles per liter | Standard Deviation 1.422 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 32, n=137, 148 | 0.06 Millimoles per liter | Standard Deviation 1.416 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 32, n=93, 95 | -0.017 Millimoles per liter | Standard Deviation 0.1827 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 40, n=138, 147 | -0.01 Millimoles per liter | Standard Deviation 1.339 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 44, n=137, 148 | 0.10 Millimoles per liter | Standard Deviation 1.344 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 48, n=131, 147 | -0.02 Millimoles per liter | Standard Deviation 1.325 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 48, n=43, 50 | -0.1 Millimoles per liter | Standard Deviation 1.87 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 36, n=135, 147 | 0.05 Millimoles per liter | Standard Deviation 0.36 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 4, n=99, 97 | 0.8 Millimoles per liter | Standard Deviation 2.21 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Urea, Week 36, n=135, 147 | 0.04 Millimoles per liter | Standard Deviation 1.392 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 8, n=73, 98 | 0.6 Millimoles per liter | Standard Deviation 2.46 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 40, n=138, 147 | 0.08 Millimoles per liter | Standard Deviation 0.342 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 12, n=99, 95 | 0.3 Millimoles per liter | Standard Deviation 2.31 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 36, n=94, 95 | -0.001 Millimoles per liter | Standard Deviation 0.1979 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 16, n=93, 96 | 0.6 Millimoles per liter | Standard Deviation 2.53 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 4, n=51, 53 | 0.01 Millimoles per liter | Standard Deviation 1.124 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 20, n=93, 97 | 0.7 Millimoles per liter | Standard Deviation 2.25 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 40, n=90, 95 | -0.002 Millimoles per liter | Standard Deviation 0.1721 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 24, n=94, 95 | 0.2 Millimoles per liter | Standard Deviation 2.49 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 44, n=91, 94 | 0.3 Millimoles per liter | Standard Deviation 1.93 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 28, n=89, 93 | 0.2 Millimoles per liter | Standard Deviation 2.41 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 44, n=91, 94 | 0.005 Millimoles per liter | Standard Deviation 0.1977 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 16, n=93, 96 | 0.05 Millimoles per liter | Standard Deviation 1.375 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 40, n=90, 95 | 0.3 Millimoles per liter | Standard Deviation 2.18 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 28, n=42, 53 | 0.15 Millimoles per liter | Standard Deviation 0.342 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 44, n=91, 94 | 0.7 Millimoles per liter | Standard Deviation 2.45 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 20, n=106, 118 | 0.28 Millimoles per liter | Standard Deviation 1.104 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, CO2, Week 48, n=91, 95 | 0.3 Millimoles per liter | Standard Deviation 2.53 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 8, n=34, 53 | -0.02 Millimoles per liter | Standard Deviation 1.205 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 4, n=151, 153 | 0.7 Millimoles per liter | Standard Deviation 2.18 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 24, n=115, 121 | 0.16 Millimoles per liter | Standard Deviation 1.037 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 8, n=122, 152 | 0.8 Millimoles per liter | Standard Deviation 2.52 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 12, n=50, 52 | 0.007 Millimoles per liter | Standard Deviation 0.1524 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 4, n=51, 53 | 0.7 Millimoles per liter | Standard Deviation 2.34 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 12, n=146, 152 | 0.4 Millimoles per liter | Standard Deviation 2.51 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 8, n=34, 53 | 0.3 Millimoles per liter | Standard Deviation 2.65 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 28, n=104, 120 | 0.30 Millimoles per liter | Standard Deviation 1.077 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 16, n=48, 53 | 0.20 Millimoles per liter | Standard Deviation 1.377 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 12, n=50, 52 | 0.2 Millimoles per liter | Standard Deviation 2.23 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 16, n=143, 149 | 0.5 Millimoles per liter | Standard Deviation 2.37 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 4, n=151, 153 | 0.016 Millimoles per liter | Standard Deviation 0.158 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 20, n=138, 152 | 0.2 Millimoles per liter | Standard Deviation 2.35 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 16, n=48, 53 | -0.008 Millimoles per liter | Standard Deviation 0.161 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 24, n=143, 150 | 0.3 Millimoles per liter | Standard Deviation 2.57 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 44, n=137, 148 | 0.07 Millimoles per liter | Standard Deviation 0.366 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 28, n=136, 150 | 0.2 Millimoles per liter | Standard Deviation 2.4 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 48, n=91, 95 | -0.1 Millimoles per liter | Standard Deviation 1.85 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 32, n=137, 148 | 0.4 Millimoles per liter | Standard Deviation 2.27 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 8, n=122, 152 | -0.012 Millimoles per liter | Standard Deviation 0.1515 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 16, n=48, 53 | 0.2 Millimoles per liter | Standard Deviation 2.32 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 4, n=151, 153 | 0.1 Millimoles per liter | Standard Deviation 1.98 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 40, n=138, 147 | 0.5 Millimoles per liter | Standard Deviation 2.38 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 12, n=146, 152 | 0.012 Millimoles per liter | Standard Deviation 0.178 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 44, n=137, 148 | 0.5 Millimoles per liter | Standard Deviation 2.01 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 36, n=94, 95 | -0.05 Millimoles per liter | Standard Deviation 1.478 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Potassium, Week 48, n=131, 147 | 0.00 Millimoles per liter | Standard Deviation 0.329 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 36, n=44, 50 | -0.4 Millimoles per liter | Standard Deviation 1.98 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 28, n=42, 53 | 0.017 Millimoles per liter | Standard Deviation 0.1971 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 40, n=42, 51 | 0.3 Millimoles per liter | Standard Deviation 2.26 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, CO2, Week 48, n=131, 147 | 0.3 Millimoles per liter | Standard Deviation 2.3 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 8, n=122, 152 | 0.0 Millimoles per liter | Standard Deviation 1.82 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 20, n=138, 152 | -0.002 Millimoles per liter | Standard Deviation 0.1823 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 4, n=51, 53 | 0.5 Millimoles per liter | Standard Deviation 2.34 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, CO2, Week 44, n=47, 51 | 0.3 Millimoles per liter | Standard Deviation 2.18 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 32, n=45, 51 | 0.032 Millimoles per liter | Standard Deviation 0.1545 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 12, n=50, 52 | 0.8 Millimoles per liter | Standard Deviation 2.2 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 8, n=34, 53 | 0.3 Millimoles per liter | Standard Deviation 2.25 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 8, n=34, 53 | 0.7 Millimoles per liter | Standard Deviation 2.42 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 36, n=44, 50 | -0.001 Millimoles per liter | Standard Deviation 0.1828 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 28, n=42, 53 | 0.00 Millimoles per liter | Standard Deviation 1.236 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 40, n=42, 51 | 0.001 Millimoles per liter | Standard Deviation 0.1657 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 20, n=46, 53 | 0.7 Millimoles per liter | Standard Deviation 2.3 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 12, n=50, 52 | 0.7 Millimoles per liter | Standard Deviation 1.97 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 24, n=47, 53 | 1.3 Millimoles per liter | Standard Deviation 2.36 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 12, n=146, 152 | 0.1 Millimoles per liter | Standard Deviation 2.01 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 28, n=42, 53 | 1.2 Millimoles per liter | Standard Deviation 3.06 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 28, n=136, 150 | -0.003 Millimoles per liter | Standard Deviation 0.1789 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 32, n=45, 51 | 0.9 Millimoles per liter | Standard Deviation 2.6 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 44, n=47, 51 | 0.011 Millimoles per liter | Standard Deviation 0.1736 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 12, n=146, 152 | 0.5 Millimoles per liter | Standard Deviation 2.27 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 20, n=93, 97 | 0.15 Millimoles per liter | Standard Deviation 1.495 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 16, n=143, 149 | 0.8 Millimoles per liter | Standard Deviation 2.2 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Phosphate, Week 48, n=43, 50 | 0.017 Millimoles per liter | Standard Deviation 0.1387 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 20, n=138, 152 | 1.1 Millimoles per liter | Standard Deviation 2.4 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 28, n=136, 150 | 1.3 Millimoles per liter | Standard Deviation 2.39 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 36, n=102, 117 | 0.31 Millimoles per liter | Standard Deviation 1.217 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 32, n=137, 148 | 1.1 Millimoles per liter | Standard Deviation 2.15 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 24, n=47, 53 | 0.4 Millimoles per liter | Standard Deviation 2.3 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 36, n=135, 147 | 1.1 Millimoles per liter | Standard Deviation 2.37 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 16, n=143, 149 | -0.2 Millimoles per liter | Standard Deviation 2.04 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 40, n=138, 147 | 1.0 Millimoles per liter | Standard Deviation 2.84 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Phosphate, Week 4, n=99, 97 | 0.017 Millimoles per liter | Standard Deviation 0.1588 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Chloride, Week 44, n=137, 148 | 1.0 Millimoles per liter | Standard Deviation 2.08 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 36, n=135, 147 | -0.002 Millimoles per liter | Standard Deviation 0.1794 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 28, n=42, 53 | 0.8 Millimoles per liter | Standard Deviation 2.75 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 32, n=45, 51 | 0.16 Millimoles per liter | Standard Deviation 1.21 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 36, n=44, 50 | 1.0 Millimoles per liter | Standard Deviation 3 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 8, n=25, 41 | 0.22 Millimoles per liter | Standard Deviation 0.466 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 32, n=45, 51 | 0.5 Millimoles per liter | Standard Deviation 2.26 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 40, n=42, 51 | 1.1 Millimoles per liter | Standard Deviation 2.6 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 32, n=45, 51 | 0.19 Millimoles per liter | Standard Deviation 0.408 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 44, n=47, 51 | 1.1 Millimoles per liter | Standard Deviation 2.57 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 12, n=40, 42 | 0.27 Millimoles per liter | Standard Deviation 0.494 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 36, n=44, 50 | 0.6 Millimoles per liter | Standard Deviation 2.63 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 16, n=39, 43 | 0.28 Millimoles per liter | Standard Deviation 0.704 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 20, n=138, 152 | 0.3 Millimoles per liter | Standard Deviation 1.95 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 36, n=44, 50 | -0.13 Millimoles per liter | Standard Deviation 1.19 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Chloride, Week 48, n=43, 50 | 0.9 Millimoles per liter | Standard Deviation 2.29 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 40, n=138, 147 | -0.006 Millimoles per liter | Standard Deviation 0.1783 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 20, n=35, 41 | 0.30 Millimoles per liter | Standard Deviation 0.799 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 40, n=42, 51 | 0.15 Millimoles per liter | Standard Deviation 0.394 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 24, n=38, 42 | 0.32 Millimoles per liter | Standard Deviation 0.636 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 44, n=137, 148 | 0.000 Millimoles per liter | Standard Deviation 0.1735 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 24, n=143, 151 | 0.3 Millimoles per liter | Standard Deviation 1.95 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 32, n=36, 41 | 0.29 Millimoles per liter | Standard Deviation 0.6 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 40, n=42, 51 | 0.7 Millimoles per liter | Standard Deviation 2.03 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 4, n=99, 97 | 0.5 Millimoles per liter | Standard Deviation 1.96 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Urea, Week 48, n=91, 95 | -0.05 Millimoles per liter | Standard Deviation 1.304 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 8, n=73, 98 | 0.1 Millimoles per liter | Standard Deviation 2.42 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Potassium, Week 48, n=43, 50 | 0.01 Millimoles per liter | Standard Deviation 0.409 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 44, n=40, 40 | 0.20 Millimoles per liter | Standard Deviation 0.278 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Urea, Week 48, n=43, 50 | 0.13 Millimoles per liter | Standard Deviation 1.305 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Glucose, Week 48, n=39, 48 | 0.11 Millimoles per liter | Standard Deviation 0.663 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Phosphate, Week 48, n=131, 147 | -0.001 Millimoles per liter | Standard Deviation 0.1619 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 12, n=99, 95 | 0.5 Millimoles per liter | Standard Deviation 2.27 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 8, n=73, 98 | 0.06 Millimoles per liter | Standard Deviation 0.483 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 8, n=36, 57 | 0.21 Millimoles per liter | Standard Deviation 1.083 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Glucose, Week 44, n=99, 116 | 0.35 Millimoles per liter | Standard Deviation 1.121 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 16, n=93, 96 | 0.7 Millimoles per liter | Standard Deviation 2.32 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Sodium, Week 48, n=43, 50 | 0.8 Millimoles per liter | Standard Deviation 1.95 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 12, n=52, 55 | 0.30 Millimoles per liter | Standard Deviation 1.357 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 20, n=93, 97 | 0.2 Millimoles per liter | Standard Deviation 2.31 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 24, n=94, 95 | 0.5 Millimoles per liter | Standard Deviation 2.19 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Sodium, Week 32, n=137, 148 | 0.5 Millimoles per liter | Standard Deviation 1.84 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Chloride, Week 28, n=89, 93 | 0.3 Millimoles per liter | Standard Deviation 2.37 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Glucose, Week 16, n=53, 52 | 0.13 Millimoles per liter | Standard Deviation 0.557 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Sodium, Week 4, n=99, 97 | 0.0 Millimoles per liter | Standard Deviation 1.97 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Potassium, Week 12, n=99, 95 | 0.01 Millimoles per liter | Standard Deviation 0.329 |
Secondary
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin
Blood samples were collected for the analysis of clinical chemistry parameter: albumin to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 28, n=89, 93 | -0.3 Grams per Liter | Standard Deviation 2.55 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 20, n=46, 53 | -0.4 Grams per Liter | Standard Deviation 2.35 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 32, n=93, 95 | -0.2 Grams per Liter | Standard Deviation 2.7 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 40, n=42, 51 | -0.1 Grams per Liter | Standard Deviation 2.72 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 36, n=94, 95 | -0.8 Grams per Liter | Standard Deviation 2.67 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 44, n=47, 51 | -0.5 Grams per Liter | Standard Deviation 2.15 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 40, n=90, 95 | -0.3 Grams per Liter | Standard Deviation 2.4 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 12, n=50, 52 | -0.2 Grams per Liter | Standard Deviation 2.67 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 44, n=91, 94 | -0.5 Grams per Liter | Standard Deviation 2.77 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 48, n=43, 50 | -0.3 Grams per Liter | Standard Deviation 2.74 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 48, n=91, 95 | -0.1 Grams per Liter | Standard Deviation 2.69 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 24, n=47, 53 | -0.6 Grams per Liter | Standard Deviation 2.24 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 4, n=151, 153 | -0.8 Grams per Liter | Standard Deviation 2.7 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 4, n=99, 97 | -0.4 Grams per Liter | Standard Deviation 2.56 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 8, n=122, 152 | -0.4 Grams per Liter | Standard Deviation 2.83 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 8, n=34, 53 | 0.7 Grams per Liter | Standard Deviation 2.73 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 12, n=146, 152 | -0.8 Grams per Liter | Standard Deviation 2.59 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 8, n=73, 98 | -0.5 Grams per Liter | Standard Deviation 2.59 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 16, n=143, 149 | -0.8 Grams per Liter | Standard Deviation 2.79 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 28, n=42, 53 | -0.6 Grams per Liter | Standard Deviation 2.26 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 20, n=138, 152 | -0.9 Grams per Liter | Standard Deviation 2.96 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 12, n=99, 95 | -0.3 Grams per Liter | Standard Deviation 2.92 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 24, n=143, 151 | -0.7 Grams per Liter | Standard Deviation 2.73 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 16, n=48, 53 | -0.2 Grams per Liter | Standard Deviation 2.77 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 28, n=136, 150 | -0.9 Grams per Liter | Standard Deviation 2.72 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 16, n=93, 96 | -0.5 Grams per Liter | Standard Deviation 2.78 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 32, n=137, 148 | -0.9 Grams per Liter | Standard Deviation 2.94 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 32, n=45, 51 | -0.7 Grams per Liter | Standard Deviation 2.39 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 36, n=135, 147 | -1.0 Grams per Liter | Standard Deviation 2.83 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 20, n=93, 97 | -0.7 Grams per Liter | Standard Deviation 2.71 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 40, n=138, 147 | -0.7 Grams per Liter | Standard Deviation 2.54 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 4, n=51, 53 | 0.2 Grams per Liter | Standard Deviation 2.21 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 44, n=137, 148 | -0.3 Grams per Liter | Standard Deviation 2.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 24, n=94, 95 | -0.8 Grams per Liter | Standard Deviation 2.86 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 48, n=131, 147 | -0.6 Grams per Liter | Standard Deviation 2.57 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 36, n=44, 50 | -0.6 Grams per Liter | Standard Deviation 2.44 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 48, n=131, 147 | -0.5 Grams per Liter | Standard Deviation 2.49 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 4, n=51, 53 | -0.2 Grams per Liter | Standard Deviation 2.41 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 8, n=34, 53 | -0.1 Grams per Liter | Standard Deviation 2.74 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 12, n=50, 52 | -0.3 Grams per Liter | Standard Deviation 2.81 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 16, n=48, 53 | -0.8 Grams per Liter | Standard Deviation 2.72 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 20, n=46, 53 | -0.8 Grams per Liter | Standard Deviation 2.82 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 24, n=47, 53 | -0.8 Grams per Liter | Standard Deviation 2.4 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 28, n=42, 53 | -1.4 Grams per Liter | Standard Deviation 2.08 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 32, n=45, 51 | -0.5 Grams per Liter | Standard Deviation 2.42 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 36, n=44, 50 | -0.9 Grams per Liter | Standard Deviation 2.48 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 44, n=47, 51 | -0.5 Grams per Liter | Standard Deviation 2.6 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 48, n=43, 50 | -0.1 Grams per Liter | Standard Deviation 2.44 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 4, n=99, 97 | -0.9 Grams per Liter | Standard Deviation 2.62 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 8, n=73, 98 | -1.0 Grams per Liter | Standard Deviation 2.89 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 12, n=99, 95 | -0.5 Grams per Liter | Standard Deviation 2.59 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 16, n=93, 96 | -1.1 Grams per Liter | Standard Deviation 2.8 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 20, n=93, 97 | -0.7 Grams per Liter | Standard Deviation 2.77 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 24, n=94, 95 | -1.0 Grams per Liter | Standard Deviation 2.74 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 28, n=89, 93 | -1.1 Grams per Liter | Standard Deviation 2.87 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 32, n=93, 95 | -1.3 Grams per Liter | Standard Deviation 2.77 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 36, n=94, 95 | -1.1 Grams per Liter | Standard Deviation 2.54 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 40, n=90, 95 | -1.3 Grams per Liter | Standard Deviation 2.84 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 44, n=91, 94 | -1.0 Grams per Liter | Standard Deviation 2.76 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | INI, Week 48, n=91, 95 | -0.5 Grams per Liter | Standard Deviation 2.69 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 4, n=151, 153 | -0.3 Grams per Liter | Standard Deviation 2.42 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 8, n=122, 152 | -0.6 Grams per Liter | Standard Deviation 2.53 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 12, n=146, 152 | -0.3 Grams per Liter | Standard Deviation 2.61 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 16, n=143, 149 | -0.7 Grams per Liter | Standard Deviation 2.63 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 20, n=138, 152 | -0.9 Grams per Liter | Standard Deviation 2.33 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 24, n=143, 151 | -0.7 Grams per Liter | Standard Deviation 2.57 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 28, n=136, 150 | -0.9 Grams per Liter | Standard Deviation 2.34 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 32, n=137, 148 | -1.0 Grams per Liter | Standard Deviation 2.45 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 36, n=135, 147 | -0.8 Grams per Liter | Standard Deviation 2.79 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 40, n=138, 147 | -1.0 Grams per Liter | Standard Deviation 2.52 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | NNRTI, Week 44, n=137, 148 | -0.8 Grams per Liter | Standard Deviation 2.22 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin | PI, Week 40, n=42, 51 | -0.5 Grams per Liter | Standard Deviation 2.37 |
Secondary
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK
Blood samples were collected for the analysis of clinical chemistry parameters: ALT, ALP, AST and CK to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 12, n=99, 95 | -1.0 International units per liter | Standard Deviation 12.48 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 40, n=138, 147 | -3.8 International units per liter | Standard Deviation 13.48 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 40, n=138, 147 | -7.7 International units per liter | Standard Deviation 237 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 4, n=51, 53 | 9.4 International units per liter | Standard Deviation 17.93 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 8, n=34, 53 | 7.9 International units per liter | Standard Deviation 17.19 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 12, n=50, 52 | 5.3 International units per liter | Standard Deviation 17.31 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 16, n=48, 53 | 6.5 International units per liter | Standard Deviation 20.92 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 20, n=46, 53 | 4.9 International units per liter | Standard Deviation 18.06 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 24, n=47, 53 | 4.1 International units per liter | Standard Deviation 14.42 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 28, n=42, 53 | 2.6 International units per liter | Standard Deviation 11.47 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 32, n=45, 51 | 3.5 International units per liter | Standard Deviation 14.88 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 36, n=44, 50 | 3.3 International units per liter | Standard Deviation 13.55 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 40, n=42, 51 | 5.4 International units per liter | Standard Deviation 17.81 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 44, n=47, 51 | 4.0 International units per liter | Standard Deviation 15.83 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 48, n=43, 50 | 2.9 International units per liter | Standard Deviation 10.69 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 4, n=99, 97 | 1.7 International units per liter | Standard Deviation 15.15 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 8, n=73, 98 | 3.3 International units per liter | Standard Deviation 18.2 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 16, n=93, 96 | -1.8 International units per liter | Standard Deviation 12.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 20, n=93, 97 | -1.9 International units per liter | Standard Deviation 13.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 24, n=94, 95 | 0.6 International units per liter | Standard Deviation 17.33 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 28, n=89, 93 | -2.4 International units per liter | Standard Deviation 9.7 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 32, n=93, 95 | -1.8 International units per liter | Standard Deviation 12.87 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 36, n=94, 95 | 1.5 International units per liter | Standard Deviation 35.82 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 40, n=90, 95 | 5.0 International units per liter | Standard Deviation 59.1 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 44, n=91, 94 | -1.6 International units per liter | Standard Deviation 13.9 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 48, n=91, 95 | -0.2 International units per liter | Standard Deviation 15.17 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 4, n=151, 153 | -2.6 International units per liter | Standard Deviation 9.82 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 8, n=122, 152 | -2.9 International units per liter | Standard Deviation 11.62 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 12, n=146, 152 | 9.5 International units per liter | Standard Deviation 160.61 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 16, n=143, 149 | -1.3 International units per liter | Standard Deviation 26.21 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 20, n=138, 152 | -2.0 International units per liter | Standard Deviation 28.04 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 24, n=143, 151 | 2.6 International units per liter | Standard Deviation 85.48 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 28, n=136, 150 | -4.5 International units per liter | Standard Deviation 11.46 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 32, n=137, 148 | -3.8 International units per liter | Standard Deviation 14.93 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 36, n=135, 147 | -3.8 International units per liter | Standard Deviation 12.44 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 44, n=137, 148 | -4.7 International units per liter | Standard Deviation 12.67 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 48, n=131, 147 | -4.6 International units per liter | Standard Deviation 12.38 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 4, n=51, 53 | -3.5 International units per liter | Standard Deviation 11.63 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 8, n=34, 53 | -2.1 International units per liter | Standard Deviation 24.59 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 12, n=50, 52 | -5.7 International units per liter | Standard Deviation 14.4 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 16, n=48, 53 | -7.3 International units per liter | Standard Deviation 17.09 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 20, n=46, 53 | -6.8 International units per liter | Standard Deviation 16.71 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 24, n=47, 53 | -7.5 International units per liter | Standard Deviation 17.9 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 28, n=42, 53 | -7.3 International units per liter | Standard Deviation 17.23 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 32, n=45, 51 | -9.3 International units per liter | Standard Deviation 16.47 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 36, n=44, 50 | -10.2 International units per liter | Standard Deviation 18.52 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 40, n=42, 51 | -8.7 International units per liter | Standard Deviation 17.37 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 44, n=47, 51 | -11.5 International units per liter | Standard Deviation 17.49 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 48, n=43, 50 | -8.0 International units per liter | Standard Deviation 16.05 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 4, n=99, 97 | -0.5 International units per liter | Standard Deviation 10.59 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 8, n=73, 98 | -1.8 International units per liter | Standard Deviation 8.55 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 12, n=99, 95 | -1.6 International units per liter | Standard Deviation 8.57 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 16, n=93, 96 | -1.7 International units per liter | Standard Deviation 10.53 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 20, n=93, 97 | -2.0 International units per liter | Standard Deviation 10.23 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 24, n=94, 95 | -1.4 International units per liter | Standard Deviation 10.23 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 28, n=89, 93 | -2.1 International units per liter | Standard Deviation 10.83 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 32, n=93, 95 | -1.6 International units per liter | Standard Deviation 11.08 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 36, n=94, 95 | -2.4 International units per liter | Standard Deviation 12.03 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 40, n=90, 95 | -0.9 International units per liter | Standard Deviation 13.77 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 44, n=91, 94 | -2.6 International units per liter | Standard Deviation 13.69 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 48, n=91, 95 | -1.9 International units per liter | Standard Deviation 13.29 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 4, n=151, 153 | -10.4 International units per liter | Standard Deviation 12.81 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 8, n=122, 152 | -10.9 International units per liter | Standard Deviation 16.5 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 12, n=146, 152 | -13.0 International units per liter | Standard Deviation 26.62 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 16, n=143, 149 | -15.7 International units per liter | Standard Deviation 22.52 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 20, n=138, 152 | -14.9 International units per liter | Standard Deviation 22.35 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 24, n=143, 151 | -14.5 International units per liter | Standard Deviation 21.88 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 28, n=136, 150 | -16.2 International units per liter | Standard Deviation 21.66 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 32, n=137, 148 | -15.8 International units per liter | Standard Deviation 21.98 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 36, n=135, 147 | -16.1 International units per liter | Standard Deviation 23.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 40, n=138, 147 | -17.2 International units per liter | Standard Deviation 22.83 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 44, n=137, 148 | -17.3 International units per liter | Standard Deviation 23.32 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 48, n=131, 147 | -18.0 International units per liter | Standard Deviation 27.97 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 4, n=51, 53 | 3.8 International units per liter | Standard Deviation 9.18 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 8, n=34, 53 | 5.1 International units per liter | Standard Deviation 8.35 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 12, n=50, 52 | 2.7 International units per liter | Standard Deviation 11.49 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 16, n=48, 53 | 3.9 International units per liter | Standard Deviation 16.81 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 20, n=46, 53 | 4.1 International units per liter | Standard Deviation 20.85 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 24, n=47, 53 | 1.5 International units per liter | Standard Deviation 7.76 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 28, n=42, 53 | 2.9 International units per liter | Standard Deviation 8.86 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 32, n=45, 51 | 3.1 International units per liter | Standard Deviation 14.13 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 36, n=44, 50 | 1.7 International units per liter | Standard Deviation 8.04 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 40, n=42, 51 | 5.7 International units per liter | Standard Deviation 24.61 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 44, n=47, 51 | 1.7 International units per liter | Standard Deviation 9.71 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 48, n=43, 50 | 1.7 International units per liter | Standard Deviation 7.09 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 4, n=99, 97 | 0.0 International units per liter | Standard Deviation 15.36 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 8, n=73, 98 | 3.3 International units per liter | Standard Deviation 25.01 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 12, n=99, 95 | -1.3 International units per liter | Standard Deviation 14.22 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 16, n=93, 96 | -2.1 International units per liter | Standard Deviation 12.73 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 20, n=93, 97 | -1.7 International units per liter | Standard Deviation 13.77 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 24, n=94, 95 | -0.4 International units per liter | Standard Deviation 14.88 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 28, n=89, 93 | -1.4 International units per liter | Standard Deviation 7.74 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 32, n=93, 95 | -2.1 International units per liter | Standard Deviation 13.06 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 36, n=94, 95 | -0.7 International units per liter | Standard Deviation 17.34 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 40, n=90, 95 | 1.0 International units per liter | Standard Deviation 20.11 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 44, n=91, 94 | 1.0 International units per liter | Standard Deviation 24.54 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 48, n=91, 95 | 0.4 International units per liter | Standard Deviation 16.57 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 4, n=151, 153 | -1.9 International units per liter | Standard Deviation 11.09 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 8, n=122, 152 | -1.3 International units per liter | Standard Deviation 18.14 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 12, n=146, 152 | 4.7 International units per liter | Standard Deviation 91.54 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 16, n=143, 149 | 0.3 International units per liter | Standard Deviation 21.8 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 20, n=138, 152 | -1.2 International units per liter | Standard Deviation 17.47 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 24, n=143, 150 | -0.1 International units per liter | Standard Deviation 31.53 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 28, n=136, 150 | -2.8 International units per liter | Standard Deviation 9.02 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 32, n=137, 148 | -2.0 International units per liter | Standard Deviation 18.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 36, n=135, 147 | -2.5 International units per liter | Standard Deviation 10.33 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 40, n=138, 147 | -2.7 International units per liter | Standard Deviation 11.14 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 44, n=137, 148 | -3.4 International units per liter | Standard Deviation 10.38 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 48, n=131, 147 | -2.9 International units per liter | Standard Deviation 10.87 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 4, n=51, 53 | 8.6 International units per liter | Standard Deviation 182.21 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 8, n=34, 53 | 67.9 International units per liter | Standard Deviation 176.14 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 12, n=50, 52 | 3.1 International units per liter | Standard Deviation 162.71 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 16, n=48, 53 | 19.4 International units per liter | Standard Deviation 253.86 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 20, n=46, 53 | 103.6 International units per liter | Standard Deviation 696.54 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 24, n=47, 53 | -3.0 International units per liter | Standard Deviation 181.03 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 28, n=42, 53 | 60.3 International units per liter | Standard Deviation 299.83 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 32, n=45, 51 | 157.1 International units per liter | Standard Deviation 988.65 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 36, n=44, 50 | -9.0 International units per liter | Standard Deviation 191.25 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 40, n=42, 51 | 193.7 International units per liter | Standard Deviation 1188.89 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 44, n=47, 51 | -6.3 International units per liter | Standard Deviation 185.69 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 48, n=43, 50 | -1.0 International units per liter | Standard Deviation 158.33 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 4, n=99, 97 | -32.7 International units per liter | Standard Deviation 717.86 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 8, n=73, 98 | 95.6 International units per liter | Standard Deviation 801.75 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 12, n=99, 95 | -16.1 International units per liter | Standard Deviation 852.44 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 16, n=93, 96 | -59.5 International units per liter | Standard Deviation 629.54 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 20, n=93, 97 | -55.7 International units per liter | Standard Deviation 623.92 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 24, n=94, 95 | -63.1 International units per liter | Standard Deviation 549.02 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK Week 28, n=89, 93 | -17.4 International units per liter | Standard Deviation 224.35 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 32, n=93, 95 | -82.8 International units per liter | Standard Deviation 587.51 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 36, n=94, 95 | -76.1 International units per liter | Standard Deviation 602.03 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 40, n=90, 95 | 40.3 International units per liter | Standard Deviation 864 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 44, n=91, 94 | 199.8 International units per liter | Standard Deviation 2043.35 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 48, n=91, 95 | 20.5 International units per liter | Standard Deviation 861.55 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 4, n=151, 153 | 18.2 International units per liter | Standard Deviation 502.12 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 8, n=122, 152 | 108.2 International units per liter | Standard Deviation 1339.52 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 12, n=146, 152 | 21.9 International units per liter | Standard Deviation 440.81 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 16, n=143, 149 | 139.9 International units per liter | Standard Deviation 1121.08 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 20, n=138, 152 | 65.5 International units per liter | Standard Deviation 656.11 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 24, n=143, 151 | 24.1 International units per liter | Standard Deviation 606.47 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 28, n=136, 150 | -10.9 International units per liter | Standard Deviation 169.29 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 32, n=137, 148 | 31.3 International units per liter | Standard Deviation 650.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 36, n=135, 147 | 19.0 International units per liter | Standard Deviation 440.56 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 44, n=137, 148 | -35.4 International units per liter | Standard Deviation 183.15 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 48, n=131, 147 | -15.1 International units per liter | Standard Deviation 212.52 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 44, n=137, 148 | -0.8 International units per liter | Standard Deviation 13.2 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 44, n=137, 148 | 0.1 International units per liter | Standard Deviation 11.2 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 8, n=73, 98 | 4.9 International units per liter | Standard Deviation 33.17 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 48, n=91, 95 | -1.2 International units per liter | Standard Deviation 10.26 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 40, n=90, 95 | -36.2 International units per liter | Standard Deviation 609.8 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 28, n=136, 150 | 53.2 International units per liter | Standard Deviation 462.07 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 48, n=131, 147 | 0.2 International units per liter | Standard Deviation 14.69 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 20, n=93, 97 | -58.1 International units per liter | Standard Deviation 622.84 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 4, n=51, 53 | 1.1 International units per liter | Standard Deviation 9.99 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 4, n=51, 53 | 2.3 International units per liter | Standard Deviation 16.78 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 8, n=34, 53 | 0.9 International units per liter | Standard Deviation 7.2 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 48, n=131, 147 | 0.5 International units per liter | Standard Deviation 10.6 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 12, n=50, 52 | 1.4 International units per liter | Standard Deviation 9.76 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 8, n=34, 53 | -0.1 International units per liter | Standard Deviation 4.6 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 16, n=48, 53 | 1.4 International units per liter | Standard Deviation 8.75 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 48, n=131, 147 | 27.3 International units per liter | Standard Deviation 272.59 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 20, n=46, 53 | 0.3 International units per liter | Standard Deviation 7.34 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 12, n=50, 52 | 1.7 International units per liter | Standard Deviation 7.21 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 24, n=47, 53 | 0.5 International units per liter | Standard Deviation 7.3 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 4, n=51, 53 | 133.5 International units per liter | Standard Deviation 907.82 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 28, n=42, 53 | 0.8 International units per liter | Standard Deviation 7.46 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 16, n=48, 53 | 1.8 International units per liter | Standard Deviation 10.69 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 32, n=45, 51 | 0.5 International units per liter | Standard Deviation 7.36 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 24, n=94, 95 | -40.7 International units per liter | Standard Deviation 588.24 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 36, n=44, 50 | 2.0 International units per liter | Standard Deviation 9.78 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 20, n=46, 53 | 0.5 International units per liter | Standard Deviation 4.29 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 40, n=42, 51 | 1.1 International units per liter | Standard Deviation 10.52 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 8, n=34, 53 | 23.5 International units per liter | Standard Deviation 174.4 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 44, n=47, 51 | 0.9 International units per liter | Standard Deviation 11.97 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 24, n=47, 53 | 1.6 International units per liter | Standard Deviation 9.93 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALT, Week 48, n=43, 50 | 0.5 International units per liter | Standard Deviation 8.04 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 12, n=146, 152 | 24.5 International units per liter | Standard Deviation 222.26 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 4, n=99, 97 | 0.7 International units per liter | Standard Deviation 7.2 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 28, n=42, 53 | 1.9 International units per liter | Standard Deviation 7.45 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 8, n=73, 98 | 5.4 International units per liter | Standard Deviation 50.2 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 12, n=99, 95 | 1.7 International units per liter | Standard Deviation 10.63 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 12, n=50, 52 | 57.9 International units per liter | Standard Deviation 406.52 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 16, n=93, 96 | -0.1 International units per liter | Standard Deviation 8.58 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 32, n=45, 51 | 0.6 International units per liter | Standard Deviation 4.93 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 20, n=93, 97 | -0.5 International units per liter | Standard Deviation 9.38 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK Week 28, n=89, 93 | -27.4 International units per liter | Standard Deviation 759.07 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 24, n=94, 95 | 0.1 International units per liter | Standard Deviation 9.95 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 36, n=44, 50 | 1.9 International units per liter | Standard Deviation 6.24 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 28, n=89, 93 | -0.4 International units per liter | Standard Deviation 12.31 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 16, n=48, 53 | 16.3 International units per liter | Standard Deviation 66.34 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 32, n=93, 95 | -0.3 International units per liter | Standard Deviation 7.79 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 40, n=42, 51 | 0.5 International units per liter | Standard Deviation 6.05 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 36, n=94, 95 | -0.4 International units per liter | Standard Deviation 8.79 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 32, n=137, 148 | 94.0 International units per liter | Standard Deviation 665.17 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 40, n=90, 95 | -0.6 International units per liter | Standard Deviation 9.62 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 44, n=47, 51 | 1.4 International units per liter | Standard Deviation 11.6 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 44, n=91, 94 | -0.4 International units per liter | Standard Deviation 7.91 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 20, n=46, 53 | 6.8 International units per liter | Standard Deviation 72.86 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALT, Week 48, n=91, 95 | -0.8 International units per liter | Standard Deviation 7.41 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, AST, Week 48, n=43, 50 | 2.1 International units per liter | Standard Deviation 8.74 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 4, n=151, 153 | -0.7 International units per liter | Standard Deviation 10.8 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 32, n=93, 95 | -42.1 International units per liter | Standard Deviation 637 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 8, n=122, 152 | -0.8 International units per liter | Standard Deviation 12.06 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 4, n=99, 97 | -0.1 International units per liter | Standard Deviation 6.29 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 12, n=146, 152 | -0.8 International units per liter | Standard Deviation 12.66 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 24, n=47, 53 | 18.2 International units per liter | Standard Deviation 86.69 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 16, n=143, 149 | -1.6 International units per liter | Standard Deviation 11.39 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 8, n=73, 98 | 1.2 International units per liter | Standard Deviation 21.48 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 20, n=138, 152 | -2.0 International units per liter | Standard Deviation 12.61 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 16, n=143, 149 | 7.0 International units per liter | Standard Deviation 189.21 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 24, n=143, 151 | -1.3 International units per liter | Standard Deviation 11.85 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 12, n=99, 95 | 0.8 International units per liter | Standard Deviation 7.35 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 28, n=136, 150 | -0.5 International units per liter | Standard Deviation 14.03 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 28, n=42, 53 | 13.5 International units per liter | Standard Deviation 93.14 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 32, n=137, 148 | -0.9 International units per liter | Standard Deviation 14.33 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 16, n=93, 96 | 0.1 International units per liter | Standard Deviation 10.96 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 36, n=135, 147 | -0.1 International units per liter | Standard Deviation 12.48 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 40, n=138, 147 | -0.4 International units per liter | Standard Deviation 13.47 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 36, n=94, 95 | -60.9 International units per liter | Standard Deviation 603.48 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 44, n=137, 148 | -0.4 International units per liter | Standard Deviation 14.67 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 20, n=93, 97 | -0.9 International units per liter | Standard Deviation 12.67 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALT, Week 48, n=131, 147 | -0.9 International units per liter | Standard Deviation 12.75 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 32, n=45, 51 | 1.5 International units per liter | Standard Deviation 64.94 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 4, n=51, 53 | -2.9 International units per liter | Standard Deviation 8.07 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 24, n=94, 95 | -0.2 International units per liter | Standard Deviation 10.4 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 8, n=34, 53 | 0.2 International units per liter | Standard Deviation 11.37 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 44, n=137, 148 | 14.9 International units per liter | Standard Deviation 173.39 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 12, n=50, 52 | 0.9 International units per liter | Standard Deviation 10.22 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 28, n=89, 93 | -0.9 International units per liter | Standard Deviation 13.48 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 16, n=48, 53 | 0.6 International units per liter | Standard Deviation 8.68 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 36, n=44, 50 | 22.3 International units per liter | Standard Deviation 62.09 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 20, n=46, 53 | 0.1 International units per liter | Standard Deviation 10.7 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 32, n=93, 95 | -0.8 International units per liter | Standard Deviation 10.01 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 24, n=47, 53 | -0.4 International units per liter | Standard Deviation 7.67 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 20, n=138, 152 | 1.6 International units per liter | Standard Deviation 114.05 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 28, n=42, 53 | 3.0 International units per liter | Standard Deviation 9.69 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 36, n=94, 95 | -1.1 International units per liter | Standard Deviation 11.7 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 32, n=45, 51 | -0.7 International units per liter | Standard Deviation 8.5 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 40, n=42, 51 | 0.3 International units per liter | Standard Deviation 48.24 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 36, n=44, 50 | 0.6 International units per liter | Standard Deviation 13.52 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 40, n=90, 95 | -0.4 International units per liter | Standard Deviation 13.96 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 40, n=42, 51 | -1.4 International units per liter | Standard Deviation 8.79 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 44, n=91, 94 | -60.2 International units per liter | Standard Deviation 576.84 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 44, n=47, 51 | -0.9 International units per liter | Standard Deviation 9.05 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 44, n=91, 94 | -0.7 International units per liter | Standard Deviation 10.69 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, ALP, Week 48, n=43, 50 | -0.2 International units per liter | Standard Deviation 9.08 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 44, n=47, 51 | 4.8 International units per liter | Standard Deviation 62.91 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 4, n=99, 97 | -0.9 International units per liter | Standard Deviation 7.92 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, AST, Week 48, n=91, 95 | 0.2 International units per liter | Standard Deviation 11.91 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 36, n=135, 147 | 10.3 International units per liter | Standard Deviation 135.08 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 12, n=99, 95 | 3.5 International units per liter | Standard Deviation 19.97 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 4, n=151, 153 | -0.5 International units per liter | Standard Deviation 8.73 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 16, n=93, 96 | -0.2 International units per liter | Standard Deviation 10.93 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | PI, CK, Week 48, n=43, 50 | 72.9 International units per liter | Standard Deviation 478.94 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 20, n=93, 97 | -0.4 International units per liter | Standard Deviation 7.93 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 8, n=122, 152 | -0.9 International units per liter | Standard Deviation 8.31 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 24, n=94, 95 | -0.6 International units per liter | Standard Deviation 8.25 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 48, n=91, 95 | -25.0 International units per liter | Standard Deviation 653.03 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 28, n=89, 93 | -0.8 International units per liter | Standard Deviation 8.8 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 12, n=146, 152 | 0.0 International units per liter | Standard Deviation 10.08 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 32, n=93, 95 | -2.0 International units per liter | Standard Deviation 8.23 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 4, n=99, 97 | -17.9 International units per liter | Standard Deviation 260.84 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 36, n=94, 95 | -2.2 International units per liter | Standard Deviation 9.41 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 16, n=143, 149 | -1.0 International units per liter | Standard Deviation 8.37 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 40, n=90, 95 | -1.9 International units per liter | Standard Deviation 9.33 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 24, n=143, 151 | 17.7 International units per liter | Standard Deviation 167.38 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, ALP, Week 44, n=91, 94 | -0.4 International units per liter | Standard Deviation 11.6 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 20, n=138, 152 | -0.7 International units per liter | Standard Deviation 9.09 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 8, n=73, 98 | -58.0 International units per liter | Standard Deviation 577.11 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 4, n=151, 153 | -2.7 International units per liter | Standard Deviation 9.6 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 24, n=143, 150 | -0.4 International units per liter | Standard Deviation 8.87 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 8, n=122, 152 | -1.0 International units per liter | Standard Deviation 10.77 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 4, n=151, 153 | 26.0 International units per liter | Standard Deviation 214.58 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 12, n=146, 152 | -0.7 International units per liter | Standard Deviation 11.04 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 28, n=136, 150 | 0.4 International units per liter | Standard Deviation 10.7 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 16, n=143, 149 | -1.0 International units per liter | Standard Deviation 10.54 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 12, n=99, 95 | -23.9 International units per liter | Standard Deviation 304.61 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 20, n=138, 152 | -1.8 International units per liter | Standard Deviation 13.77 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 32, n=137, 148 | 1.5 International units per liter | Standard Deviation 16.84 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 24, n=143, 151 | 0.4 International units per liter | Standard Deviation 12.75 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 40, n=138, 147 | 22.6 International units per liter | Standard Deviation 195.23 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 28, n=136, 150 | -1.0 International units per liter | Standard Deviation 13.18 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 36, n=135, 147 | 0.2 International units per liter | Standard Deviation 9 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 32, n=137, 148 | -1.8 International units per liter | Standard Deviation 13.63 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | INI, CK, Week 16, n=93, 96 | -1.9 International units per liter | Standard Deviation 686.38 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 36, n=135, 147 | -1.0 International units per liter | Standard Deviation 11.86 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, AST, Week 40, n=138, 147 | 0.1 International units per liter | Standard Deviation 9.4 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, ALP, Week 40, n=138, 147 | -0.4 International units per liter | Standard Deviation 13.19 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK | NNRTI, CK, Week 8, n=122, 152 | -3.6 International units per liter | Standard Deviation 108.28 |
Secondary
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Blood samples were collected for the analysis of clinical chemistry parameter: bilirubin, direct bilirubin and creatinine to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 44, n=91, 94 | 0.9 Micromoles per liter | Standard Deviation 4.34 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 12, n=99, 95 | 0.0 Micromoles per liter | Standard Deviation 1.14 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 36, n=44, 50 | -10.5 Micromoles per liter | Standard Deviation 21.75 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 16, n=93, 96 | 0.0 Micromoles per liter | Standard Deviation 1.14 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 48, n=91, 95 | 1.1 Micromoles per liter | Standard Deviation 3.72 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 20, n=93, 97 | -0.2 Micromoles per liter | Standard Deviation 0.96 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 8, n=34, 53 | -6.6 Micromoles per liter | Standard Deviation 13.76 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 24, n=94, 94 | -0.1 Micromoles per liter | Standard Deviation 1.07 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 4, n=151, 153 | 1.4 Micromoles per liter | Standard Deviation 3.87 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 28, n=89, 93 | -0.1 Micromoles per liter | Standard Deviation 0.97 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 40, n=42, 51 | -11.0 Micromoles per liter | Standard Deviation 22.2 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 32, n=93, 95 | -0.2 Micromoles per liter | Standard Deviation 1.24 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 8, n=122, 152 | 1.4 Micromoles per liter | Standard Deviation 3.84 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 36, n=94, 95 | -0.2 Micromoles per liter | Standard Deviation 1.33 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 12, n=99, 95 | -2.47 Micromoles per liter | Standard Deviation 10.973 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 12, n=146, 152 | 2.0 Micromoles per liter | Standard Deviation 4.69 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin. Week 44, n=91, 94 | 0.0 Micromoles per liter | Standard Deviation 1.14 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 12, n=50, 52 | -10.2 Micromoles per liter | Standard Deviation 20.18 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 48, n=91, 95 | 0.0 Micromoles per liter | Standard Deviation 1.01 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 16, n=143, 149 | 3.3 Micromoles per liter | Standard Deviation 14.12 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 4, n=151, 153 | 0.1 Micromoles per liter | Standard Deviation 1.14 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 48, n=43, 50 | -10.7 Micromoles per liter | Standard Deviation 21.77 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 8, n=122, 152 | 0.1 Micromoles per liter | Standard Deviation 1.24 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 20, n=138, 152 | 2.1 Micromoles per liter | Standard Deviation 4.9 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 12, n=146, 152 | 0.2 Micromoles per liter | Standard Deviation 1.38 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 40, n=138, 147 | 0.0 Micromoles per liter | Standard Deviation 1.55 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 16, n=143, 149 | 0.7 Micromoles per liter | Standard Deviation 6.82 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 32, n=45, 51 | 2.29 Micromoles per liter | Standard Deviation 10.124 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 24, n=143, 151 | 1.8 Micromoles per liter | Standard Deviation 3.91 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 20, n=138, 152 | 0.1 Micromoles per liter | Standard Deviation 1.32 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 4, n=99, 97 | 0.2 Micromoles per liter | Standard Deviation 3.92 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 24, n=143, 151 | 0.1 Micromoles per liter | Standard Deviation 1.34 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 28, n=136, 150 | 2.4 Micromoles per liter | Standard Deviation 4.11 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 28, n=136, 150 | 0.1 Micromoles per liter | Standard Deviation 1.29 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 16, n=48, 53 | -10.0 Micromoles per liter | Standard Deviation 20.13 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 32, n=137, 148 | 0.0 Micromoles per liter | Standard Deviation 1.31 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 32, n=137, 148 | 2.2 Micromoles per liter | Standard Deviation 4.76 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 36, n=135, 147 | 0.0 Micromoles per liter | Standard Deviation 1.47 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 8, n=73, 98 | 0.4 Micromoles per liter | Standard Deviation 3.96 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 36, n=135, 147 | 1.8 Micromoles per liter | Standard Deviation 4.14 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 44, n=137, 148 | 0.1 Micromoles per liter | Standard Deviation 1.28 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 16, n=93, 96 | -3.93 Micromoles per liter | Standard Deviation 9 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 48, n=131, 147 | 0.1 Micromoles per liter | Standard Deviation 1.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 40, n=138, 147 | 2.2 Micromoles per liter | Standard Deviation 4.43 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 4, n=51, 53 | 1.46 Micromoles per liter | Standard Deviation 7.726 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 12, n=99, 95 | 0.6 Micromoles per liter | Standard Deviation 4.41 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 8, n=34, 53 | 0.87 Micromoles per liter | Standard Deviation 7.777 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 44, n=137, 148 | 2.0 Micromoles per liter | Standard Deviation 4.15 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 12, n=50, 52 | -1.66 Micromoles per liter | Standard Deviation 8.971 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 20, n=46, 53 | -9.2 Micromoles per liter | Standard Deviation 20.21 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 16, n=48, 53 | -0.90 Micromoles per liter | Standard Deviation 8.658 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 48, n=131, 147 | 2.2 Micromoles per liter | Standard Deviation 4.59 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 20, n=46, 53 | 1.63 Micromoles per liter | Standard Deviation 8.709 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 16, n=93, 96 | 0.6 Micromoles per liter | Standard Deviation 4.3 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 24, n=47, 53 | 0.48 Micromoles per liter | Standard Deviation 7.143 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 4, n=51, 53 | -1.2 Micromoles per liter | Standard Deviation 2.34 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 28, n=42, 53 | 3.06 Micromoles per liter | Standard Deviation 9.741 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 44, n=137, 148 | 3.24 Micromoles per liter | Standard Deviation 8.892 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 36, n=44, 50 | 2.20 Micromoles per liter | Standard Deviation 7.347 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 8, n=34, 53 | -0.9 Micromoles per liter | Standard Deviation 2.16 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 40, n=42, 51 | 1.10 Micromoles per liter | Standard Deviation 9.155 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 20, n=93, 97 | 0.9 Micromoles per liter | Standard Deviation 4.08 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 44, n=47, 51 | 3.01 Micromoles per liter | Standard Deviation 8.981 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 12, n=50, 52 | -1.6 Micromoles per liter | Standard Deviation 2.16 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 48, n=43, 50 | 4.41 Micromoles per liter | Standard Deviation 10.009 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 24, n=47, 53 | -9.6 Micromoles per liter | Standard Deviation 20.64 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 4, n=99, 95 | -1.61 Micromoles per liter | Standard Deviation 8.848 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, direct bilirubin, Week 16, n=48, 53 | -1.7 Micromoles per liter | Standard Deviation 2.12 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 8, n=73, 98 | -3.93 Micromoles per liter | Standard Deviation 10.03 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 24, n=94, 94 | 0.2 Micromoles per liter | Standard Deviation 3.72 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 20, n=93, 97 | -3.73 Micromoles per liter | Standard Deviation 9.101 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 20, n=46, 53 | -1.5 Micromoles per liter | Standard Deviation 2.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 24, n=94, 94 | -4.25 Micromoles per liter | Standard Deviation 8.281 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 4, n=99, 97 | 0.0 Micromoles per liter | Standard Deviation 1.11 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 28, n=89, 93 | -3.54 Micromoles per liter | Standard Deviation 10.713 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 24, n=47, 53 | -1.4 Micromoles per liter | Standard Deviation 2.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 32, n=93, 95 | -3.48 Micromoles per liter | Standard Deviation 10.591 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 28, n=89, 93 | 1.1 Micromoles per liter | Standard Deviation 3.58 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 36, n=94, 95 | -4.31 Micromoles per liter | Standard Deviation 10.36 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 28, n=42, 53 | -1.6 Micromoles per liter | Standard Deviation 2.43 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 40, n=90, 95 | -3.08 Micromoles per liter | Standard Deviation 9.913 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 28, n=42, 53 | -10.0 Micromoles per liter | Standard Deviation 22.42 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 44, n=91, 94 | -3.33 Micromoles per liter | Standard Deviation 9.165 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 32, n=45, 51 | -1.4 Micromoles per liter | Standard Deviation 2.48 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 48, n=91, 95 | -2.99 Micromoles per liter | Standard Deviation 9.442 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 32, n=93, 95 | 0.7 Micromoles per liter | Standard Deviation 4.67 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 4, n=151, 153 | 2.86 Micromoles per liter | Standard Deviation 7.456 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 36, n=44, 50 | -1.8 Micromoles per liter | Standard Deviation 2.29 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 8, n=122, 152 | 0.86 Micromoles per liter | Standard Deviation 8.263 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 4, n=51, 53 | -9.0 Micromoles per liter | Standard Deviation 20.62 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 12, n=146, 152 | 1.47 Micromoles per liter | Standard Deviation 7.928 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 40, n=42, 51 | -1.8 Micromoles per liter | Standard Deviation 2.29 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 16, n=143, 149 | 1.67 Micromoles per liter | Standard Deviation 8.934 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 36, n=94, 95 | 0.5 Micromoles per liter | Standard Deviation 4.07 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 20, n=138, 152 | 3.04 Micromoles per liter | Standard Deviation 8.836 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 44, n=47, 51 | -1.5 Micromoles per liter | Standard Deviation 2.22 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 24, n=143, 151 | 4.42 Micromoles per liter | Standard Deviation 14.819 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 32, n=45, 51 | -8.9 Micromoles per liter | Standard Deviation 21.34 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 28, n=136, 150 | 3.61 Micromoles per liter | Standard Deviation 10.627 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 48, n=43, 50 | -1.5 Micromoles per liter | Standard Deviation 2.35 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 32, n=137, 148 | 2.26 Micromoles per liter | Standard Deviation 9.033 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 40, n=90, 95 | 0.6 Micromoles per liter | Standard Deviation 4.28 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 36, n=135, 147 | 2.98 Micromoles per liter | Standard Deviation 10.596 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 40, n=90, 95 | -0.1 Micromoles per liter | Standard Deviation 1.1 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 40, n=138, 147 | 3.39 Micromoles per liter | Standard Deviation 9.496 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 8, n=73, 98 | 0.0 Micromoles per liter | Standard Deviation 1.13 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 48, n=131, 147 | 3.84 Micromoles per liter | Standard Deviation 11.86 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 44, n=47, 51 | -9.6 Micromoles per liter | Standard Deviation 20.32 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 48, n=131, 147 | 0.69 Micromoles per liter | Standard Deviation 7.241 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 28, n=42, 53 | 3.05 Micromoles per liter | Standard Deviation 6.908 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 8, n=73, 98 | 1.56 Micromoles per liter | Standard Deviation 9.444 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 12, n=99, 95 | 3.03 Micromoles per liter | Standard Deviation 10.203 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 44, n=137, 148 | 1.21 Micromoles per liter | Standard Deviation 6.686 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 4, n=51, 53 | 0.3 Micromoles per liter | Standard Deviation 6.95 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 8, n=34, 53 | 0.1 Micromoles per liter | Standard Deviation 5.76 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 12, n=50, 52 | 1.7 Micromoles per liter | Standard Deviation 7.11 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 16, n=48, 53 | 0.6 Micromoles per liter | Standard Deviation 6.42 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 20, n=46, 53 | 1.5 Micromoles per liter | Standard Deviation 12.45 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 24, n=47, 53 | 2.7 Micromoles per liter | Standard Deviation 11.87 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 28, n=42, 53 | 0.9 Micromoles per liter | Standard Deviation 7.7 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 32, n=45, 51 | 2.7 Micromoles per liter | Standard Deviation 8.64 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 36, n=44, 50 | 2.6 Micromoles per liter | Standard Deviation 7.35 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 40, n=42, 51 | 3.5 Micromoles per liter | Standard Deviation 12.74 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 44, n=47, 51 | 3.7 Micromoles per liter | Standard Deviation 9.1 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Bilirubin, Week 48, n=43, 50 | 2.3 Micromoles per liter | Standard Deviation 5.23 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 4, n=99, 97 | -0.7 Micromoles per liter | Standard Deviation 3.93 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 8, n=73, 98 | 0.9 Micromoles per liter | Standard Deviation 12.43 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 12, n=99, 95 | -0.5 Micromoles per liter | Standard Deviation 4.69 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 16, n=93, 96 | -0.2 Micromoles per liter | Standard Deviation 4.35 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 20, n=93, 97 | -0.5 Micromoles per liter | Standard Deviation 4.32 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 24, n=94, 94 | -0.5 Micromoles per liter | Standard Deviation 3.88 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 28, n=89, 93 | -0.4 Micromoles per liter | Standard Deviation 4.85 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 32, n=93, 95 | -1.1 Micromoles per liter | Standard Deviation 4.54 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 36, n=94, 95 | -0.6 Micromoles per liter | Standard Deviation 4.62 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 40, n=90, 95 | -1.0 Micromoles per liter | Standard Deviation 4.26 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 44, n=91, 94 | -0.7 Micromoles per liter | Standard Deviation 4.72 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Bilirubin, Week 48, n=91, 95 | -0.9 Micromoles per liter | Standard Deviation 3.96 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 4, n=151, 153 | -0.4 Micromoles per liter | Standard Deviation 2.85 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 8, n=122, 152 | -0.4 Micromoles per liter | Standard Deviation 2.43 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 12, n=146, 152 | -0.2 Micromoles per liter | Standard Deviation 3.01 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 16, n=143, 149 | -0.5 Micromoles per liter | Standard Deviation 2.66 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 20, n=138, 152 | -0.1 Micromoles per liter | Standard Deviation 2.81 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 24, n=143, 151 | -0.3 Micromoles per liter | Standard Deviation 2.84 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 28, n=136, 150 | -0.4 Micromoles per liter | Standard Deviation 3.04 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 32, n=137, 148 | -0.3 Micromoles per liter | Standard Deviation 2.57 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 36, n=135, 147 | -0.2 Micromoles per liter | Standard Deviation 2.61 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 40, n=138, 147 | -0.2 Micromoles per liter | Standard Deviation 2.61 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 44, n=137, 148 | -0.1 Micromoles per liter | Standard Deviation 2.72 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Bilirubin, Week 48, n=131, 147 | 0.1 Micromoles per liter | Standard Deviation 2.98 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 4, n=51, 53 | 0.3 Micromoles per liter | Standard Deviation 1.4 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 8, n=34, 53 | -0.1 Micromoles per liter | Standard Deviation 1.44 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 12, n=50, 52 | 0.3 Micromoles per liter | Standard Deviation 1.39 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, direct bilirubin, Week 16, n=48, 53 | 0.0 Micromoles per liter | Standard Deviation 1.3 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 20, n=46, 53 | 0.0 Micromoles per liter | Standard Deviation 1.86 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 24, n=47, 53 | 0.2 Micromoles per liter | Standard Deviation 1.72 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 28, n=42, 53 | -0.3 Micromoles per liter | Standard Deviation 1.52 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 32, n=45, 51 | 0.2 Micromoles per liter | Standard Deviation 1.74 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 36, n=44, 50 | 0.2 Micromoles per liter | Standard Deviation 1.49 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 40, n=42, 51 | 0.2 Micromoles per liter | Standard Deviation 1.43 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 44, n=47, 51 | 0.3 Micromoles per liter | Standard Deviation 1.52 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Direct bilirubin, Week 48, n=43, 50 | 0.2 Micromoles per liter | Standard Deviation 1.36 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 4, n=99, 97 | 0.0 Micromoles per liter | Standard Deviation 1.19 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 8, n=73, 98 | 0.7 Micromoles per liter | Standard Deviation 6.76 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 12, n=99, 95 | 0.0 Micromoles per liter | Standard Deviation 1.29 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 16, n=93, 96 | -0.3 Micromoles per liter | Standard Deviation 1.06 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 20, n=93, 97 | -0.2 Micromoles per liter | Standard Deviation 1.23 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 24, n=94, 94 | -0.3 Micromoles per liter | Standard Deviation 1.16 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 28, n=89, 93 | -0.2 Micromoles per liter | Standard Deviation 1.3 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 32, n=93, 95 | -0.4 Micromoles per liter | Standard Deviation 1.15 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 36, n=94, 95 | -0.3 Micromoles per liter | Standard Deviation 1.18 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 40, n=90, 95 | -0.4 Micromoles per liter | Standard Deviation 1.24 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin. Week 44, n=91, 94 | -0.3 Micromoles per liter | Standard Deviation 1.11 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Direct bilirubin, Week 48, n=91, 95 | -0.1 Micromoles per liter | Standard Deviation 1.28 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 4, n=151, 153 | 0.1 Micromoles per liter | Standard Deviation 1.12 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 8, n=122, 152 | 0.0 Micromoles per liter | Standard Deviation 1.03 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 12, n=146, 152 | 0.0 Micromoles per liter | Standard Deviation 1.08 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 16, n=143, 149 | -0.1 Micromoles per liter | Standard Deviation 1.09 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 20, n=138, 152 | -0.2 Micromoles per liter | Standard Deviation 1.08 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 24, n=143, 151 | -0.1 Micromoles per liter | Standard Deviation 1.06 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 28, n=136, 150 | -0.2 Micromoles per liter | Standard Deviation 1.19 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 32, n=137, 148 | -0.2 Micromoles per liter | Standard Deviation 1.06 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 36, n=135, 147 | -0.2 Micromoles per liter | Standard Deviation 1.09 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 40, n=138, 147 | -0.2 Micromoles per liter | Standard Deviation 1.01 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 44, n=137, 148 | -0.1 Micromoles per liter | Standard Deviation 1.08 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Direct bilirubin, Week 48, n=131, 147 | 0.0 Micromoles per liter | Standard Deviation 1.16 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 4, n=51, 53 | 2.16 Micromoles per liter | Standard Deviation 6.737 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 8, n=34, 53 | 1.17 Micromoles per liter | Standard Deviation 5.605 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 12, n=50, 52 | 3.01 Micromoles per liter | Standard Deviation 5.406 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 16, n=48, 53 | 2.88 Micromoles per liter | Standard Deviation 5.918 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 20, n=46, 53 | 5.00 Micromoles per liter | Standard Deviation 9.336 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 24, n=47, 53 | 2.47 Micromoles per liter | Standard Deviation 6.821 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 32, n=45, 51 | 3.79 Micromoles per liter | Standard Deviation 6.54 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 36, n=44, 50 | 2.36 Micromoles per liter | Standard Deviation 6.291 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 40, n=42, 51 | 3.46 Micromoles per liter | Standard Deviation 6.166 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 44, n=47, 51 | 2.73 Micromoles per liter | Standard Deviation 6.169 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | PI, Creatinine, Week 48, n=43, 50 | 1.86 Micromoles per liter | Standard Deviation 5.575 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 4, n=99, 95 | 1.64 Micromoles per liter | Standard Deviation 10.592 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 16, n=93, 96 | 0.36 Micromoles per liter | Standard Deviation 8.651 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 20, n=93, 97 | 0.86 Micromoles per liter | Standard Deviation 9.608 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 24, n=94, 94 | 0.87 Micromoles per liter | Standard Deviation 10.493 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 28, n=89, 93 | 0.92 Micromoles per liter | Standard Deviation 10.086 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 32, n=93, 95 | 0.86 Micromoles per liter | Standard Deviation 9.754 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 36, n=94, 95 | 1.34 Micromoles per liter | Standard Deviation 9.369 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 40, n=90, 95 | 1.66 Micromoles per liter | Standard Deviation 10.272 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 44, n=91, 94 | 0.98 Micromoles per liter | Standard Deviation 10.443 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | INI, Creatinine, Week 48, n=91, 95 | 0.47 Micromoles per liter | Standard Deviation 9.602 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 4, n=151, 153 | 1.77 Micromoles per liter | Standard Deviation 6.484 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 8, n=122, 152 | 1.05 Micromoles per liter | Standard Deviation 6.79 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 12, n=146, 152 | 0.44 Micromoles per liter | Standard Deviation 6.096 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 16, n=143, 149 | 1.98 Micromoles per liter | Standard Deviation 8.475 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 20, n=138, 152 | 1.27 Micromoles per liter | Standard Deviation 7.023 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 24, n=143, 151 | 1.28 Micromoles per liter | Standard Deviation 6.553 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 28, n=136, 150 | 1.50 Micromoles per liter | Standard Deviation 7.483 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 32, n=137, 148 | 2.01 Micromoles per liter | Standard Deviation 7.811 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 36, n=135, 147 | 1.54 Micromoles per liter | Standard Deviation 7.354 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine | NNRTI, Creatinine, Week 40, n=138, 147 | 0.99 Micromoles per liter | Standard Deviation 7.471 |
Secondary
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance
Blood samples were collected for the analysis of clinical chemistry parameter: creatinine clearance to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 24, n=47, 53 | -1.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 44, n=91, 94 | 2.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.88 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 8, n=121, 152 | -1.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.35 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 20, n=138, 152 | -3.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.64 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 32, n=137, 148 | -3.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.42 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 36, n=135, 147 | -3.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.97 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 48, n=131, 147 | -5.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 11.72 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 32, n=45, 51 | -3.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 12.3 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 44, n=47, 51 | -4.5 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.63 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 40, n=137, 147 | -4.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.97 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 44, n=136, 148 | -4.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.75 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 20, n=93, 97 | 3.5 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.77 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 24, n=94, 94 | 3.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.26 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 28, n=89, 93 | 3.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 11.02 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 32, n=92, 95 | 3.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.4 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 36, n=94, 95 | 3.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 11.19 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 40, n=89, 95 | 2.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.45 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 48, n=90, 94 | 3.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.74 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 4, n=151, 153 | -3.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.06 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 12, n=146, 152 | -1.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.9 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 16, n=143, 148 | -1.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 24, n=142, 151 | -4.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.67 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 28, n=136, 150 | -4.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.68 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 4, n=51, 53 | -2.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.77 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 8, n=34, 53 | -1.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.19 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 12, n=50, 52 | 2.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 11.04 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 16, n=48, 53 | 0.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 11.02 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 20, n=46, 53 | -2.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.8 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 28, n=42, 53 | -4.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 11.82 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 36, n=44, 50 | -3.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.68 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 40, n=42, 51 | -2.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.71 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 48, n=43, 50 | -5.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 12.22 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 4, n=99, 95 | 1.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.51 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 8, n=72, 98 | 3.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.84 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 12, n=99, 93 | 2.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 11.32 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 16, n=93, 96 | 3.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.71 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 16, n=93, 96 | -0.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.59 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 28, n=42, 53 | -4.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.46 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 48, n=90, 94 | -1.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.73 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 16, n=143, 148 | -2.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.06 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 12, n=146, 152 | -0.5 Milliliters per minute per 1.73meter^2 | Standard Deviation 7.03 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 20, n=138, 152 | -1.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 7.41 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 28, n=136, 150 | -2.4 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.67 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 32, n=45, 51 | -5.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 7.56 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 32, n=137, 148 | -2.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.8 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 24, n=142, 151 | -2.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 7.67 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 36, n=135, 147 | -2.5 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.16 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 44, n=136, 148 | -2.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 7.45 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 4, n=99, 95 | -2.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 11.28 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 48, n=131, 147 | -1.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.25 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 12, n=99, 93 | -3.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.6 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 36, n=44, 50 | -3.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.08 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 4, n=51, 53 | -2.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.02 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 40, n=42, 51 | -4.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 7.25 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 40, n=137, 147 | -2.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.9 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 8, n=34, 53 | -1.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 6.58 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 44, n=47, 51 | -4.2 Milliliters per minute per 1.73meter^2 | Standard Deviation 7.58 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 20, n=93, 97 | -1.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.58 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 12, n=50, 52 | -3.7 Milliliters per minute per 1.73meter^2 | Standard Deviation 6.99 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 8, n=72, 98 | -1.9 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.28 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 28, n=89, 93 | -1.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.55 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 16, n=48, 53 | -3.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 7.63 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 32, n=92, 95 | -2.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.69 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 48, n=43, 50 | -3.1 Milliliters per minute per 1.73meter^2 | Standard Deviation 6.54 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 36, n=94, 95 | -2.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.3 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 20, n=46, 53 | -5.0 Milliliters per minute per 1.73meter^2 | Standard Deviation 9.26 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 40, n=89, 95 | -2.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.14 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 44, n=91, 94 | -1.6 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.9 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | INI, Week 24, n=94, 94 | -1.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 10.38 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | PI, Week 24, n=47, 53 | -3.8 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.51 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 4, n=151, 153 | -2.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 8.1 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance | NNRTI, Week 8, n=121, 152 | -1.3 Milliliters per minute per 1.73meter^2 | Standard Deviation 7.72 |
Secondary
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase
Blood samples were collected for the analysis of clinical chemistry parameter: lipase to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 36, n=135, 147 | 6.9 Units per liter | Standard Deviation 68.07 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 48, n=43, 50 | -1.5 Units per liter | Standard Deviation 19.38 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 36, n=94, 95 | 5.2 Units per liter | Standard Deviation 21.04 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 4, n=99, 97 | 8.1 Units per liter | Standard Deviation 34.32 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 8, n=72, 98 | 0.7 Units per liter | Standard Deviation 9.79 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 4, n=51, 53 | -2.2 Units per liter | Standard Deviation 16.83 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 12, n=99, 93 | 4.3 Units per liter | Standard Deviation 17.7 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 40, n=89, 95 | 3.5 Units per liter | Standard Deviation 11.71 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 16, n=93, 97 | 4.4 Units per liter | Standard Deviation 22.42 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 8, n=34, 53 | -2.6 Units per liter | Standard Deviation 6.71 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 20, n=94, 97 | 2.5 Units per liter | Standard Deviation 17.23 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 40, n=42, 51 | 2.2 Units per liter | Standard Deviation 26.77 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 12, n=146, 152 | 3.0 Units per liter | Standard Deviation 30.94 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 32, n=92, 95 | 3.2 Units per liter | Standard Deviation 18.68 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 16, n=47, 53 | -0.5 Units per liter | Standard Deviation 18.71 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 44, n=91, 94 | 4.3 Units per liter | Standard Deviation 21.59 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 20, n=46, 53 | -2.5 Units per liter | Standard Deviation 17.9 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 48, n=90, 94 | 5.0 Units per liter | Standard Deviation 24.95 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 24, n=94, 95 | 2.2 Units per liter | Standard Deviation 15.17 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 4, n=151, 153 | 5.7 Units per liter | Standard Deviation 50.44 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 24, n=47, 53 | -2.0 Units per liter | Standard Deviation 16.61 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 8, n=121, 152 | 2.6 Units per liter | Standard Deviation 25.04 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 16, n=145, 149 | 2.5 Units per liter | Standard Deviation 27.82 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 20, n=138, 152 | 0.9 Units per liter | Standard Deviation 13.53 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 32, n=45, 51 | -2.2 Units per liter | Standard Deviation 19.27 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 24, n=142, 151 | 3.4 Units per liter | Standard Deviation 24.81 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 36, n=44, 50 | -0.8 Units per liter | Standard Deviation 17.96 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 28, n=136, 150 | 0.8 Units per liter | Standard Deviation 24.38 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 32, n=137, 148 | 9.1 Units per liter | Standard Deviation 78.96 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 28, n=89, 94 | 5.6 Units per liter | Standard Deviation 28.06 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 40, n=138, 147 | 7.1 Units per liter | Standard Deviation 43.53 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 28, n=42, 53 | -0.7 Units per liter | Standard Deviation 18.6 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 44, n=136, 148 | 1.6 Units per liter | Standard Deviation 24.46 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 44, n=47, 51 | -1.2 Units per liter | Standard Deviation 18.28 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 48, n=131, 146 | 3.1 Units per liter | Standard Deviation 32.54 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 12, n=49, 52 | -1.4 Units per liter | Standard Deviation 17.24 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 48, n=131, 146 | 0.9 Units per liter | Standard Deviation 16.6 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 16, n=47, 53 | 1.4 Units per liter | Standard Deviation 17.4 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 24, n=47, 53 | -2.7 Units per liter | Standard Deviation 16.3 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 32, n=45, 51 | 2.5 Units per liter | Standard Deviation 18.35 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 4, n=99, 97 | 3.8 Units per liter | Standard Deviation 30.44 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 20, n=94, 97 | 0.9 Units per liter | Standard Deviation 17.07 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 32, n=92, 95 | 5.4 Units per liter | Standard Deviation 22.79 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 40, n=89, 95 | 1.7 Units per liter | Standard Deviation 16.6 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 12, n=146, 152 | -1.9 Units per liter | Standard Deviation 17.59 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 16, n=145, 149 | 6.1 Units per liter | Standard Deviation 40.62 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 28, n=136, 150 | 1.2 Units per liter | Standard Deviation 15.79 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 36, n=135, 147 | 1.7 Units per liter | Standard Deviation 19.14 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 4, n=51, 53 | 1.2 Units per liter | Standard Deviation 19.34 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 8, n=34, 53 | 2.5 Units per liter | Standard Deviation 25.36 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 12, n=49, 52 | -2.2 Units per liter | Standard Deviation 15.95 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 20, n=46, 53 | -0.6 Units per liter | Standard Deviation 17.49 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 28, n=42, 53 | 0.2 Units per liter | Standard Deviation 16.18 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 36, n=44, 50 | -1.2 Units per liter | Standard Deviation 18.18 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 40, n=42, 51 | -1.8 Units per liter | Standard Deviation 19.4 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 44, n=47, 51 | 1.4 Units per liter | Standard Deviation 17.94 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | PI, Week 48, n=43, 50 | -1.3 Units per liter | Standard Deviation 15.73 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 8, n=72, 98 | -0.5 Units per liter | Standard Deviation 14.46 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 12, n=99, 93 | 1.8 Units per liter | Standard Deviation 21.29 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 16, n=93, 97 | 0.6 Units per liter | Standard Deviation 16.13 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 24, n=94, 95 | 2.2 Units per liter | Standard Deviation 18.91 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 28, n=89, 94 | 5.1 Units per liter | Standard Deviation 24.2 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 36, n=94, 95 | 0.1 Units per liter | Standard Deviation 13.82 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 44, n=91, 94 | 4.8 Units per liter | Standard Deviation 23.54 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | INI, Week 48, n=90, 94 | 3.9 Units per liter | Standard Deviation 23.48 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 4, n=151, 153 | 0.1 Units per liter | Standard Deviation 20.35 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 8, n=121, 152 | 1.5 Units per liter | Standard Deviation 16.94 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 20, n=138, 152 | 1.3 Units per liter | Standard Deviation 37.14 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 24, n=142, 151 | 5.4 Units per liter | Standard Deviation 28.22 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 32, n=137, 148 | 1.9 Units per liter | Standard Deviation 21.3 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 40, n=138, 147 | 0.5 Units per liter | Standard Deviation 17.62 |
| Current ART | Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase | NNRTI, Week 44, n=136, 148 | 1.1 Units per liter | Standard Deviation 20.52 |
Secondary
Change From Baseline Values for Fasting Lipid Panel Over Time Including Week 48
Blood samples were collected for the analysis of fasting lipid parameters- total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Week 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Over Time Including Week 48 | Total cholesterol, Week 48, n=231, 242 | 0.08 Millimoles per liter | Standard Deviation 0.688 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Over Time Including Week 48 | HDL cholesterol, Week 48, n=231, 242 | 0.040 Millimoles per liter | Standard Deviation 0.2702 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Over Time Including Week 48 | LDL cholesterol, Week 48, n=224, 238 | 0.098 Millimoles per liter | Standard Deviation 0.6105 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Over Time Including Week 48 | Triglycerides, Week 48, n=231, 242 | -0.159 Millimoles per liter | Standard Deviation 0.867 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Over Time Including Week 48 | Triglycerides, Week 48, n=231, 242 | -0.033 Millimoles per liter | Standard Deviation 0.7844 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Over Time Including Week 48 | Total cholesterol, Week 48, n=231, 242 | -0.04 Millimoles per liter | Standard Deviation 0.665 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Over Time Including Week 48 | LDL cholesterol, Week 48, n=224, 238 | -0.017 Millimoles per liter | Standard Deviation 0.5314 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Over Time Including Week 48 | HDL cholesterol, Week 48, n=231, 242 | 0.002 Millimoles per liter | Standard Deviation 0.2682 |
Secondary
Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48
Blood samples were collected for the analysis of fasting lipid panel: triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Week 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, LDL cholesterol, Week 48, n=116, 119 | 0.078 Millimoles per liter | Standard Deviation 0.6885 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Cholesterol, Week 48, n=40, 45 | -0.06 Millimoles per liter | Standard Deviation 0.629 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, LDL cholesterol, Week 48, n=37, 43 | 0.075 Millimoles per liter | Standard Deviation 0.5774 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Triglycerides, Week 48, n=72, 77 | -0.078 Millimoles per liter | Standard Deviation 0.4964 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Triglycerides, Week 48, n=119, 120 | -0.015 Millimoles per liter | Standard Deviation 0.6121 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Cholesterol, Week 48, n=72, 77 | 0.18 Millimoles per liter | Standard Deviation 0.614 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Cholesterol, Week 48, n=119, 120 | 0.06 Millimoles per liter | Standard Deviation 0.743 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, HDL cholesterol, Week 48, n=40, 45 | 0.130 Millimoles per liter | Standard Deviation 0.2272 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, HDL cholesterol, Week 48, n=72, 77 | 0.074 Millimoles per liter | Standard Deviation 0.2339 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, HDL cholesterol, Week 48, n=119, 120 | -0.011 Millimoles per liter | Standard Deviation 0.2936 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, LDL cholesterol, Week 48, n=71, 76 | 0.144 Millimoles per liter | Standard Deviation 0.484 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Triglycerides, Week 48, n=40, 45 | -0.733 Millimoles per liter | Standard Deviation 1.5612 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, LDL cholesterol, Week 48, n=71, 76 | -0.015 Millimoles per liter | Standard Deviation 0.5333 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Triglycerides, Week 48, n=119, 120 | -0.014 Millimoles per liter | Standard Deviation 0.6761 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, Cholesterol, Week 48, n=119, 120 | -0.02 Millimoles per liter | Standard Deviation 0.626 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Cholesterol, Week 48, n=40, 45 | 0.06 Millimoles per liter | Standard Deviation 0.744 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, HDL cholesterol, Week 48, n=119, 120 | 0.028 Millimoles per liter | Standard Deviation 0.2577 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | NNRTI, LDL cholesterol, Week 48, n=116, 119 | -0.040 Millimoles per liter | Standard Deviation 0.5246 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, Triglycerides, Week 48, n=40, 45 | 0.060 Millimoles per liter | Standard Deviation 0.996 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, HDL cholesterol, Week 48, n=40, 45 | 0.001 Millimoles per liter | Standard Deviation 0.3429 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Triglycerides, Week 48, n=72, 77 | -0.117 Millimoles per liter | Standard Deviation 0.8052 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | PI, LDL cholesterol, Week 48, n=37, 43 | 0.043 Millimoles per liter | Standard Deviation 0.5545 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, HDL cholesterol, Week 48, n=72, 77 | -0.038 Millimoles per liter | Standard Deviation 0.2308 |
| Current ART | Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48 | INI, Cholesterol, Week 48, n=72, 77 | -0.12 Millimoles per liter | Standard Deviation 0.674 |
Secondary
Change From Baseline Values for Plasma HIV-1 RNA
Plasma for quantitative HIV-1 RNA were collected at indicated time points. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as: HIV-1 RNA(log 10) at Week 48 - HIV-1 RNA(log 10) at Baseline.
Time frame: Baseline and Week 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values for Plasma HIV-1 RNA | -0.013 log10 copies/mL | Standard Deviation 0.194 |
| Current ART | Change From Baseline Values for Plasma HIV-1 RNA | 0.012 log10 copies/mL | Standard Deviation 0.1201 |
Secondary
Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio.Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48 | Urine albumin/creatinine ratio, Week 4,n=210, 221 | 0.32 Grams per mole | Standard Deviation 3.948 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48 | Urine albumin/creatinine ratio, Week 24,n=198, 208 | -0.08 Grams per mole | Standard Deviation 3.36 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48 | Urine albumin/creatinine ratio, Week 48,n=191, 197 | 0.15 Grams per mole | Standard Deviation 6.049 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48 | Urine protein/creatinine, Week 4, n=234, 236 | -0.66 Grams per mole | Standard Deviation 11.803 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48 | Urine protein/creatinine, Week 24, n=208, 232 | -2.49 Grams per mole | Standard Deviation 8.028 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48 | Urine protein/creatinine, Week 48, n=206, 225 | -1.72 Grams per mole | Standard Deviation 9.551 |
| Current ART | Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48 | Urine protein/creatinine, Week 24, n=208, 232 | 1.67 Grams per mole | Standard Deviation 20.505 |
| Current ART | Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48 | Urine albumin/creatinine ratio, Week 4,n=210, 221 | 0.06 Grams per mole | Standard Deviation 6.383 |
| Current ART | Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48 | Urine protein/creatinine, Week 4, n=234, 236 | 1.85 Grams per mole | Standard Deviation 31.997 |
| Current ART | Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48 | Urine albumin/creatinine ratio, Week 24,n=198, 208 | -0.11 Grams per mole | Standard Deviation 8.552 |
| Current ART | Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48 | Urine protein/creatinine, Week 48, n=206, 225 | 6.70 Grams per mole | Standard Deviation 112.353 |
| Current ART | Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48 | Urine albumin/creatinine ratio, Week 48,n=191, 197 | -0.14 Grams per mole | Standard Deviation 5.286 |
Secondary
Change From Baseline Values in Urine Creatinine Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine creatinine. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Creatinine Over Time Including Week 48 | Week 4, n=304, 302 | -543.9 Micromoles per liter | Standard Deviation 8693.94 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Creatinine Over Time Including Week 48 | Week 24, n=282, 297 | -341.8 Micromoles per liter | Standard Deviation 9286.26 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Creatinine Over Time Including Week 48 | Week 48, n=282, 291 | -342.9 Micromoles per liter | Standard Deviation 8965.01 |
| Current ART | Change From Baseline Values in Urine Creatinine Over Time Including Week 48 | Week 4, n=304, 302 | -305.5 Micromoles per liter | Standard Deviation 8787.62 |
| Current ART | Change From Baseline Values in Urine Creatinine Over Time Including Week 48 | Week 24, n=282, 297 | -270.4 Micromoles per liter | Standard Deviation 8437.76 |
| Current ART | Change From Baseline Values in Urine Creatinine Over Time Including Week 48 | Week 48, n=282, 291 | -521.6 Micromoles per liter | Standard Deviation 7873.28 |
Secondary
Change From Baseline Values in Urine Phosphate Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine phosphate. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Phosphate Over Time Including Week 48 | Week 4, n=302, 300 | -0.460 Millimoles per liter | Standard Deviation 15.2707 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Phosphate Over Time Including Week 48 | Week 24, n=281, 294 | 0.286 Millimoles per liter | Standard Deviation 16.1887 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Phosphate Over Time Including Week 48 | Week 48, n=280, 291 | -0.369 Millimoles per liter | Standard Deviation 14.2441 |
| Current ART | Change From Baseline Values in Urine Phosphate Over Time Including Week 48 | Week 4, n=302, 300 | 1.483 Millimoles per liter | Standard Deviation 15.0378 |
| Current ART | Change From Baseline Values in Urine Phosphate Over Time Including Week 48 | Week 24, n=281, 294 | 0.640 Millimoles per liter | Standard Deviation 14.4201 |
| Current ART | Change From Baseline Values in Urine Phosphate Over Time Including Week 48 | Week 48, n=280, 291 | 1.254 Millimoles per liter | Standard Deviation 15.6532 |
Secondary
Change From Baseline Values in Urine pH Over Time Including Week 48
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). The dipstick test gives results in a semi-quantitative manner. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine pH Over Time Including Week 48 | Week 4, n=298, 295 | 0.08 pH | Standard Deviation 0.886 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine pH Over Time Including Week 48 | Week 24, n=274, 291 | 0.18 pH | Standard Deviation 1.021 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine pH Over Time Including Week 48 | Week 48, n=274, 283 | 0.09 pH | Standard Deviation 1.036 |
| Current ART | Change From Baseline Values in Urine pH Over Time Including Week 48 | Week 4, n=298, 295 | -0.13 pH | Standard Deviation 0.935 |
| Current ART | Change From Baseline Values in Urine pH Over Time Including Week 48 | Week 24, n=274, 291 | 0.01 pH | Standard Deviation 0.87 |
| Current ART | Change From Baseline Values in Urine pH Over Time Including Week 48 | Week 48, n=274, 283 | -0.02 pH | Standard Deviation 0.951 |
Secondary
Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine retinol binding protein. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.
Time frame: Baseline (Day 1) and at Week 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48 | -1.8913 Nanomoles per liter | Standard Deviation 14.10125 |
| Current ART | Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48 | 1.4289 Nanomoles per liter | Standard Deviation 15.70559 |
Secondary
Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48
Urine biomarker samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The dipstick test gives results in a semi-quantitative manner. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. The urine specific gravity was measured as the ratio of urine density compared with water density.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48 | Week 4, n=298, 295 | -0.0009 Ratio of urine density to water density | Standard Deviation 0.008 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48 | Week 24, n=274, 291 | -0.0008 Ratio of urine density to water density | Standard Deviation 0.00784 |
| CAB LA+RPV LA (Q4W) | Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48 | Week 48, n=274, 283 | -0.0009 Ratio of urine density to water density | Standard Deviation 0.00772 |
| Current ART | Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48 | Week 4, n=298, 295 | -0.0000 Ratio of urine density to water density | Standard Deviation 0.00785 |
| Current ART | Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48 | Week 24, n=274, 291 | -0.0000 Ratio of urine density to water density | Standard Deviation 0.0077 |
| Current ART | Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48 | Week 48, n=274, 283 | -0.0002 Ratio of urine density to water density | Standard Deviation 0.00768 |
Secondary
Change From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm
The PIN questionnaire explores the bother of pain at the injection site and injection site reactions (ISR), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections.This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial.Scores range from 1 to 5, and questions are phrased in such a way as to ensure that 1 always equated with the most favourable perception of vaccination, and 5 the most unfavourable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.The score of a domain is calculated as the mean of all items with the domain.Higher scores represent worse perception of injection. LOCFwas used as primary method of analysis
Time frame: Week 5 and at Weeks 41 and 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm | Bother of ISRs, Week 41 | -0.21 Scores on the scale | Standard Deviation 0.532 |
| CAB LA+RPV LA (Q4W) | Change From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm | Bother of ISRs, Week 48 | -0.21 Scores on the scale | Standard Deviation 0.524 |
| CAB LA+RPV LA (Q4W) | Change From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm | Leg movement, Week 41 | -0.52 Scores on the scale | Standard Deviation 0.903 |
| CAB LA+RPV LA (Q4W) | Change From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm | Leg movement, Week 48 | -0.59 Scores on the scale | Standard Deviation 0.95 |
| CAB LA+RPV LA (Q4W) | Change From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm | Sleep, Week 41 | -0.56 Scores on the scale | Standard Deviation 0.877 |
| CAB LA+RPV LA (Q4W) | Change From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm | Sleep, Week 48 | -0.56 Scores on the scale | Standard Deviation 0.937 |
| CAB LA+RPV LA (Q4W) | Change From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm | Acceptance, Week 41 | -0.49 Scores on the scale | Standard Deviation 1.094 |
| CAB LA+RPV LA (Q4W) | Change From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm | Acceptance, Week 48 | -0.54 Scores on the scale | Standard Deviation 1.08 |
Secondary
Change in Treatment Satisfaction Over Time Using HIVTSQ Change (HIVTSQc) at Week 48 in Q4W Arm
The HIVTSQ for total treatment satisfaction score is computed with 1-11 items. These 1-11 items are summed to produce a score with a possible range of -33 to 33. The item 12 in the scale will be calculated as an individual score.The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores will be imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score should not be computed and will remain missing.LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. Data has been presented with respect to actual treatment received to the participants
Time frame: Week 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Change in Treatment Satisfaction Over Time Using HIVTSQ Change (HIVTSQc) at Week 48 in Q4W Arm | 29.05 Scores on a scale | Standard Deviation 6.978 |
Secondary
Cmax in Plasma for RPV LA Evaluable at Week 41
Blood samples will be collected at indicated time points for PK analysis of RPV LA.
Time frame: Week 41- 1 Week post dose
Population: PK population. Only those participants with data available at the specified data points were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| CAB LA+RPV LA (Q4W) | Cmax in Plasma for RPV LA Evaluable at Week 41 | 110.36 Nanograms per milliliter |
Secondary
Ctrough for RPV LA Evaluable
Blood samples will be collected at indicated time points for PK analysis of RPV LA.
Time frame: Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: PK population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Ctrough for RPV LA Evaluable | Pre-dose, Week 48, n=216 | 90.28 Nanograms per milliliter |
| CAB LA+RPV LA (Q4W) | Ctrough for RPV LA Evaluable | Pre-dose, Week 40, n=208 | 76.24 Nanograms per milliliter |
| CAB LA+RPV LA (Q4W) | Ctrough for RPV LA Evaluable | Pre-dose, Week 44, n=223 | 83.65 Nanograms per milliliter |
| CAB LA+RPV LA (Q4W) | Ctrough for RPV LA Evaluable | Pre-dose, Week 8, n=251 | 38.58 Nanograms per milliliter |
| CAB LA+RPV LA (Q4W) | Ctrough for RPV LA Evaluable | Pre-dose, Week 12, n=261 | 47.00 Nanograms per milliliter |
| CAB LA+RPV LA (Q4W) | Ctrough for RPV LA Evaluable | Pre-dose, Week 16, n=247 | 53.87 Nanograms per milliliter |
| CAB LA+RPV LA (Q4W) | Ctrough for RPV LA Evaluable | Pre-dose, Week 20, n=233 | 54.14 Nanograms per milliliter |
| CAB LA+RPV LA (Q4W) | Ctrough for RPV LA Evaluable | Pre-dose, Week 24, n=231 | 61.26 Nanograms per milliliter |
| CAB LA+RPV LA (Q4W) | Ctrough for RPV LA Evaluable | Pre-dose, Week 28, n=232 | 66.53 Nanograms per milliliter |
| CAB LA+RPV LA (Q4W) | Ctrough for RPV LA Evaluable | Pre-dose, Week 32, n=218 | 70.93 Nanograms per milliliter |
| CAB LA+RPV LA (Q4W) | Ctrough for RPV LA Evaluable | Pre-dose, Week 36, n=209 | 73.00 Nanograms per milliliter |
Secondary
Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41
Blood samples will be collected at indicated time points for PK analysis of CAB LA.
Time frame: Week 41- 1 Week post dose
Population: PK population. Only those participants with data available at the specified data points were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| CAB LA+RPV LA (Q4W) | Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41 | 3.3862 Micrograms per milliliter |
Secondary
Number of Participants Discontinued or Withdrawn Due to AEs When Baseline Third Agent Treatment Class Was Used Over Time Including Week 48
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
Time frame: Up to Week 48
Population: Safety population.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants Discontinued or Withdrawn Due to AEs When Baseline Third Agent Treatment Class Was Used Over Time Including Week 48 | PI | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants Discontinued or Withdrawn Due to AEs When Baseline Third Agent Treatment Class Was Used Over Time Including Week 48 | INI | 6 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants Discontinued or Withdrawn Due to AEs When Baseline Third Agent Treatment Class Was Used Over Time Including Week 48 | NNRTI | 5 Participants |
| Current ART | Number of Participants Discontinued or Withdrawn Due to AEs When Baseline Third Agent Treatment Class Was Used Over Time Including Week 48 | PI | 2 Participants |
| Current ART | Number of Participants Discontinued or Withdrawn Due to AEs When Baseline Third Agent Treatment Class Was Used Over Time Including Week 48 | INI | 0 Participants |
| Current ART | Number of Participants Discontinued or Withdrawn Due to AEs When Baseline Third Agent Treatment Class Was Used Over Time Including Week 48 | NNRTI | 3 Participants |
Secondary
Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
Time frame: Up to Week 48
Population: Safety population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48 | 13 Participants |
| Current ART | Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48 | 5 Participants |
Secondary
Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48
The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. The urine parameters were graded according to Division of AIDS (DAIDS) scale where Grade 1 indicates mild (trace to 1+), Grade 2 indicates moderate (2+) and Grade 3 indicates severe (3+ or higher). Only participants with abnormal findings for urinalysis at any visit has been presented.
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48.
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 24, 4+, n=279, 298 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 24, 2+, n=279, 298 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin,Baseline (Day 1),Trace, n=303, 301 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Baseline (Day 1), 1+, n=303, 301 | 6 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Baseline (Day 1), 2+, n=303, 301 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Baseline (Day 1), 3+, n=303, 301 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Baseline (Day 1), Trace, n=303, 301 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Baseline (Day 1), 1+, n=303, 301 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Baseline (Day 1), 2+, n=303, 301 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Baseline (Day 1), 3+, n=303, 301 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Baseline (Day 1), Trace, n=303, 301 | 16 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Baseline (Day 1), 1+, n=303, 301 | 4 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Baseline (Day 1), 2+, n=303, 301 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Baseline (Day 1), 3+, n=303, 301 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase,Baseline,Trace,n=303,301 | 25 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Baseline, 1+, n=303, 301 | 14 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Baseline, 2+, n=303, 301 | 14 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Baseline, 3+, n=303, 301 | 5 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine nitrite, Baseline, positive, n=303, 301 | 11 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Baseline, Trace, n=303, 301 | 19 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Baseline, 1+, n=303, 301 | 8 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Baseline, 2+, n=303, 301 | 7 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Baseline, 3+, n=303, 301 | 5 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Baseline, Trace, n=303, 301 | 14 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Baseline, 1+, n=303, 301 | 6 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Baseline, 2+, n=303, 301 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Baseline, 3+, n=303, 301 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Baseline, 4+, n=303, 301 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 4, Trace, n=303, 302 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 4, 1+, n=303, 302 | 9 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 4, 2+, n=303, 302 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 4, 3+, n=303, 302 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 4, Trace, n=303, 302 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 4, 1+, n=303, 302 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 4, 2+, n=303, 302 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 4, 3+, n=303, 302 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 4, Trace, n=303, 302 | 9 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 4, 1+, n=303, 302 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 4, 2+, n=303, 302 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 4, 3+, n=303, 302 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 4, Trace,n=303, 302 | 25 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 4, 1+, n=303, 302 | 14 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 4, 2+, n=303, 302 | 14 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 4, 3+, n=303, 302 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine nitrite, Week 4, positive, n=303, 302 | 10 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 4, Trace, n=303, 302 | 15 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 4, 1+, n=303, 302 | 9 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 4, 2+, n=303, 302 | 5 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 4, 3+, n=303, 302 | 4 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 4, Trace, n=303, 302 | 10 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 4, 1+, n=303, 302 | 8 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 4, 2+, n=303, 302 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 4, 3+, n=303, 302 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 4, 4+, n=303, 302 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 24, Trace, n=279, 298 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 24, 1+, n=279, 298 | 10 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 24, 3+, n=279, 298 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 24, Trace, n=279, 298 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 24, 1+, n=279, 298 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 24, 2+, n=279, 298 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 24, 3+, n=279, 298 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 24, Trace, n=279, 298 | 16 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 24, 1+, n=279, 298 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 24, 2+, n=279, 298 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 24, 3+, n=279, 298 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase,Week 24, Trace, n=279,298 | 22 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 24, 1+, n=279, 298 | 14 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 24, 2+, n=279, 298 | 6 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 24, 3+, n=279, 298 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine nitrite, Week 24, positive, n=279, 298 | 9 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 24, Trace, n=279, 298 | 13 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 24, 1+, n=279, 298 | 5 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 24, 2+, n=279, 298 | 6 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 24, 3+, n=279, 298 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 24, Trace, n=279, 298 | 10 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 24, 1+, n=279, 298 | 4 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 24, 2+, n=279, 298 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 24, 3+, n=279, 298 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 48, Trace, n=279, 290 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 48, 1+, n=279, 290 | 9 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 48, 2+, n=279, 290 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 48, 3+, n=279, 290 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 48, Trace, n=279, 290 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 48, 1+, n=279, 290 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 48, 2+, n=279, 290 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 48, 3+, n=279, 290 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 48, Trace, n=279, 290 | 13 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 48, 1+, n=279, 290 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 48, 2+, n=279, 290 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 48, 3+, n=279, 290 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 48, Trace,n=279,290 | 24 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 48, 1+, n=279, 290 | 13 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 48, 2+, n=279, 290 | 7 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 48, 3+, n=279, 290 | 5 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine nitrite, Week 48, positive, n=279, 290 | 10 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 48, Trace, n=279, 290 | 11 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 48, 1+, n=279, 290 | 5 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 48, 2+, n=279, 290 | 4 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 48, 3+, n=279, 290 | 6 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 48, Trace, n=279, 290 | 10 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 48, 1+, n=279, 290 | 4 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 48, 2+, n=279, 290 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 48, 3+, n=279, 290 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 48, 4+, n=279, 290 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 48, Trace,n=279,290 | 27 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 4, 4+, n=303, 302 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 48, 2+, n=279, 290 | 7 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 48, Trace, n=279, 290 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin,Baseline (Day 1),Trace, n=303, 301 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 24, Trace, n=279, 298 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 48, 2+, n=279, 290 | 4 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Baseline (Day 1), 2+, n=303, 301 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 24, 1+, n=279, 298 | 13 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Baseline (Day 1), 3+, n=303, 301 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 24, 2+, n=279, 298 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Baseline (Day 1), Trace, n=303, 301 | 1 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 48, 1+, n=279, 290 | 8 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Baseline (Day 1), 1+, n=303, 301 | 1 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 24, 3+, n=279, 298 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Baseline (Day 1), 2+, n=303, 301 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 48, 1+, n=279, 290 | 15 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Baseline (Day 1), 3+, n=303, 301 | 1 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 24, Trace, n=279, 298 | 1 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Baseline (Day 1), Trace, n=303, 301 | 17 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 48, 2+, n=279, 290 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Baseline (Day 1), 1+, n=303, 301 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 24, 1+, n=279, 298 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Baseline (Day 1), 2+, n=303, 301 | 1 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 48, 3+, n=279, 290 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Baseline (Day 1), 3+, n=303, 301 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 24, 2+, n=279, 298 | 1 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase,Baseline,Trace,n=303,301 | 18 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 48, 3+, n=279, 290 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Baseline, 1+, n=303, 301 | 16 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 24, 3+, n=279, 298 | 1 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Baseline, 2+, n=303, 301 | 8 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 48, 3+, n=279, 290 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Baseline, 3+, n=303, 301 | 5 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 24, Trace, n=279, 298 | 13 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine nitrite, Baseline, positive, n=303, 301 | 11 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 48, Trace, n=279, 290 | 1 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Baseline, Trace, n=303, 301 | 12 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 24, 1+, n=279, 298 | 1 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Baseline, 1+, n=303, 301 | 9 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 48, 3+, n=279, 290 | 6 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Baseline, 2+, n=303, 301 | 5 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 24, 2+, n=279, 298 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Baseline, 3+, n=303, 301 | 3 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 48, 1+, n=279, 290 | 2 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Baseline, Trace, n=303, 301 | 20 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 24, 3+, n=279, 298 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Baseline, 1+, n=303, 301 | 12 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 48, 2+, n=279, 290 | 3 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Baseline, 2+, n=303, 301 | 1 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase,Week 24, Trace, n=279,298 | 17 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Baseline, 3+, n=303, 301 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 48, 2+, n=279, 290 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Baseline, 4+, n=303, 301 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 24, 1+, n=279, 298 | 14 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 4, Trace, n=303, 302 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine nitrite, Week 48, positive, n=279, 290 | 6 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 4, 1+, n=303, 302 | 5 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 24, 2+, n=279, 298 | 14 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 4, 2+, n=303, 302 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 48, 3+, n=279, 290 | 2 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Week 4, 3+, n=303, 302 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 24, 3+, n=279, 298 | 7 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 4, Trace, n=303, 302 | 2 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 48, Trace, n=279, 290 | 15 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 4, 1+, n=303, 302 | 2 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine nitrite, Week 24, positive, n=279, 298 | 10 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 4, 2+, n=303, 302 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 48, Trace, n=279, 290 | 9 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine glucose, Week 4, 3+, n=303, 302 | 1 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 24, Trace, n=279, 298 | 10 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 4, Trace, n=303, 302 | 15 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 48, Trace, n=279, 290 | 12 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 4, 1+, n=303, 302 | 2 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 24, 1+, n=279, 298 | 6 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 4, 2+, n=303, 302 | 1 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 48, 1+, n=279, 290 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 4, 3+, n=303, 302 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 24, 2+, n=279, 298 | 4 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 4, Trace,n=303, 302 | 29 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 48, 4+, n=279, 290 | 1 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 4, 1+, n=303, 302 | 15 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 24, 3+, n=279, 298 | 6 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 4, 2+, n=303, 302 | 9 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 48, 2+, n=279, 290 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine leukocyte esterase, Week 4, 3+, n=303, 302 | 4 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 24, Trace, n=279, 298 | 21 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine nitrite, Week 4, positive, n=303, 302 | 12 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 48, 1+, n=279, 290 | 5 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 4, Trace, n=303, 302 | 18 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 24, 1+, n=279, 298 | 12 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 4, 1+, n=303, 302 | 10 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine ketones, Week 48, 3+, n=279, 290 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 4, 2+, n=303, 302 | 5 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 24, 2+, n=279, 298 | 3 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine occult blood, Week 4, 3+, n=303, 302 | 3 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 48, 1+, n=279, 290 | 6 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 4, Trace, n=303, 302 | 13 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 24, 3+, n=279, 298 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 4, 1+, n=303, 302 | 7 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine bilirubin, Baseline (Day 1), 1+, n=303, 301 | 7 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 4, 2+, n=303, 302 | 4 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 24, 4+, n=279, 298 | 0 Participants |
| Current ART | Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48 | Urine protein, Week 4, 3+, n=303, 302 | 0 Participants |
Secondary
Number of Participants With AEs by Using Baseline Third Agent Treatment Class Overtime Including Week 48
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.
Time frame: Up to Week 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With AEs by Using Baseline Third Agent Treatment Class Overtime Including Week 48 | Any AE, INI, n=102, 99 | 99 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With AEs by Using Baseline Third Agent Treatment Class Overtime Including Week 48 | Any AE, NNRTI, n=155, 155 | 148 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With AEs by Using Baseline Third Agent Treatment Class Overtime Including Week 48 | Any AE, PI, n=51, 54 | 47 Participants |
| Current ART | Number of Participants With AEs by Using Baseline Third Agent Treatment Class Overtime Including Week 48 | Any AE, INI, n=102, 99 | 68 Participants |
| Current ART | Number of Participants With AEs by Using Baseline Third Agent Treatment Class Overtime Including Week 48 | Any AE, NNRTI, n=155, 155 | 116 Participants |
| Current ART | Number of Participants With AEs by Using Baseline Third Agent Treatment Class Overtime Including Week 48 | Any AE, PI, n=51, 54 | 36 Participants |
Secondary
Number of Participants With Confirmed Virologic Failure (CVF)
The CVF is defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL. The outcome displays only visits during which at least one new CVF occurs. Plasma samples were collected for quantitative analysis of HIV-1 RNA.
Time frame: Weeks 8, 12, 20, 24, 32 and 40
Population: ITT-E Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With Confirmed Virologic Failure (CVF) | Week 8 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Confirmed Virologic Failure (CVF) | Week 12 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Confirmed Virologic Failure (CVF) | Week 20 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Confirmed Virologic Failure (CVF) | Week 24 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Confirmed Virologic Failure (CVF) | Week 32 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Confirmed Virologic Failure (CVF) | Week 40 | 3 Participants |
| Current ART | Number of Participants With Confirmed Virologic Failure (CVF) | Week 32 | 3 Participants |
| Current ART | Number of Participants With Confirmed Virologic Failure (CVF) | Week 8 | 0 Participants |
| Current ART | Number of Participants With Confirmed Virologic Failure (CVF) | Week 24 | 2 Participants |
| Current ART | Number of Participants With Confirmed Virologic Failure (CVF) | Week 12 | 0 Participants |
| Current ART | Number of Participants With Confirmed Virologic Failure (CVF) | Week 40 | 4 Participants |
| Current ART | Number of Participants With Confirmed Virologic Failure (CVF) | Week 20 | 2 Participants |
Secondary
Number of Participants With Disease Progression
Disease progression was defined as HIV-associated conditions, acquired immunodeficiency syndrome (AIDS), and death through 48 Weeks. Data of participants who experienced disease progression to Centers for Disease Control and Prevention (CDC) Stage III or death has been presented.
Time frame: Up to Week 48
Population: ITT-E Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With Disease Progression | 8 Participants |
| Current ART | Number of Participants With Disease Progression | 8 Participants |
Secondary
Number of Participants With Genotypic Resistance Through Week 48
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.
Time frame: At the time of CVF
Population: CVF Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, ETR, sensitive | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, ATV/r, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ABC, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, ATV/r, resistance possible | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, IDV/r, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, ATV/r, sensitive | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ABC, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, DRV/r, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, NVP, resistant | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, DRV/r, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ABC, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, DRV/r, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, FTC, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, FPV/r, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, EFV, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, FPV/r, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, FTC, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, FPV/r, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, NVP, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, IDV/r, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, TDF, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, IDV/r, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, FTC, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, LPV/r, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, TDF, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, LPV/r, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, NVP, sensitive | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, LPV/r, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, TDF, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, NFV, resistant | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, EFV, sensitive | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, NFV, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ZDV, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, NFV, sensitive | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, RPV, resistant | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, RTV, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ZDV, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, RTV, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, DLV, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, RTV, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ZDV, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, SQV/r, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, RPV, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, SQV/r, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, d4T, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, SQV/r, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, ETR, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, TPV/r, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, d4T, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, TPV/r, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, RPV, sensitive | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, TPV/r, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, d4T, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | INI, DTG, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, ATV, sensitive | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | INI, DTG, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ddI, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | INI, DTG, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, 3TC, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | INI, EVG, resistant | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ddI, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | INI, EVG, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, ETR, resistance possible | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | INI, EVG, sensitive | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ddI, sensitive | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | INI, RAL, resistant | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, 3TC, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | INI, RAL, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, ATV, resistant | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | INI, RAL, sensitive | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, EFV, resistant | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, DLV, resistant | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | PI, ATV, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, DLV, resistance possible | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, 3TC, sensitive | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, DLV, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, FTC, resistant | 2 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, IDV/r, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, DLV, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, EFV, resistant | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, EFV, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, EFV, sensitive | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, ETR, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, ETR, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, ETR, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, NVP, resistant | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, NVP, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, NVP, sensitive | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, RPV, resistant | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, RPV, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, RPV, sensitive | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, 3TC, resistant | 2 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, 3TC, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, 3TC, sensitive | 2 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ABC, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ABC, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, FTC, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, FTC, sensitive | 2 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, TDF, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, TDF, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, TDF, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ZDV, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ZDV, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ZDV, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, d4T, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, d4T, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, d4T, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ddI, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ddI, resistance possible | 2 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ddI, sensitive | 2 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, ATV, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, ATV, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, ATV, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, ATV/r, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, ATV/r, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, ATV/r, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, DRV/r, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, DRV/r, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, DRV/r, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, FPV/r, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, FPV/r, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, FPV/r, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, IDV/r, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, IDV/r, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, LPV/r, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, LPV/r, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, LPV/r, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, NFV, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, NFV, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, NFV, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, RTV, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, RTV, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, RTV, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, SQV/r, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, SQV/r, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, SQV/r, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, TPV/r, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, TPV/r, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | PI, TPV/r, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | INI, DTG, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | INI, DTG, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | INI, DTG, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | INI, EVG, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | INI, EVG, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | INI, EVG, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | INI, RAL, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | INI, RAL, resistance possible | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | INI, RAL, sensitive | 4 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NNRTI, DLV, resistant | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Through Week 48 | NRTI, ABC, sensitive | 4 Participants |
Secondary
Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48
Plasma samples were collected from participants who met confirmed virologic withdrawal criteria to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.
Time frame: At the time of CVF
Population: CVF Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, DLV, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, DTG, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, RAL, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, EFV, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, ETR, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, ETR, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, NVP, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, NVP, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, NVP, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, RPV, resistant, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ZDV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV/r, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DTG, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, 3TC, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, NVP, sensitive, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, RPV, resistant, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, RPV, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, RPV, sensitive, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, 3TC, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, FTC, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, FTC, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, FTC, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, TDF, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, TDF, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, TDF, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, 3TC, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ABC, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ABC, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ABC, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ZDV, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ZDV, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DLV, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, DLV, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ddI, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ddI, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV, resistant, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV, sensitive, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV/r, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV/r, resistance possible, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ZDV, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, EFV, sensitive, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, d4T, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, EFV, resistant, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, EFV, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV/r, sensitive, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, DRV/r, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, ETR, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, ETR, resistance possible,n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, ETR, sensitive, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, NVP, resistant, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, NVP, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, d4T, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, d4T, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ddI, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, DRV/r, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, DRV/r, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, FPV/r, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, TPV/r, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, FPV/r, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, FPV/r, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, TPV/r, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, IDV/r, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, LPV/r, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, NFV, resistant, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, NFV, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, NFV, sensitive, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, RTV, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, RTV, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, RTV, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, SQV/r, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, SQV/r, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, IDV/r, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, IDV/r, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, LPV/r, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, LPV/r, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, d4T, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ddI, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ddI, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ddI, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV/r, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV/r, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, DRV/r, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, DRV/r, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, DRV/r, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, FPV/r, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, FPV/r, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, FPV/r, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, IDV/r, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, IDV/r, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, IDV/r, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, LPV/r, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, LPV/r, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, LPV/r, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, NFV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, NFV, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, NFV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, RTV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, RTV, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, RTV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, SQV/r, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, SQV/r, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, SQV/r, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, TPV/r, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, TPV/r, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, TPV/r, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DTG, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DTG, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, EVG, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, EVG, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, EVG, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, RAL, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, RAL, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, RAL, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, DLV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DLV, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, DLV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, EFV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, EFV, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, TDF, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ZDV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ZDV, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, SQV/r, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, TPV/r, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, DTG, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, DTG, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, EVG, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, EVG, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, EVG, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, RAL, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, RAL, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, DLV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, DLV, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, DLV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, EFV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, EFV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, ETR, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, RPV, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, RPV, sensitive, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, 3TC, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, 3TC, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, 3TC, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ABC, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ABC, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ABC, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, FTC, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, FTC, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, FTC, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, TDF, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, TDF, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, TDF, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ZDV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ZDV, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, d4T, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, d4T, resistance possible, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, EFV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, ETR, resistant,, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, ETR, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, ETR, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, NVP, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, NVP, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, NVP, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, RPV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, RPV, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, RPV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, 3TC, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, 3TC, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ABC, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ABC, resistance possible,, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ABC, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, FTC, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, FTC, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, FTC, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, TDF, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, TDF, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ZDV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, d4T, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, d4T, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, d4T, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ddI, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ddI, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ddI, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, LPV/r, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, LPV/r, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, NFV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, NFV, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, NFV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, RTV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, RTV, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV/r, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV/r, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV/r, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, DRV/r, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, DRV/r, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, DRV/r, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, FPV/r, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, FPV/r, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, FPV/r, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, IDV/r, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, IDV/r, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, RTV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, SQV/r, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, SQV/r, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, SQV/r, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, TPV/r, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, TPV/r, resistance possible, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, TPV/r, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, IDV/r, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DTG, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DTG, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DTG, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, LPV/r, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, EVG, resistant, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, EVG, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, EVG, sensitive, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, RAL, resistant, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, RAL, resistance possible, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, RAL, sensitive, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, 3TC, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, RTV, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DTG, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, RPV, resistant, n=0, 3 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, RAL, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, EVG, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, EFV, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, RTV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, ETR, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, EVG, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, ETR, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, RPV, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, NVP, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, EVG, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, NVP, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DTG, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, NVP, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, RAL, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, RPV, sensitive, n=0, 3 | 2 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, RAL, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, 3TC, resistant, n=0, 3 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV/r, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, RTV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, RAL, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DTG, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, SQV/r, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, FTC, sensitive, n=0, 3 | 2 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ZDV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, TPV/r, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, TPV/r, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, DLV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, NVP, sensitive, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, 3TC, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, RPV, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DLV, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, RPV, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, IDV/r, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, RPV, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, DLV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, 3TC, resistant, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, 3TC, sensitive, n=0, 3 | 2 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, FTC, resistant, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, EFV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, FTC, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV/r, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, FTC, sensitive, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ABC, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, 3TC, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, TDF, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, TDF, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, TDF, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, SQV/r, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ABC, resistance possible,, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, 3TC, sensitive, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV/r, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ABC, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, SQV/r, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ABC, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ABC, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ABC, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, TDF, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, TPV/r, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ZDV, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, DTG, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, DLV, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, RAL, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DLV, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, DTG, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, FTC, resistant, n=0, 3 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ddI, resistance possible, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, DTG, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ddI, sensitive, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV/r, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, EVG, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, FTC, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, EVG, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV/r, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, SQV/r, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ZDV, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, EVG, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, DRV/r, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, DLV, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ZDV, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, RAL, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, TDF, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, EFV, resistant, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, RAL, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, EFV, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV/r, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DTG, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV/r, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, DLV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, EFV, sensitive, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, TDF, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, ETR, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, DLV, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, ETR, resistance possible,n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ZDV, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, ETR, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, DLV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, NVP, resistant, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, DRV/r, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, NVP, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, d4T, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, EFV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, d4T, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ZDV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, d4T, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, EFV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, DRV/r, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, TPV/r, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, ETR, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, DRV/r, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, LPV/r, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ddI, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, DRV/r, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, RPV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, FPV/r, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, d4T, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, TPV/r, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, RPV, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, FPV/r, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, DRV/r, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, FPV/r, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, RPV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, d4T, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, TPV/r, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, 3TC, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, LPV/r, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, LPV/r, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, NFV, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, 3TC, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, NFV, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, EVG, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, NFV, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, 3TC, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, IDV/r, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, RTV, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, d4T, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, RTV, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ABC, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, RTV, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, FPV/r, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, SQV/r, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ABC, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, SQV/r, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ddI, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, IDV/r, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ABC, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, IDV/r, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, RAL, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, LPV/r, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, FTC, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, d4T, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ddI, resistance possible, n=0, 3 | 1 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, d4T, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, FTC, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ddI, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, FPV/r, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ddI, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, FTC, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ddI, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ddI, sensitive, n=0, 3 | 2 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, TDF, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, EVG, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV/r, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, TDF, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV/r, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, LPV/r, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, DRV/r, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, TDF, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, DRV/r, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, FPV/r, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, DRV/r, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ZDV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, FPV/r, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, LPV/r, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, FPV/r, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ZDV, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, FPV/r, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ZDV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, IDV/r, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, RAL, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, IDV/r, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, d4T, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, IDV/r, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, NFV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, LPV/r, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, EFV, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, LPV/r, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, IDV/r, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, LPV/r, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, EFV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, NFV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, NFV, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, NFV, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, ETR, resistant,, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, NFV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DTG, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, ETR, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, RTV, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, NFV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, RTV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, ETR, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, SQV/r, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, IDV/r, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, SQV/r, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, NVP, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, SQV/r, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, RTV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, TPV/r, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, NVP, resistance possible, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, TPV/r, resistance possible, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, EVG, resistance possible, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, TPV/r, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, NVP, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DTG, resistant, n=0, 3 | 0 Participants |
Secondary
Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48
Number of participants with plasma HIV-1 RNA \<200 copies/mL at Week 48 using the snapshot algorithm was assessed based on the antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART.
Time frame: Week 48
Population: ITT-E Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48 | 286 Participants |
| Current ART | Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48 | 295 Participants |
Secondary
Number of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48
Plasma samples were collected for quantitative analysis of HIV-1 RNA. Number of participants with plasma HIV-1 RNA \<50 copies/mL at Week 48 using FDA snapshot algorithm was assessed to demonstrate antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART. The HIV-1 RNA \<50 copies/mL per snapshot algorithm was determined by the last available on-treatment HIV-1 RNA measurement within the analysis visit window of interest.
Time frame: Week 48
Population: ITT-E Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48 | 285 Participants |
| Current ART | Number of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48 | 294 Participants |
95% CI: [-6.7, 0.7]
Secondary
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement. Safety Population comprised of all randomized participants who received at least one dose of IP during the maintenance phase of the study (on or after Day 1 visit). Participants will be assessed according to actual treatment received.
Time frame: Up to Week 48
Population: Safety Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) | Any non-SAE | 263 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) | Any SAE | 13 Participants |
| Current ART | Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) | Any non-SAE | 117 Participants |
| Current ART | Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) | Any SAE | 14 Participants |
Secondary
Number of Participants With Phenotypic Resistance Through Week 48
Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria.The CVF population comprised of all participants in ITT-E population who met CVF criteria.Phenotypic Resistance data for following drugs:CAB,dolutegravir(DTG),elvitegravir(EVG), raltegravir(RAL),delavirdine(DLV),efavirenz(EFV),etravirine(ETR),nevirapine(NVP),RPV,lamivudine(3TC),abacavir(ABC),emtricitabine(FTC),tenofovir(TDF),zidovudine(ZDV),stavudine(d4T),didanosine(ddI), atazanavir(ATV),darunavir(DRV),fosamprenavir(FPV),indinavir(IDV),lopinavir(LPV),nelfinavir(NFV),rito-navir(RTV),saquinavir(SQV) and tipranavir(TPV) in participants meeting CVF criteria is presented.Phenotypic resistance, partially sensitive, and Sensitive were defined based on fold change(FC) value from Monogram as:resistance(FC\>clinical higher cutoff/biologic cutoff),partially sensitive(FC \<=clinical higher cutoff and \> clinical lower cutoff),sensitive(FC \<= clinical lower cutoff/biologic cutoff).
Time frame: At the time of CVF
Population: CVF Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ZDV, resistant, n=3, 3 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, ETR, partially sensitive, n=3, 3 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ZDV, sensitive, n=3, 3 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, FTC, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, d4T, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, ETR, sensitive, n=3, 3 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, d4T, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | INI, RAL, resistant, n=3, 4 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ddI, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, NVP, resistant, n=3, 3 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ddI, partially sensitive, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | INI, DTG, partially sensitive, n=3, 4 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ddI, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, NVP, sensitive, n=3, 3 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, ATV, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | INI, RAL, sensitive, n=3, 4 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, ATV, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, RPV, resistant, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, DRV, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | INI, CAB, sensitive, n=3, 4 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, DRV, partially sensitive, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, RPV, sensitive, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, DRV, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, DLV, resistant, n=3, 3 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, FPV, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, 3TC, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, FPV, partially sensitive, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | INI, DTG, sensitive, n=3, 4 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, FPV, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, 3TC, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, IDV, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, DLV, sensitive, n=3, 3 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, IDV, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ABC, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, LPV, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ABC, partially sensitive, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, LPV, partially sensitive, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | INI, CAB, resistant, n=3, 4 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, LPV, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ABC, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, NFV, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, EFV, resistant, n=3, 3 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, NFV, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | INI, EVG, resistant, n=3, 4 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, RTV, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, FTC, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, RTV, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, EFV, sensitive, n=3, 3 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, SQV, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, TDF, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, SQV, partially sensitive, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | INI, DTG, resistant, n=3, 4 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, SQV, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, TDF, partially sensitive, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, TPV, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, ETR, resistant, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, TPV, partially sensitive, n=3, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, TDF, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | PI, TPV, sensitive, n=3, 3 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Through Week 48 | INI, EVG, sensitive, n=3, 4 | 2 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, TPV, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | INI, CAB, resistant, n=3, 4 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | INI, CAB, sensitive, n=3, 4 | 4 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | INI, DTG, resistant, n=3, 4 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | INI, DTG, partially sensitive, n=3, 4 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | INI, DTG, sensitive, n=3, 4 | 4 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | INI, EVG, resistant, n=3, 4 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | INI, EVG, sensitive, n=3, 4 | 4 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | INI, RAL, resistant, n=3, 4 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | INI, RAL, sensitive, n=3, 4 | 4 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, DLV, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, DLV, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, EFV, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, EFV, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, ETR, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, ETR, partially sensitive, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, ETR, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, NVP, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, NVP, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, RPV, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NNRTI, RPV, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, 3TC, resistant, n=3, 3 | 1 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, 3TC, sensitive, n=3, 3 | 2 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ABC, partially sensitive, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ABC, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, FTC, resistant, n=3, 3 | 1 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, FTC, sensitive, n=3, 3 | 2 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, TDF, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, TDF, partially sensitive, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, TDF, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ZDV, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ZDV, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, d4T, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, d4T, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ddI, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ddI, partially sensitive, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ddI, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, ATV, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, ATV, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, DRV, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, DRV, partially sensitive, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, DRV, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, FPV, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, FPV, partially sensitive, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, FPV, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, IDV, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, IDV, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, LPV, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, LPV, partially sensitive, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, LPV, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, NFV, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, NFV, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, RTV, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, RTV, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, SQV, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, SQV, partially sensitive, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, SQV, sensitive, n=3, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, TPV, resistant, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | PI, TPV, partially sensitive, n=3, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Through Week 48 | NRTI, ABC, resistant, n=3, 3 | 0 Participants |
Secondary
Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48
Plasma samples were collected from participants who met confirmed virologic withdrawal criteria to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Phenotypic Resistance data for the following drugs: CAB, DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented. Phenotypic resistance, partially sensitive, and Sensitive were defined based on FC value from Monogram as: resistance (FC\>clinical higher cutoff/biologic cutoff), partially sensitive (FC \<=clinical higher cutoff and \> clinical lower cutoff), sensitive (FC \<= clinical lower cutoff/biologic cutoff).
Time frame: At the time of CVF
Population: CVF Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, FPV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, SQV, partially sensitive, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, SQV, partially sensitive, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, IDV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, SQV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, SQV, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, TPV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, RPV, sensitive, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, TPV, partially sensitive, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, TPV, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ABC, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, CAB, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, TPV, partially sensitive, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DTG, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, LPV, partially sensitive, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DTG, partially sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, TPV, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DTG, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, CAB, resistant , n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, EVG, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, FTC, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, EVG, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, CAB, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, RAL, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, DLV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, LPV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, ETR, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, ETR, partially sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, ETR, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, NVP, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ZDV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, NVP, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, DTG, partially sensitive, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, RPV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, d4T, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, RPV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, 3TC, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, DTG, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, 3TC, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ddI, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ABC, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, EVG, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ABC, partially sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, FTC, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, FTC, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, DTG, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, TDF, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, EVG, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, TDF, partially sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, TDF, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, RAL, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ZDV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, DRV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, RAL, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, d4T, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, NFV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, DLV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ddI, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, DRV, partially sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ddI, partially sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, DLV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, IDV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, EFV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, NFV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, DRV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, EFV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, FPV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, LPV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, FPV, partially sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, ETR, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, FPV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, ETR, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, IDV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, ETR, partially sensitive, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, RTV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, LPV, partially sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, TPV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, LPV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, NVP, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, NFV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, SQV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, NFV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, NVP, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, RTV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, RPV, resistant, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, RTV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, DRV, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, SQV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, TPV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, SQV, partially sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, 3TC, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, SQV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, FPV, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, TPV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, TPV, partially sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ABC, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, CAB, resistant , n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ZDV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, CAB, sensitive, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ABC, partially sensitive, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DTG, resistant, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, FPV, partially sensitive, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DTG, partially sensitive, n=2, 1 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, CAB, resistant , n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DTG, sensitive, n=2, 1 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, FTC, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, EVG, resistant, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, FPV, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, EVG, sensitive, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, TDF, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, RAL, resistant, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, TDF, partially sensitive, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, RAL, sensitive, n=2, 1 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, d4T, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, DLV, resistant, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, TDF, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, DLV, sensitive, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, IDV, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, EFV, resistant, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, RAL, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, EFV, sensitive, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ZDV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, ETR, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, IDV, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, ETR, partially sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, d4T, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, ETR, sensitive, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ddI, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, NVP, resistant, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, LPV, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, NVP, sensitive, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ddI, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, RPV, resistant, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, DLV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, RPV, sensitive, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ddI, partially sensitive, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, 3TC, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, LPV, partially sensitive, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, 3TC, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, 3TC, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ABC, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ABC, partially sensitive, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, LPV, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ABC, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, FTC, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, EFV, resistant, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, FTC, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, DRV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, TDF, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, NFV, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, TDF, partially sensitive, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, DRV, partially sensitive, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, TDF, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, DRV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ZDV, resistant, n=2, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, FPV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ZDV, sensitive, n=2, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, NFV, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, d4T, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, EFV, sensitive, n=0, 3 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, d4T, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, IDV, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ddI, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, RTV, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ddI, partially sensitive, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, LPV, resistant, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ddI, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, FPV, partially sensitive, n=1, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, RTV, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV, sensitive, n=2, 0 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ABC, sensitive, n=1, 0 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, DRV, resistant, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, SQV, resistant, n=2,0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, DRV, partially sensitive, n=2, 0 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, RTV, sensitive, n=1, 0 | 1 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, FTC, resistant, n=0, 3 | 1 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, NVP, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, RPV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ABC, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, TDF, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, DRV, partially sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, FPV, partially sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, IDV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, LPV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, NFV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, TPV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, RAL, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, RAL, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, DLV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, EFV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, EFV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, ETR, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, ETR, partially sensitive, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, ETR, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, RPV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ABC, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, FTC, sensitive, n=0, 3 | 2 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, DRV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, IDV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, TPV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, TPV, partially sensitive, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, TPV, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, DRV, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, FPV, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, FPV, partially sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, FPV, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, IDV, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, IDV, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, LPV, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, LPV, partially sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, LPV, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, NFV, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, NFV, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, RTV, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, RTV, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, SQV, resistant, n=2,0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, SQV, partially sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, SQV, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, TPV, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, TPV, partially sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, CAB, resistant , n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, CAB, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, DTG, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, DTG, partially sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, DTG, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, EVG, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, EVG, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, RAL, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, INI, RAL, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, DLV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, DLV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, EFV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, EFV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, ETR, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, ETR, partially sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, ETR, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, NVP, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NNRTI, RPV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, 3TC, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, 3TC, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ABC, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ABC, partially sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, FTC, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, FTC, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, TDF, partially sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, TDF, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ZDV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ZDV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, d4T, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, d4T, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ddI, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ddI, partially sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, NRTI, ddI, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, ATV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, DRV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, DRV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, FPV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, FPV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, IDV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, LPV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, LPV, partially sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, NFV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, RTV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, RTV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, SQV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, SQV, partially sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, SQV, sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, TPV, resistant, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | PI, PI, TPV, partially sensitive, n=1, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, CAB, resistant , n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, CAB, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DTG, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DTG, partially sensitive, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, DTG, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, EVG, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, INI, EVG, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, DLV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, NVP, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, NVP, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NNRTI, RPV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, 3TC, resistant, n=0, 3 | 1 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, 3TC, sensitive, n=0, 3 | 2 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ABC, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ABC, partially sensitive, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, TDF, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, TDF, partially sensitive, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, TDF, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ZDV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ZDV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, d4T, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, d4T, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ddI, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ddI, partially sensitive, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, NRTI, ddI, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, ATV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, DRV, partially sensitive, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, DRV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, FPV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, FPV, partially sensitive, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, FPV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, IDV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, LPV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, LPV, partially sensitive, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, LPV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, NFV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, NFV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, RTV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, RTV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, SQV, resistant, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, SQV, partially sensitive, n=0, 3 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, SQV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | INI, PI, TPV, sensitive, n=0, 3 | 3 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, CAB, resistant , n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, CAB, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DTG, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DTG, partially sensitive, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, DTG, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, EVG, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, EVG, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, RAL, resistant, n=2, 1 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, INI, RAL, sensitive, n=2, 1 | 1 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, DLV, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, DLV, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, EFV, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, EFV, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, ETR, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, ETR, partially sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, ETR, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, NVP, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, NVP, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, RPV, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NNRTI, RPV, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, 3TC, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, 3TC, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ABC, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ABC, partially sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ABC, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, FTC, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, FTC, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, TDF, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, TDF, partially sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, TDF, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ZDV, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ZDV, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, d4T, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, d4T, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ddI, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ddI, partially sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, NRTI, ddI, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, ATV, sensitive, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, DRV, resistant, n=2, 0 | 0 Participants |
| Current ART | Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48 | NNRTI, PI, DRV, partially sensitive, n=2, 0 | 0 Participants |
Secondary
Number of Participants With Severity of Adverse Events
Severity of adverse events (AEs) were defined as per The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.0, November 2014. Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE.
Time frame: Up to Week 48
Population: Safety Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events | Grade 1 | 101 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events | Grade 3 | 27 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events | Grade 2 | 158 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events | Grade 4 | 8 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events | Grade 5 | 0 Participants |
| Current ART | Number of Participants With Severity of Adverse Events | Grade 4 | 4 Participants |
| Current ART | Number of Participants With Severity of Adverse Events | Grade 5 | 1 Participants |
| Current ART | Number of Participants With Severity of Adverse Events | Grade 1 | 115 Participants |
| Current ART | Number of Participants With Severity of Adverse Events | Grade 2 | 81 Participants |
| Current ART | Number of Participants With Severity of Adverse Events | Grade 3 | 19 Participants |
Secondary
Number of Participants With Severity of Adverse Events by Baseline Third Agents
Severity of AEs were defined as per The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE.
Time frame: Up to Week 48
Population: Safety population.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | INI, Grade 4 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | INI, Grade 5 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | PI, Grade 1 | 22 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | PI, Grade 2 | 20 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | PI, Grade 3 | 4 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | PI, Grade 4 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | PI, Grade 5 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | INI, Grade 1 | 40 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | INI, Grade 2 | 50 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | INI, Grade 3 | 8 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | NNRTI, Grade 1 | 39 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | NNRTI, Grade 2 | 88 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | NNRTI, Grade 3 | 15 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | NNRTI, Grade 4 | 6 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Severity of Adverse Events by Baseline Third Agents | NNRTI, Grade 5 | 0 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | NNRTI, Grade 2 | 47 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | INI, Grade 4 | 2 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | INI, Grade 2 | 23 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | NNRTI, Grade 4 | 2 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | PI, Grade 1 | 20 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | INI, Grade 3 | 3 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | PI, Grade 2 | 11 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | INI, Grade 5 | 0 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | PI, Grade 3 | 4 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | NNRTI, Grade 3 | 12 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | PI, Grade 4 | 0 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | NNRTI, Grade 1 | 55 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | PI, Grade 5 | 1 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | NNRTI, Grade 5 | 0 Participants |
| Current ART | Number of Participants With Severity of Adverse Events by Baseline Third Agents | INI, Grade 1 | 40 Participants |
Secondary
Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48
Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).
Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH>9.0, n=303, 302 | 1 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH>9.0, n=303, 301 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=5, n=279, 298 | 23 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=5.5, n=303, 301 | 78 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=5.5, n=279, 298 | 85 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=5, n=303, 302 | 41 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=6, n=279, 298 | 66 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=7, n=303, 301 | 32 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=6.5, n=279, 298 | 44 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=5.5, n=303, 302 | 78 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=7, n=279, 298 | 32 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=5, n=303, 301 | 44 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=7.5, n=279, 298 | 16 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=6, n=303, 302 | 73 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=8.5, n=279, 298 | 2 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=7.5, n=303, 301 | 12 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH>9.0, n=279, 298 | 4 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=6.5, n=303, 302 | 49 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=5, n=279, 290 | 45 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=6, n=303, 301 | 85 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=5.5, n=279, 290 | 69 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=7, n=303, 302 | 38 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=6, n=279, 290 | 61 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=8, n=303, 301 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=6.5, n=279, 290 | 47 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=7.5, n=303, 302 | 12 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=7, n=279, 290 | 31 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=8, n=279, 298 | 7 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=7.5, n=279, 290 | 17 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=8, n=303, 302 | 8 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=8, n=279, 290 | 6 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=8.5, n=303, 301 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=8.5, n=279, 290 | 0 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=8.5, n=303, 302 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH>9.0, n=279, 290 | 3 Participants |
| CAB LA+RPV LA (Q4W) | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=6.5, n=303, 301 | 47 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH>9.0, n=279, 290 | 2 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=5, n=303, 301 | 42 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=5.5, n=303, 301 | 80 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=6, n=303, 301 | 72 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=6.5, n=303, 301 | 45 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=7, n=303, 301 | 34 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=7.5, n=303, 301 | 19 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=8, n=303, 301 | 7 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH=8.5, n=303, 301 | 1 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Baseline, pH>9.0, n=303, 301 | 1 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=5, n=303, 302 | 53 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=5.5, n=303, 302 | 93 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=6, n=303, 302 | 67 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=6.5, n=303, 302 | 41 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=7, n=303, 302 | 28 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=7.5, n=303, 302 | 14 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=8, n=303, 302 | 3 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH=8.5, n=303, 302 | 2 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 4, pH>9.0, n=303, 302 | 1 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=5, n=279, 298 | 26 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=5.5, n=279, 298 | 96 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=6, n=279, 298 | 67 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=6.5, n=279, 298 | 52 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=7, n=279, 298 | 31 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=8, n=279, 298 | 8 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=8.5, n=279, 298 | 2 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH>9.0, n=279, 298 | 1 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=5, n=279, 290 | 43 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=5.5, n=279, 290 | 83 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=6, n=279, 290 | 58 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=6.5, n=279, 290 | 48 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=7, n=279, 290 | 30 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=7.5, n=279, 290 | 17 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=8, n=279, 290 | 5 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 48, pH=8.5, n=279, 290 | 4 Participants |
| Current ART | Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48 | Week 24, pH=7.5, n=279, 298 | 15 Participants |
Secondary
Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48
Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Percentage change from Baseline is calculated as: value at Week 48 minus Baseline value divided by Baseline value multiplied by 100.
Time frame: Baseline (Day 1) and at Week 48
Population: Safety population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48 | Cholesterol, Week 48, Overall, n=231, 242 | 3.25 Percent change | Standard Deviation 15.563 |
| CAB LA+RPV LA (Q4W) | Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48 | HDL cholesterol, Week 48, Overall, n=231, 242 | 5.059 Percent change | Standard Deviation 20.5368 |
| CAB LA+RPV LA (Q4W) | Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48 | LDL cholesterol, Week 48, Overall, n=224, 238 | 6.762 Percent change | Standard Deviation 31.7209 |
| CAB LA+RPV LA (Q4W) | Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48 | Triglycerides, Week 48, Overall, n=231, 242 | 0.708 Percent change | Standard Deviation 43.516 |
| Current ART | Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48 | Triglycerides, Week 48, Overall, n=231, 242 | 8.203 Percent change | Standard Deviation 51.7632 |
| Current ART | Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48 | Cholesterol, Week 48, Overall, n=231, 242 | 0.13 Percent change | Standard Deviation 13.379 |
| Current ART | Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48 | LDL cholesterol, Week 48, Overall, n=224, 238 | 1.029 Percent change | Standard Deviation 19.4719 |
| Current ART | Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48 | HDL cholesterol, Week 48, Overall, n=231, 242 | 2.132 Percent change | Standard Deviation 18.0473 |
Secondary
Percentage of Participants With a Virologic Failure Using Snapshot Algorithm by Baseline Third Agent
Percentage of participants with virologic failure endpoint as per FDA snapshot algorithm at Week 48 was assessed based on the non-inferior antiviral activity of switching IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-RNA \>=50 copies/mL per snapshot algorithm was determined using a Cochran-Mantel Haenszel test stratified by baseline third agent class: INI, NNRTI, or PI.
Time frame: Week 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Percentage of Participants With a Virologic Failure Using Snapshot Algorithm by Baseline Third Agent | PI, n=51, 54 | 2.0 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With a Virologic Failure Using Snapshot Algorithm by Baseline Third Agent | INI, n=102, 99 | 0 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With a Virologic Failure Using Snapshot Algorithm by Baseline Third Agent | NNRTI, n=155, 155 | 2.6 Percentage of participants |
| Current ART | Percentage of Participants With a Virologic Failure Using Snapshot Algorithm by Baseline Third Agent | NNRTI, n=155, 155 | 0.6 Percentage of participants |
| Current ART | Percentage of Participants With a Virologic Failure Using Snapshot Algorithm by Baseline Third Agent | PI, n=51, 54 | 0 Percentage of participants |
| Current ART | Percentage of Participants With a Virologic Failure Using Snapshot Algorithm by Baseline Third Agent | INI, n=102, 99 | 2.0 Percentage of participants |
Secondary
Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm
The PIN questionnaire explores the bother of pain at the injection site and injection site reactions(ISR), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections.This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial.Scores range from 1 to 5, and questions are phrased in such a way as to ensure that 1 always equated with the most favourable perception of vaccination, and 5 the most unfavourable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.The score of a domain is calculated as the mean of all items with the domain.Higher scores represent worse perception of injection. LOCF was used as primary method of analysis
Time frame: Weeks 5, 41 and 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, Week 5, total, n=296 | 141 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction,Week 5, very acceptable, n=296 | 77 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, Week 5, moderate, n=296 | 54 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, Week 5, little, n=296 | 15 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, Week 5, not at all, n=296 | 9 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 5, total, n=296 | 86 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 5, very acceptable, n=296 | 103 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 5, moderate, n=296 | 59 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 5, little, n=296 | 29 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 5, not at all, n=296 | 19 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, Week 41, total, n=300 | 188 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, Week 41, very acceptable, n=300 | 77 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, Week 41, moderate, n=300 | 24 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, Week 41, little, n=300 | 6 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, Week 41, not at all, n=300 | 5 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 41, total, n=300 | 166 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 41, very acceptable, n=300 | 85 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 41, moderate, n=300 | 31 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 41, little, n=300 | 12 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 41, not at all, n=300 | 6 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, week 48, total, n=303 | 202 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, Week 48, very acceptable, n=303 | 69 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, Week 48, moderate, n=303 | 21 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, Week 48, little, n=303 | 8 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Local reaction, Week 48, not at all, n=303 | 3 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 48, total, n=303 | 168 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 48, very acceptable, n=303 | 95 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 48, moderate, n=303 | 26 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 48, little, n=303 | 11 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm | Pain, Week 48, not at all, n=303 | 3 Percentage of participants |
Secondary
Percentage of Participants With Plasma HIV-1 RNA <50copies/mL Using Snapshot Algorithm by Baseline Third Agent
Percentage of participants with HIV-1 RNA \< 50copies/mL endpoint as per FDA snapshot algorithm at Week 48 was assessed based on the non-inferior antiviral activity of switching IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-RNA \<50 copies/mL per snapshot algorithm was determined using a Cochran-Mantel Haenszel test stratified by baseline third agent class: INI, NNRTI, or PI.
Time frame: Week 48
Population: ITT-E population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Plasma HIV-1 RNA <50copies/mL Using Snapshot Algorithm by Baseline Third Agent | PI, n=51, 54 | 92 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Plasma HIV-1 RNA <50copies/mL Using Snapshot Algorithm by Baseline Third Agent | INI, n=102, 99 | 94 Percentage of participants |
| CAB LA+RPV LA (Q4W) | Percentage of Participants With Plasma HIV-1 RNA <50copies/mL Using Snapshot Algorithm by Baseline Third Agent | NNRTI, n=155, 155 | 92 Percentage of participants |
| Current ART | Percentage of Participants With Plasma HIV-1 RNA <50copies/mL Using Snapshot Algorithm by Baseline Third Agent | PI, n=51, 54 | 94 Percentage of participants |
| Current ART | Percentage of Participants With Plasma HIV-1 RNA <50copies/mL Using Snapshot Algorithm by Baseline Third Agent | INI, n=102, 99 | 96 Percentage of participants |
| Current ART | Percentage of Participants With Plasma HIV-1 RNA <50copies/mL Using Snapshot Algorithm by Baseline Third Agent | NNRTI, n=155, 155 | 95 Percentage of participants |
Secondary
Plasma Trough Concentration (Ctrough) for CAB LA Evaluable
Blood samples will be collected at indicated time points for pharmacokinetic (PK) analysis of CAB LA. PK population includes all participants who received CAB and / or RPV and underwent PK sampling during the study, and provided CAB and /or RPV plasma concentration data.
Time frame: Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Population: PK population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| CAB LA+RPV LA (Q4W) | Plasma Trough Concentration (Ctrough) for CAB LA Evaluable | Pre-dose, Week 8, n=252 | 1.2277 Micrograms per milliliter |
| CAB LA+RPV LA (Q4W) | Plasma Trough Concentration (Ctrough) for CAB LA Evaluable | Pre-dose, Week 12, n=261 | 1.6925 Micrograms per milliliter |
| CAB LA+RPV LA (Q4W) | Plasma Trough Concentration (Ctrough) for CAB LA Evaluable | Pre-dose, Week 16, n=248 | 1.9533 Micrograms per milliliter |
| CAB LA+RPV LA (Q4W) | Plasma Trough Concentration (Ctrough) for CAB LA Evaluable | Pre-dose, Week 20, n=233 | 2.1036 Micrograms per milliliter |
| CAB LA+RPV LA (Q4W) | Plasma Trough Concentration (Ctrough) for CAB LA Evaluable | Pre-dose, Week 24, n=234 | 2.2537 Micrograms per milliliter |
| CAB LA+RPV LA (Q4W) | Plasma Trough Concentration (Ctrough) for CAB LA Evaluable | Pre-dose, Week 28, n=232 | 2.4300 Micrograms per milliliter |
| CAB LA+RPV LA (Q4W) | Plasma Trough Concentration (Ctrough) for CAB LA Evaluable | Pre-dose, Week 32, n=219 | 2.4483 Micrograms per milliliter |
| CAB LA+RPV LA (Q4W) | Plasma Trough Concentration (Ctrough) for CAB LA Evaluable | Pre-dose, Week 36, n=209 | 2.4681 Micrograms per milliliter |
| CAB LA+RPV LA (Q4W) | Plasma Trough Concentration (Ctrough) for CAB LA Evaluable | Pre-dose, Week 40, n=209 | 2.5126 Micrograms per milliliter |
| CAB LA+RPV LA (Q4W) | Plasma Trough Concentration (Ctrough) for CAB LA Evaluable | Pre-dose, Week 44, n=221 | 2.7748 Micrograms per milliliter |
| CAB LA+RPV LA (Q4W) | Plasma Trough Concentration (Ctrough) for CAB LA Evaluable | Pre-dose, Week 48, n=217 | 2.8378 Micrograms per milliliter |
Other Pre-specified
Number of Participants With Different Demographic Parameters for Inter-subject Variability
Blood samples were planned to be collected at indicated time points for PK analysis of CAB LA and RPV LA. Demographic parameters including, but not limited to, age, sex, race, body weight, body mass index, and relevant laboratory parameters were planned to be evaluated as potential predictors of inter subject variability for pharmacokinetic parameters.
Time frame: Upto Week 48
Population: PK Population. This was an exploratory Outcome Measure. Data will not be analyzed and reported.